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1. INTRODUCTION 
1.1. MALARIA 
1.1.1. ETIOLOGY OF MALARIA 
 
Malaria is a life-threatening disease transmitted by mosquitoes. The disease 
was supposed to come from fetid marshes, hence the name mal aria (bad air). In 
1880, scientists discovered the real culprit of malaria is a parasite. Later they 
discovered that the parasite is transmitted from person to person through the bite of a 
female mosquito of the genus Anopheles, which requires blood to nurture her eggs. 
Anopheles gambiae is the most efficient, so most dreaded species.  
Malaria is a protozoan disease caused by unicellular parasites of the genus 
Plasmodium. Four representatives cause the disease in humans: 
• Plasmodium falciparum (causes malaria tropica) 
• Plasmodium vivax (malaria tertiana) 
• Plasmodium malariae (malaria quartana) 
• Plasmodium ovale (malaria tertiana) 
Most attention is directed toward P. falciparum. P. vivax and P. falciparum are the 
most common, but P. falciparum is responsible for the most lethal type of malaria 
infection. Plasmodium belongs to the Apicomplexa strain. This phylum is 
characterized by a cytoplasmic apical complex, that probably facilitates the 
penetration in the host cell. This unusual plastid-like organelle, also called apicoplast, 
is acquired through evolution by endosymbiosis of unicellular green algae and is 
related to the chloroplast of plants.1 Together with the Microspora, the Apicomplexa 
form the Sporozoa.  
 
 
 
                                            
1
 Jomaa, H., Wiesner, J., Sanderbrand, S., Altincicek, B., Weidemeyer, C., Hintz, M., Turbachova, I., 
Eberl, M., Zeidler, J., Lichtenthaler, H.K., Soldati, D. and Beck E. Science 1999, 285, 1573-1576.  
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1.1.2. LIFE CYCLE OF P. FALCIPARUM 
 
A complex life cycle with different stages (sporozoites, trophozoites,…) and 
different hosts is often seen in Sporozoa. Generally, Sporozoa are characterized by 
the presence of infective stages in their life cycle which are in a spore or transmitted 
via a vector. 
 
 
 
Figure 1.1: The life cycle of Plasmodium species: detailed description in the text. 
 
In the case of malaria, the sporozoites enter the human host when an infected 
Anopheles mosquito takes a blood meal (1) (Figure 1.1). First, the sporozoites 
migrate to the liver where they multiply asexually. Each sporozoite develops into a 
tissue schizont containing approximately 10000 to 30000 merozoites (2). This 
process is called the “pre-erythrocytic schizogoni”. These merozoites leave the liver 
cells and enter the blood stream where they penetrate red blood cells (3). During a 
48-hour period asexual reproduction occurs. Successively there are stages of rings 
(4), trophozoites (5) and blood schizonts (6). In this intra-erythrocytic stage, 
hemoglobin serves as nourishment for the parasite. In the segmentation stage (7) 
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(“erythrocytic schizogoni”), every schizont divides into 6-24 merozoites (8). By lysis of 
red blood cells the new merozoites enter the bloodstream to infect new red blood 
cells. A small portion of trophozoites undergoes differentiation into female (9) and 
male (10) gametocytes. The gametocytes are taken up by the mosquito when it bites 
an infected individual (11). Subsequently, the gametocytes develop in the mid-gut 
either in macrogametes () (12) or in flagellated microgametes () (13). The male 
and female gametes fuse and form a zygote (14), which penetrates the gut wall (16) 
as a motile ookinete (15). The ookinete undergoes a reductive division and some 
normal divisions towards an oocyst (17) under the external membrane of the 
mosquito midgut. This oocyst will produce thousands of sporozoites, which are 
released after rupture of the oocyst (18). The sporozoites migrate to the salivary 
glands (19) where they are appropriately placed to infect a new individual. In case of 
P. vivax and P. ovale some sporozoites turn into hypnozoites, a dormant form which 
can cause relapses months or years after the initial infection.  
 
1.1.3. SYMPTOMS AND DIAGNOSIS OF MALARIA 
 
Malaria is characterized by extreme exhaustion associated with paroxysms of 
high fever, sweating, shaking chills, headache, vomiting and anaemia. Malaria 
symptoms appear about 9 to 14 days after the infectious mosquito bite, although this 
time space varies with different plasmodium species. The clinical symptoms of 
malaria are exclusively caused by the erythrocytic parasite stages. With the release 
of the parasites from infected erythrocytes, cell debris responsible for the 
characteristic fever spike pattern enters the blood stream. P. falciparum produces 
specific proteins that are embedded in the cell membrane of infected erythrocytes, 
and as a consequence they stick to the walls of pre-venous capillaries.  
If left untreated, the infection can progress rapidly to become life-threatening. 
Malaria can kill by infecting and destroying red blood cells (anaemia) and by clogging 
the capillaries that carry blood to the brain (cerebral malaria) or other vital organs. A 
perilous but treatable complication of malaria is hypoglycaemia due to parasite 
metabolism in red blood cells.2 The diagnosis of malaria is set by a blood swab, 
                                            
2
 White, N. J., Miller, K. D., Marsh, K., Berry, C. D., Turner, R. C., Williamson, D. H., Brown, J. Lancet 
1987, 1, 708-711. 
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which is subjected to a Giemsa colouring. With this colouring agent the 
intraerythrocytic stages are visualised (Figure 1.2).3 
 
 
 
Figure 1.2: Arrows indicate the ring forms (4 in Figure 1.1) of P. falciparum in erythrocytes 
(Giemsa stain, 1000×) (Figure reprinted from “Web Atlas of Medical Parasitology”, 
http://atlas.or.kr). 
 
1.1.4. EPIDEMIOLOGY OF MALARIA 
 
Today approximately 40% of the world's population, mostly living in the world's 
poorest countries, are at risk of malaria. The disease was once more widespread, but 
it was successfully eliminated from many countries with temperate climates during 
the mid 20th century. Today malaria is found throughout the tropical and sub-tropical 
regions of the world and causes more than 300 million acute infections. Generally, it 
is accepted that every year between 700000 and 2.7 million people die of malaria, 
most of the victims being African children.4 It is estimated that every 40 seconds a 
child dies from malaria.5 However, it is very difficult to obtain exact figures. Malaria is 
endemic in parts of Asia, Africa, Central and South America, Oceania, and certain 
Caribbean islands. P. falciparum malaria is most common in Africa, south of the 
Sahara, accounting in large part for the extremely high mortality in this region. There 
are also worrying indications of the spread of P. falciparum malaria into new regions 
of the world and its reappearance in areas where it had been eliminated. In endemic 
areas in Africa, every year between 400 and 900 million cases of acute fever by 
children younger than 5 years, are reported, but how many are caused by malaria is 
                                            
3
 Giemsa, G. Centralblatt für Bakteriologie 1904, 32, 307-313. 
4
 Snow, R. W., Craig, M., Deichmann, U., Marsh, K. Bull. World Health Ogan. 1999, 77, 624-640. 
5
 Sachs, J. , Malaney, P. Nature 2002, 415, 680-685. 
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difficult to estimate. Making a correct diagnosis is indeed a huge problem in these 
countries. Furthermore, the cases of malaria that are reported are just the tip of the 
iceberg, or “the ears of the hippopotamus”, if we stay in the African context.6 The 
disease has sometimes an asymptomatic course. The extent of the impact of malaria 
induced anaemia and hypoglycaemia have only recently been appreciated. Also the 
economical damage, as a result of disease or chronicle brain damage, and children 
with a low birth weight, as a result of an infected mother, must be considered.  
 
1.1.5. MALARIA PROPHYLAXIS 
 
Apart from drug treatment of infected patients the disease is generally 
controlled via its vector, the Anopheles mosquito. First of all, it is very important to 
avoid contact with the Anopheles mosquito. The mosquitoes are controlled with 
insecticide spraying and as the mosquito only bites during the night, it is very 
important to sleep under mosquito nets in risk areas. 
Chemoprophylaxis is the second essential strategy in malaria prophylaxis. 
Drugs are preferably tissue schizonticides, because they kill early development 
stages of the parasite and prevent the invasion of erythrocytes. However since it is 
impossible to predict the infection before clinical symptoms begin, this mode of 
therapy is more theoretical than practical. Today, chemoprophylaxis of malaria relies 
essentially on four major strategies: chloroquine, proguanil in combination with 
chloroquine or atovaquone, mefloquine and doxycycline. These drugs are blood 
schizonticides and will be discussed in paragraph 1.1.7. The risk of an infection 
remains, since only the parasites in the blood are killed. A combination of 
measurements is necessary because up to date no antimalarial drug has proven 
efficient enough to completely prevent malaria. 
 
1.1.6. RESISTANCE 
 
The use of antimalarial drugs to treat fever is an important cause of resistance. 
Continual exposure of malarial parasite populations to different drugs may have 
                                            
6
 Breman, J. G. Am. J. Trop. Med. Hyg. 2001, 64, 1-11. 
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selected not only for resistance to individual drugs but also for genetic traits that favor 
initiation of resistance to novel unrelated antimalarials.7 Of all Plasmodium species P. 
falciparum has the highest ability to develop drug resistance.8 Chloroquine resistant 
forms of P. vivax are also reported, especially in Papua New Guinea and Indonesia. 
Among the other species no resistance has been documented yet.9  
The capacity to acquire resistance depends on several factors. First, the 
mechanism of action is very important. Drugs which target a single enzyme can loose 
their activity by a single mutation in a gene, the so-called monogenic resistance. 
Another important factor is the pharmacokinetic profile. A window of opportunity 
where drug levels fall between sub-therapeutic and sub-selective levels was 
proposed for certain antimalarial drugs.10 In this interval, parasites are not killed by 
the drug, although there is a certain selective pressure for resistance present 
whereby the resistant strains are selected. Even if all parasites of a first infection are 
killed, these low plasma concentrations exert a positive selective pressure 
afterwards. The selective pressure for resistance is related to a long elimination half-
life and this behaviour is especially important in areas where the disease is very 
endemic. The ideal pharmacokinetic profile of an antimalarial drug would comprise a 
rapid achievement of drug levels above the minimal inhibitory concentration (MIC), 
maintenance of such drug levels until all parasites from the initial infection have been 
killed and then the rapid fall of drug levels to sub-selective concentrations. 
Also, the efficiency of parasite kill (log-kill rate) is obviously a very important 
factor since only the surviving part of the parasite population has the opportunity to 
develop resistance. For this reason combination therapy is useful. 
Endemicity is also an important factor. Endemic malaria is correlated with the 
immunity of the population. The efficacy of chemotherapy will increase in places 
where the population demonstrates a potent immune response for malaria and, as a 
result, the opportunity for manifestion and spread of resistant strains will decrease. 
The challenges in antimalarial drug discovery remain attractive by the rising 
resistance issue. 
                                            
7
 Rathod, P. K., McErlean, T., Lee, P.–C. Proc. Natl. Acad. Sci. USA 1997, 94, 9389-9393. 
8
 Winstanley, P. A., Ward, S. A., Snow, R. W. Microbes Infect. 2002, 4, 157-164. 
9
 Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H., Meshnik, S. R. The Lancet Infectuous 
Diseases 2002, 2, 209-218. 
10
 Watkins, W. M., Mosobo, M. Trans. Roy. Soc. Trop. Med. Hyg. 1993, 87, 75-78. 
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1.1.7. DRUGS AGAINST MALARIA  
 
Malaria was the first disease to be treated with a pure substance (quinine) and 
the first to be treated with a synthetic drug (methylene blue). Antimalarial agents can 
be classified in many ways. They can be ranked by the stages of the life cycle which 
are targeted by the drug. They are divided in: blood schizonticides, tissue 
schizonticides, hypnozoiticides and gametocytocides. Another possible classification 
is based on the mechanism of action. In this concise overview established 
antimalarial drugs as well as agents under developments are discussed. Figure 1.3 
shows an erythrocyte infected with a trophozoite. It gives an overview of the targets 
and the corresponding established and new antimalarial drugs. 
 
 
 
Figure 1.3: Schematic representation of an intra-erythrocytic P. falciparum trophozoite, 
highlighting key parasite intracellular compartments and the site of action of some of the 
major classes of antimalarial drugs. Efforts are ongoing to develop new drugs against an 
even wider range of subcellular compartments and parasite targets. (Figure reprinted from 
Nature Reviews Drug Discovery 2004, 3, 509-520) 
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1.1.7.1. QUININE AND RELATED DERIVATIVES 
1.1.7.1.1 4-Aminoquinolines 
 
Chloroquine (1.1) (Figure 1.4), a synthetic 4-aminoquinoline, can be 
considered as one of the most important antimalarials ever. The inhibition of the so-
called hem polymerization is generally accepted as mechanism of action. The 
trophozoit digests small peptides from hemoglobin. As a result, hem is metabolised to 
ferriprotoporphyrine IX (FPIX) (also called hematin),11 which is toxic for the parasite. 
Therefore the parasite converts FPIX into hemozoin which accumulates in the food 
vacuole (Figure 1.3). This can be microscopically seen as the malaria pigment (Red 
dots in Figure 1.2). The inhibition of hem polymerization, by complexation of 4-
aminoquinolines with FPIX, gives rise to harmful hem metabolites which accumulate 
and destroy the parasite’s membrane and thereby comprise cell viability.12 Hem is 
also spontaneously oxidized, and some moves to the cytoplasm where it is destroyed 
by reduced glutathione. The inhibition of this proces is considered as an extra 
mechanism.  
The activity of 4-aminoquinolines depends on their basic amino group, which 
in the acidic food vacuole becomes protonated thereby allowing these derivatives to 
accumulate. This mechanism is also known as the weak base effect.13 The main 
function is however the inhibition of hem polymerization and the oxidative and 
glutathione-dependent hem degradation. But this remains still a matter of 
debate.14,15,16 Chloroquine can also be used as a prophylactic drug.  
As a result of addition to table salt, in an attempt toward a global eradication of 
malaria, the first cases of chloroquine resistance appeared at the end of the 1950s. 
Nevertheless, it has taken a long time before the first resistance against chloroquine 
was reported.17 Chloroquine resistance is linked to multiple factors, including 
                                            
11
 Bray, P. G., Ward, S. A., O’Neill, P. M. Curr. Top. Microbiol. Immunol. 2005, 295, 3-38.  
12
 Slater, A. F. G. Pharmacol. Ther. 1993, 57, 203-235. 
13
 Ginsburg, H., Nissani, E., Krugliak, M. Biochem. Pharmacol. 1989, 38, 2645-2654. 
14
 Tilley, L., Loria, P., Foley, M. The History of Antimalarial Drugs, in: Antimalarial Chemotherapy: 
Mechanisms of Action, Resistance, and New Directions in Drug Discovery (Ed.: P. J. Rosenthal), 
Humana Press Inc.,Totowa, 87-121. 
15
 Egan, T. J. Targets 2003 3, 115-124. 
16
 O´Neill, P. M., Ward, S. A., Berry, N. G., Jeyadevan, J. P., Biagini, G. A., Asadollaly, E., Park, B. K., 
Bray, P. G. Curr. Top. Med. Chem. 2006, 6, 479-507. 
17
 Winstanley, P. A., Ward, S. A., Snow, R. W. Microbes Infect. 2002, 4, 157-164. 
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changes in transport proteins.18 The substitution of lysine for threonine in codon 76 of 
the pfcrt gen, which codes for a vacuolar membrane transporter protein,19 is strongly 
associated with chloroquine resistance.20 Accumulation of chloroquine in the food 
vacuole is more pronounced in chloroquine-sensitive strains, then in chloroquine-
resistant strains. This observation shows that there is a specific 4-aminoquinoline 
saturable binding site, which is correlated with the concentration of hematin (FPIX). 
Saturable chloroquine uptake is due to the binding of chloroquine to hematin rather 
than active uptake: using Ro 40-4388, a potent plasmepsine I inhibitor of hemoglobin 
digestion, a reduction in the number of chloroquine binding sites was demonstrated.21 
The link with the pfcrt gene is not yet elucidated. The consequences of the codon 76 
mutation can be neutralized by the use of chloroquine resistance reversers, such as 
verapamil by restoring the positive charge of lysine. The pfmdr1 gene codes for P-
glycoprotein homologue 1, another membrane transporter. Polymorphism in the 
pfmdr1 gene, for instance an aspartic acid to tyrosine point mutation in codon 86, has 
been associated with chloroquine resistance in some countries, but not in others, so 
the evidence has not been convincing. Mutations of this gene would also be 
responsible for mefloquine (vide infra) and quinine resistance. Moreover, chloroquine 
resistant parasites are less sensitive to quinine (vide infra).22,23  
Chloroquine resistance is also linked to a higher content of reduced 
glutathione in the parasite;24 therefore, new combination drugs have been designed 
(vide infra). In spite of this, chloroquine still represents the most frequently used 
antimalarial drug owing to its high tolerance and low production costs. However, as a 
result of the worldwide spread of severe resistance to chloroquine more than ten 
African countries have switched their first-line treatment to sulfadoxine-
pyrimethamine which useful lifespan is also more or less terminated (see 1.1.7.3.). 
As a prophylactic agent, chloroquine can only be administered as monotherapy in 
areas where no resistance has been reported. 
                                            
18
 Mutabingwa, T., Nzila, A., Mberu, E., Nduati, E., Winstanley, P., Hills, E., Watkins, W. Lancet 2001, 
358, 1218-1223.  
19
 Wellems, T. E., Walker-Jonah, A., Pantom, L. J. Proc. Natl. Acad. Sci. USA 1991, 88, 3382-3386. 
20
 Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H., Meshnik, S. R. The Lancet Infectious 
Diseases 2002, 2, 209-218. 
21
 Bray, P. G., Mungthin, M., Ridley, R. G., Ward, S. A. Mol. Pharmacol. 1998, 54, 170-179. 
22
 Zalis, M. G., Pang, L., Silveira, M. S., Milhous, W. K., Wirth, D. F. Am. J. Trop. Med. Hyg. 1998, 58, 
630-637. 
23
 Le Bras, J., Durand, R. Fundam. Clin. Pharmacol. 2003, 17, 147-153. 
24
 Atamna, H., Ginsburg, H. J. Biol. Chem. 1995, 270, 24876-24883. 
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Due to some reported cases of agranulocytosis in the mid 1980s, the use of 
the related amodiaquine (1.2) has been limited. There is however a renewed interest 
in using this drug, because of its efficacy, especially against low-level chloroquine-
resistant P. falciparum.25 Amodiaquine is among the antimalarial drugs currently 
recommended by the WHO.26  
Pyronaridine (1.3) is structurally related to chloroquine and amodiaquine and 
is a very active 4-aminoquinoline derivative. However, it is registered only on the 
Chinese market, due to failure to meet international regulatory standards.27 Most 
likely, it also acts as an inhibitor of hem polymerization.  
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Figure 1.4: Structures of quinine and derivatives. 
                                            
25
 Ridley, R. G. Nature 2002, 415, 686-693. 
26
 http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf 
27
 Olliaro, P. L., Milhous, W. K. in Antimalarial Chemotherapy (Ed.: Rosenthal, P. J.), Humana press, 
Totowa, NJ, 2001, 219-232. 
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1.1.7.1.2 Quinine and arylaminoalcohols  
 
Quinine (1.4) (Figure 1.4), the principal alkaloid of the Chinchona bark, has 
already been used in the treatment of malaria and fever for 350 years. Since the 
nineteen thirties, synthetic drugs derived from quinine have been developed, but 
quinine still plays an important role in the treatment of multiresistant malaria.  
The mechanism of action of quinine and other arylaminoalcohols is probably 
different from the mechanism of 4-aminoquinolines. Recently, it has been proposed 
that arylaminoalcohols prevent the fusion of haemoglobin shuttling vesicles to the 
food vacuole.28 Quinine is also toxic against schizonts and against gametocytes of P. 
malariae and P. vivax. In most areas quinine is still the only drug available for 
intravenous treatment of severe malaria. Its diastereomer quinidine is 2-3 fold more 
active, but cannot be used as antimalarial drug because of cardial toxicity.29 
Mefloquine (1.5), an arylaminoalcohol, is the reference drug for treating 
chloroquine-resistant malaria. Unfortunately, it suffers from a plethora of side effects 
(headache, palpitations, vertigo, anxiety, hallucinations, insomnia) and cannot be 
administered in the first trimester of pregnancy. Mefloquine can be used as a 
prophylactic drug in chloroquine-resistant areas, but is expensive and the 
neuropsychiatric side effects are very annoying. 
Halofantrine (1.6) is highly effective. It is toxic for schizonts and gametocytes, 
but its use is strongly restricted by its potential to induce heart arrhythmias.30 The N-
desbutyl analogue appeared less cardiotoxic than halofantrine.31 
Lumefantrine (1.7) is structurally similar to halofantrine, but induces fewer 
cardiotoxic side effects.32 Although its antimalarial activity is weaker than 
halofantrine, it is administered in a combination with arthemether (vide infra). In vitro 
the N-desbutyl derivative is fourfold more active than the parent drug.33,34 
                                            
28
 Fitch, C. D. Life. Sci., 2004, 74, 1957-1972. 
29
 Karle, J. M., Karle, I. L., Gerena, L., Milhous, W. K. Antimicrob. Agents Chemother. 1992, 36, 1538-
1544. 
30
 Newton, P., White, N. Annu. Rev. Med. 1999, 50, 179-192. 
31
 Wesche, D. L., Schuster, B. G., Wang, B. X., Woosley, R. L. Clin. Pharmacol. Ther. 2000, 67, 521-
529. 
32
 van Agtmael, M., Bouchaud, O., Malvy, D., Delmont, J., Danis, M., Barette, S., Gras, C., Bernard, J., 
Touze, J.E., Gathmann, I., Mull, R. Int. J. Antimicrob. Agents 1999, 12, 159-169. 
33
 Basco, L. K., Peytavin, G., Gimenez, F., Genissel, B., Farinotti, R., Le Bras, J. Trop. Med. Parasitol. 
1994, 45, 45-46. 
34
 Noedl, H., Allmendinger, T., Prajakwong, S., Wernsdorfer, G., Wernsdorfer, W. H. Antimicrob. 
Agents Chemother. 2001, 45, 2106-2109. 
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A main factor in the resistance against mefloquine, halofantrine and 
lumefantrine is the increase in copy numbers of the pfmdr1 gene coding for a 
membrane transporter (PfMDR1) which transports arylaminoalcohols into the food 
vacuole.35,36,37,38,39 
1.1.7.1.3 8-Aminoquinolines 
 
Primaquine (1.8, Figure 1.4) is an 8-aminoquinoline that has been used since 
the 1940s for the eradication of liver stages.40 Against blood stages, however, 
primaquine is inactive at pharmacologically achieveble concentrations. Toxicological 
concerns have led to restrictions in the use of primaquine. The major disadvantage of 
the 8-aminoquinolines is the induction of hemolytic anaemia in patients with glucose 
6-phosphate dehydrogenase (G6PD) deficiency as a potentially life-threatening 
adverse effect. The incidence of this genetic anomaly is particularly high in areas 
where malaria is endemic. 
Tafenoquine (1.9) is a derivative of primaquine. This 8-aminoquinoline is less 
toxic than primaquine, has a longer plasma half-life and is active against blood and 
liver stages. The mode of action against blood stages is probably due to the inhibition 
of hem polymerization. The activity against liver stages is probably related to toxic 
metabolites which affect mitochondrial processes.41 Nevertheless, the real 
mechanism of action of 8-aminoquinolines stays unclear. 
 
1.1.7.1.4 New chloroquine analogues and hem polymerization inhibitors 
 
The extensive use of chloroquine led to the existence of resistant strains. 
However, the research for new chloroquine derivatives is still actual, since the 
emergence of chloroquine-resistant strains is rare.42 This is probably because the 
                                            
35
 White, N. J. J. Clin. Invest. 2004, 113, 1084-1092. 
36
 Duraisingh, M. T., Cowman, A. F. Acta Trop. 2005, 94, 181-190. 
37
 Uhlemann, A.−C., Ramharter, M., Lell, B., Kremsner, P. G., Krishna, S. J. Infect. Dis. 2005, 192, 
1830-1835. 
38
 Uhlemann, A.−C., Krishna, S. CTMI 2005, 295, 39-53. 
39
 Woodrow, C. J., Krishna, S. Cell. Mol. Life. Sci. 2006, 63, 1586-1596. 
40
 Shanks, G. D., Kain, K. C., Keystone, J. S. Clin. Infect. Dis. 2001, 33, 381-385. 
41
 Brueckner, R. P., Ohrt, C., Braid, J. K., Milhous, W. in Antimalarial Chemotherapy (Ed.: Rosenthal, 
P. J.), Humana press, Totowa, NJ, 2001, 123-125. 
42
 Wellems, T. E., Plowe, C. V. J. Infect. Dis. 2001, 184, 770-776. 
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hem polymerization seems not to depend on any enzymes and as a consequence a 
simple mutation cannot cause resistance.43 
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Figure 1.5: New chloroquine derivatives. 
 
Incorporation of an aromatic group in the side chain of chloroquine, as present 
in amodiaquine (1.3) and pyronaridine (1.4), resulted in analogues which overcome 
chloroquine resistance. Naphthoquine (1.10), ferroquine (1.11) and isoquine (1.12) 
are examples of newer chloroquine analogues (Figure 1.5). Shortening of the 
diamino alkyl side chain (e.g., AQ13, 1.13) and dimerisation (e.g., piperaquine, 1.14) 
are two other reported options to overcome chloroquine resistance.11,16,44,45,46 
 
                                            
43
 Sanchez, C. P., Lanzer, M. Curr. Opin. Infect. Dis. 2000, 13, 653-658. 
44
 Stocks, P. A., Raynes, K. J., Ward, S. A. The History of Antimalarial Drugs, in: Antimalarial 
Chemotherapy: Mechanisms of Action, Resistance, and NewDirections in Drug Discovery (Ed.: P. J. 
Rosenthal), Humana Press Inc.,Totowa, 235-253. 
45
 O´Neill, P. M., Bray, P. G., Hawley, S. R., Ward, S. A., Park, B. K. Pharmacol. Ther., 1998, 77, 29-
58. 
46
 Foley, M., Tilley, L. Pharmacol. Ther., 1998, 78, 55-87. 
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Figure 1.6: Structures of new hem polymerization inhibitors. 
 
WR 243251 (1.15, Figure 1.6) is a derivative of mepacrine. Studies 
demonstrated that 1.15 was active against a chloroquine-resistant P. falciparum 
strain in monkeys. It also inhibits the development of P. vivax sporozoites in 
mosquitoes.47,48 The mechanism of action is probably dual: the inhibition of the hem 
polymerization and the inhibition of the parasitic cellular respiration.49,50 
                                            
47
 Berman, J., Brown, L., Miller, R., Andersen, S. L., McGreevy, P., Schuster, B. G., Ellis, W., Ager, A., 
Rossan, R. Antimicrob. Agents Chemother. 1994, 38, 1753-1756. 
48
 Coleman, R. E., Polsa, N., Eikarat, N., Kollars Jr., T. M., Sattabongkot, J. Am. J. Trop. Med. Hyg. 
2001, 65, 214-218. 
49
 Dorn, A., Scovill, J. P., Ellis, W. Y., Matile, H., Ridley, R. G., Vennerstrom, J. L. Am. J. Trop. Med. 
Hyg. 2001, 65, 19-20. 
50
 Suswam, E., Kyle, D., Lang-Unnasch, N. Exp. Parasitol. 2001, 98, 180-187. 
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Compound 1.16 is an example of a conjugate consisting of two active 
molecules linked by an ester linkage, which can be cleaved by esterases to release 
the active species, i.e. a P. falciparum glutathione reductase inhibitor and a 4-
aminoquinoline.51 Several atypical compounds were developed, amongst which 
many synthetic derivatives of cryptolepine. 2,7-Dibromocryptolepine (1.17) emerged 
as the most active compound. Also here, this activity mostly relies on the inhibition of 
the hem polymerization.52 
Several atypical compounds, such as 1.18 and 1.19, were discovered as hem 
polymerization inhibitors using extensive screening by in vitro microassays.53 Another 
class of novel hem polymerization inhibitors, such as compound 1.20, was originally 
designed as protease inhibitors.54,55 Their potential is questioned because of cross-
resistance with choroquine. 
 
1.1.7.2. ARTEMISININ DERIVATIVES 
1.1.7.2.1 Artemisinin and first generation semi-synthetic artemisinins 
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Figure 1.7: Artemisinin and derivatives. 
 
                                            
51
 Davioud-Charvet, E., Delarue, S., Biot, C., Schwobel, B., Boehme, C. C., Mussigbrodt, A., Maes, L., 
Sergheraert, C., Grellier, P., Schirmer, R. H., Becker, K. J. Med. Chem. 2001, 44, 4268-4276.  
52
 Wright, C. W., Addae-Kyereme, J., Breen, A. G., Brown, J. E., Cox, M. F., Croft, S. L., Gokcek, Y., 
Kendrick, H., Phillips, R. M., Pollet, P. L. J. Med. Chem. 2001, 44, 3187-3194. 
53
 Kurosawa, Y., Dorn, A., Kitsuyi-Shirane, M., Shimada, H., Satoh, T., Matile, H., Hofheinz, W., 
Masciadri, R., Kansy, M., Ridley, R. G. Antimicrob. Agents Chemother. 2000, 44, 2638-2644. 
54
 Brinner, K. M., Kim, J. M., Habashita, H., Gluzman, I. Y., Goldberg, D. E., Ellman, J. A. Bioorg. Med. 
Chem. 2002, 10, 3649-3661. 
55
 Choi, C. Y. H., Schneider, E. L., Kim, J. M., Gluzman, I. Y., Goldberg, D. E., Ellman, J. A., Marletta, 
M. A. Chem. Biol. 2002, 9, 881-889. 
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The plant Artemisia annua, with the sesquiterpene lactone artemisinin (1.21) 
as an active ingredient has been used for at least 2000 years in traditional Chinese 
medicine and since 1596 for the treatment of fever. Semi-synthetic artemisinin 
derivatives artemether (1.23), arteether (1.24) and artesunate (1.25) have been 
increasingly used for about 20 years, and all are prodrugs which are metabolized to 
the main active compound dihydroartemisinin (1.22) (Figure 1.7). Dihydroartemisinin 
is a mixture of - and -epimers whose ratio depends on both the reaction conditions 
and the choice of solvents.56 Artesunate is the hemisuccinate ester of 
dihydroartemisinin and exists only as -epimer. It is prepared by treatment of 
dihydroartemisinin with succinic acid in the presence of DMAP.57 Artemether and 
arteether are obtained by methylation or ethylation of dihydroartemisinin with the 
formation of the two epimers in a ratio of : 22:78.56 
The artemisinin derivatives act faster than any other antimalarial drug and are 
the most active antimalarial drugs known today. As a result of the short plasma half-
life, the artemisinins are increasingly combined with other antimalarial drugs with 
longer plasma half-lives, such as mefloquine. These combinations decrease the risk 
to induce resistance and since 2001 the WHO condemns the use of artemisinins in 
monotherapy. Other artemisin-based combination treatments (ACT’s) are artesunate 
with amodiaquine, artemether with lumefantrine and dihydroartemisinin in 
combination with piperaquine.  
The artemisinins are active against gametocytes. The biological activity 
depends on the cleavage of the crucial peroxide bond after contact with Fe2+-hem 
inside the food vacuole, thus generating free radicals that can alkylate the hem 
molecule.58 By this mechanism, the detoxification of free hem may be inhibited.59 
Alkylation of essential parasite proteins may contribute to the antimalarial activity.60 
The alkylation properties of peroxides could imply a limitation in the antimalarial use. 
Not surprisingly, these compounds also attract attention as anticancer drugs. 
Another recent theory is the activation of artemisinin by Fe2+ in the cytoplasm. 
This process would take place close to an ATP-dependent calcium pump (PfATP6) 
                                            
56
 Haynes, R. K., Chan, H.–W., Cheung, M.–K., Lam, W.–L., Soo, M.–K., Tsang, H.–W., Voerste, A., 
Williams, I. D. Eur. J. Org. Chem. 2002, 1, 113-132. 
57
 Utzinger, J., Shuhua, X., Keiser, J., Minggan, C., Jiang, Z., Tanner, M. Curr. Med. Chem. 2001, 8, 
1841-1859. 
58
 Olliaro, P. L., Haynes, R. K., Meunier, B., Yuthavong, Y. Trends Parasitol. 2001, 17, 122-126. 
59
 Cazelles, J., Robert, A., Meunier, B. J. Org. Chem. 2002, 67, 609-619. 
60
 Bisutthibhan, J., Pan, X. Q., Hossler, P. A., Walker, D. J., Yowell, C. A., Carlton, J., Dame, J. B., 
Meshnick, S. R. J. Biol. Chem. 1998, 273, 16192-16198.  
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located at the endoplasmatic reticulum. This pump would be inhibited by irreversible 
binding of the activated artemisinin, restraining parasite growth.61 How the inhibition 
of PfATP6 leads to the rapid killing of the parasite is unknown. There have been no 
clinical reports on artemisinin resistance. Similarly, as discussed for the 4-
aminoquinolines, this might be explained by the fact that no enzyme is involved in the 
major mode of action. However, it must be mentioned that it has been possible to 
create a PfATP6 resistant against artemisinins by the exchange of just one amino 
acid (Leu263Glu).62 
A combination of lumefantrine (1.7) and artemether (1.23) has recently been 
approved as co-artemether or Riamet®.63 Both compounds inhibit hem detoxification 
in the food vacuole resulting in a synergistic effect.64 
Since a synergistic effect of pyronaridine with artemisinin has been 
demonstrated in vitro,65 research of a combination therapy involving pyronaridine-
artesunate is in progress.66 
 
1.1.7.2.2 Second generation semisynthetic artemisinines and synthetic 
endoperoxides 
 
Although artemisinine itself and several semi-synthetic derivatives are in use 
today, concerns exist about their high cost of production, low oral activity and the 
duration of administration these agents require. A major drawback of the currently 
available semisynthetic artemisinin derivatives is that they are prone to hydrolysis, 
resulting in a short biological half-life and the generation of the potentially neurotoxic 
dihydroartemisinin (1.22). The search for new synthetic peroxide drug candidates is 
in progress.67 
 
                                            
61
 Eckstein-Ludwig, U., Webb, R. J., Van Goethem, I. D. A., East, J. M., Lee, A. G., Klimura, M., 
O’Neill, P. M., Bray, P. G., Ward, S. A., Krishna, S. Nature 2003, 424, 957-961. 
62
 Uhlemann, A.−C., Cameron, A., Eckstein-Ludwig, U., Fischbarg, J., Iserovich, P., Zuniga, F. A., 
East, M., Lee, A., Brady, L., Haynes, R. K., Krishna, S. Nature Struct. Mol. Biol. 2005, 12, 628-629. 
63
 Omari, A. A., Preston, C., Garner, P. Cochrane Database Syst. Rev. 2002, 3, CD003125. 
64
 Hassan Alin, M., Bjorkman, A., Wernsdorfer, W. H. Am. J. Trop. Med. Hyg. 1999, 61, 439-445. 
65
 Gupta, S., Thapar, M. M., Mariga, S. T., Wernsdorfer, W. H., Bjorkman, A. Exp. Parasitol. 2002, 
100, 28-35. 
66
 MMV-Medicines for Malaria Venture, Annual report 2000. 
67
 Vennerstrom, J. L., Arbe-Barnes, S., Brun, R., Charman, S. A., Chiu, F. C. K., Chollet, J., Dong, Y., 
Dorn, A., Hunziker, D., Matile, H., McIntosh, K., Padmanilayam, M., Santo Tomas, J., Scheurer, C., 
Scorneaux, B., Tang, Y., Urwyler, H., Wittlin S., Charman W. N. Nature 2004, 430, 900-904. 
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Figure 1.8: Structures of new artemisinin derivatives. 
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To remedy the major drawbacks of artemisinins, considerable effort has gone 
into the design of more stable derivatives with improved bioavailability. Most 
variations address position 10 where the exocyclic oxygen has been substituted for 
several substituents. Alkyl, aryl and heteroaryl residues have been placed at this 
position (Figure 1.8). Derivatives 1.2668 and 1.2769 are highly water soluble and 
compound 1.26 proved more stable than artesunate. Both were developed for 
intravenous administration. The p-trifluoromethylphenoxy derivative 1.28 proved to be 
superior to artesunate after oral application in a malaria-infected mouse model.70 
Additional robust and orally active derivatives such as 1.29 were obtained by non-
acetal linkage of the side chain to the artemisinin core.71 It was further rationalized 
that a piperazine ring in the side chain, such as in compound 1.30, may lead to 
enrichment of the drug inside the food vacuole mediated by the weak base effect.72 
Furthermore, modifications have also been applied to other positions. Several 
reviews cover this issue in depth.73 Also, artemisinin-derived trioxane dimers, such as 
compound 1.31, containing various linkers were synthesized.74,75 Simplification of the 
artemisinin core led to synthetic 3-aryl trioxanes, such as 1.32.76 Upon oral 
application in a murine model, 1.32 was twice as active as artemisinin.77  
                                            
68
 Li, Q. G., Peggins, J. O. , Lin, A. J., Masonic, K. J., Trotman, K. M., Brewer, T. G. Trans. R. Soc. 
Trop. Med. Hyg. 1998, 92, 332-340.  
69
 Li, Y., Zhu, Y. M., Jiang, H. J., Pan, J. P., Wu, G. S., Wu, J. M., Shi, Y. L., Yang, J. D., Wu, B. A. J. 
Med. Chem. 2000, 43, 1635-1640.  
70
 O'Neill, P. M., Miller, A., Bishop, L. P., Hindley, S., Maggs, J. L., Ward, S. A., Roberts, S. M., 
Scheinmann, F., Stachulski, A. V., Posner, G. H., Park, B. K. J. Med. Chem. 2001, 44, 58-68.  
71
 Posner, G. H., Parker, M. H., Northrop, J., Elias, J. S., Ploypradith, P., Xie, S., Shapiro, T. A. J. Med. 
Chem. 1999, 42, 300-304. 
72
 Hindley, S., Ward, S. A., Storr, R. C., Searle, N. L., Bray, P. G., Park, B. K., Davies, J., O'Neill, P. M. 
J. Med. Chem. 2002, 45, 1052-1063.  
73
 (a) O´Neill, P. M. Expert Opin. Investig. Drugs 2005, 14, 1117-1128. (b) Posner, G. H., Krasavin, M., 
McCutchen, M., Ploypradith, P., Maxwell, J. P., Elias, J. S., Parker, M. H. The History of Antimalarial 
Drugs, in: Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug 
Discovery (Ed.: P. J. Rosenthal), Humana Press Inc., Totowa, 255-263. (c) Ploypradith, P. Acta Trop. 
2004, 89, 329-342. (d) Borstnik, K., Paik, I., Shapiro, T. A., Posner, G. H. Int. J. Parasitol. 2002, 32, 
1661-1667. (e) Vroman, J. A., Alvim-Gaston, M., Avery, M. A. Curr. Pharm. Des. 1999, 5, 101-138. (f) 
O´Neill, P. M., Posner, G. H. J. Med. Chem. 2004, 47, 2945-2964.  
74
 Posner, G. H., Ploypradith, P., Parker, M. H., O'Dowd, H., Woo, S. H., Northrop, J., Krasavin, M., 
Dolan, P., Kensler, T. W., Xie, S., Shapiro, T. A. J. Med. Chem. 1999, 42, 4275-4280.  
75
 Posner, G. H., Northrop, J., Paik, I. H., Borstnik, K., Dolan, P., Kensler, T. W., Xie, S., Shapiro, T. A. 
Bioorg. Med. Chem. 2002, 10, 227-232.  
76
 Posner, G. H., Jeon, H. B., Parker, M. H., Krasavin, M., Paik, I. H., Shapiro, T. A. J. Med. Chem. 
2001, 44, 3054-3058.  
77
 Posner, G. H., Cumming, J. N., Woo, S. H., Ploypradith, P., Xie, S., Shapiro, T. A. J. Med. Chem. 
1998, 41, 940-951. 
 - 20 -
Based on the hypothesis that the mechanism of the artemisinins depends on 
the generation of free radicals by cleavage of the peroxide function, it can be 
assumed that other endoperoxides not related to the artemisinin structure may also 
exhibit antimalarial activity. Consequently, yingzhaosu A (1.33), which similarly to 
artemisinin was isolated from a traditional Chinese medicinal plant (Artabotrys 
uncinatus), and the synthetic derivative arteflene (1.34) were active against malaria.78 
After successful preclinical trials, arteflene (1.34) has already been tested on patients 
with uncomplicated malaria in Africa.79 However, its moderate clinical efficacy and 
difficult synthesis prevented its further development.80 The development of 
antimalarial endoperoxides has recently been comprehensively reviewed.81 
More readily accessible are 1,2,4,5-tetraoxanes such as compound 1.35, 
which differ significantly from artemisinin.82 After oral application to mice infected with 
P. berghei, compound 1.35 was slightly more active than artemisinin, but less active 
than arteether. Furthermore, different oxazines were synthesized as potential 
antimalarial drugs. The standard dissociation energy of the N−O bond is similar to 
that of the O−O bond, the N−O bond is thus prone to undergo homolytic cleavage, 
resulting in the generation of radicals. As expected, some of these compounds 
exhibited significant in vitro activity against P. falciparum. By choosing a suitable 
substitution pattern, a relatively low cytotoxicity was achieved.83 The growth of P. 
falciparum was inhibited by compound 1.36 (IC50 = 3.2 M). 
DU-1102 (1.37) is the most active example of a class of hybrids between new 
artemisinin-like peroxides and a 4-aminoquinoline.84 These so-called trioxaquines 
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aim to combine both pharmacological features. It is expected that the 4-
aminoquinoline moiety facilitates the transport to the food vacuole, whereas the 
trioxane is activated by free FeII-hem liberated during the digestion of hemoglobin. 
Compound 1.39 (Figure 1.8) is another example of such a hybrid compound. 
Likewise, chimera of mefloquine and a 10-trifluoromethylartemisinine have been 
prepared. 
The 1,2,4-trioxolane OZ-277 (1.38, figure 1.8) is the first synthetic antimalarial 
endoperoxide which recently entered clinical trials. With the sterically hindrance of an 
adamantane residue on one and a cyclohexane group on the other side, the critical 
balance between stability and reactivity could be obtained.67,85 Addition of an 
aminoacyl residue further provided the correct polarity and solubility resulting in the 
desired pharmacological properties. 
 
1.1.7.3. ANTIFOLATES 
 
Tetrahydrofolic acid has a key role in the biosynthesis of thymine, purine 
nucleotides and several amino acids (Met, Gly, Ser, Glu, His). In contrast to humans, 
Plasmodia spp can synthesize dihydrofolic acid from simple precursors. 
Dihydropteroate synthase (DHPS) which is absent in humans and dihydrofolate 
reductase (DHFR) which is sufficiently different from the human enzyme are two 
important target enzymes in the treatment of malaria (Figure 1.9). 
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Figure 1.9: Simplified folate pathway showing the targets of the antifolates. 
 
The use of antifolates against malaria86,87,88,89,90 and the potential of other 
enzymes of the folate biosynthesis pathway as drug targets have been reviewed.91,92  
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1.1.7.3.1 Established antifolates 
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Figure 1.10: Structures of major antifolate drugs. 
 
Pyrimethamine (1.40, Figure 1.10) inhibits DHFR. It is mostly combined with 
the DHPS inhibitor sulfadoxine (1.41) to obtain a synergistic effect. The approval of 
this combination, known as SP, has been retracted in Belgium, because of rapid 
resistance development and possible side effects. Chloroquine and SP were the two 
most widely used antimalarial drugs. At an accelerating rate both are failing to 
produce the desired effect in most malaria endemic regions.93  
Another important antifolate drug is the prodrug proguanil (1.42). Proguanil 
yields the active metabolite cycloguanil through oxidative ring closure. Cycloguanil 
(1.43) is structurally very similar to pyrimethamine and represents the active form that 
inhibits DHFR. Proguanil is usually well tolerated and is commonly applied in 
combination with chloroquine.94 
Genetic polymorphism by antifolate resistant strains is well-documented. 
Resistance against DHFR inhibitors developed through consecutive accumulation of 
mutations in the dhfr gene. A key mutation to resistance is the replacement of serine 
108 by asparagine (Ser108Asn), which reduces the sensitivity of PfDHFR towards 
pyrimethamine and cycloguanil 10-fold. Also a triple (Ser108Asn, Asn51Ile and 
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Cys59Arg) and a quadruple mutant are currently seen. In parallel to the situation with 
DHFR the selection of strains which have accumulated several mutations in the dhps 
gene have led to considerable resistance.95 Although no crystal structure of PfDHPS 
is available, homology modelling based on the crystal structure of DHPSases of 
different species have provided some insight in how mutations in the dhps gene 
affect sulfonamide binding.96,97,98,99 The Ala437Gly and Lys540Glu mutations in the 
dhps gene correlate strongly with resistance. In both enzymes the mutations cause a 
reduced affinity of the drug for the enzyme.  
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Figure 1.11: Structures of the combination Lap-Dap®. 
 
Chlorproguanil-dapsone, known as Lap-Dap®, is a combination which has 
been recently introduced on the market to replace sulfadoxine-pyrimethamine (Figure 
1.11).100 Chlorproguanil (1.44) is converted by cytochrome P450 into 
chlorcycloguanil, acting as a DHFR inhibitor. Dapsone (1.45) is a drug used in the 
treatment of leprosy. Dapsone acts similarly to sulfadoxine as an inhibitor of DHPS. 
Studies in Africa were very promising, but in South East Asia the combination 
seemed not to be very efficient, probably due to mutation in the dhfr gene.101 The 
plasma half-lifes of both drugs are low, thereby lowering the chance of resistance, but 
to decrease the risk of resistance even more a combination of Lap-Dap® with 
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artesunate (CDA) is under development.100 In a phase II clinical study CDA showed 
significant shorter parasite clearance time than chlorproguanil/dapsone alone.102 
Lap-Dap® is active against strains with the three mutations (Ser108Asn, 
Asn51Ile and Cys59Arg) in the dhfr gene, but concerns have been expressed that 
the quadruple mutation may be spread when Lap-Dap® is extensively used.103 Cross 
resistance between several antifolates is also described.  
 
1.1.7.3.2 Novel DHFR inhibitors and other antifolates under development 
 
JPC-2056 (1.46) is a prodrug, which is converted via oxidative ring closure to 
the corresponding dihydrotriazine. It is a promising candidate for pre-clinical 
development. The dioxypropylene linker allows the adoption of a high affinity 
conformation while avoiding any repulsive interaction with the Asn108 side chain of 
DHFR. Cycloguanil derivative (1.47) has only one substituent at the 6-position. This 
modification has been designed to circumvent another mutation (Ala16Val) leading to 
resistance. Through the move of the chloro substituent to the meta position the 
critical repulsing interaction by the Asn108 side chain can be avoided.104 The m-
bromo derivative (1.48) of pyrimethamine inhibits the quadruple mutant DHFR with a 
Ki of 5.1 nM. 
Trimethoprim (1.49) which is widely used in combination with 
sulfamethoxazole for the treatment of bacterial infections is less active against 
PfDHFR than pyrimethamine or cycloguanil (Ki against wild type PfDHFR 10.3 nM). 
Through replacement of one of the methoxy groups by a benzyloxy group as in 1.50 
activity against the wild type DHFR could be markedly improved (Ki = 0.4 nM). Other 
structural analogues of known DHFR inhibitors, such as diaminoquinazolines (1.51), 
are reported. 
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Compound 1.52 is a precursor of methotrexate that is only converted to the 
parent drug in parasites. It inhibits the growth of the quadruple resistant strain and 
proved to be non toxic against human cells.105 
Resistance against antifolates is not exclusively based on the mutations in the 
dhfr and dhps gene described above. In addition to de novo synthesis, parasites can 
also acquire folate from the host via an active transport system. Probenicid (1.53) 
normally used as uricosuricum inhibits this transport system and shows some 
antifolate resistance reversing properties in vitro.106, 107 
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Figure 1.12: Antifolates in development. 
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1.1.7.4. ANTIBIOTICS 
 
A variety of antibiotics such as tetracyclines, macrolides, lincosamides, 
chloramphenicol, spectinomycin, all of which are translation inhibitors in prokaryotic 
systems, are considered to inhibit protein synthesis inside the apicoplast.108 
Doxycycline (1.54, Figure 1.13) is the most frequently used antibiotic in antimalarial 
therapy, either as a prophylactic agent, or in combination with chloroquine, for 
treatment of multiresistant malaria.94 Clindamycin (1.55) is a valuable alternative 
since doxycycline is contra-indicated in small children and pregnant women.109 
Clindamycin binds the 50S subunit of ribosomes in bacteria and inhibits the 
prokaryote-like protein synthesis machinery of the apicoplast. This results in an arrest 
of the replication of the organelle.110 
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Figure 1.13: Structures of two important antibiotics in the treatment of malaria. 
 
1.1.7.5. COMPOUNDS ACTING ON THE RESPIRATORY CHAIN 
 
Malarone® is a fixed combination of atovaquone (1.56, Figure 1.14) and 
proguanil (1.42).111,112 Like its structural analogue ubiquinone (1.57), atovaquone 
inhibits the mitochondrial electron transport by inhibiting the cytochrome c reductase 
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complex, which causes a collapse of the membrane potential.113 Remarkably, not 
cycloguanil but proguanil itself is responsible for this synergistic effect. Proguanil 
reduces the concentration of atovaquone necessary for the collapse of the 
membrane potential. The underlying mechanism is unknown.114,115 Malarone is a 
usual combination for the prophylaxis against malaria. Especially the activity against 
liver stages is advantageous as the parasites are killed before an infection of red 
blood cells can be established.116 However, the long-term efficacy seems to be 
limited, due to a documented mutation of the cytochrome gene.117 
-Methoxyacrylates, which are used as agricultural fungicides, are known to 
act through a mechanism similar to that of atovaquone. Therefore, a series of -
methoxyacrylate derivatives was screened for antimalarial activity.118 Compound 1.58 
demonstrated the lowest IC50 value (0.28 nM) ever recorded for an antimalarial drug 
but rapid development of resistance was observed.119  
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Figure 1.14: Structures of mitochondrial electron transport inhibitors. 
 
1.1.7.6. PROTEASE INHIBITORS 
 
Hemoglobine is consumed in the food vacuole of the P. falciparum parasite 
during its intra-erythrocytic stages. A lot of specific proteases are involved in this 
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proces, such as the aspartoproteases plasmepsin I, II and IV120,121 and the cysteine 
proteases falcipain-2 and 3. Inhibitors of these well-characterized enzymes are 
potential new drug candidates. Potential inhibitors were designed through 
modification of available inhibitors of cathepsin D (a human aspartoprotease), such 
as compound 1.59,122 and by using the crystal structure of plasmepsin II, for de novo 
design of inhibitors, such as compound 1.60 (Figure 1.15).123 Some compounds, 
such as Ro 42-1118 (1.61) were originally described as plasmepsin II inhibitors, but 
exhibited a 16 to 80-fold higher potency against plasmepsin IV.121 Compounds 1.62 
and 1.63 are cysteine protease inhibitors and showed promising IC50 values 
(respectively 4 and 0.4 nM) against in vitro P. falciparum growth. 
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Figure 1.15: Structures of protease inhibitors. 
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Attempts to develop non-peptide falcipain-2 inhibitors led to the identification of 
chalcones (e.g., 1.64) and phenothiazine like compounds (e.g., 1.65). Compound 
1.64 is the chalcone with the highest reported in vitro activity (IC50 = 230 nM).124 
 
1.1.7.7. INHIBITORS OF FATTY ACID SYNTHESIS 
 
The presence of a fatty acid biosynthesis pathway in the apicoplast (vide infra 
paragraph 1.2.3.) of P. falciparum has recently been established (Figure 1.3). This 
pathway represents the so-called “type II system” (FAS-II)125 common to plants and 
bacteria, but distinct from the so-called “type I system” (FAS-I)126 of animals including 
humans. Thiolactomycin (1.66, Figure 1.16), a natural antibiotic, specifically inhibits 
the FAS-II system and shows in vitro growth inhibition of P. falciparum (IC50 = 50 
M).125 Triclosan (1.67), known as preservative in toothpastes, is a significantly more 
acitive (IC50  1 M against FabI, an enzyme involved in FASII),127 but is not suitable 
for oral use.  
 
O
OH
Cl Cl Cl
S
HO
O
triclosan 1.67thiolactomycin 1.66
 
 
Figure 1.16: Structures of inhibitors of the P. falciparum fatty acid biosynthesis. 
 
1.1.7.8. INHIBITORS OF PHOSPHOLIPID METABOLISM 
 
The malaria parasite needs big amounts of phospholipids such as 
phosphatidylcholine for the synthesis of new membranes during the intra-erythrocytic 
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development. The phospholipid metabolism as a target for antimalarial drugs has 
been reviewed.128, 129 Compound G25 (1.68, Figure 1.17) emerged as a lead from the 
first generation of bis quaternary ammonium compounds. It inhibits the growth of 
cultured parasites with an IC50 value of 0.64 nM. Due to toxic side effects and the lack 
of oral bioavailability, a second generation was developed in which the quaternary 
ammonium groups were replaced by bioisosteric amidino and guanidino groups. 
However, compound MS1 (1.69), a lead of the second generation, still carries 
permanent charges. MS1 displays high in vitro activity (IC50 = 0.3 nM), but the desired 
oral activity could not be obtained.  
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Figure 1.17: Structures of inhibitors of phospholipid metabolism. 
 
Success came with a third generation of bis-thiazolium compounds. 
Compound TE3 (1.70) represents a thioester prodrug which is rapidly cleaved and 
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rearranged in blood to the bis-thiazolium compound T3 (1.71, IC50 = 2.25 nM). Bis-
ammonium compounds cross the infected erythrocyte by parasite induced new 
permeability pathways (NPP) and enters the parasite using a choline transporter. 
Inside the parasites the phosphatidylcholine de novo synthesis is inhibited either 
through the inhibition of the choline uptake or the inhibition of enzymes of this 
pathway or the combination of both effects.130 The bis-ammoninum compounds can 
be regarded as dual drugs since they have shown to bind also to FPIX.  
 
1.1.7.9. INHIBITORS OF FARNESYL TRANSFERASE 
  
Farnesyl transferase inhibitors are known from anticancer therapy, because 
the farnesylation of proteins is important for signal transduction. Protein farnesylation 
has also been demonstrated in Plasmodium.131 The reaction catalyzed by farnesyl 
transferase is depicted in Figure 1.18.  
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Figure 1.18: Farnesyl transferase catalyzed reaction. 
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Farnesyl transferase is a heterodimeric zinc protein, which catalyzes the 
transfer of a farnesyl moiety, from farnesylpyrophosphate to the carboxyterminal 
CaaX-recognition sequence of proteins (C = cysteine, a = amino acid with aliphatic 
side chain, X = serine or methionine). Most inhibitors are thiol free Caax peptide 
mimetics. Among the most active farnesyl transferase inhibitors (Figure 1.19) are the 
biphenyl derivative FTI-2135 (1.72, in vitro antimalarial activity IC50 = 4.4 M) and the 
benzophenone-based compound Schl-4116 (1.73, in vitro antimalarial activity IC50 = 
75 nM).132,133 Despite the high sequence homologies within the active sites of human 
and parasitic farnesyl transferases, the design of specific inhibitors appears feasible, 
as demonstrated by the Schl-4116 compound.134 
Bisphosphonates (Figure 1.19), used in the treatment of osteoporosis, are 
assumed to inhibit farnesyl pyrophosphate synthase.135 Compounds 1.74 and 1.75 
appeared active in vitro (IC50 respectively 5.1 and 7.7 M).  
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Figure 1.19: Structures of farnesyl transferase inhibitors (1.72-1.73) and farnesyl 
pyrophosphate synthase inhibitors (1.74-1.75). 
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1.1.7.10. INHIBITORS OF GLYCOLYSIS 
 
Some enzymes involved in the glycolytic pathway of P. falciparum, such as 
lactate dehydrogenase, are significantly different from their human isozymes and are 
well characterized.136 High-throughput screening and structure-based design may 
afford specific inhibitors. The malaria parasite exclusively depends on glycolysis for 
its energy supply, since a Krebs cycle is absent.137 The structures of other glycolytic 
enzymes, such as fructose-1,6-bisphosphate aldolase and triosephosphate 
isomerase have been solved and afford new attractive targets for drug design.138,139 
1.1.7.11. OTHER ANTIMALARIAL COMPOUNDS 
 
A number of reviews discuss new targets and lead structures for 
malaria.140,141,142,143 In Figure 1.20 some recent lead structures that can act as 
platform for the design of new antimalarial drugs are displayed. WR182393 (1.76) is 
an analogue of chlorproguanil that cannot be cyclised. It is only active against the 
liver stages and shows a different mechanism of action.144 
Dioncophyllines such as 1.77 are isolated from tropical lianas that are applied 
in traditional medicine in African and Asian countries.145 Febrifugine (1.78), an active 
ingredient from the Chinese plant Dichora febrifuga, has proven antimalarial activity, 
both in vivo as in vitro, but shows some severe adverse effects. Its metabolite, 3’’-
ketofebrifugine (1.79), appeared to be less toxic and was slightly more active than 
chloroquine.146 The mode of action of the dioncophyllines and the febrifugines is 
unknown to date. 
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Figure 1.20: Other new antimalarial compounds. 
 
Diamidines have a long history as antiprotozoal agents. Today, pentamidine 
(1.80) is the only diamidine in clinical use for trypanosomiasis. Diamidines enter the 
infected erythrocyte through new permeability pathways (NPP) and the parasite 
through the choline carrier. Recently, it has been proposed that diamidines act 
against Plasmodium through the FPIX-binding (see 1.1.7.1) and the inhibition of 
mitochondrial functions.147 Furamidine (1.81) (DB75) in which the pentamidine 
flexibel chain has been replaced by a rigid 2,5-substituted furyl residue is the most 
advanced compound.148 Because these compounds are insufficiently absorbed from 
the gastrointestinal tract after oral administration, O-methylamidoxim-prodrugs are 
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made. DB289 (1.82) is in phase II clinical trials against P. vivax and uncomplicated P. 
falciparum infections. This trial demonstrated high efficiency and good tolerability for 
this drug.149 Several diamidines are under preclinical development. The high in vitro 
activity against multi-resistant strains, the oral bioavailability of alkylamidoxim 
prodrugs and the efficiency and tolerability of DB289 in a first clinical trial suggest 
that the diamidines constitute a highly promising class of antimalarials. 
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1.2. THE NON-MEVALONATE PATHWAY AS DRUG 
TARGET  
1.2.1. DRUG DISCOVERY AND THE ISOPRENOID BIOSYNTHESIS 
 
Due to the increasing resistance against conventional anti-malarial drugs, there is 
an urgent need for new efficient and safe treatments. The discovery of novel 
therapeutics largely relies on four strategies150: 
• modification of existing anti-parasitic drugs into improved drugs with higher 
activity, less side effects or (and) more favourable pharmacokinetic properties, 
label extension is another possibility,  
• the “piggy back” strategy: targets being pursued for other indications but 
present in parasites will facilitate the identification of new lead compounds. 
These leads can be further developed into selective “drugable” compounds, 
• “de novo” drug discovery: new hits can be found by target based screening of 
chemical libraries for a specific biological activity in whole parasite assays or 
against a specific protein and subsequently developed.  
• another “de novo” strategy relies on the investigation of parasite selective 
biochemical pathways affording information on the drug target properties of 
these pathways. Inhibitors of such a pathway can be discovered by screening 
procedures or through rational drug design strategies.  
The latter approach is particularly attractive in the discovery of new 
chemotherapeutic agents. Pathogenic micro-organisms often possess specific 
biochemical pathways which are essential for their survival and do not occur in 
mammals. Inhibitors of these pathways may show antiparasitic activity combined with 
low toxicity in humans.  
The “non-mevalonate pathway” shows excellent target properties for antimalarial 
drug discovery. This pathway is responsible for the biosynthesis of dimethylallyl 
pyrophosphate (DMAPP) and its isomer isopentenyl pyrophosphate (IPP) in 
plasmodia. Both pyrophosphates are the building blocks for an impressive group of 
biomolecules, the isoprenoids. Since we selected the “non-mevalonate pathway” as a 
target to design new antimalarials, this pathway will be discussed in detail. 
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isoprene
 
 
Figure 1.21: Structure of isoprene. 
 
Isoprenoids are natural products and polymers composed of isoprene (2-
methyl-1,3-butadiene, Figure 1.21) units. Two C5 units condense to form geranyl 
pyrophosphate (C10), which condenses with another molecule of IPP to form farnesyl 
pyrophosphate (C15). In humans these pyrophosphates are important for the 
biosynthesis of steroids, vitamine D, bile salts, cholesterol, etc. In plants they are 
crucial building blocks for primary and secondary metabolites: the terpenes (C5 and 
C15 compounds), squalene (an assembly of two C15 units) and carotenoids (an 
assembly of C20 units), chlorophylls and plastoquinones. Isoprenoids such as sterols, 
ubiquinones, dolichols and carotenoids are essential for all organisms. Today there 
are over 30000 structures known with an isoprenoid substructure.  
 
1.2.2. THE MEVALONATE VERSUS THE NON-MEVALONATE 
PATHWAY 
 
In animals (including humans), fungi, archaebacteria and some eubacteria, 
isoprenoids are synthesized by the mevalonate pathway, which has been well-
characterized since the 1960s (Figure 1.22). The mevalonate pathway starts with the 
condensation of three molecules of acetyl coenzyme A (acetyl CoA) into 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA), which is reduced to mevalonate by HMG-
CoA reductase. Mevalonate is converted by phosphorylation and an elimination step 
into isopentenyl pyrophosphate (IPP).151  
Until the 1980s it was thought that the mevalonate pathway was the only 
biosynthetic avenue to isoprenoids, but labelling studies conflicted with this 
hypothesis. The incorporation of labelled acetate, glucose and pyruvate in bacterial 
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terpenoids gave unexpected patterns.152 Surprising labelling patterns were also 
obtained by incorporation of 13C-labelled glucose in ubiquinones in Escherichia coli 
and ginkgolides in Ginkgo biloba. A mechanism starting with the condensation of 
glyceraldehyde 3-phosphate and pyruvate was proposed.153,154 The resulting 1-
deoxy-D-xylulose 5-phosphate (DOXP) was incorporated into the prenyl chains of 
ubiquinone from E. coli. At the same time the research group of Rohmer elucidated a 
different pathway for isoprenoid biosynthesis.155,156 These reports were the first to 
show the existence of an alternative mevalonate-independent pathway for isoprenoid 
biosynthesis in plants and bacteria. This mevalonate-independent pathway is also 
called non-mevalonate pathway, DOXP pathway, Rohmer pathway or 2-C-methyl-D-
erythritol 4-phosphate (MEP) pathway (Figure 1.22).  
The DOXP pathway is absent in humans and fungi, but present in many 
eubacteria and some protozoa.157,158 In some eubacteria, however, a functional 
DOXP and a mevalonate pathway co-exist.159 In plants, both pathways are present 
with the DOXP pathway being operative in the plastids and the mevalonate pathway 
in the cytosol.160 Since it is essential for survival of the parasites and absent in 
humans, the DOXP pathway represents a promising target for developing novel anti-
infectious agents  
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Figure 1.22: Overview of the isoprenoid biosynthesis via the mevalonate and the DOXP 
pathway (CDP = diphosphocytidyl). 
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Figure 1.22 depicts the DOXP pathway. Investigation of this pathway was 
mainly performed on E.coli and various plants. The enzymes involved have been 
cloned from a variety of higher plants, bacteria and protozoa.161 
The first reaction of the DOXP pathway is the condensation of D-
glyceraldehyde 3-phosphate and pyruvate by means of DOXP synthase (DXS). The 
gene of DXS was discovered independently by several research groups.162,163,164 
DOXP was previously known as a precursor for thiamine diphosphate and pyridoxol 
phosphate in E. coli.  
In the second step, DOXP is converted into the branched-chain polyol 2-C-
methyl-D-erythritol 4-phosphate (MEP) by DOXP reductoisomerase (DXR, IspC). This 
enzyme catalyzes a reversible rearrangement and a NADPH-dependent 
reduction.165,166 Currently, DXR is clinically the most relevant and also the best 
studied enzyme of the DOXP pathway.  
In the next step 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) is 
formed by a nucleotidylation with CDP-ME synthase (IspD, YgbP) and CTP as 
cofactor. It is subsequently phosphorylated at the 2-position by CDP-ME kinase 
(CMK, IspE) with the formation of CDP-ME-2-phosphate . The latter is cyclized by 
ME-cPP synthase (IspF, YgbB) into 2-C-methyl-D-erythritol-2,4-cyclodiphosphate 
(ME-cPP) and subsequently transformed to 2-hydroxymethyl-cis-but-2-en-4-yl 
diphosphate (HMBPP) by HMBPP synthase (GcpE, IspG). In the last step, HMBPP is 
converted to IPP or DMAPP. Both reactions can be catalyzed by IPP/DMAPP 
synthase (IDS, LytB, IspH). In contrast to organisms that rely on the mevalonate 
pathway, organisms using the DOXP pathway are not dependent on isopentenyl 
diphosphate isomerase (IDI), which catalyzes the isomerisation of IPP into DMAPP.  
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1.2.3. DOXP PATHWAY IN P. FALCIPARUM 
 
Previous studies revealed very low HMG-CoA reductase activity in P. 
falciparum.167 Attempts to establish HMG-CoA reductase inhibitors as antimalarial 
drugs failed,168 suggesting the absence of a mevalonate pathway in P. falciparum. In 
1999 Jomaa and coworkers found that P. falciparum relies on the DOXP pathway, 
where it is localized inside a plastid-like organelle, the apicoplast. By searching for 
genes encoding enzymes of the DOXP pathway, similarities were found between 
known bacterial sequences of DXR and sequences in the genome of P. falciparum.  
In general, the genes encoding for DXR show a great degree of similarity 
among different species. Nevertheless, if the alignment of the amino acid sequence 
between E. coli, Bacillus subtilis, Synechocystis and P. falciparum is compared, DXR 
of P. falciparum has a unique amino-terminal extension. This extension exists of 
approximately 70 amino acids, from which the first 30 amino acids are part of an 
endoplasmic reticulum signal peptide and the last 44 amino acids form a typical 
plastidial targeting sequence. This extra polypeptide chain implies that DXR, once it 
is formed, finds its way to the apicoplast.  
If the gene of this targeting sequence is fused to the gene of green fluorescent 
protein (GFP) and these genes are brought to expression by transfected Toxoplasma 
gondii, it can be visualized that GFP accumulates in the apicoplast. In the apicoplast 
of Apicomplexa, as well as in the chloroplast of plants, isoprenoids are synthesized 
via the DOXP pathway. Also, the synthesis of fatty acids and, potentially hem, take 
place in the apicoplast. The apicoplast has been acquired during the evolution by 
endosymbiosis with an alga, which subsequently has lost its photosynthetic activity. 
The apicoplast contains an independent genome. This genome is responsible 
only for the self-reproduction of the apicoplast. The genes for the isoprenoid 
biosynthesis are part of the nuclear DNA. Thus, the enzymes involved in this 
biosynthesis inside the apicoplast are all encoded by the nuclear genome, 
synthesized in the cytosol and transported to the apicoplast. Therefore, these 
enzymes have an apicoplast-targeting sequence. 
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1.2.4. FOSMIDOMYCIN, AN INHIBITOR OF THE DOXP PATHWAY 
1.2.4.1. DISCOVERY AND ANTIBACTERIAL ACTIVITY 
 
During the 1970s, Japanese researchers isolated the antibiotic fosmidomycin 
(1.83, Figure 1.23) from Streptomyces lavendulae. It proved to be effective for the 
treatment of urogenital tract infections in an early phase II study (see 1.2.4.5.). With 
the emergence of more potent antibiotics, further development on fosmidomycin was 
discontinued. The mechanism of action was unknown until 1998 when fosmidomycin 
and its derivative FR900098 (1.84, Figure 1.23) were shown to represent highly 
specific inhibitors of DXR, the second enzyme of the DOXP pathway.169,170 
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Figure 1.23: Structure of fosmidomycin, FR900098 and fosfomycin. 
 
The presence of the DOXP and/or mevalonate pathway in some bacteria and 
the corresponding MIC values of fosmidomycin are summarized in table 1.1. 
 
 
 
DOXP 
pathway DXR 
Mevalonate 
pathway 
MIC 
(50%)(µg/ml) 
fosmidomycin 
(1.83) 
Escherichia coli present present absent 1.56 
Pseudomonas 
aeruginosa present present present 0.39-6.25* 
Salmonella 
typhi present present ??? 6.25 
Staphylococcus 
aureus 
certain 
enzymes absent present >100 
Neisseria 
gonorrhoea present present ??? >100 
Clostridium 
difficile present present 
certain 
enzymes >100 
Mycobacterium 
tuberculosis present present absent >100 
 
 
Table 1.1: Presence or absence of the DOXP and/or mevalonate pathway in some bacteria 
and the corresponding MIC values of fosmidomycin (* sensitivity for fosmidomycin is 
variable)171,172 
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From Table 1.1 it can be deduced that there is no absolute correlation 
between the presence of the DOXP pathway and the sensitivity to fosmidomycin. 
This conclusion can be drawn from two different studies.171,172 The mechanism of 
non-sensitivity or resistance to fosmidomycin could be based on three principles.  
 
• The absence of the target DXR. 
 
• The absence of a glycerol 3-phosphate transporter (glp T) activity. Indeed, in 
E. coli, fosmidomycin is transported into the bacterium via this transporter. 
Mutations in the glp T gene are linked to resistance to fosmidomycin and 
fosfomycin (Figure 1.23). Fosfomycin is a well-kown antibiotic which also 
contains a C−P bond and disturbs the formation of peptidoglycan and bacterial 
cell wall synthesis.173,174 Based on their structural similarity, both antibiotics 
are brought in the bacterial cell by the same transport system. Therefore, 
simultaneous resistance of both phosphonate antibiotics is often seen.171 The 
transcription of the glpT gene is highly dependent on the presence of cAMP. 
The gene is part of the glpTQ-operon which contains a cAMP receptor protein 
(CRP)-binding box. E. coli strains which are deficient in adenylate cyclase 
show fosmidomycin resistance, which can be reversed by adding cAMP to the 
medium.175 Fosmidomycin-resistant strains of P. aeruginosa all proved 
deficient in glp T activity.176 Recombinant DXR from Mycobacterium 
tuberculosis (Rv2870c) and recombinant DXR from E. coli (IspC) are very 
similar. The DXR of M. tuberculosis is only active in the presence of a divalent 
magnesium cation. Nevertheless M. tuberculosis is resistant to concentrations 
of fosmidomycin that are at least 3 orders of magnitude greater than the IC50 
determined in vitro for DXR. Indeed, analysis of the genome of M. tuberculosis 
demonstrates the absence of genes that encode for proteins with significant 
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similarity in primary structure to glpT.177 Attempts to express glpT in M. 
tuberculosis have been unsuccessful. It is however possible that metabolic 
transformation or efflux mechanisms contribute to the observed resistance.  
 
• As a result of efforts to find a gene related to the transport mechanism of 
fosmidomycin other than glpT, fsr was discovered. It encodes for an efflux 
protein with 409 amino acids and a molecular weight of 43303 Da. Fsr can 
cause resistance by transformation of sensitive strains. The transformation of 
E. coli DH5 with two different plasmids, pTH4N (with a high-copy-number) 
and pIT1 (with a low-copy-number), increases the MIC from 6 g/ml to 400 
g/ml and 25 g/ml respectively. Although, the increase in the level of the fsr 
protein seems to have no direct effect on the levels of isoprenoids. The fsr 
protein contains 12 lipophilic transmembrane segments, which are also 
present in other antibiotic-export proteins.178 
 
1.2.4.2. SENSITIVITY OF P. FALCIPARUM STRAINS TOWARDS FOSMIDOMYCIN, 
FR900098 AND CHLOROQUINE 
 
IC50 values of fosmidomycin and FR900098 on different P. falciparum strains 
(HB3, Honduras, A2, Gambia, and Dd2, Indochina) are summarized in Table1.2 and 
compared with chloroquine. FR900098 is more active than fosmidomycin, but 5 to 10 
times less active than chloroquine against chloroquine sensitive strains. It is however 
twice as active as chloroquine against the chloroquine resistant Dd2 strain. 
 
 
 IC50 (nM)  P. falciparum strain 
fosmidomycin FR900098 chloroquine 
HB3 350 ± 170 170 ± 100 20 ± 5 
A2 370 ± 45 171 ± 45 37 ± 7 
Dd2 290 ± 130 90 ± 20 200 ± 30 
Numbers are mean values ± standard deviations 
 
Tabel 1.2: In vitro antimalarial activity of fosmidomycin and FR900098 against three different 
P. falciparum strains.1 
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1.2.4.3. PHARMACOKINETICS OF FOSMIDOMYCIN 
 
In a murine malaria model, mice infected with P. vinckei were cured by 
fosmidomycin after oral (p.o.) or intraperitoneal (i.p.) administration. The efficacy was 
lower upon oral administration presumably due to a poor absorption rate.179  
The plasma concentrations of fosmidomycin (Figure 1.23) after intravenous 
(i.v.) administration of 30 mg/kg (± 2.2 g), intramuscular (i.m.) administration of 7.5 
mg/kg (± 560 mg) and p.o. administration of 500 mg fosmidomycin in healthy adult 
male volunteers is shown in Figure 1.24.  
 
 
Figure 1.24: Plasma concentrations of fosmidomycin after a single dosis (from ref. 181). 
 
The AUC’s are respectively 210, 42.2 and 14.0 g.h/ml. Phase I study results 
indicate that fosmidomycin is well tolerated in healthy adult male volunteers even 
when given in repeated doses of 8g/day i.v. for 7 days, 4 g/day i.m. for 5 days, and 4 
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g/day p.o. for 7 days.180 As shown in Figure 1.24 a peak serum concentration of 2.33 
mg/l was reached at 2.36 h after oral administration. The plasma half-life was 1.87 h, 
which is very short and not very useful in a therapeutic setting. The biological 
availability is 80.3% after i.m. administration and 30% after oral administration. After 
oral administration of 500 mg fosmidomycin the gastrointestinal absorption rate was 
between 20-40%. The recovery rate in urine was 85.5%, 66.4% and 26% after i.v., 
i.m. and p.o. administration, respectively. There are no other active metabolites found 
in the urine. In repeated dose studies, no accumulation could be observed and the 
serum protein binding was found to be less than 1% in man.181,182 
 
1.2.4.4. TOXICOLOGY 
 
The remarkably low toxicity is one of the major advantages of fosmidomycin. 
The LD50 in rats is approximately 12 g/kg and 8g/kg after oral and subcutaneous 
administration, respectively.183 In the phase I clinical trials, the effect of fosmidomycin 
was investigated after oral administration in single dose to 127 healthy male 
volunteers.180 Administered doses were 250 mg to 1 g p.o., 1 g i.m. and several 
doses to 4 g i.v.. No changes in haematological (WBC, RBC, thrombocytes, 
hemoglobine, hematocrit) and biochemical (ureum, creatinine, total proteins, 
bilirubine, alkaline phosphatase, AST, ALT, glucose, iron, cholesterol, triglycerides, 
Ca2+, PO43-) parameters were observed. No adverse side-effects were observed in 
ECG, heartbeat, blood pressure and breath rythmn. Also no adverse events in urine 
investigation (pH, ketones, bilirubine, urobilinogene, glucose, proteins, blood) were 
reported. When administered in repeated doses of 8 g/day i.v. for 7 days, 4 g/day i.m. 
for 5 days and 4 g/day p.o. for 7 days, no adverse events were reported. Alterations 
in the intestinal flora caused mild side effects, such as loose stools, flatulence and 
diarrhoea. 
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1.2.4.5. CLINICAL TRIALS 
 
Fosmidomycin was already evaluated in the mid 1980s in an early phase I 
study and a phase II study for the management of urinary tract infections (UTI). The 
efficacy was good and no adverse side effects were observed.181  
In recent clinical trials conducted in Gabon and Thailand fosmidomycin was 
examined as an antimalarial agent.184 Then patients suffering from acute 
uncomplicated P. falciparum infection, were treated with 1200 mg of fosmidomycin 
three times a day for 7 days. The drug was very well tolerated and effective against 
multi-resistant P. falciparum parasite strains. Only mild side effects, such as 
diarrhoea, were reported, probably due to the antibacterial activity of fosmidomycin. 
The parasite and fever clearance times were approximately 2 days and similar to that 
of common antimalarials such as chloroquine or mefloquine. In another study, the 
duration of the treatment was shortened to 4 days and cure rates higher than 80% on 
day 14 were observed.185 However, a high recrudescence rate was observed when 
fosmidomycin was given in monotherapy, possibly as a consequence of its extremely 
short plasma half-life. A complete cure could be achieved by combining 
fosmidomycin with artesunate or clindamycin. After trials with several currently used 
antimalarial drugs, clindamycin appeared a suitable combination partner.186 
Fosmidomycin has been found to act synergistically with clindamycin, as well as with 
artesunate. In many cases synergistic interactions are seen when multiple drugs 
target the same metabolic pathway, even when the actual enzyme targets are quite 
distant from each other. The activity of some bisphosphonates (farnesyl 
pyrophosphate synthase inhibitors) is also strongly potentiated by fosmidomycin.135(b) 
Very recent studies in Gabon indicate that a three-day treatment of children (7-
14 year) with fosmidomycin-clindamycin is superior to the standard therapy with 
chloroquine or sulfadoxine-pyrimethamin.187,188,189 The synergistic effect of 
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clindamycin is probably due to its inhibition of the replication of the apicoplast, the 
organelle that harbors the enzymes of the DOXP pathway. A combination of 
fosmidomycin with artesunate (children 7-14 year) gave cure rates of 95% by day 14 
and 100% by day 28, respectively with a 2 day and 3 day regimen.190 Also in these 
clinical trials no adverse side-effects were reported. 
 
1.2.5.  1-DEOXY-D-XYLULOSE-5-PHOSPHATE 
REDUCTOISOMERASE (DXR, ISPC) 
1.2.5.1. MECHANISTIC STUDIES OF DXR 
 
DXR is responsible for the conversion of DOXP into MEP. The reaction of 
DXR consists of two steps (Figure 1.25). It is accepted that DOXP is first isomerized 
into 2-C-methyl-D-erythrose 4-phosphate, which is subsequently converted into MEP. 
In the first step, the C3−C4 bond in DOXP is cleaved with the direct formation of a 
bond between C2 and C4 to produce the 2-C-methyl-D-erythrose 4-phosphate 
intermediate, which is then reduced by NADPH into MEP. The aldehyde intermediate 
remains attached to the enzyme during the reaction, so it is impossible to detect it as 
a free molecule.166  
Two possible mechanisms are suggested for the isomerisation: an -ketol 
rearrangement and a retroaldolization/aldolization. The -ketol rearrangement is 
similar to the mechanism proposed for ketol-acid reductoisomerase. Recently, 
Rohmer et al. suggested a retroaldolization/aldolization.191 In the 
retroaldolization/aldolization, deprotonation of the C4-hydroxyl group, followed by 
cleavage of the C3−C4 bond gives glycoaldehyde phosphate and the enol(ate) of 
hydroxyacetone. Subsequent aldolization gives the intermediate. The most relevant 
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mechanism is still a matter of debate. As discussed in paragraph 1.3.1.4. several 
analogues were made to distinguish between both mechanisms. 
The stereochemistry of the reduction step was studied by Proteau et al.192 and 
Arigoni et al.,193 who found that the pro-S-hydride from NADPH was delivered to the 
re face of the aldehyde. Based on the stereochemical features of the NADPH-
dependent reduction, DXR is classified as a class B dehydrogenase.192,194 
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Figure 1.25: Two mechanisms proposed for DXR conversion of DOXP into 2-C-methyl-D-
erythrose 4-phosphate. 
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1.2.5.2. ENZYME KINETICS  
 
Kinetic analysis of DXR shows that fosmidomycin binding is based on 
competitive/non-competitive inhibition mechanism. An analysis of the progress 
curves for MEP synthesis in the presence of inhibitor revealed a slow, tight-binding 
mode of inhibition by fosmidomycin and two kinetically distinguishable Ki values have 
been reported for the E. coli enzyme. A conformational change is induced after 
bonding of fosmidomycin to the enzyme (EI). This conformational change is essential 
for tight binding and requires prior formation of a DXR-NADPH complex.166 The 
formation of additional hydrogen bonds between the enzyme and NADPH in the 
closed conformation correlates with observation that NADPH is essential for the 
strong binding to the inhibitor. Based on the slow timescale of DXR domain 
movement compared to the rate of inhibitor diffusion, it is possible to explain the slow 
onset of inhibition that has been observed for fosmidomycin.  
 
1.2.5.3.  3D STRUCTURE OF DXR 
 
Until now, four high and medium resolution X-ray structures of DXR from E. 
coli have been published. The first structure reported concerns the apo-enzyme 
(Figure 1.26).195  
The second holo structure is a binary complex with NADPH and a sulphate ion 
in the active site.196 These two reports are less useful for inhibitor design as they do 
not reveal any information on the interactions between ligand and enzyme.  
DXR is a homodimer. Each monomer shows a V-like shape or saddle form 
and is composed of 3 domains. The amino-terminal dinucleotide binding domain 
(amino acids 1-150), which forms 1 arm of the V-like shape, consists of a  sheet 
with 7 parallel strands (1-7) which are connected by six  helices (1-6). These 
are responsible for the binding of NADPH. The other arm of the saddle (amino acids 
312-398) contains four  helices (12-15), which form the carboxyl-terminal domain. 
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Figure 1.26: (A) X-ray structures of E. coli DXR with NADPH modelled into the structure. 
Colored in blue: the dinucleotide binding domain, colored in green: the carboxyl-terminal 
four-helix bundle domain; colored in red: the connective domain. Colored in ochre: the 
flexible loop. (B) Topology diagram of DXR. The color code is the same as in (A). (Figure 
from ref. 195) 
 
These 2 domains are connected by a four-stranded  sheet (8-11), in turn 
connected by five  helices (7-11) (Figure 1.26). The molecule can move around 
this domain, which can be considered as a kind of hinge. This part also comprises 
the active site of the enzyme. It contains the binding site for the divalent cation, for 
the phosphate part of the substrate and also a flexible loop (amino acids 186-216). 
There are two essential conformations. In one conformation the loop hangs over the 
active site and touches the dinucleotide binding domain. In the other conformation 
the flexible loop hardly bulges out of the active site and folds back towards the four 
helix bundle. This last conformation is probably the substrate binding conformation 
and the first conformation is the active conformation where the flexible loop acts as a 
kind of lid. Plausibly, an interaction between the dinucleotide and His257 and Trp212 
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is important. The two monomers form a dimer and are connected via 11 (in both 
monomers) and the loop, which connects -helix 11 and -helix 12, i.e. the apical 
part of the V. The substrate is believed to bind in the cavity between the dinucleotide 
binding domain and the four carboxyl terminal helices. 
Next, Steinbacher et al. reported a complex DXR with fosmidomycin and a 
Mn2+ ion, but without the cofactor.197 In Steinbacher’s model (Figure 1.27) Mn2+ is 
bound to a cluster of the carboxylic acids Asp 150, Glu 152 and Glu231. All residues 
form monodentate ligands and a regular octahedral coordination sphere is completed 
by water molecules. The N-formyl oxygen of fosmidomycin is found in the trans 
position to Glu231, whereas the N-hydroxyl oxygen is located trans to Asp150. The 
phosphonate moiety is anchored by numerous hydrogen bounds to Ser186, Ser222, 
Asn227 and Lys228. According to this study hydrophobic contacts of the linker do not 
contribute to the high affinity of the inhibitor. Steinbacher’s model represents the 
structure of fosmidomycin bound to DXR in its open conformation.  
 
 
 
 
Figure 1.27: Binding of fosmidomycin on the active site of DXR. Fosmidomycin is colored in 
yellow, the catalytic loop of DXR in purple, the divalent cation in pink and important amino 
acids in the active site are colored in blue, green and orange. The N-formyl oxygen is located 
trans of Glu231 and the N-hydroxy oxygen is located trans of Asp-150. The phosphonate 
group forms hydrogen bonding to Ser186, Ser222, Asn227 and Lys228. (Figure from ref. 
197) 
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Most recently, Mac Sweeney et al. reported the ternary structures of a wild-
type and SeMet-labelled DXR, cocrystallized with fosmidomycin, magnesium and the 
cofactor NADPH. This reveals a binding mode that is not mediated by a metal ion. 
The absence of the expected metal ion from the structure can be explained by the 
low metal affinity of DXR in the crystallization buffer (pH = 5). The ternary complex of 
the DXR, NADPH and the substrate DOXP is also presented and was used as model 
of metal-mediated fosmidomycin binding.198 By contrast to the open conformation of 
Steinbacher’s model, Mac Sweeney et al. proposed a tight-binding conformation 
where fosmidomycin is buried in a solvent-shielded binding site. Hydrophobic 
interactions were observed with the highly conserved residues Trp212, Met214 and 
Met276 (Figure 1.28 A). The nicotinamide ring of NADPH also contributes to the 
formation of a hydrophobic binding pocket. 
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Figure 1.28: (A) Simplified schematic diagram of fosmidomycin binding to DXR. (B) 
Simplified schematic diagram of DOXP binding to DXR. 
 
The DOXP backbone (Figure 1.28 B) interacts with the -indole of Trp212 and 
the carbonyl group of C2 is hydrogen bonded to Glu 152 and the nitrogen of Ser151. 
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The hydroxyl group of C3 is involved in hydrogen bonds with Lys125 and Glu231, 
while the C4 hydroxyl group is hydrogen bonded to Glu152, Asn227 and Lys228.  
The most remarkable difference between the ternary complexes in the 
presence of NADPH and the other structures of DXR is that in the former an induced 
fit adaptation of the connective and C-terminal domains upon small molecule binding 
was observed. This resulted in a closed enzyme conformation, which is in agreement 
with the 2-step binding mode of fosmidomycin as proposed by Koppisch and 
coworkers.166 In addition, the flexible loop connecting both domains (residues 206-
216) undergoes an induced fit adaptation and adopts a conformation that allows it to 
function as a lid over the active site. As a result, the active site is shielded from the 
solvent. The -indole of Trp212 provides the key interaction with the substrate or 
fosmidomycin backbone.198 The fact that the same enzyme conformation was 
observed in both ternary complexes, despite the different crystallization conditions, 
indicates that the closed conformation represents most likely the physiologically 
relevant complex in solution. The open conformation in complex with fosmidomycin 
represents the initial, lower affinity enzyme-inhibitor complex. The ternary complexes 
also reveal a difference in binding mode between inhibitor and substrate. Also certain 
amino acids in the binding site, such as His209 could play a role in the “pre-
orientation” of the substrate in a conformation that favors retroaldolization/aldolization 
or -ketol rearrangement.198  
Based on these data, it may be concluded that the enzyme can adopt several 
conformations. Although the Mac Sweeney structure provides important information, 
a main drawback is that the enzyme is not catalytically active at the crystallization pH 
of 5 and that the protein-ligand interactions may differ from the in vivo situation. 
Therefore, conclusions with respect to the putative protein-ligand interactions should 
be drawn very carefully. Recently, Silber et al. reported a computer based AFMoC 
study as an in silico predictor of the binding affinity of ligands to DXR.199(a) A 
computational approach to determine the 3D structure of P.falciparum DXR was also 
described. Docking studies were carried out on known DXR inhibitors using the 
modeled P.falciparum DXR, and a correlation was obtained between ligand binding 
affinity and empirical docking score.199(b) 
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Furthermore, there is also a complex reported with two bisphosphonate 
inhibitors and manganese bound to DXR. These inhibitors appear to bind in a 
completely different fashion than fosmidomycin.200 The DXR structure of Zymomonas 
mobilis is also solved. Unfortunately only the apo structure and the DXR-NADPH 
complex are reported.201 The active site of the DXR of both organisms shows high 
similarity.  
 
1.2.5.4. MODE OF ACTION OF FOSMIDOMYCIN 
 
Fosmidomycin acts as a transition state analogue with the retrohydroxamic 
acid moiety chelating the metal ion and the phosphonate group resembling the 
phosphate group of the substrate (Figure 1.29). The X-ray structure of DXR 
complexed with fosmidomycin and a divalent cation,197 reveals that the N-formyl 
oxygen and the N-hydroxy oxygen of fosmidomycin displace two water molecules 
that were bound to the divalent cation (Figure 1.27). The divalent cation is required 
for the reduction step but whether it is required for the initial isomerisation step has 
not been elucidated yet. 
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Figure 1.29: Mechanism of the conversion of DOXP into MEP and the complexation of the 
divalent cation by fosmidomycin (1.83). FR900098 (1.84) acts in the same way. 
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Replacement of the formyl-hydrogen of fosmidomycin by a methyl group yields 
FR900098 (1.84). The methyl group of FR900098 is predicted to contact the side 
chain of Trp212 of the catalytic loop (Figure 1.28). The corresponding methyl group is 
also present in DOXP, which supports the view that fosmidomycin binds substrate-
like and not intermediate-like (Figure 1.30).197 This is also supported by the higher 
affinity of FR900098 compared to fosmidomycin.1 Indeed, the extra methyl group can 
be superimposed upon DOXP (Figure 1.29). 
 
 
 
Figure 1.30: Comparison between bonding of DOXP (green) and fosmidomycin (black) with 
DXR. (Figure from ref. 197) 
 
1.3. FOSMIDOMYCIN AS A LEAD IN DRUG DESIGN 
1.3.1. ANALOGUES OF FOSMIDOMYCIN 
 
The relatively high doses of fosmidomycin required for parasite clearance 
compared with chloroquine and the unfavourable pharmacokinetic properties 
prompted researchers to modify this lead. Fosmidomycin consists of a phosphonate 
and a retrohydroxamate moiety connected by a three carbon spacer and structural 
modifications at these positions have been considered. In the next paragraphs, we 
give an overview of the reported modifications. 
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1.3.1.1. MODIFICATIONS OF THE RETROHYDROXAMATE MOIETY 
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Figure 1.31: Structures of fosmidomycin analogues with an altered retrohydroxamate moiety. 
 
Hydroxamic acids are known to have strong metal ion chelating properties.202 
The activity of several matrix metalloproteinase-, cyclooxygenase- and lipoxygenase 
inhibitors relies on the presence of an hydroxamic moiety.203 The same is true for 
several antibacterial and antifungal agents.204 Hydroxamic acids are also responisble 
for the activity of several inhibitors of angiotensin converting enzyme, neutral 
endopeptidase, urease and peptide deformylase.205  
Hydroxamic acids 1.85 and 1.86 were synthesized and compared to 
fosmidomycin. Analogue 1.86 showed a high inhibitory activity towards E. coli DXR 
(Ki = 54 nM vs 40 nM for fosmidomycin).206 
                                            
202
 (a) Kurzak, B., Kozlowski, H., Farkas, E. Coord. Chem. Rev. 1992, 114, 169-200. (b) Boukhris, S., 
Souizi, A., Robert, A. Tetrahedron Lett. 1996, 37, 179-182. 
203
 (a) Whittaker, M., Floyd, C. D., Brown, P., Gearing, A. J. H. Chem. Rev. 1999, 99, 2735-2776. (b) 
Cheng, M., De, B., Pikul, S., Almstead, N. G., Natchus, M. G., Anastasio, M. V., McPhail, S. J., Snider, 
C. E., Taiwo, Y. O., Chen, L., Dunaway, C. M., Gu, F., Dowty, M. E., Mieling, G. E., Janusz, M. J., 
Wang-Weigand, S. J. Med. Chem. 2000, 43, 369-380 and references therein. 
204
 (a) Weber, G. Cancer Res. 1983, 43, 3466-3492. (b) Miller, M. J. Acc. Chem. Res. 1986, 19, 49-56. 
(c) Miller, M. J. Chem. Rev. 1989, 89, 1563-1579. 
205
 Marmion, C. J., Griffith, D., Nolan, K. B. Eur. J. Inorg. Chem. 2004, 3003-3016. 
206
 Kuntz, L., Tritsch, D., Grosdemange-Billiard, C., Hemmerlin, A., Willem, A., Bach, T.J., Rohmer, M. 
Biochem. J. 2005, 386, 127-135. 
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In analogue 1.87 the retrohydroxamate group was replaced by a hydroxyurea 
moiety. Enzyme assays revealed that these analogues have no relevant inhibitory 
properties.207,208 
Benzoxazolone or oxazolopyridinone analogues 1.88 were synthesized and 
tested as inhibitors for the ajmalicine production in plant cells of Catharantus 
roseus.209 Ajmalicine represents a monoterpenoid indole alkaloid. Interestingly, four 
phosphonate diethyl esters ((X = CH, Y = 5-Cl, Z = O), (X = CH, Y = 5-Cl and 6-Br, Z 
= O), (X = CH, Y = 6-Cl, Z = S) and (X = N, Y = 6-Br, Z = O)) exerted a significant 
inhibition of ajmalicine accumulation at 125 M (45-85%). 
 
1.3.1.2. MODIFICATIONS OF THE PROPYL CHAIN 
 
The changes in the propyl chain are reported by the research laboratories of 
Fujisawa and date from the early 1980s (Figure 1.32). The MIC of analogues 1.89-
1.94 was determined against S. aureus, Bacillus subtilis, Proteus vulgaris, E. coli and 
P. aeruginosa. 
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Figure 1.32: Overview of reported modifications of the propyl chain. 
 
                                            
207
 Wienser, J., Jomaa, H. unpublished results. 
208
 Kurz, T., Geffken, D., Wackendorf, C. Z. Naturforsch. B 2003, 58, 106. 
209
 (a) Mincheva, Z., Courtois, M., Andreu, F., Rideau, M., Viaud-Massuard, M.–C. Phytochemistry 
2005, 66, 1797-1803. (b) Courtois, M., Mincheva, Z., Andreu, F., Rideau, M., Viaud-Massuard, M.–C. 
J. Enzym. Inhib. Med. Ch. 2004, 19, 559-565. 
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Shortening the length of the propylene spacer, such as in compounds 1.89 
and 1.90, compromised the antibacterial activity.210 Likewise, no inhibitors of DXR 
that are significantly larger than fosmidomycin have been reported to date. This is 
consistent with the recently obtained X-ray structures.   
The further screening of other congeners, isolated from Streptomyces 
rubellomurius, yielded 3-(N-acetyl-N-hydroxyamino)-2(R)-hydroxypropylphosphonic 
acid (1.92).211,212 Analogues 1.91 and 1.92 showed no significant activity compared 
with fosmidomycin. 
The Fujisawa laboratories also reported the synthesis of N-acyl derivatives of 
3-(N-hydroxyamino)-1-trans-propenylphosphonic acid. Analogue 1.93 as well as 
fosmidomycin have been isolated from Streptomyces lavendulae. Analogue 1.94 
showed a MIC against E.coli of 10 g/ml compared with 12.5 g/ml for 
fosmidomycin.212 
Very recently, our group reported the synthesis and biological evaluation of a 
series of cyclopropane derivatives.213 The cyclopropane derivative 1.95 with reduced 
conformational flexibility in the backbone was as active as fosmidomycin (1.83) (IC50 
= 480 nM on P. falciparum Dd2 strain) and slightly less active than FR900098 (1.84).  
 
1.3.1.3. MODIFICATIONS OF THE PHOSPHONATE MOIETY 
 
Only a few modifications of the phosphonate functionality were reported 
(Figure 1.33). Kurz et al.214 and Woo et al.215 reported the synthesis of the carboxylic 
acid analogue 1.96. The latter study comprised another analogue (1.97) with a 
sulfamate group. None of these analogues showed activity against DXR. These 
results suggest that the presence of two ionisable groups on the phosphonate group 
plays an important role in the biological activity.  
 
                                            
210
 Hemmi, K., Takeno, H., Hashimoto, M., Kamiya, T. Chem. Pharm. Bull. 1982, 30, 111-118. 
211
 Hemmi, K., Takeno, H., Hashimoto, M., Kamiya, T. Chem. Pharm. Bull.1981, 29, 646-650. 
212
 Hashimoto, M., Hemmi, K., Takeno, H., Kamiya, T. Tetrahedron Lett. 1980, 21, 99-102. 
213
 Devreux, V., Wiesner, J., Goeman, J.L., Van der Eycken, J., Jomaa, H., Van Calenbergh, S. J. 
Med. Chem. 2006, 49, 2656-2660. 
214
 Kurz, T., Geffken, D., Wackendorff, C. Z. Naturforsch. B 2003, 58, 457. 
215
 Woo, Y.–H., Fernandes, R. P. M., Proteau, P. J. Bioorg. Med. Chem. 2005, 14, 2375-2385.  
 - 61 -
H N
O
OOH
H N O S
O
O
NH2
OH
OH O
1.96 1.97
 
 
Figure 1.33: Analogues of fosmidomycin with a modified phophonate moiety. 
 
1.3.1.4. SUBSTRATE OR TRANSITION STATE ANALOGUES  
 
DXR binds NADPH and a divalent cation, which causes a slight 
conformational change, followed by binding of the substrate to cause a more drastic 
conformational change prior to the enzyme reaction. As discussed in paragraph 
1.2.5.1. two different mechanisms are proposed for the rearrangement step, the 
formation of the 2-C-methyl-D-erythrose 4-phosphate intermediate. Several 
analogues of DOXP have been synthesized (Figure 1.34). Analogues that are 
accepted as substrate in the DXR-reaction could provide valuable information about 
the mechanism and the sterical requirements of the enzyme. 
To distinguish between an -ketol and a retroaldolization mechanism, Hoeffler 
et al. have tested 3-deoxy and 4-deoxy analogues of DOXP as substrates for E. coli 
DXR.191 An -ketol rearrangement is possible with the 4-deoxy analogue 1.98. It was 
however not converted to the corresponding product, 3-deoxy methylerythritol 
phosphate. These findings point in the direction of a retroaldolization. Likewise, the 3-
deoxy analogue of DOXP (1.99) was not accepted as a substrate. Instead, both 
deoxy-analogues behaved as mixed competitive/non-competitive inhibitors of DXR. 
The same results were obtained upon replacement of the 3- or 4-position by a 
fluor atom (Figure 1.34).216 The 4-fluoro-DOXP analogue (1.100) can theoretically 
undergo an -ketol rearrangement, but this reaction was not observed. 
The 1-fluoro analogue of DOXP (1.102) appeared to be a good substrate (Km 
= 227 M vs. DOXP = 50 M).216,217 This pleads in favour of the retroaldolization, 
since the fluor could stabilize the negative charge arising in case of reaction in -
position of the fluor atom. Besides, in the case of an -ketol mechanism, the strongly 
                                            
216
 Wong, A., Munos, J. W., Devasthali, V., Johnson, K. A., Liu, H. Org. Lett. 2004, 6, 3625-3628. 
217
 Fox, D. T., Poutler, C. D. J. Org. Chem. 2005, 70, 1978-1985. 
 - 62 -
electron-withdrawing fluor atom would destabilize the positive charge on the 
aldehyde oxygen. 
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Figure 1.34: Overview of reported analogues of DOXP, MEP and the 2-C-methyl-D-erythrose 
4-phosphate intermediate. 
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The other analogues, CF3-DOXP (1.103), CF2-DOXP (1.104) and Et-DOXP 
(1.105), reported by Fox et al., were weak inhibitors of DXR. The presence of a 
hydrate form, which may not bind as thightly as the ketone, and their increase in 
steric bulk are possible reasons for this weak inhibition. These results illustrate that 
strict size requirements are present for the C1 position. 
The phosphonate analogue of DOXP (1.106) did not show significant inhibitory 
activity of DXR. However, it was transformed into 1.107, which is MEP with a C−P 
bond. Both compounds were synthesized by Rohmer and coworkers.218,219 
The Et-DOXP (1.105), DOXP-phosphonate (1.106), 3-deoxy-DOXP (1.99) and 
4-deoxy-DOXP (1.98) analogues were also reported by Phaosiri et al.,220 together 
with two other analogues which were tested on Synechocystis PCC6803 DXR. One 
compound 1.108, in which the methyl ketone moiety was replaced by an isosteric 
amido group, acted as a weak inhibitor because of the poorer electrophilicity at the 
carbonyl moiety. The Ki is about half of the Km of DOXP, suggesting a more 
favourable binding, possibly through hydrogen bonding. Compound 1.109 with 
opposite stereochemistry at the C4 position relative to DOXP, had a Ki value 
comparable to the Km of DOXP, suggesting that the stereochemistry at C4 of the 
substrate is not critical for binding, but is essential for catalysis. 
In the assay with Synechocystis PCC6803 DXR, 3-deoxy-DOXP and 4-deoxy-
DOXP behaved as competitive inhibitors, while Hoeffler et al. classified these 
deoxygenated compounds as mixed type inhibitors of E. coli DXR. The Ki of the 
deoxy analogues compared favourably to the Km of DOXP demonstrating that the C3 
and C4 OH are not critical for binding, but essential for catalysis.  
The Et-DOXP binds Synechocystis PCC6803 DXR at the same site of DOXP, 
but apparently the added steric bulk prevents successful turnover. DOXP-
phosphonate appears as an alternate substrate. The change from a phosphate to a 
phosphonate led to a drop in affinity but still allowed turnover probably because this 
modification is distant from the part of the molecule undergoing transformation. 
 
                                            
218
 Meyer, O., Grosdemange-Billiard, C., Tritsch, D., Rohmer, M. Org. Biomol. Chem. 2003, 1, 4367-
4372. 
219
 Hirsch, G., Grosdemange-Billiard, C., Tritsch, D., Rohmer, M. Tetrahedron Lett. 2004, 45, 519-521. 
220
 Phaosiri, C., Proteau, P. J. Bioorg. Med. Chem. Lett. 2004, 21, 5309-5312. 
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Recently, the amide 1.108 and five analogues (1.110-1.114) were prepared by 
Walker and Poulter.221 In analogues 1.110-1.112 the methyl group of DOXP was 
replaced by hydroxyl, hydroxylamino and methoxy moieties, respectively. In 
analogues 1.113 and 1.114, the acetyl group of DOXP was replaced by a 
hydroxymethyl and aminomethyl group. Except from analogues 1.111 and 1.114, all 
were very weak inhibitors of E. coli DXR with IC50 values from 0.25 to 1.0 mM. 
Analogue 1.111 was argued to be one atom too long to fit in the restricted volume of 
the pocket. In addition, Et-DOXP was confirmed to be a weak inhibitor. In derivative 
1.114, the amino group is supposed to be protonated and not able to complex the 
metal ion.  
Recently, Proteau and coworkers described the synthesis of the phosphate 
analogues of fosmidomycin (1.115) and FR900098 (1.116).215 The former had 
previously been isolated from Pseudomonas fluorescens PK-52 and is known as 
fosfoxacin.222 The latter proved a very potent inhibitor of Synechocystis DXR (Ki = 
0.002 M vs. fosmidomycin = 0.057 M) . 
 
1.3.2. PRODRUGS 
 
As a consequence of the strong hydrophilic properties, fosmidomycin shows a 
moderate biological availability of approximately 30%. At physiological pH, 
phosphonic acids occur in their ionised form and, therefore, pass poorly through 
membranes by passive diffusion. To enhance the in vivo availability of drugs with a 
phosphonic acid group, this group is often masked by a protective group. In this way 
a neutral and essentially lipophilic molecule is obtained. A requirement for the 
preservation of the activity is that the protective group is cleaved under physiological 
conditions to liberate the active form. Different prodrug derivatives of FR900098 
(1.84) have been synthesized and evaluated.223,224 
 
                                            
221
 Walker, J. R., Poulter, C. D. J. Org. Chem. 2005, 70, 9955-9959. 
222
 Katayama, N., Tsubotani, S., Nozaki, Y., Harada, S., Ono, H. J. Antibiot. 1990, 43, 238-246. 
223
 Noren, J. O., Helgstrand, E., Johansson, N. G., Misiorny, A., Stening, G. J. Med. Chem. 1983, 26, 
264-270.  
224
 Serafinowska, H. T., Ashton, R. J., Bailey, S., Harnden, M. R., Jackson, S. M., Sutton, D. J. Med. 
Chem. 1995, 38, 1372-1379. 
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1.3.2.1. DIARYL ESTERS 
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Figure 1.35: Diaryl ester prodrugs of FR900098. 
 
The implementation of aryl and acyloxyalkyl esters in acyclic 
phosphononucleotides improved the bioavailability drastically.224 Based on these 
results Reichenberg and coworkers transformed the phosphonate moiety of 
FR900098 into phosphodiaryl esters, expected to be hydrolysed by non-specific 
plasma esterases.225 The antimalarial activity of the prodrugs (Figure 1.35) was 
tested in Plasmodium vinckei-infected mice. 
The unsubstituted diphenyl ester 1.117 was significantly more active than 
FR900098 after oral administration. In contrast the bis-(2-methylphenyl) ester 1.118 
was significantly less active than FR900098. Steric hindrance by the ortho substituent 
probably hampers access by the esterases. The bis-(4-methoxyphenyl) ester 1.119 
proved the most efficient and equaled the activity of FR900098 administered by i.p. 
route. 
 
1.3.2.2. ACYLOXYALKYL ESTERS 
 
Concerns about the toxicity of the phenol derivatives generated by hydrolysis 
of the phenolic prodrugs prompted Ortmann and coworkers to make a series of 
                                            
225
 Reichenberg, A., Wiesner, J., Weidemeyer, C., Dreiseidler, E., Sanderbrand, S., Altincicek, B., 
Beck, E., Schlitzer, M., Jomaa, H. Bioorg. Med. Chem. Lett. 2001, 11, 833-835. 
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acyloxyalkyl ester prodrugs of FR900098 (Figure 1.36).226,227 The activity of these 
prodrugs was tested in a same way as the diaryl esters. Prodrug 1.120 appeared less 
active and prodrug 1.121 was more active than FR900098. To avoid the formation of 
formaldehyde during hydrolysis, other analogues were prepared. The 
pivaloyloxyethyl ester 1.122 and the benzoyloxyethyl ester 1.123 displayed activities 
comparable to FR900098. The activities appeared to improve when less bulky acyl 
residues were used. Both the acetyloxyethyl ester 1.124 and the propionyloxyethyl 
ester 1.125 proved more effective than FR900098. In contrast, the 
propionyloxyisobutyl derivative 1.126 caused an activity drop. Treatment with 20 
mg/kg 1.124 p.o., was slightly more effective than 40 mg/kg p.o. FR900098. This 
difference was due to higher plasma concentrations of FR900098. The two 
bis[(alkoxycarbonyloxy)ethyl] esters 1.127 and 1.128 were more active than 
FR900098. Until today, all these prodrugs were only tested in murine models. 
Compound 1.129 showed lower activity. 
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Figure 1.36: Overview of reported alkoxycarbonyloxyethyl ester prodrugs of FR900098. 
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 Ortmann, R., Wiesner, J., Reichenberg, A., Henschker, D., Beck, E., Jomaa, H., Schlitzer, M. 
Bioorg. Med. Chem. Lett. 2003, 13, 2163-2166. 
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1.3.3. OBJECTIVES: DESIGN OF NEW INHIBITORS FOR DXR 
 
Increased efforts in antimalarial drug discovery are urgently needed. The goal 
must be to develop safe, affordable and effective new drugs to counter the spread of 
malaria parasites that are resistant to existing agents. 
The research presented in this thesis is part of a larger multidisciplinary project 
with the common objective of developing new antimalarials that interfere with the 
DOXP pathway. 
 
The scope of this thesis is to discover new inhibitors of DXR with the potential 
to be developed through subsequent research into a new medication for malaria. 
Fosmidomycin will be used as lead and the main objective is the synthesis of a series 
of analogues in order to expand the structure-activity relationship (SAR) of 
fosmidomycin analogues as DXR inhibitors. 
Our investigations will be described in five chapters. 
 
• Chapter 2.2.1 describes the synthesis of analogues characterized by 
modifications of the N-hydroxyformamido group (Figure 1.37).  
 
In the next three chapters, modifications on the propyl chain are described (Figure 
1.37). 
 
• The synthesis of an entirely new class of fosmidomycin analogues possessing 
differently substituted phenyl moieties in -position of the phosphonate is 
described in chapter 2.3.1 
  
• Chapter 2.3.2 discusses the synthesis of a series of analogues featuring 
restricted conformational mobility. 
 
• To expand the structure-activity relationship of fosmidomycin and FR900098, 
analogues were synthesized in which the methylene group in -position of the 
phosphonate moiety was replaced by an oxygen atom. The synthesis of 
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analogues that combine this -oxa or a -oxa modification with a hydroxamic 
acid moiety are reported in chapter 2.3.3. 
 
• In chapter 2.4 ensuing studies involving the synthesis of analogues that mimic 
the transition state are described. 
 
The biological activities of the synthesized compounds are described in chapter 3.  
 
H N P
O
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O
- methyl, ethyl and hydroxyethyl in place of OH together with
replacement of formyl by acetyl, benzoyl, naphthoyl and palmitoyl
- substitution
of retrohydroxamic acid
by hydroxamic acids
- introduction of substituted phenyl moieties at the 
α-position of the phosphonate moiety
- incorporation of the propyl chain in a 
cyclopentane ring
- introduction of oxygen atom in the propyl chain
 
 
Figure 1.37: Overview of the planned modifications on fosmidomycin. 
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2. DESIGN AND SYNTHESIS OF INHIBITORS OF DXR 
 
After introducing shortly the phosphonate group (2.1.) we will discuss our design and 
synthesis work in three chapters: 
- 2.2. Modifications of the hydroxamide moiety 
- 2.3. Modifications of the propyl chain 
- 2.4. Synthesis of a transition state analogue 
 
2.1. BRIEF INTRODUCTION ON PHOSPHONATE 
CHEMISTRY 
2.1.1. SYNTHESIS OF THE PHOSPHONATE MOIETY 
 
Since the phosphonic acid group is important in the binding of fosmidomycin to 
DXR, the introduction of the C−P bond is an essential issue in the synthesis of 
metabolically stable analogues. Many papers and reviews deal with the synthesis of 
phosphonic acids.228 Two primary challenges associated with the synthesis of 
phosphonic acids are the formation of the C−P bond and the cleavage of the 
protective groups. Four major reaction types to form a C−P bond can be considered.  
 
2.1.1.1. THE MICHAELIS-ARBUSOV REACTION 
 
The Michaelis-Arbusov synthesis is the reaction of a trialkyl phosphite with an 
alkyl halide under elevated temperature with the formation of a dialkyl phosphonic 
ester. In this reaction a quaternary alkoxyphosphonium intermediate is formed, 
followed by a dealkylation accompanied by valency expansion of phosphorus to form 
a P=O bond. This latter proces which represents a valence shell expansion of 
phosphorus from 8 to 10 electrons is made possible by the availability of vacant 3d 
orbitals. 
 
                                            
228
 (a) Engel, R. Chem. Rev. 1977, 77, 349-367. (b) Fields, S. C. Tetrahedron 1999, 55, 12237-12273. 
(c) Enders, D., Saint-Dizier, A., Lannou, M.−I., Lenzen, A. Eur. J. Org. Chem. 2006, 29-49. 
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2.1.1.2. THE MICHAELIS-BECKER REACTION 
 
The Michaelis-Becker synthesis involves reaction of the alkali salt of a 
dialkylphosphite with an alkyl halide and the formation of the corresponding dialkyl 
phosphonic ester. 
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2.1.1.3. A MICHAEL ADDITION OF ALKYLPHOSPHITE TO AN ACTIVATED 
DOUBLE BOND 
 
The addition of a phosphorus nucleophile to an acceptor-substituted alkene or 
alkyne, such as an ,-unsaturated aldehyde or ketone, results in the corresponding 
dialkyl phosphonic ester. 
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2.1.1.4. THE ADDITION OF ALKYLPHOSPHITE TO AN AZIRIDINE OR EPOXIDE 
 
Another possibility to obtain a C−P bond is the opening of an aziridine or 
epoxide with trialkyl phosphite or the alkali salt of a dialkyl phosphite. 
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with X = O or N 
 
2.1.2. CLEAVAGE OF THE PHOSPHONATE ESTERS 
 
The cleavage of phosphonic acid dialkyl esters can be achieved by reflux in 
concentrated HCl. These harsh conditions often result in complex reaction mixtures 
and poor yields. A mild alternative is the transesterification with bromotrimethylsilane 
(TMSBr) or iodotrimethylsilane (TMSI) into the corresponding bistrimethylsilyl diester 
of the phosphonic acid.229 This can subsequently be hydrolysed upon reaction with 
H2O. An other alternative is the use of dibenzyl phosphite. The resulting dibenzyl 
phosphonate ester can be cleaved by hydrogenolysis. 
 
2.1.3. PROPERTIES OF FREE PHOSPHONIC ACIDS 
 
Phosphonic acids are rather strong acids, with a higher acidity than carboxylic 
acids, but lower than similar sulfonic acids. In general the pKa’s are between 2.4 and 
                                            
229
 (a) McKenna, C. E., Schmidhauser, J. C. S. Chem. Comm. 1979, 739. (b) McKenna, C. E., Higa, 
M. T., Cheung, N. H., McKenna, M.–C. Tetrahedron Lett. 1977, 2, 155-158. 
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2.9 and between 7.7 and 9, respectively. The negative charge of the phosphonate 
anion is spread over two oxygen atoms by mesomery. 
As expected, electron withdrawing groups on the -position of the 
phosphonate raise the acidity. The first pKa of methylphosphonic acid is 2.38 and 
lowers to 1.63 in trichloromethylphoshonic acid.230 
The phosphonic acid group is strongly polar. Derivatives with a short carbon 
skeleton are highly water soluble. In organic solvents marked intermolecular 
hydrogen bonding takes place. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                            
230
 Quin, L. D., A guide to organophosphorus chemistry, Wiley Interscience (2000). 
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2.2. MODIFICATIONS OF THE HYDROXAMIDE MOIETY 
2.2.1. MODIFICATIONS ON NITROGEN 
2.2.1.1. RATIONALE 
 
At the start of this project we envisaged the synthesis of fosmidomycin analogues 
with a modified N-hydroxyformamide moiety. These analogues 2.1-2.9 are shown in 
Table 2.1.  
 
Table 2.1: Overview of fosmidomycin analogues. 
 
PNR
R'
R'
O
O
OH
OH
 
 R R’ R” 
fosmidomycin (1.83) H OH H 
FR900098 (1.84) CH3 OH H 
2.1 CH3 CH3 H 
2.2 CH3 CH2CH3 H 
2.3 H CH3 H 
2.4 H CH2CH3 H 
2.5 CH3 CH3 CH3 
2.6 CH3 (CH2)2OH H 
2.7 Ph (CH2)2OH H 
2.8 1-naphtyl (CH2)2OH H 
2.9 C15H31 (CH2)2OH H 
 
 
First, we explored the possibility to replace the OH substituent on the nitrogen 
by a methyl, ethyl or hydroxyethyl group. The methyl and ethyl substituents in 
compounds 2.1-2.4 were introduced because in the transition state of the enzymatic 
conversion of DOXP there is also a methyl function on C2, which corresponds with 
the nitrogen in fosmidomycin and FR900098 after superposition (Figure 1.29). The 
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hydroxyethyl moiety on the nitrogen in compound 2.6 was introduced to investigate 
the effect of an extended distance between the hydroxyl function and the nitrogen.  
Compounds 2.7-2.9 represent analogous compounds with more lipophylic acyl 
groups. Although the efficacy of fosmidomycin for the treatment of acute 
uncomplicated malaria was recently proven in several clinical trials, relatively high 
doses of fosmidomycin were required to achieve the desired results. This is partly 
due to the highly polar nature of this molecule. Therefore, we addressed the question 
whether it might be possible to obtain more lipophilic DXR inhibitors by replacing the 
formyl or acetyl residue of fosmidomycin or FR900098 by sterically more demanding 
residues. 
The choice of altered acyl moieties in compounds 2.7, 2.8 and 2.9 was based 
on unpublished biological results. The same is true for the introduction of a methyl in 
the -position of the phosphonate (2.5).231  
 
2.2.1.2. SYNTHESIS 
 
The N-methyl- and N-ethylacetamide derivatives 2.1 and 2.2 were synthesized 
as shown in Scheme 2.1 starting from N-(3-bromopropyl)phthalimide (2.10).232 A 
Michaelis-Arbusov reaction with an excess of triethyl phosphite under reflux, followed 
by treatment of 2.11 with hydrazine monohydrate yielded diethyl 3-
aminopropylphosphonate (2.12). After purification by column chromatography, amine 
2.12 was acetylated with acetyl chloride. The resulting amide 2.13 was deprotonated 
with sodium hydride and alkylated with iodomethane or iodoethane to give 2.14 and 
2.15, respectively. Deprotection of the phosphonate esters to give the desired 
phosphonates 2.1 and 2.2 was accomplished with TMSI or TMSBr. Generally TMSI 
gave better yields and shorter reaction times. 
            
                                            
231
 Wiesner, J., Jomaa, H. unpublished results. 
232
 Gali, H., Prabhu, K. R., Karra, S. R., Katti, K. V. J. Org. Chem. 2000, 65, 676-680. 
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Scheme 2.1: Reagents and conditions (a) triethyl phosphite, reflux, 12 h (98%), (b) 
NH2NH2.H2O, EtOH, reflux, overnight (94%), (c) acetyl chloride, pyridine, CH2Cl2, rt, 3 h (82 
%), (d) MeI or EtI, NaH, THF, rt, overnight (72% and 67% respectively), (e) TMSI, CH2Cl2, rt, 
2 h (100 %).  
 
The formyl analogues 2.3 and 2.4 were prepared by nucleophilic attack of the 
commercially available N-methylformamide or N-ethylformamide on diethyl (3-
bromopropyl)phosphonate (2.16) after deprotonation with sodium hydride (Scheme 
2.2). The yields for these reactions were 52% and 72%, respectively. This method 
was also succesfully applied using N-methylacetamide or N-ethylacetamide to 
synthesize products 2.1 and 2.2, thereby providing a more efficient method. 
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2.16 2.14 R = CH3 ,R' = CH3
2.15 R = CH3 ,R' = C2H5
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2.1 R = CH3 ,R' = CH3
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O O
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Scheme 2.2: Reagents and conditions (a) N-methylformamide, N-methylacetamide, N-
ethylformamide or N-ethylacetamide, NaH, DMF, rt, 16 h (52-72%), (b) TMSI, CH2Cl2, rt, 2 h 
(100 %). 
 
An attempt to prepare the hydroxyethyl and hydroxymethyl analogues in the 
same way as the formyl analogues 2.3 and 2.4, using TBDMS protected N-
hydroxyethyl- and N-hydroxymethylacetamide failed (Scheme 2.3). The preparation 
of the hydroxymethyl analogue by reaction of amide 2.13 with paraformaldehyde and 
anhydrous potassium carbonate in dioxane was also unsuccessful. 
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OEt
OEt
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Scheme 2.3: Reagents and conditions: NaH, DMF, overnight. 
 
An attempt to react 2,2-dimethyl-1,3-oxazolidine 2.19, which was prepared 
according to a literature procedure,233 with diethyl (3-bromopropyl)phosphonate 
(2.16) was not successful either (Scheme 2.4). Although only activated bromides 
have been used for such alkylation reactions,234 we succeeded in preparing the 
hydroxyethyl analogues 2.6-2.9 by selective nucleophilic attack of the amino group of 
ethanolamine to diethyl (3-bromopropyl)phosphonate (2.16) to yield compound 2.21 
                                            
233
 Bergmann, E. D. Chem Rev. 1953, 53, 309-352. 
234
 Falb, E., Bechor, Y., Nudelman, A., Hassner, A., Albeck, A., Gottlieb, H. E. J. Org. Chem. 1999, 64, 
498-506. 
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in 68% yield. Characterization by NMR of the side products revealed further reaction 
of the NH group with diethyl (3-bromopropyl)phosphonate (2.16) towards compound 
2.22. The use of an excess of 5 equivalents of ethanolamine allowed to reduce this 
side reaction.  
Compound 2.21 was subsequently acylated with palmitoyl-, benzoyl-, 1-
naphthoyl- and acetyl chloride under Schotten-Baumann conditions to achieve 
selective acylation of the amine in 70-80% yield. Final deprotection of 2.23 afforded 
the target compounds 2.6-2.9. 
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Scheme 2.4: Reagents and conditions (a) diethyl (3-bromopropyl)phosphonate, Et3N, THF, 0 
°C	rt, 1.5 h, (b) ethanolamine, K2CO3, acetonitrile, rt, 10 h (68%), (c) acetyl chloride, 
palmitoyl chloride, benzoyl chloride or 1-naphthoyl chloride, Schotten-Baumann conditions 
(1:1 THF:50% NaOAc), rt, 3 h (70%), (d) TMSI, CH2Cl2, rt, 2 h (100%). 
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For the synthesis of the -methyl analogue 2.5 we first tried a similar approach 
as outlined in Scheme 2.1, i.e. deprotonation of an  proton of diethyl 
ethylphosphonate with nBuLi and nucleophilic attack on N-(2-bromoethyl)phthalimide. 
Due to purification problems we had to look for an alternative approach. A successful 
attempt (Scheme 2.5) started from benzyl 2-bromoethyl ether (2.24) which was 
subjected to a reaction with diethyl ethylphosphonate in the presence of nBuLi to 
afford phosphonate 2.25. Benzyl deprotection of 2.25 by catalytic hydrogenation 
gave 2.26. Alcohol 2.26 was converted to the corresponding mesylate (2.27), which 
was displaced by an azido anion. Azide 2.28 was reduced with triphenylphosphine in 
pyridine, followed by addition of NH4OH, to give amine 2.29. This amine was further 
acetylated with acetyl chloride and alkylated with iodomethane to obtain compound 
2.5 in an overall yield of 5%. 
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Scheme 2.5: Reagents and conditions (a) diethyl ethylphosphonate, nBuLi, -78 °C, 3 h 
(28%), (b) H2, Pd/C, MeOH, rt, 5 h (83%), (c) methanesulfonyl chloride, pyridine, DMF, 0 °C, 
20 h (100%), (d) NaN3, DMF, 95 °C, 1.5 h (56%), (e) triphenylphosphine, pyridine, NH4OH, 3 
h (63%), (f) acetyl chloride, pyridine, CH2Cl2, rt, 2 h (86%), (g) MeI, NaH, THF, rt, overnight 
(25%) (h) TMSI, CH2Cl2, rt, 2 h (100%). 
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2.2.2. MODIFICATION OF THE RETROHYDROXAMIC ACID  
2.2.2.1. INTRODUCTION 
 
Two types of fosmidomycin/FR900098 analogues in which the hydroxyamide 
moiety is part of cyclic system were considered (Figure 2.1). First we explored the 
possibility to replace the N-hydroxyacetamide by a 2-substituted 1,2-oxazinan-3-one 
(2.38), which originates from connecting the terminal methyl group of FR900098 with 
the oxygen atom of the hydroxylamine part via two methylene units. 
The 4-substituted 1-hydroxyazetidin-2-one 2.42b is obtained by connecting the 
terminal methyl group of FR900098 with the carbon in -position of the phosphonate. 
We also planned to prepare 2.42a with a shorter linker between the 
hydroxyazetidinone and the phosphonate moiety. 
 
N
O
O
P
O OH
OH
2.38
HON
O
P OHOH
O
n = 1-2
2.42a (n = 1)
2.42b (n = 2)
 
 
Figure 2.1: Structures of compounds 2.38 and 2.42. 
 
2.2.2.2. SYNTHESIS 
 
The synthesis of compounds 2.38 is shown in Scheme 2.6. 1,2-Oxazinan-3-
one (2.36) was prepared by a method adapted from Wolfe and coworkers.235 It 
started from butyrolactone (2.32), which was heated at 75 °C with a 45% solution of 
hydrogen bromide in acetic acid followed by treatment with methanol to give methyl 
-bromobutyrate 2.33. The bromide was displaced by N-hydroxyphthalimide to give 
compound 2.34. The aminooxy group in 2.34 was deprotected upon treatment with 
methylhydrazine for 1.5 h at -10 °C. Deprotection with hydrazine under reflux was too 
drastic since it caused hydrolysis of the methyl ester. The cyclization of 2.35 was 
                                            
235
 Wolfe, S., Wilson, M.−C., Cheng, M.-H., Shustov, G. V., Akuche, C. I. Can. J. Chem. 2003, 81, 
937-960. 
 - 84 -
achieved with trimethylaluminium in THF. A nucleophilic substitution of diethyl 
bromopropylphosphonate with 2.36 using Et3N in THF failed due to insolubility of the 
oxazinone. It also failed with potassium fluoride-alumina in DMF (Table 2.2). More 
effective in this case was the treatment of 2.36 with potassium carbonate in acetone. 
The resulting phosphonate 2.37 was deprotected with TMSBr in CH2Cl2 to yield 2.38 
that was further purified via reversed phase HPLC. 
 
Table 2.2: Overview of reaction conditions tested to transform 2.36 to 2.37. 
 
Solvent Base Temp. Yield 
dry THF Et3N (1.1 eq.) rt No reaction 
dry THF Et3N (1.1 eq.) 70 °C (reflux) No reaction 
dry DMF KF-Al2O3 (40% wt) rt No reaction 
acetone K2CO3 (2 eq.) 60 °C (reflux) 43% 
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Scheme 2.6: Reagents en conditions (a) 45% HBr-HOAc, MeOH, 75 °C, 4 h (53%), (b) N-
hydroxyphthalimide, Et3N, MeCN, reflux, 3 h (71%), (c) MeNHNH2, CH2Cl2, 0 °C, 1.5 h 
(100%), (d) AlMe3, toluene, reflux, 2 h (20%), (e) diethyl (3-bromopropyl)phosphonate, K2CO3 
in acetone, reflux, 1 h (43%), (f) TMSBr, CH2Cl2, rt, 2 h (36%). 
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Our attempt toward the synthesis of N-hydroxy -lactam 2.42 is outlined in 
Scheme 2.7. Bromide 2.40 was obtained by a three-step sequence as described by 
Rajendra and Miller.236 Vinyl acetic acid was converted to an benzyl protected O-
acylhydroxamate, which was subjected to modified Ganem’s cyclization conditions to 
provide hydroxamate 2.40 in 39% yield.  
 
OH
O
N
O
P OEtOEt
O
2.39
x
n = 1-2
HON
O
P OHOH
O
n = 1-2
2.40 2.41a (n = 1)
2.41b (n = 2) 2.42a (n = 1)2.42b (n = 2)
(a)-(c) (d)
OO
BnO
N
O
OO
BnO
Br
 
 
Scheme 2.7: Reagents en conditions: (a) i.(COCl)2 ii. NH2OH.HCl/KOH/CH3OH, (b) 
PhCH2OC(=O)Cl, pyridine, (c) Br2/K2CO3, 5-10% H2O/CH3CN, (d) triethyl phosphite, reflux or 
nBuLi, CH3P(O)(OEt)2, THF, -78 °C. 
 
Neither Michaelis-Arbusov conditions nor a reaction with diethyl 
methylphosphonate and nBuLi allowed to transform 2.40 into 2.41a or 2.41b. 
Complex reaction mixtures were obtained, from which we were unable to isolate the 
desired product. 
 
 
 
 
 
 
 
 
                                            
236
 Rajendra, G., Miller, M. J. Tetrahedron Lett. 1985, 26, 5385-5388. 
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2.3. MODIFICATIONS OF THE PROPYL CHAIN 
2.3.1. MODIFICATIONS ON THE -POSITION OF THE 
PHOSPHONATE GROUP 
 
Adapted from: “Synthesis of -substituted fosmidomycin analogues as highly potent 
Plasmodium falciparum growth inhibitors” Timothy Haemers, Jochen Wiesner, Sara 
Van Poecke, Jan Goeman, Dajana Henschker, Edwald Beck, Hassan Jomaa, Serge 
Van Calenbergh in Bioorg. Med. Chem. Lett. 2006, 16, 1888-1891  
 
And “Synthesis of -Aryl-Substituted and Conformationally Restricted Fosmidomycin 
Analogues as Promising Antimalarials” Timothy Haemers, Jochen Wiesner, Roger 
Busson, Hassan Jomaa, Serge Van Calenbergh in Eur. J. Org. Chem. 2006, 17, 
3856-3863.  
 
This work is also the subject of a PCT patent application “Organophosphoric 
derivatives useful as anti-parasitic agents”  
 
2.3.1.1. INTRODUCTION AND RETROSYNTHESIS 
 
In the 1970s, Okuhura and colleagues reported the first isolation of 
fosmidomycin as a structurally simple antibiotic from Streptomyces lavendulae. In 
recent years, fosmidomycin received considerable attention due to its promising 
antimalarial activity, and recent clinical trials conducted in Gabon and Thailand 
confirmed the potential of fosmidomycin as an antimalarial drug.184,185 In 1998, the 
molecular target of fosmidomycin was discovered to be 1-deoxy-D-xylulose 5-
phosphate (DOXP) reductoisomerase.169,170 This enzyme plays an essential role in 
the mevalonate-independent pathway for the synthesis of isoprenoids, and is absent 
in humans.156 Fosmidomycin was found to be a potent inhibitor for the DOXP 
reductoisomerase (DXR) of P. falciparum.1 After this important discovery, much 
attention has been focused on the chemical synthesis of fosmidomycin analogues. 
FR900098, the acetyl analogue of fosmidomycin, was shown to be approximately 
twice as active against P. falciparum in vitro, as well as in a P. vinckei mouse model.1 
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Chemical variations of fosmidomycin were mainly directed to increase the 
inhibitory activity against DXR or to achieve inhibitors with improved physicochemical 
properties. To study the structure-activity relationships, hydroxamic moiety 
modifications, including benzoxazolone and oxazolopyridinone functionalities (Figure 
1.31), have been reported.209(b) Also, the phosphonate moiety has been altered to 
produce prodrugs with improved oral bioavailability.225,226,227 
Surprisingly, modifications addressing the three-carbon spacer are scarce. In 
this chapter, we report the discovery of a series of -aryl-substituted fosmidomycin or 
FR900098 derivatives, 3.1 and 3.2 (Figure 3.1).  
 
OHPNR
OH
O
O
OH
R1
R2
3.1a-e (R = H)
3.2a-e (R = CH3)
a: R1 = H; R2 = H
b: R1 = Me; R2 = H
c: R1 = OMe; R2 = H
d: R1 = Cl; R2 = H
e: R1 = Cl; R2 = Cl
 
 
Figure 3.1: Structures of -aryl-substituted analogues of fosmidomycin and FR900098. 
 
Although strategies to synthesise products with a C−P bond are well 
documented,228 introducing aryl substituents in the -position of a phosphonate 
[resulting in a P-CH(Ar)-C motif] is quite challenging. Fosmidomycin was first 
synthesized in the early 1980s by Hemmi et al. using a Michaelis-Becker reaction.210 
This approach cannot be easily adapted to allow the synthesis of -substituted 
derivatives. 
3-Aryl-substituted 3-phosphorylpropanals were anticipated to be appropriate 
intermediates for the synthesis of a small series of -aryl-substituted fosmidomycin 
analogues. Depending on the availability of the starting material, a 
lithiation/allylation/alkene oxidation sequence or a Michael addition will be considered 
for the synthesis of these intermediates (Scheme 3.1). A drawback of this strategy is 
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that every derivative has to be synthesized de novo, which does not permit 
preparation of an extended series of the envisaged analogues. However, when the 
proposed routes give the desired analogues in good overall yields, they might be 
valuable for scale-up purposes, e.g., to prepare a selected inhibitor for in vivo 
studies. Retrosynthetic analysis toward the synthesis of the desired α-substituted 
fosmidomycin analogues is depicted in Scheme 3.1. 
To sort out the influence of the lipophilicity and electronic properties of this 
phenyl moiety, substituents were introduced according to Topliss methodology.237 
Briefly, in this methodology an operational scheme is used to quickly identify the 
optimum substitution on a benzene ring for maximizing drug potency by virtue of 
resulting changes in hydrophobic, electronic and steric effects. 
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Scheme 3.1: Retrosynthetic route toward analogues 3.1 and 3.2. 
 
2.3.1.2. SYNTHESIS 
 
Two synthetic pathways toward the aldehyde synthons were followed 
(Scheme 3.2). The first one started from the appropriate diethyl benzylphosphonate, 
which upon treatment with nBuLi in the presence of allyl bromide, afforded 3.6a,b in 
                                            
237
 a) Topliss, J. G. J. Med. Chem. 1972, 15, 1006-1011, b) Topliss, J. G. J. Med. Chem. 1977, 20, 
463-469. 
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97 and 33% yields, respectively.238 Oxidation of 3.6a,b to the vicinal cis-diol with 
osmium tetraoxide in the presence of 4-methylmorpholine N-oxide, followed by 
sodium periodate cleavage gave aldehydes 3.9a,b, which could be used in the next 
step without further purification. 
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Scheme 3.2: Reagents and conditions: (a) (i) nBuLi, THF, -50 to -70 °C, 15 min, (ii) allyl 
bromide, -70 °C	reflux, 3 h (97%), (b) (i) OsO4, 4-methylmorpholine N-oxide, dioxane, rt, in 
the dark overnight, (ii) NaIO4, rt, 2 h (100%) (c) triethyl phosphite, phenol, 100 °C, 24 h (70-
85%) (d) 2 N HCl, 60-70 °C, 3-4 h (76-83%). 
 
When the proper benzylphosphonate was not commercially available, an 
alternative strategy to prepare the desired aldehydes was followed. A 1,4-addition of 
triethyl phosphite to the appropriately substituted cinnamaldehyde in the presence of 
phenol gave the acetals 3.8c-e in 70-85% yield.239 Subsequent deprotection of the 
diphenyl acetal afforded in 76-83% yield the corresponding aldehydes, which 
appeared stable enough to be purified by flash chromatography.  
                                            
238
 Flitsch, W., Lubisch, W., Rosche, J. Liebigs Ann. Chem. 1987, 8, 661-664. 
239
 Harvey, R. G. Tetrahedron 1966, 22, 2561-2573. 
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If necessary, substituted cinnamaldehydes were synthesized. A reaction with 
vinyl acetate and the corresponding aldehydes in the presence of Ba(OH)2 (Scheme 
3.3)240 resulted in complex reaction mixtures and low yields (< 20%).  
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Scheme 3.3: Reagents and conditions: (a) Ba(OH)2, THF, 65 °C, 10 h (17-20%). 
 
In our hands a palladium-catalyzed synthesis from acrolein diethyl acetal and 
the corresponding aryl iodide was more efficient (yield 58-74%).241 The reaction takes 
place in the presence of Pd(OAc)2, nBu4NOAc, K2CO3, KCl and DMF at 90 °C, 
followed by the addition of 2 N HCl. Under these modified Heck conditions the 
cinnamaldehyde is selectively formed and not the propanoate ester (Scheme 3.4). 
Only the (E)-isomer was obtained, as deduced from the large coupling (16 Hz) 
between the vinylic hydrogen atoms. 
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Scheme 3.4: Reagents and conditions: (a) Pd(OAc)2, nBu4NOAc, K2CO3, KCl, DMF, 90 °C, 
1.5 h (58-74%). 
                                            
240
 Mahata, P. K., Barun, O., Ila, H., Junjappa, H. Synlett. 2000, 9, 1345-1347. 
241
 Battistuzzi, G., Cacchi, S., Fabrizi, G. Org. Lett. 2003, 5, 777-780. 
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Conversion of the appropriate aldehydes (3.9a-e) to the desired analogues 3.1 
and 3.2 is depicted in Scheme 3.5. 
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Scheme 3.5: Reagents and conditions: (a) O-benzylhydroxylamine hydrochloride, pyridine, 
EtOH, rt, 1.5-6 h (67-92%), (b) NaCNBH3, MeOH, HCl, rt, 3-16 h (91-96%) (c) acetyl chloride, 
CH2Cl2, Et3N, 0 °C or carbonyldiimidazole, HCOOH, CH2Cl2, rt, 5 h (79-85%) (or 2-
thioxothiazolidine-3-carbaldehyde, CH2Cl2, rt, 3 d (89%)  for 3.12a), (d) H2, Pd/C, MeOH, rt, 5 
h (20-85%) (e) TMSBr, CH2Cl2, rt, 2 h, almost quantitative. 
 
Treatment of 3.9a-e with O-benzylhydroxylamine yielded (67-92 %) oximes 
3.10a-e. 13C NMR spectroscopy revealed the presence of two geometric isomers, 
which were reduced with sodium cyanoborohydride to produce the benzyloxyamines 
3.11a-e in 91-96 % yield. Subsequent acetylation of 3.11a-e with acetyl chloride 
afforded 3.13a-e in good yield. Different methods were investigated for the 
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formylation of 3.11. Since the mixed anhydride method was unsuccessful, compound 
3.11a was formylated with 2-thioxothiazolidine-3-carbaldehyde, prepared by reaction 
between 2-mercaptothiazoline and formic acid using DCC as coupling agent. A 
drawback of this approach was the long reaction time (more than 3 days at room 
temperature). Consequently, 3.11c,d,e were formylated using formic acid and 1,1’-
carbonyldiimidazole in dichloromethane. This method reduced the reaction time 
considerably. 
Benzyl deprotection by catalytic hydrogenation proved tricky, especially in the 
formyl series, where this reaction generally led to the formation of two reaction 
products. After their separation, mass spectrometry was useful in assigning these 
compounds as the desired product and the corresponding deoxygenated derivative, 
i.e. the amide. Further structural evidence for this deoxygenation was furnished by a 
1H COSY NMR spectrum of the side product, which shows a strong coupling 
between the NCH2 protons and a heteroatom-bound proton at 
 = 7.04 ppm. This 
coupling is normally absent in the desired products, as may be expected for such 
long-range 4J(CH2NOH) coupling. 
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Figure 3.6: 1H COSY NMR spectrum of product 3.16c, which shows a strong coupling 
between the NCH2 protons and a heteroatom-bound proton at 
 = 7.04 ppm. 
 
Also, the characteristic 13C NMR upfield shifts of the N-CH2 carbon signal are 
in agreement with the absence of the OH group on the nitrogen atom (-substituent 
effect). Indeed, for the deoxygenated product 3.16c the N-CH2 signal appeared at 
 = 
35.8 ppm, while for product 3.14c two signals at 
 = 47 and 44 ppm were found 
(Figure 3.7). This indicates that 3.14c (and also 3.14e) exists as a mixture of syn- 
and anti-NOH rotamers in a 2:1 ratio. 
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13C-NMR (75 MHz, CDCl3): d = 16.05 (d, 3JC,P = 5.9 Hz, 
OCH2CH3), 16.15 (d, 3JC,P = 5.9 Hz, OCH2CH3), 26.40 (CH2CHP, major), 27.02 (CH2CHP, minor), 39.56 (d, 
1JC,P = 139.2 Hz, CHP, major), 40.66 (d, 1JC,P = 137.2 
Hz, CHP, minor), 44.56 (d, 3JC,P = 16.6 Hz, NCH2, 
minor); 47.05 (d, 3JC,P = 16.1 Hz, NCH2, major), 55.03 
(OCH3), 62.07 (d, 2JC,P = 6.9 Hz, OCH2CH3, major), 
62.25 (d, 2JC,P = 6.8 Hz, OCH2CH3, minor), 62.69 (d, 
2JC,P = 6.3 Hz, OCH2CH3, major), 62.83 (d, 2JC,P = 5.9 
Hz, OCH2CH3, minor), 113.89 (=CmH, minor), 114.11 
(=CmH, major), 125.94 (d, 2JC,P = 7.3 Hz, =Ci, major), 
126.75 (d, 2JC,P = 6.4 Hz, =Ci, minor), 130.05 (=CoH), 
158.77 (=Cp, minor), 158.90 (=Cp, major), 156.84 (C=O, 
major), 162.56 (C=O, minor) ppm.
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13C-NMR (75 MHz, CDCl3): d = 15.89 (d, 3JC,P = 4.8 Hz, 
OCH2CH3), 16.03 (d, 3JC,P = 5.0 Hz, OCH2CH3), 29.45 
(CH2CHP), 35.80 (d, 3JC,P = 16.5 Hz, NCH2), 40.89 (d, 
1JC,P = 116.2 Hz, CHP), 54.85 (OCH3), 61.68 (d, 2JC,P = 
7.8 Hz, OCH2CH3), 62.35 (d, 2JC,P = 6.7 Hz, OCH2CH3), 
113.93 (d, JC,P = 2.0 Hz, =CmH), 126.61 (d, JC,P = 7.4 Hz, 
=Ci), 129.78 (d, JC,P = 6.6 Hz, =CoH), 158.58 (d, JC,P = 
2.8 Hz, =Cp), 161.25 (C=O) ppm.
 
 
Figure 3.7: 13C NMR’s of 3.14c and 3.16c. 
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Compounds 3.14c,e and 3.15a-e were finally deprotected with 4 equivalents of 
TMSBr in CH2Cl2 at ambient temperature to afford 3.1c,e and 3.2a-e after purification 
by reversed-phase HPLC. Although this reaction was almost quantitative, minor 
amounts of deacylated products were detected, probably due to small amounts of 
HBr in the TMSBr reagent. Compounds 3.16a,c were deprotected in the same way, 
and evaluated for their activity to demonstrate the importance of the NOH group.  
In a 1H NMR experiment compound 3.2b was subjected to higher 
temperatures to investigate the influence on the two rotamers. In table 3.1 the proton 
shifts at 80 °C demonstrated the coalescence of the syn- and anti-NOH rotamers. 
Also the 13C NMR spectra confirmed this coalescence by elevated temperatures. 
Unfortunately, attempts carried out at Advanced Separation Technologies Inc. 
(Whippany, NJ, USA) to resolve the racemate 3.1e into its pure enantiomers using a 
whole range of chiral columns remained unsuccessful. We believe that the proton on 
C- is too acidic to allow isolation of the pure enantiomers. 
 
Table 3.1: comparison of 1H NMR (D2O, 500 MHz) data of compound 3.2b by two different 
temperatures. 
 
 
 (ppm) by 27 °C 
 (ppm) by 80 °C 
CH2N syn: 3.58 & 3.38 
anti: 3.53 & 3.46 
3.55 & 3.42 
CHP syn: 2.85 
anti: 3.06 
2.87 
C-CH2-C syn: 2.35 & 2.18 
anti: 2.47 & 2.18 
2.38 & 2.17 
Me-Ar syn: 2.30 
anti: 2.30 
2.30 
MeC=O syn: 2.02 
anti: 1.70 
1.95 (broad signal) 
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2.3.2. CYCLOPENTANE FOSMIDOMYCIN ANALOGUES 
 
Adapted from: “Synthesis of -Aryl-Substituted and Conformationally Restricted 
Fosmidomycin Analogues as Promising Antimalarials” Timothy Haemers, Jochen 
Wiesner, Roger Busson, Hassan Jomaa, Serge Van Calenbergh in Eur. J. Org. 
Chem. 2006, 17, 3856-3863.  
 
2.3.2.1. RATIONALE 
 
Fosmidomycin exhibits close structural similarities with the intermediate from 
the DXR catalyzed reaction (Figure 1.29). Both share a formyl and phosphonate (or 
phosphate) moiety separated by five chemical bonds. Earlier results confirmed that 
extension or shortening of the linker has a negative effect on the inhibitory activity.242 
To acquire greater understanding in the structure-activity relationship of 
fosmidomycin, we considered the synthesis of analogues of fosmidomycin featuring a 
strongly reduced mobility. Such strategy is often followed in medicinal chemistry to 
deduce the “active conformation” of highly flexible molecules. Conformationally 
restricted -aminobutyric acid (GABA) analogues, for instance, have been used to 
help identify three major GABA receptors. GABA is a highly flexible molecule, 
therefore, it can attain many low-energy conformations that bind to the different 
GABA receptors.243 Fosmidomycin, consists of a linear highly flexible chain of three 
carbon atoms bearing a phosphonate functionality on one side and a 
hydroxyformamide functionality on the other side. Obviously, this chain can adopt a 
lot of conformations. One of the possibilities to reduce the number of possible 
conformations is restrict the free rotation around these three bonds. This can be 
realized via connection of the α- and β-carbon giving rise to a three-membered ring. 
Indeed, by incorporating the α- and β-carbon atoms in a cyclopropane ring, we 
recently demonstrated that rigidification of fosmidomycin might result in potent DXR 
inhibitors.213 Consequently, it was thought that other conformationally restricted 
analogues like 3.3 and 3.4 should be investigated. 
 
                                            
242
 Wiesner, J., Jomaa, H. Unpublished results. 
243
 Chebib, M., Johnston, G. A. R. Clin. Exp. Pharmacol. Physiol. 1999, 26, 937-940. 
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Figure 3.8: Structures of the target conformationally restricted analogues of fosmidomycin 
and FR900098. 
2.3.2.2. SYNTHESIS 
 
The global strategy employed for the synthesis of the desired cyclopentane 
analogues, is based on the synthesis of the -substituted analogues. We anticipated 
that, when applied to cyclopent-2-enone, a Michael addition could be a useful 
approach to prepare the envisaged fosmidomycin analogues 3.3 and 3.4, from 
cyclopent-2-enone (Scheme 3.9). 
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Scheme 3.9: Reagents and conditions: (a) triethyl phosphite, phenol, 100 °C, 24 h (90%), (b) 
O-benzylhydroxylamine, pyridine, EtOH, rt, 6 h (90%), (c) NaCNBH3, MeOH, HCl, rt, 17 h 
(80%), (d) acetyl chloride, CH2Cl2, Et3N, 0 °C, 2 h (95%) or carbonyldiimidazole, HCOOH, 
CH2Cl2, rt, 5 h (97%), (e) H2, Pd/C, MeOH, rt, 5 h (19-46%), (f) TMSBr, CH2Cl2, rt, 2 h, almost 
quantitative. 
 - 98 -
Indeed, Michael addition of triethyl phosphite to this cyclic ,-unsaturated 
ketone gave direct access to the diethyl 3-oxocyclopentylphosphonate 3.19.239 The 
remaining part of the synthesis involved the same transformations as used for the -
aryl phosphonates. Separation of the diastereomeric pairs was realized after the 
hydrogenolysis. The cis and trans isomers were assigned by 1H NOEDIF NMR 
experiments: an interaction between the NOH group and the methyl groups of the 
phosphonate ester was observed for cis-3.24 and cis-3.25, as opposed to the trans 
isomers, where such a contact was missing (Figure 3.10). 
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Figure 3.10: 1H NOEDIF NMR (CDCl3, 500 MHz) after irradiation of the hydroxyl proton 
(NOH) of cis-3.25 (interaction between POCH2CH3 and NOH) and 1H NOEDIF NMR after 
irradiation of the hydroxyl proton (NOH) of trans-3.25 (contact is missing between POCH2CH3 
and NOH). 
 
The 13C NMR spectra of compounds 3.24 further point to the presence of a 
major and a minor form, probably as a result of restricted rotation in the 
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retrohydroxamic group, with preferential formation of the syn isomer due to a likely 
hydrogen bond between the N-hydroxy group and the carbonyl group. 
 
2.3.3. INTRODUCTION OF AN OXYGEN ATOM IN - AND -
POSITION OF THE PHOSPHONATE FUNCTION 
 
Adapted from: “Synthesis of - and -oxa Isosters of Fosmidomycin and FR900098 
as Antimalarial Candidates” Timothy Haemers, Jochen Wiesner, Dirk Gießmann, 
Andreas Link, Hassan Jomaa, and Serge Van Calenbergh submitted for publication. 
  
2.3.3.1. INTRODUCTION 
 
1-Deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) catalyzes the 
conversion of 1-deoxy-D-xylulose 5-phosphate (DOXP) to 2-C-methyl-D-erythritol 4-
phosphate (MEP). This conversion involves two consecutive steps (Figure 4.1). The 
enzyme first catalyzes an intramolecular rearrangement of DOXP into the 
intermediate 2-C-methyl-D-erythrose 4-phosphate. This step requires a divalent metal 
ion to induce a partial positive charge on the C2 carbon, allowing the C4 atom to 
attack it. Several studies have been reported on the mechanism of this isomerisation 
step.191,217,216 A second step involves an NADPH-dependent reduction of the 
aldehyde intermediate. 
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Figure 4.1: The conversion of 1-deoxy-D-xylulose 5-phosphate (DOXP) to 2-C-methyl-D-
erythritol 4-phosphate (MEP) by deoxyxylulose 5-phosphate reductoisomerase (DXR). 
 
The X-ray structural data that are available today aid in defining the structural 
requirements for the design of potent DXR inhibitors. A complex of DXR with 
 - 100 -
fosmidomycin with an open conformation revealed that no hydrophobic contacts are 
present between the three carbon spacer and the rigid part of the binding site or with 
the partially ordered catalytic loop.197 Although, in a more recent ternary complex of 
DXR with fosmidomycin and NADPH, which exhibits a so-called tight-binding 
conformation, hydrophobic contacts were observed.198 Changes of the linker, that do 
not prolong the linker, such as the reported aryl modification in -position, appear to 
target the open conformation, since a small and totally enclosed inhibitor-binding 
pocket is proposed.198  
Recently, Proteau and coworkers described the synthesis of the phosphate 
analogues of fosmidomycin (1.99) and FR900098 (1.100).215 The former had 
previously been isolated from Pseudomonas fluorescens PK-52 and is known as 
fosfoxacin.222 The latter proved to be a very potent inhibitor of Synechocystis DXR. 
These results prompted us to investigate a related series of - and -oxa analogues 
4.1-4.6 (Chart 4.1). 
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Chart 4.1: Structures of fosmidomycin, FR900098, reported (1.99, 1.100, 1.70, 1.71) and 
synthesized (4.1-4.6) analogues. 
 
Compounds 4.1 and 4.2 are analogues of fosmidomycin and FR900098, 
respectively, in which the -methylene function was replaced by an oxygen atom. 
Since a phosphonomethoxy group has been successfully employed as a stable iso-
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electronic alternative of a methyl phosphate moiety to produce antiviral 
nucleosides,244 compounds 4.1 and 4.2 were selected as possible bioisosteres of 
1.99 and 1.100. 
The bridging oxygen of the phosphate group of DOXP may be involved in 
interactions with amino acids in the binding site.218 Since only hydrophobic contacts 
with the methylene linker were reported, the introduction of an oxygen atom in - or 
-position in search for hydrogen bonding, seems less compelling. Moreover, the 
introduction of the electronegative oxygen atom could cause a perturbation of the 
electronic properties, in casu the deprotonation of the phosphonate group218 or 
hydroxamate group, which becomes slightly more acidic. As a consequence of the 
logical decrease of the second pKa, the phosphonate could appear rather in his 
doubly ionised form, which is more favourable for an ideal binding. Analogues 4.3 
and 4.4 combine the -oxa modification with an hydroxamic acid moiety, as generally 
found as metal-binding group in matrix metalloproteinase inhibitors. Rohmer and 
coworkers reported that such metal chelating group, when replacing the N-
hydroxyformamido moiety of fosmidomycin, as in compound 1.70 or its N-methyl 
analogue 1.71, yielded potent inhibitors of DXR which were also capable to inhibit E. 
coli growth.206 Poulter and Walker reported an analogue of DOXP in which the acetyl 
was replaced by a hydroxamic acid, but it did not inhibit the enzyme,221 probably 
because the molecule did not longer fit in the confined volume of the active site, as a 
consequence of its one-atom longer chain. This is consistent with the most recently 
reported X-ray structure.198  
Analogues 4.5 and 4.6, which are constitutional isomers of 4.3 and 4.4, were 
also synthesized. They combine a hydroxamic acid moiety with an oxygen in -
position that could possibly mimic the C4 hydroxyl group present in the substrate. 
The C4 hydroxyl group is involved in hydrogen bonding with Glu152, Asn227 and 
Lys228.198  
 
 
                                            
244
 De Clercq, E., Holy. A. Nat. Rev. Drug Discov. 2005, 4, 928-940. 
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2.3.3.2. SYNTHESIS OF - AND -OXA ISOSTERS OF FOSMIDOMYCIN AND 
FR900098 
2.3.3.2.1 Synthesis of compounds 4.1 and 4.2 
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Scheme 4.1: Reagents and conditions: (a) 1,3,5-trioxane, 1,2-dichloroethane, HCl, 5 °C	25 
°C, 16 h, (b) t-butyl N-benzyloxycarbamate or allyl N-benzyloxycarbamate, NaH, DMF, rt, 2 
h, (c) see text, (d) N-(benzyloxy)acetamide (4.15), NaH, DMF, rt, overnight, (e) see text, (f) 
H2, Pd/C, MeOH, rt, 3 h, (g) TMSBr, CH2Cl2, rt. 
 
A first attempt (step e in Scheme 4.1) towards the synthesis of analogue 4.2 
started from the commercially available diethyl hydroxymethylphosphonate (4.7) 
using an intermolecular reaction between 4.7, acetohydroxamic acid and 
paraformaldehyde.245 Because water must be removed from the reaction mixture, 
                                            
245
 Geffken, D. Arch. Pharm. 1985, 318, 895-902. 
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dried molecular sieves or a Dean Stark apparatus were both separately evaluated. 
Unfortunately these attempts were not successful and no product was obtained.  
Treatment of 4.7 with 1,3,5-trioxane, in the presence HCl gas, afforded 
(chloromethoxy)methylphosphonate (4.8) (58%), as reported by Kim and 
coworkers.246 This chloromethyl ether was used in the next step without purification, 
albeit it was only 67% pure. An attempt to couple N-hydroxyacetamide directly to 4.8 
with NaH in DMF resulted in complex mixtures. Coupling of 4.8 with t-butyl N-
benzyloxycarbamate in the presence of NaH resulted in 4.9a, but in the following 
deprotection step with trifluoroacetic acid or 4N HCl in dioxane, only compound 4.7 
was obtained. To explore an alternative N-protective group that is resistant to NaH, 
N-Allyloxycarbonyl-O-benzylhydroxylamine was prepared from commercially 
available O-benzylhydroxylamine hydrochloride and allyl chloroformate. The coupling 
resulted in poor yield (16%). Unfortunately, deprotection of the allyl protecting group 
using Pd(Ph3P)4 and dimedone in THF also failed. 247 
In both cases we were not able to isolate the desired product from the 
complex reaction mixtures. We also tried to trap 4.10 by adding acetic anhydride to 
the deprotection reaction, but this also resulted in an unresolvable reaction mixture. 
Hence, 4.8 was coupled to N-(benzyloxy)acetamide (4.15) which was prepared from 
acetylation of O-benzylhydroxylamine hydrochloride. A complex reaction mixture was 
obtained from which 4.11 could be isolated in a modest yield of 23%. 
Catalytic hydrogenation of 4.11 gave the desired product 4.12 besides 
significant amounts of the corresponding amide. This side reaction was confirmed by 
the 1H-NMR spectrum in which the -protons were split by the amide proton. 
Deprotection of 4.12 to 4.2 with TMSBr failed due to cleavage and formation of 4.7, 
which was confirmed by LC-MS and NMR. This was not fully unexpected since TMSI 
cleaved the same C−O bond in a similar uracil derivative, but TMSCl left the same 
bond intact.248 In view of the problems encountered to produce analogue 4.2, it 
became clear that other protecting groups of the phosphonate were required. 
Scheme 4.2 depicts our successful approach to the synthesis of analogues 4.1 
and 4.2. Retrohydroxamic acids 4.14 and 4.15, obtained by acylation of O-
benzylhydroxylamine 4.13, were treated with paraformaldehyde and potassium tert-
                                            
246
 Kim, C. U., Misco, P. F., Martin, J. C. Nucleosides and Nucleotides 1990, 9, 579-585. 
247
 Kunz, H., Unverzagt, C. Angew. Chem., Int. Ed. Engl. 1984, 23, 436-437. 
248
 (a) Kundu, N. G., Hertzberg, R. P., Schmitz, S. A., Khatri, S. G., Kunda, N. G., Sikdar, S. J. Chem. 
Soc. Perkin Trans 1 1985, 7, 1295-1300. (b) Kundu, N. G., Khatri, S. G. Synthesis 1985, 3, 232-324. 
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butoxide to give the hydroxymethylated products 4.16 and 4.17, which were 
subsequently converted to the chlorides 4.18 and 4.19 as reported by Zhu et al.249 
Since attempts to crystallize the chlorides from ethyl acetate led to hydrolysis to 
alcohols 4.16 and 4.17, crude 4.18 and 4.19 were directly used in the Williamson 
synthesis with 4.21. Addition of one equivalent of NaH did not prove effective to 
increase the moderate yield. Compound 4.21 was prepared by a neat reaction with 
dibenzyl phosphite, paraformaldehyde and triethylamine. The perbenzylated 
compounds 4.22 and 4.23 were finally deprotected by catalytic hydrogenation to yield 
the phosphonic acids 4.1 and 4.2, which were purified by reversed phase HPLC. 
Since the N,O-acetal in 4.22 and 4.23 is acid sensitive, it was very important to use 
neutral Pd/C catalyst to prevent cleavage. Sajiki et al. reported a remarkable supplier 
dependent disparity in properties of Pd/C catalysts. Pd/C catalysts of some suppliers 
appeared to be acidic enough to cleave triethylsilylethers without H2.250 -Oxa 
analogue 4.2 proved to be stable in H2O for more than two weeks, as revealed by 1H-
NMR. 
In view of the promising biological results (see chapter 3) of the -aryl 
analogues of fosmidomycin, attempts were made to combine the -oxa modification 
with an aryl group in -position (Scheme 4.3). The synthesis was based on a similar 
approach used to prepare 4.1 and 4.2, but with racemic benzyl hydroxyl aryl 
methylphosphonates instead of 4.21. Differently substituted hydroxyl aryl 
methylphosphonates were prepared from dibenzyl phosphite (4.20) and the 
appropriate aryl aldehyde in the presence of MgO.251 This strategy could also give 
entrance to chiral -aryl--oxa analogues, since the synthesis of enantiomerically 
pure hydroxyl aryl methylphosphonates are reported.252 Unfortunately, we were 
unable to deprotect 4.26/4.27 neither by hydrogenolysis nor with BCl3. In both cases 
decomposition was observed. 
 
                                            
249
 Zhu, J., Robin, S. , Goasdoné, N. , Goasdoné, C., Loupy, A., Galons, H. Synlett 1995, 97-98. 
250
 (a) Sajiki, H., Ikawa, T., Hirota, K. Tetrahedron Lett. 2003, 44, 7407-7410. (b) Ikawa, T., Sajiki, H., 
Hirota, K. Tetrahedron 2004, 60, 6189-6195. 
251
 Katritzky, A. R., Rogovoy, B. V., Mitrokhin, A. Y. ARKIVOC 2002, 13, 17-27. 
252
 Cermak, D. M., Du, Y., Wiemer, D. F. J. Org. Chem. 1999, 64, 388-393. 
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Scheme 4.2: Reagents and conditions: (a) carbonyldiimidazole, HCOOH, rt, 3 h (87%) or 
acetyl chloride, CH2Cl2, Et3N, 0 °C, 1.5 h (86%), (b) paraformaldehyde, t-BuOK, 60 °C, 4 h 
(79% and 48%), (c) SOCl2, CH2Cl2, 10 °C, 30 min (100%), (d) paraformaldehyde, Et3N, 90 
°C, 12 h (56%), (e) CH2Cl2, rt, 16 h (21% and 38%) (f) H2, Pd/C, MeOH, rt, 3 h (34% and 
43%). 
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Scheme 4.3: Reagents and conditions: (a) MgO, HP(O)(OBn)2, rt, (b) CH2Cl2, rt , (c) H2, 
Pd/C, MeOH, rt or BCl3, CH2Cl2, -78 °C. 
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2.3.3.2.2 Synthesis of compounds 4.3 and 4.4 
 
The synthesis of the hydroxamate 4.3 and its N-methyl analogue 4.4 is 
depicted in Scheme 4.4.  
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Scheme 4.4: Reagents and conditions: (a) ethyl bromoacetate, NaH, DMF, rt, 3 h (80%), (b) 
NaOH, H2O, 30 °C, 2 h (94%), (c) carbonyldiimidazole, NH2-O-BnHCl, Et3N, rt, 3 h (83%), 
(d) MeI, NaH, rt, overnight (56%), (e) H2, Pd/C, MeOH, rt, 3 h (80% and 89%), (f) TMSBr, 
CH2Cl2, rt, 2 h (52% and 45%). 
 
Diethyl hydroxymethylphosphonate (4.7) was reacted with ethyl bromoacetate 
in the presence of two equivalents sodium hydride in THF to give 4.30 in 80% yield. 
Hydrolysis of 4.30 with one equivalent of sodium hydroxide followed by neutralisation 
gave acid 4.31 in 94% yield. An attempt to react diethylhydroxymethyl phosphonate 
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directly with chloroacetic acid in the presence of two equivalents of sodium hydride 
resulted in a poor yield.  
Several methods have been developed for the preparation of hydroxamic 
acids and are well documented in the literature. Hydroxamic acids have generally 
been synthesized in solution from nitro compounds or through reaction of O/N-
protected hydroxylamines, such as NH2-O-Bn, N-t-BOC-O-THP, N-t-BOC-O-TBDMS, 
N,O-bis-(phenoxycarbonyl)hydroxylamine, N,O-bis-(tert-butoxycarbonyl)hydroxyl-
amine and N,N,O-tris(trimethylsilyl)hydroxylamine with activated carboxylic acids.253 
Treatment of carboxylic acid 4.31 with CDI and NH2-O-Bn afforded the N-
benzyloxyamide 4.32. A possible simplification consists of the direct conversion of 
the ester 4.30 to the N-benzyloxyamide 4.32 according to a recently published 
procedure.254 A methyl group was introduced by deprotonation of 4.32 with sodium 
hydride in THF followed by addition of methyl iodide to give 4.34. Finally, hydroxamic 
acid 4.3 and its N-methylated analogue 4.4 were obtained after catalytic 
debenzylation (Pd/C) and deprotection of the phosphonate moieties with two 
equivalents of TMSBr in dichloromethane.  
 
2.3.3.2.3 Synthesis of compounds 4.5 and 4.6 
 
The synthesis of the N-hydroxy carbamates 4.5 and 4.6 is depicted in Scheme 
4.5. Treatment of dimethylhydroxyethyl phosphonate with CDI and O-
benzylhydroxylamine afforded 4.37. N-methylation, as described for 4.34, yielded 
4.39. The benzyl protecting groups of 4.37 and 4.39 were removed by catalytic 
hydrogenolysis (Pd/C) to give 4.38 and 4.40. Finally, the phosphonate esters were 
deprotected as outlined above. 
 
                                            
253
 (a) Tamaki, K., Ogita, T., Tanzawa, K., Sugimura, Y. Tetrahedron Lett. 1993, 34, 683-686. (b) 
Altenburger, J. M., Mioskowski, C., d'Orchymont, H., Schirlin D., Schalk, C., Tarnus, C. Tetrahedron 
Lett. 1992, 33, 5055. c) Staszak, M. A., Doecke, C. W. Tetrahedron Lett. 1994, 33, 6021-6024. (d) 
Ando, W., Tsumaki, H. Synth. Commun. 1983, 13, 1053-1056. 
254
 Gissot, A., Volonterio, A., Zanda, M. J. Org. Chem. 2005, 70, 6925-6928. 
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Scheme 4.5: Reagents and conditions: (a) carbonyldiimidazole, NH2-O-BnHCl, Et3N, rt, 3 h 
(73%), (b) MeI, NaH, rt, overnight (68%), (c) H2, Pd/C, MeOH, rt, 3 h, (98% and 97%), (d) 
TMSBr, CH2Cl2, rt, 2 h, quantitative. 
 
Analogue 4.43 represents a -oxa isoster of FR900098 (Scheme 4.6). In a first 
attempt, 4.15 was converted to the N-chlorohydroxamate in the presence of t-butyl 
hypochlorite.255 The coupling with 4.36 failed. Hower, a reaction with 
bis(trifluoroacetoxy)iodo benzene (PIFA) yielded compound 4.41, albeit in moderate 
yield. Unfortunately, the hydrogenolysis in the next step resulted in a mixture of 4.36 
and 4.42 and the latter one was formed in low yield (14% as revealed by NMR). Due 
to the low yields the synthesis of this compound was abandoned. Analogue 4.43 is 
probably not very stable, because of a hemiacetal structure. 
 
                                            
255
 Glover, S. A., Mo, G. J. Chem. Soc., Perkin Trans. 2 2002, 1728-1739. 
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Scheme 4.6: Reagents and conditions: (a) PIFA, CH2Cl2, -30 °C, (b) H2, Pd/C, MeOH, rt. 
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2.4. SYNTHESIS OF TRANSITION STATE ANALOGUE 
2.4.1. INTRODUCTION 
 
Another part of our research project focused on the synthesis of a transition 
state analogue (5.1) of the DOXP reductoisomerase reaction (Figure 5.1). Some 
studies were performed to unravel the mechanism of DXR. According to Rohmer et 
al. a retroaldolization/aldolization mechanism is more plausible than an -ketol 
rearrangement (vide supra). It appears, however, that both the C3 and C4 hydroxyls 
are important for the catalysis via chelation with a divalent metal ion.191,216,217 Proteau 
and coworkers demonstrated that the C3 hydroxyl group is not critical for the binding 
of DOXP to DXR, but is essential to be converted by the enzyme. Likewise the 
hydroxyl group at the C4 position of DOXP is important for the isomerisation step, but 
appears not critical for the binding.220 Indeed, DOXP analogues lacking the hydroxyl 
group at C3 or C4 were found to be competitive or reversible mixed type inhibitors of 
DXR.191,220 Isosteric analogues of DOXP and MEP with a C−P bond (1.106 and 1.107 
see 1.3.1.4.) have been described by the group of Rohmer.218,219 While these 
analogues showed no inhibition for DXR, 1.106 was accepted as an alternative 
substrate with reduced affinity for DXR. It was argued that turnover of 1.106 is still 
possible because it differs from the natural substrate at a position that is distant form 
the part of the molecule undergoing transformation. Although the bridging oxygen of 
the phosphate group may be implied in interactions with amino acid(s) of the 
substrate binding site,218 a C−P bond is crucial to confer resistance to hydrolytic 
cleavage compared to a P−O bond. Nevertheless, Proteau and coworkers recently 
reported the phosphate analogues of fosmidomycin and FR900098 to exhibit 
somewhat lower Ki values than fosmidomycin when tested on Synechocystis DXR 
(19 and 2 nM versus 58 nM). Because of the presence of a C−P bond in 
fosmidomycin, however, we decided to retain a phosphonate moiety in the envisaged 
transition state analogue. 
In the transition state the methyl group at the C2 position is essential for 
affinity of the aldehyde intermediate to the enzyme.191 The hydroxyl group on the C2 
position of the intermediate is also necessary to ligate the divalent cation in the 
enzyme.197 Based on this information we decided to synthesize analogue 5.1, which 
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possesses all these critical features but has the opposite configuration at C3 
(corresponding to C2 of the intermediate) and with an acetyl function in stead of the 
aldehyde. The acetyl group was chosen since FR900098 shows better affinity for 
DXR than fosmidomycin. Hence, structural elements believed to stabilize the 
interaction of the transition state with the enzyme were conserved in 5.1. 
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Figure 5.1: Comparison between the transition state and compound 5.1. 
 
2.4.2. SYNTHESIS 
 
Several routes towards the synthesis of transition state analogue 5.1 were 
explored. Our first attempts started from 1,2-O-isopropylidene--D-xylofuranose. The 
xylofuranose moiety can indeed be used as starting material as it contains the same 
optical configuration as our target compound. The primary OH group of 5.2 was 
selectively protected as tert-butyldimethylsilyl ether 5.3 (Route A, scheme 5.1). 
Swern oxidation yielded ketone 5.4, which was subjected to a Wittig reaction to afford 
alkene 5.5. Compound 5.5 was treated with m-chloroperoxybenzoic acid (MCPBA) to 
yield the desired epoxide 5.6. The epoxide was reduced with LiAlH4 to afford the 
alcohol, whose required configuration was confirmed with NOESY. A contact 
between C(3)OH and C(2)H was observed. The alcohol at the C3 position was 
protected with benzyl bromide. Deprotection of the TBDMS protecting group and 
replacement by a triflate resulted in compound 5.10. 
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Scheme 5.1: Attempts to synthesize 5.1 from xylofuranose. Reagents and conditions (a) 
TBDMSCl, DMAP, pyridine, 0 °C, 1.5 h , (b) (COCl)2, DMSO, Et3N, CH2Cl2, -55 °C	rt, (c) 
methyltriphenylphosphonium bromide, NaH, DMSO, 3 h, (d) MCPBA, CH2Cl2, rt, 30 h, (e) 
LiAlH4, THF, 0 °C, 2 h, (f) benzylbromide, NaH, nBu4NI, THF, rt, 12 h, (g) TBAF, THF, rt, 4h, 
(h) trifluoromethanesulfonic acid anhydride, pyridine, CH2Cl2, -30 °C, 0.5 h,  (i) dibenzyl 
methylphosphonate, HMPA, nBuLi, THF, -78 °C. 
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In the next step the introduction of the phosphonate via an alkylation reaction 
was envisaged. Despite the resulting complication of the NMR spectra, dibenzyl 
protection of the phosphonate was chosen, because they could be simultaneously 
removed with the C3 benzyl protected OH group. Unfortunately, we were unable to 
obtain compound 5.11. A literature search revealed that others faced similar 
problems to introduce the phosphonate group on a hindered -face of a 1,2-O-
isopropylidene--D-xylofuranose derivative.219 An attempt to introduce the 
phosphonate group at the alkene stage was also unsuccessful, most probably due to 
steric hindrance (Route B, scheme 5.1). Therefore this strategy was abandoned and 
we decided to introduce the envisaged stereochemistry using catalytic asymmetric 
dihydroxylation as a key step in the synthesis.  
This approach started with the introduction of the crucial vicinal diol by using a 
Sharpless asymmetric hydroxylation on alkene 5.18 (Scheme 5.2). This ,-
unsaturated ester could be obtained by oxidation of 3-(benzyloxy)propan-1-ol (5.16) 
with Dess-Martin periodinane followed by Wittig olefination with the corresponding 
triphenylphosphorane. This olefination occurred with high (E)-selectivity.256,257 We 
found that Dess-Martin periodinane gave cleaner results than Swern oxidation. The 
vicinal diol 5.19 was obtained via Sharpless asymmetric hydroxylation of 5.18 with 
AD-mix-. The stereoselectivity of the hydroxylation was satisfactory with an 
enantiomeric excess of 92% (Determined by HPLC analysis on a chiralcel OD-H 
250×4.6 column with hexane:EtOH 98:2. To determine this enantiomeric excess we 
required the enantiomer of 5.19, which was obtained using AD-mix-)(Figure 5.2). 
The optical rotations of compounds 5.19 and 5.20 were 6.4 and 36.0, respectively.  
Subsequently, the vicinal diol 5.19 was protected as an acetonide to provide 5.20. 
Hydrolysis with KOH in aqueous MeOH and acidification provided carboxylic acid 
5.21. This acid was converted to ketone 5.22 upon treatment with 2 equivalents of 
MeLi. Catalytic hydrogenolysis of 5.22 with Pd/C gave alcohol 5.23. To introduce the 
phosphonate group alcohol 5.23 was first converted to iodide 5.24. This conversion 
was achieved by employing the chlorodiphenylphosphane/imidazole/iodine reagent 
combination in toluene. This method allows easy purification by removal of 
diphenylphosphonic acid by aqueous extraction. Because of the presumed lability, 
                                            
256
 Kodama, M., Shiobara, Y., Sumitomo, H., Fukuzumi, K., Minami, H., Miyamoto, Y. J. Org. Chem. 
1988, 53, 1437-1441. 
257
 Chakraborty, T. K., Tapadar, S. Tetrahedron Lett. 2003, 44, 2541-2543. 
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iodide 5.24 was directly subjected to an Arbusov reaction to furnish the phosphonic 
ester 5.25. Finally, the acetonide and the diethyl phosphonic ester were 
simultaneously deprotected with bromotrimethylsilane to obtain the desired product 
5.1 in almost quantitative yield. The final products were purified by RP-HPLC 
(phenomenex C18 column).  
 
 
 
Figure 5.2: Chromatogram of compound 5.19 mixed with its enantiomer on a chiralcel OD-H 
250×4.6 column eluted with hexane:EtOH 98:2 obtained by simultaneous UV and DA 
detection. Ranges: 0.0 to 20.0 min, 190.0 to 280.1 nm, -58.7 to 294.7 mAu. 
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Scheme 5.2: Reagents and conditions (a) Dess-Martin periodinane 15 wt%, CH2Cl2, H2O, 0 
°C, 1 h, (b) Ph3P=C(Me)CO2Et, toluene, reflux, 30 min (68% over 2 steps), (c) AD-mix , 
MeSO2NH2, tBuOH, H2O, 0 °C, 24 h (66%, ee = 92%), (d) 2,2-dimethoxypropane, TsOH, dry 
acetone, rt, 4 h (94%), (e) KOH, MeOH, reflux, HCl, 1 h (93%), (f) MeLi, dry THF, 0 °C, 1 h 
(69%), (g) H2, Pd/C, MeOH, rt, 24 h (71%), (h) chlorodiphenylphosphane, imidazole, iodine, 
NaOH, toluene, rt, 5 min, (i) P(OEt)3, reflux, 12 h (81% over 2 steps), (j) TMSBr, CH2Cl2, rt, 2 
h, quantitative.  
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3. BIOLOGICAL RESULTS 
 
All final compounds were tested for inhibition of recombinant E. coli DXR. E. coli 
DXR is easier to handle than P. falciparum DXR and both show a high degree of 
similarity. The assay used was based on the photometric measurement of the 
NADPH turnover associated with the DXR catalyzed reaction. In addition, the in vitro 
antimalarial activity was determined of compounds which scored well in the E. coli 
DXR inhibition assay. Intra-erythrocytic stages of the P. falciparum strains D2d or 
3D7 were incubated with serial dilutions of the drugs and the viability of the parasites 
was assessed by their ability to incorporate [3H]hypoxanthine into DNA. The exact 
protocols are described in the experimental part. Fosmidomycin and FR900098 were 
included as reference compounds. The D2d strain is a progeny of the Indochina 
clone W2, which is a representative of the most highly resistant strains of P. 
falciparum. It is resistant to chloroquine, quinine, pyrimethamine, cycloguanil and 
sulfadoxine. Clone 3D7 is resistant to sulfadoxine due to its ability to use exogenous 
folate, but is sensitive to chloroquine, cycloguanil or pyrimethamine.7  
 
3.1. BIOLOGICAL EVALUATION OF COMPOUNDS WITH A 
MODIFIED RETROHYDROXAMIC ACID  
 
Compared with fosmidomycin, amides 2.1-2.5 showed no interesting inhibitory 
activity of DXR (Table 6.1). The replacement of the N−OH by a N−Me is not 
favourable and demonstrates the importance of the N−OH group for metal chelation. 
Proteau et al. confirmed these unpublished results in a recent publication. It is clear 
that removal of the N-hydroxy group would be expected to greatly decrease the 
potency of the analogues. With the absence of a group capable of chelating the 
metal ion, the inhibition constants increase to millimolar concentrations. The results 
for compounds 2.1-2.5 are also in accordance with the results of Walker and 
Poulter.221 Thus, a negatively charged or neutral donor atom is required for the 
chelation of the active site divalent cation. Comparison between the activities of 
FR900098 with a methyl group in -position (1.130) and 2.5 demonstrates also the 
importance of the N−OH group.  
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Analogues 2.6-2.9, with an extended N−O bond showed no inhibition either, 
probably because these larger structures can not be accommodated in the DOXP 
binding site. The marginal effect of 2.9 (IC50 = 17 M) needs to be interpreted 
carefully since this compound suffers from poor solubility thereby possibly disturbing 
the inhibition assay. Analogue 2.38 showed no inhibition on the recombinant E. coli 
DXR.  
 
PNR
R'
R'
O
O
OH
OH
 
compound R R’         R” 
IC50 (M) 
E. coli 
DXR 
fosmidomycin (1.83) H OH H 0.043 
FR900098 (1.84) CH3 OH H 0.043 
-Me FR900098 (1.130)* CH3 OH CH3 0.037* 
2.1 CH3 CH3 H > 30 
2.2 CH3 CH2CH3 H > 30 
2.3 H CH3 H > 30 
2.4 H CH2CH3 H > 30 
2.5 CH3 CH3 CH3 > 30 
2.6 CH3 (CH2)2OH H > 30 
2.7 Ph (CH2)2OH H > 30 
2.8         1-naphtyl (CH2)2OH H > 30 
2.9 C15H31 (CH2)2OH H 17 
N
O
O
P
O OH
OH
2.38
 
   > 30 
 
 
Table 6.1: IC50 values against recombinant E. coli DXR (* unpublished result). 
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3.2. BIOLOGICAL EVALUATION OF COMPOUNDS WITH AN 
-ARYL SUBSTITUTED PROPYL SPACER 
 
Compared with fosmidomycin, all -aryl substituted analogues (paragraph 
2.3.1) were weaker inhibitors of E. coli DXR (Table 6.2). Analysis of the order of DXR 
inhibitory potency in the N-acetyl series (3.2d  3.2e > 3.2a > 3.2b > 3.2c) indicates 
that the activity is mainly +-controlled (4-Cl  3,4-diCl > H > 4-Me > 4-MeO).  
Although generally weaker than fosmidomycin in inhibiting E. coli DXR, all -
substituted analogues studied surpass the activity of fosmidomycin to inhibit the 
parasite growth. Remarkably, the formyl analogues 3.1c and 3.1e consistently 
outperformed the acetyl derivatives 3.2c and 3.2e, both in the enzyme and the 
parasite growth inhibition assay. An opposite trend was observed for the parent 
fosmidomycin/FR900098 couple in the parasite growth inhibition assay. This is in 
accordance with previous studies.1 Interestingly, a noteworthy correlation was 
observed between the IC50 values of 3.1c, 3.1e and 3.2a-e for DXR and their IC50 for 
the malaria strains, indicating that E. coli DXR inhibition is a useful predictor to 
estimate the in vitro antimalarial activity. Our findings show that this correlation only 
appears to hold when considering a set of closely related analogues. Indeed, while 
fosmidomycin is clearly superior to the -substituted analogues as DXR inhibitor, it is 
less active in inhibiting P. falciparum growth.  
The drop in activity observed for compound 3.17a,c confirms the importance of 
the N-hydroxyl group for biological activity. However it should be noted that the IC50’s 
of amides 3.17a and 3.17c for the 3D7 strain are only 2-fold higher than that of 
fosmidomycin. These results indicate that the -phenyl and -(p-methoxyphenyl) 
moieties contribute to the observed activities. This finding is also confirmed by the 
inactivity of 3-acetamidopropylphosphonic acid as DXR inhibitor.258 
Compound 3.1e emerged as the most promising analogue of this series. Its in 
vitro antimalarial activity indicated that it is twelve-fold more active than fosmidomycin 
and also exceeds the activity of FR900098, the most potent analogue known to date. 
Apparently, the lipophilic and electronegative properties of the 3,4-dichloro-
substitution pattern selectively favour the interaction with the P. falciparum DXR 
                                            
258
 Mercklé, L., Andrés-Gómez, A. d., Dick, B., Cox, R. J., Godfrey, C. R. A. ChemBioChem, 2005, 6, 
1866-1874. 
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homologue. Alternatively, the aromatic ring in the -position may improve the 
capacity of this and related compounds to enter the parasite cells. 
 
N
R3
O
R
P
O OH
OH
R1
R2
 
compound R3 R R1 R2 
IC50 (M) E. coli 
DXRa 
IC50 (M) 
Dd2 
IC50 (M) 
3D7 
3.2a OH CH3 H H 0.311 ± 0.120 0.35 0.55 
3.2b OH CH3 Me H 0.396 ± 0.061 0.22 0.95 
3.1c OH H OMe H 0.156 ± 0.043 0.20 0.36 
3.2c OH CH3 OMe H 0.459 ± 0.109 0.27 0.85 
3.2d OH CH3 Cl H 0.099 ± 0.026 0.095 0.35 
3.1e OH H Cl Cl 0.059 ± 0.020 0.028 0.090 
3.2e OH CH3 Cl Cl 0.119 ± 0.019 0.090 0.25 
3.17a H H H H 2.391 ± 0.545 7.5 2.0 
3.17c H OMe H H 1.373 ± 0.508 11 2.5 
fosmidomycin     0.030 ± 0.008 0.36 1.1 
FR900098     0.030 ± 0.008 0.18 0.32 
 
aMean values ± standard deviation of 3 to 5 independent measurements 
 
Table 6.2: IC50 values of -aryl-substituted analogues against recombinant E. coli DXR and 
Dd2 and 3D7 P. falciparum strains. 
 
Because of these promising results, compound 3.1e was scaled up and 
subjected to an initial in vivo study. P. vinckei and P. yoelii infected mice were treated 
with 100 mg/kg 3.1e administered by i.p. injection once daily for 2 days. In parallel, 
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mice were treated with the same dose of fosmidomycin. P. vinckei can be considered 
as the standard malaria test organism for rodents. Remarkably, in P. vinckei infected 
mice there was no effect with 3.1e, while complete parasite clearance was observed 
with fosmidomycin. In P. yoelii infected mice, neither 3.1e nor fosmidomycin proved 
effective. Further study is necessary to confirm and explain these preliminary results. 
Very recently, Kurz et al. reported the synthesis and antimalarial activity of 
prodrugs of -arylmethyl substituted derivatives of fosmidomycin.259 This study 
suggests that it may be worth trying to make prodrugs of compound 3.1e and 
investigate their biological activity.  
 
3.3. BIOLOGICAL EVALUATION OF CYCLOPENTYL 
COMPOUNDS  
 
Amongst the fosmidomycin analogues in which the C–C–C spacer is part of a 
cyclopentane ring, the trans analogues proved notably more active than the cis 
isomers but less than fosmidomycin (Table 6.3). This is in agreement with recent 
results of our group obtained with cyclopropane fosmidomycin analogues, where a 
trans orientation of the phosphonate group and the hydroxyamide moiety also yielded 
the most potent inhibitor.213 Remarkably, in the cyclopentane series, the inhibitory 
activity of the formyl analogues surpassed that of the acetyl derivatives, while the 
opposite trend was observed in the cyclopropane series.213 In view of the acceptable 
activity of trans-3.3 it seems worthwhile to separate the racemate and to test the pure 
enantiomers on their biological activity. Moreover, regarding the acceptable activities 
of the conformationally restricted analogues trans-3.3 and 1.95 it would also be 
interesting to synthesize less rigid compounds, e.g. - or -methylated compounds. 
 
                                            
259
 Schlüter, K., Walter, R. D., Bergmann, B., Kurz, T. Eur. J. Med. Chem. 2006, 41, 1385-1397. 
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N P OHOH
OH
R
O
O
 
Compounds R IC50 (M) 
fosmidomycin  0.029 
FR900098  0.035 
trans-3.3 H 0.20 
cis-3.3 H 2.3 
trans-3.4 CH3 2.3 
cis-3.4 CH3 12 
 
 
Table 6.3: Inhibitory activity of cyclopentyl analogues on recombinant E. coli DXR enzyme. 
 
3.4. BIOLOGICAL EVALUATION OF OXA COMPOUNDS 
 
The biological results for the oxa analogues are summarized in table 6.4. In the 
series with the inversed hydroxamates and carbamates the N-methyl substituted 
analogues proved superior to their non-methylated analogues. Compound 1.71, 
originally made by Rohmer et al., was marginally less active than fosmidomycin and 
FR900098 in the E. coli DXR inhibition assay. The results of 4.4 and 4.6 show that 
introduction of an oxygen atom in the propyl chain is more favourable in -position of 
the phosphonate moiety than in -position. Introduction of an oxygen atom in the -
position of the phosphonate moiety generates carbamates 4.5 and 4.6 which were 
weak inhibitors of E. coli DXR, as shown by the relatively high IC50 values. 
Apparently the interaction observed between the C4 hydroxyl group of the substrate 
with Glu152, Asn227 and Lys228 cannot be accomodated by the -oxygen. In 
contrast, compound 4.4 proved to be almost equipotent to FR900098 and marginally 
more active than compound 1.71. Comparison of IC50 values of analogues 4.2 and 
4.4 demonstrates that, when combined with a -oxa modification, the hydroxamate 
seems slightly favourable to the N-hydroxyacetamido group as metal chelating 
moiety.  
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compound structure 
IC50 (M) E. 
coli DXRa 
IC50 (M) 3D7 
1.71 P
O
OH
OH
O
N
OH
 
0.093 0.994 
4.1 N O P
O
OH
OH
OH
O
 
1.105 5.192 
4.2 N O P
O
OH
OH
OH
O
 
0.087 0.348 
4.3 P
O
OH
OHO
O
HN
OH
 
>3 - 
4.4 P
O
OH
OHO
O
N
OH
 
0.072 0.228 
4.5 P
O
OH
OHO
O
HN
OH
 
>3 - 
4.6 P
O
OH
OHO
O
N
OH
 
4.942 - 
fosmidomycin  0.054 0.983 
FR900098  0.062 0.373 
 
aMean values of 3 to 5 independent measurements  
Table 6.4: Inhibitory activity of oxa analogues on recombinant E. coli DXR enzyme. 
 
The introduction of an oxygen atom in the linker does not contribute favourably 
to the hydrophobic interactions which are present in the crystal structure of DXR from 
Sweeney et al., although on this E. coli DXR inhibition assay analogue 4.4 was more 
 - 128 -
potent than analogue 1.71 with the methylene linker. This points out that an oxygen 
atom in -position slightly influences the ionisation and as such the binding, even if 
hydrophobic interactions are playing a part. Likewise, it is also possible that the ether 
linkage is still hydrophobic enough to ensure a tight bonding of the inhibitor. In order 
to confirm that there is no hydrogen bonding involved, a crystal structure of DXR 
complexed with analogue 4.4 is highly desirable. 
Furthermore, compound 4.2 outperformed its formyl analogue 4.1. An opposite 
trend was observed in the fosmidomycin/FR900098 couple, where fosmidomycin is 
superior to FR900098. Nevertheless, in this series of compounds fosmidomycin stays 
the best inhibitor on this E. coli DXR inhibition assay.  
On the P. falciparum 3D7 strain, compounds 4.2 and 4.4 surpassed 
fosmidomycin and even FR900098, with analogue 4.4 as the most promising 
analogue. Analogue 4.4 is almost twice as active as FR900098 and four times more 
active than fosmidomycin. 
 
3.5. BIOLOGICAL EVALUATION OF TRANSITION STATE 
ANALOGUE 5.1 
 
5.1
P
O
OH
OH
(R)(S)Me
O
HO Me
OH
1.107
P
O
OH
OH
(R)
(S)
OH
OH
OH
 
 
Analogue 1.107 is the only structure reported to date that can be considered as a 
transition state analogue. It concerns a phosphonate analogue of MEP. The influence 
of 1.107 on the growth of E. coli was tested by the agar diffusion method on agar 
plates (5 cm diameter) inoculated with a bacteria suspension (100 L, 5 × 107 cells). 
No growth inhibition zone was observed around 6 mm Whatman No. 1 paper disks in 
the presence of 1.107 (50 or 100 g), whereas the presence of fosmidomycin (10 
g), induced the formation of a clear growth inhibition zone. Also the activity on E. 
coli DXR was investigated. DXR was capable of converting 1.107 into 1.106, which is 
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a phosphonate analogue of DOXP. Unfortunately, an intermediate analogue 5.1 did 
not demonstrate remarkable inhibition on E. coli DXR either.  
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4. EXPERIMENTAL DATA 
4.1. SYNTHESIS 
4.1.1. GENERAL 
 
IUPAC names were generated with Chemdraw Ultra 8.0 (Chemoffice 2004, 
Cambridge Soft, Cambridge, USA). All reactions were carried out under inert (N2) 
atmosphere. Precoated Merck silica gel F254 plates and precoated Macherey-Nagel 
(Düren, Germany) silica gel F254 plates were used for TLC and spots were examined 
under UV light at 254 nm and revealed by a phosphomolybdic-cerium sulphate 
solution, iodine vapour or bromocresol green solution. Column chromatography was 
performed on ICN silica gel (63-200 M). NMR spectra were obtained with a Varian 
Mercury 300 spectrometer. Chemical shifts are given in parts per million (ppm) (
 
relative to residual solvent peak, in the case of CDCl3 7.26 ppm for 1H and 77.4 ppm 
for 13C. Coupling constants are expressed in Hz. Abbreviations used are: s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet, br. s = broad signal. All signals 
assigned to hydroxyl and to amino groups were exchangeable with D2O. Structural 
assignment was confirmed with COSY, NOEDIF, NOESY, DEPT and/or HMQC if 
necessary. Mass spectra and exact mass measurements were performed on a 
quadrupole/orthogonal-acceleration time-of-flight (Q/oaTOF) tandem mass 
spectrometer (qTof 2, Micromass, Manchester, U.K.) equipped with a standard 
electrospray ionization (ESI) interface. Samples were infused in a ACN/water (1:1) 
mixture at 3L/min. Most chemicals were obtained from Sigma-Aldrich or Acros 
Organics and were used without further purification.  
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4.1.2. RECIPES AND SPECTRAL DATA 
 
Diethyl [3-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)propyl]phosphonate (2.11). 
N
O
O
P
O OEt
OEt
 
N-(3-Bromopropyl)phthalimide (3 g, 11.2 mmol) was added to triethyl phosphite (9.3 
g, 60.0 mmol) slowly at room temperature. The reaction mixture was refluxed for 12 
h, and then excess triethyl phosphite and other volatile compounds were distilled out 
under reduced pressure (3 mmHg) at 60 °C. The pure phosphonate 2.11 (3.6 g, 
98%) was obtained as a pale yellow viscous oil. The 1H NMR spectrum matched the 
published spectrum.260  
1H-NMR (300 MHz, CDCl3): 
 = 1.08 (t, J = 7.0 Hz, 6H, OCH2CH3), 1.59 − 1.51 (m, 
2H, CH2CH2P), 1.77 − 1.62 (m, 2H, CH2CH2P), 3.51 (t, J = 6.7 Hz, 2H, NCH2), 3.85 
(m, 4H, OCH2CH3), 7.51 (m, 2H, arom. H), 7.59 (m, 2H, arom. H) ppm. 
Exact mass (ESI-MS): calculated for C15H21NO5P [M+H]+: 326.1157, found: 
326.1160. 
 
Diethyl 3-aminopropylphosphonate (2.12) 
H2N P
O OEt
OEt
 
Hydrazine monohydrate (5.2 g, 10.4 mmol) was added dropwise to a solution of 
phthalimide 2.11 (1.12 g, 3.5 mmol) in ethanol (50 mL) at room temperature. The 
reaction mixture was heated under reflux overnight. The precipitated phthalyl 
hydrazide was filtered, and the solvent was removed under reduced pressure. 
Evaporation of the solvent produced phosphonate 2.12 as a yellow viscous oil. The 
crude phosphonate 2.12 was purified by flash chromatography to yield pure 2.12 (1.9 
g, 94%) (CH2Cl2/MeOH/ammonia in MeOH, 75:24:1). The spectral data matched with 
the literature data.261  
                                            
260
 Chun, Y.−J., Park, J.−H., Oh, G.−M., Hong, S.−I., Kim, Y.−J. Synthesis 1994, 909-910. 
261
 Bako, P., Novak, T., Ludanyi, K., Pete, B., Toke, L., Keglevich, G. Tetrahedron: Asymmetry 1999, 
10, 2373-2380. 
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1H-NMR (300 MHz, CDCl3): 
 = 1.33 (t, J = 7.0 Hz, 6H, OCH2CH3), 1.42 (bs, 2H, 
NH2), 1.85 − 1.79 (m, 4H, CH2CH2P), 2.86 (t, J = 6.0 Hz, 2H, NCH2), 4.15 − 4.06 (m, 
4H, OCH2CH3) ppm. 
Exact mass (ESI-MS): calculated for C7H19NO3P [M+H]+: 196.1103, found: 
196.0752. 
 
Diethyl 3-acetamidopropylphosphonate (2.13) 
N
H
P
O OEt
OEtMe
O
 
To a solution of phosphonate 2.12 (1.47 g, 7.5 mmol) in CH2Cl2 (6 mL) was added 
acetylchloride (1.18 g, 7.5 mmol) and pyridine (1.19 g, 7.5 mmol). The reaction was 
cooled by 0 °C. After 3 h the reaction was finished as revealed by TLC and the 
reaction mixture was evaporated and purified by flash chromatography to yield 2.13 
(1.46 g, 82%)(CH2Cl2/MeOH, 9:1).  
1H-NMR (300 MHz, CDCl3): 
 = 1.33 (t, J = 7.0 Hz, 6H, OCH2CH3), 1.85 − 1.79 (m, 
4H, CH2CH2P), 1.81 (s, 3H, CH3C=O), 3.05 (m, 2H, NCH2), 4.15 − 4.06 (m, 4H, 
OCH2CH3), 7.81 (br. s, 1H, NH) ppm. 
Exact mass (ESI-MS): calculated for C9H21NO4P [M+H]+: 238.1209, found: 
238.1231. 
 
Diethyl [3-(N-methylacetamido)propyl]phosphonate (2.14) 
N P
O OEt
OEtMe
O
Me
 
To a solution of phosphonate 2.13 (0.55 g, 2.4 mmol) in THF (9 mL) was added 
sodium hydride (64.2 mg, 2.6 mmol) in small portions. This reaction mixture was 
stirred by room temperature for 30 minutes. Iodomethane (0.38 g, 2.6 mmol) was 
added dropwise to the reaction mixture and the solution was stirred over night. The 
crude reaction mixture was evaporated in vacuo and purified by flash 
chromatography (CH2Cl2/MeOH, 99:1	98:2	97:3) to yield 2.14 as a viscous oil 
(0.44 g, 72%). 
1H-NMR (300 MHz, CDCl3): 
 = 1.33 (m, 6H, OCH2CH3), 1.65 − 1.86 (m, 4H, 
CH2CH2P), 2.16 and 2.21 (2 × s, 3H, CH3C=O, major and minor form), 2.82 − 2.99 (2 
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× s, 3H, NCH3, minor and major form), 3.62 − 3.85 (m, 2H, NCH2), 4.10 − 4.31 (m, 
4H, OCH2CH3) ppm. 
Exact mass (ESI-MS): calculated for C10H23NO4P [M+H]+: 252.1366, found: 
252.1357. 
 
Diethyl 3-(N-ethylacetamido)propylphosphonate (2.15) 
N P
O OEt
OEtMe
O
Et
 
To a solution of phosphonate 2.13 (0.36 g, 1.5 mmol) in THF (10 mL) was added 
sodium hydride (43.5 mg, 1.8 mmol) in small portions. This reaction mixture was 
stirred by room temperature for 30 minutes. Iodoethane (0.35 g, 2.3 mmol) was 
added dropwise to the reaction mixture and the solution was stirred overnight. The 
crude reaction mixture was evaporated in vacuo and purified by flash 
chromatography (CH2Cl2/MeOH, 99:1	98:2	97:3) to yield 2.15 as a viscous oil 
(0.27 g, 67%). 
1H-NMR (300 MHz, CDCl3): 
 = 1.02 − 1.63 (m, 9H, OCH2CH3 and NCH2CH3), 1.65 − 
1.78 (m, 4H, CH2CH2P), 1.82 and 2.11 (2 × s, 3H, CH3C=O, minor and major form), 
3.22 − 3.38 (m, 4H, NCH2CH2 and NCH2CH3), 3.97 − 4.13 (m, 4H, OCH2CH3) ppm. 
Exact mass (ESI-MS): calculated for C11H25NO4P [M+H]+: 266.1521, found: 
266.1533. 
 
[3-(N-Acetyl-N-methyl-amino)-propyl]-phosphonic acid (2.1) 
N P
O OH
OHMe
O
Me
 
Trimethylsilyl iodide (240 mg, 1.2 mmol) was added dropwise at 0 °C with stirring to a 
solution of phosphonic ester 2.14 (100 mg, 0.4 mmol) in dichloromethane (4 mL) , 
and stirring was continued at room temperature for 2 h. Organic solvents were 
removed in vacuo. The crude yellow foam was dissolved in ethanol, decolourized 
over a active carbon patch and subsequently precipitated from ethanol/Et2O to yield 
the pure phosphonic acid 2.1 in almost quantitative yield. 
 - 137 -
1H-NMR (300 MHz, D2O): mixture of amide rotamers 
 = 1.42 − 1.78 (m, 4H, 
CH2CH2P), 1.85 and 1.93 (2 × s, 3H, CH3C=O, major and minor form), 2.74 − 2.92 (2 
× s, 3H, NCH3, minor and major form), 3.20 − 3.54 (m, 2H, NCH2) ppm. 
13C-NMR (75 MHz, D2O): mixture of amide rotamers 
 = 21.04 and 20.44 (CH3C=O, 
major and minor form), 22.06 (d, 2JC,P = 3.2 Hz, CH2CH2P) and 21.92 (d, 
2JC,P = 3.5 Hz, CH2CH2P), 25.44 (d, JC,P = 130.7 Hz, CH2CH2P) and 25.14 (d, 
JC,P = 131.6 Hz, CH2CH2P), 33.50 and 36.35 (NCH3), 49.15 (d, 3JC,P = 20.2 Hz, 
NCH2) and 52.43 (d, 3JC,P = 19.5 Hz, NCH2), 174.1 (CH3C=O) ppm. 
Exact mass (ESI-MS): calculated for C6H13NO4P [M-H]-: 194.0581, found: 194.0224. 
 
[3-(N-Acetyl-N-ethyl-amino)-propyl]-phosphonic acid (2.2) 
N P
O OH
OHMe
O
Et
 
Trimethylsilyl iodide (208 mg, 2.0 mmol) was added dropwise at 0 °C with stirring to a 
solution of phosphonic ester 2.15 (92 mg, 0.35 mmol) in dichloromethane (4 mL) , 
and stirring was continued at room temperature for 2 h. Organic solvents were 
removed in vacuo. The crude yellow foam was dissolved in ethanol, decolourized 
over a active carbon patch and subsequently precipitated from ethanol/Et2O to yield 
the pure phosphonic acid 2.2 in almost quantitative yield. 
1H-NMR (300 MHz, D2O): mixture of amide rotamers 
 = 0.91 and 0.99 (2 × t, J = 7.0 
Hz, 3H, NCH2CH3, major and minor form), 1.08 − 1.21 (m, 2H, CH2CH2P), 1.46 − 
1.69 (m, 2H, CH2CH2P), 1.71 and 1.94 (2 × s, 3H, CH3C=O, minor and major form), 
3.09 − 3.28 (m, 4H, NCH2CH3 and NCH2CH2) ppm. 
13C-NMR (75 MHz, D2O): mixture of amide rotamers 
 = 12.06 and 12.86 
(NCH2CH3), 20.49 and 20.78 (CH3C=O, major and minor form), 22.49 (d, 
2JC,P = 4.8 Hz, CH2CH2P) and 23.41 (d, 2JC,P = 4.9 Hz, CH2CH2P), 26.41 (d, 
JC,P = 131.6 Hz, CH2CH2P) and 26.59 (d, JC,P = 131.3 Hz, CH2CH2P), 41.19 and 
43.99 (NCH2CH3), 46.95 (d, 3JC,P = 20.7 Hz, NCH2) and 50.20 (d, 3JC,P = 20.1 Hz, 
NCH2), 173.6 (CH3C=O) ppm. 
Exact mass (ESI-MS): calculated for C7H15NO4P [M-H]-: 208.0737, found: 208.0753. 
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Diethyl [3-(N-methylformamido)propyl]phosphonate (2.17) 
N P
O
OEt
OEt
H
Me
O
 
To a solution of N-methylformamide (0.3 g, 5 mmol) in DMF (5 mL) was added 
sodium hydride (144 mg, 6 mmol). The reaction mixture was stirred for 30 minutes 
and diethyl(3-bromo-propyl)phosphonate (1.35 g, 5 mmol) was added to this solution 
and stirred for 16 h. All volatile compounds were removed under reduced pressure 
and the residue was diluted with CH2Cl2 and extracted with water. The organic layer 
was dried over MgSO4 and evaporated under reduced pressure. The crude residue 
was purified by flash chromatography (CH2Cl2/MeOH, 98:2	97:3) to yield 2.17 as a 
viscous oil (0.61 g, 52%). 
1H-NMR (300 MHz, DMSO): 
 = 1.20 (m, 6H, OCH2CH3), 1.60 − 1.64 (m, 4H, 
CH2CH2P), 2.69 and 2.86 (2 × s, 3H, NCH3, major and minor form), 3.23 − 3.32 (m, 
2H, NCH2), 7.95 (s, 1H, HC=O) ppm. 
Exact mass (ESI-MS): calculated for C9H21NO4P [M+H]+: 238.1209, found: 
238.1226. 
 
Diethyl [3-(N-ethylformamido)propyl]phosphonate (2.18) 
N P
O
OEt
OEt
H
Et
O
 
To a solution of N-ethylformamide (0.36 g, 5 mmol) in DMF (5 mL) was added 
sodium hydride (144 mg, 6 mmol). The reaction mixture was stirred for 30 minutes 
and diethyl(3-bromo-propyl)phosphonate (1.35 g, 5 mmol) was added to this solution 
and stirred for 16 h. All volatile compounds were removed under reduced pressure 
and the residue was diluted with CH2Cl2 and extracted with water. The organic layer 
was dried over MgSO4 and evaporated under reduced pressure. The crude residue 
was purified by flash chromatography (CH2Cl2/MeOH, 97:3) to yield 2.18 as a viscous 
oil (0.85 g, 72%). 
1H-NMR (300 MHz, DMSO): mixture of amide rotamers 
 = 0.99 and 1.06 (2 × t, J = 
7.2 Hz, 3H, NCH2CH3, two forms), 1.20 (t, J = 7.2 Hz, 6H, OCH2CH3), 1.62 − 1.63 (m, 
4H, CH2CH2P), 3.12 − 3.29 (m, 4H, NCH2CH3 and NCH2CH2), 3.93 − 3.98 (m, 4H, 
POCH2CH3) 7.95 and 8.01(2 × s, 1H, HC=O, two forms) ppm. 
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Exact mass (ESI-MS): calculated for C10H23NO4P [M+H]+: 252.1365, found: 
252.1372. 
 
[3-(N-Formyl-N-methyl-amino)-propyl]-phosphonic acid (2.3) 
N P
O
OH
OH
H
Me
O
 
1H-NMR (300 MHz, D2O): mixture of amide rotamers 
 = 1.36–1.47 (m, 2H, 
CH2CH2P), 1.61–1.71 (m, 2H, CH2CH2P), 2.41 and 2.63 (2 × s, 3H, NCH3), 3.16–
3.27 (m, 2H, NCH2), 7.81 and 7.92 (2 × s, 1H, HC=O, minor and major form) ppm.  
13C-NMR (75 MHz, D2O): mixture of amide rotamers 
 = 21.44 (d, 2JCP = 3.0 Hz, 
CH2CH2P) and 22.60 (d, 2JCP = 3.8 Hz, CH2CH2P), 25.44 (d, JCP = 134.5 Hz, 
CH2CH2P), 32.60 and 35.07 (NCH3), 51.95 (d, 3JCP = 18.9 Hz, NCH2) and 48.72 (d, 
3JCP = 19.7 Hz, NCH2), 165.3 (HC=O) ppm. 
Exact mass (ESI-MS): calculated for C5H11NO4P [M-H]-: 180.0424, found: 180.0449. 
 
[3-(N-Ethyl-N-formyl -amino)-propyl]-phosphonic acid (2.4) 
N P
O
OH
OH
H
Et
O
 
1H-NMR (300 MHz, D2O): mixture of amide rotamers 
 = 0.93 and 1.00 (2 × t, 3H, 
NCH2CH3, major and minor form), 1.10 − 1.19 (m, 2H, CH2CH2P), 1.46 − 1.71 (m, 
2H, CH2CH2P), 3.11 − 3.28 (m, 4H, NCH2CH3 and NCH2CH2), 7.81 and 7.87 (2 × s, 
1H, HC=O, major and minor form) ppm. 
13C-NMR (75 MHz, D2O): mixture of amide rotamers 
 = 11.96 and 13.80 
(NCH2CH3), 22.17 (d, 2JC,P = 4.8 Hz, , CH2CH2P) and 23.33 (d, 2JC,P = 4.9 Hz, , 
CH2CH2P), 26.41 (d, JC,P = 131.2 Hz, PCH2) and 27.26 (d, JC,P = 131.0 Hz, PCH2), 
37.65 and 43.22 (NCH2CH3), 49.38 (d, 3JC,P = 19.0 Hz, NCH2), 173.6 (HC=O) ppm. 
Exact mass (ESI-MS): calculated for C6H13NO4P [M-H]-: 194.0581, found: 194.0591. 
 
Diethyl [3-(2-hydroxyethylamino)propyl]phosphonate (2.21) 
N
H
P
O
OEt
OEtHO
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A solution of diethyl 3-bromopropylphosphonate (2.0 mL, 10 mmol) in acetonitrile (5 
ml) was added to a suspension of ethanolamine (3.0 mL, 50 mmol) and potassium 
carbonate (14 g, 0.1 mol) in acetonitrile (15 mL). When TLC revealed that all starting 
material was gone, excess potassium carbonate was filtered off and the solvent of 
the filtrate was removed under reduced pressure. The residue was mixed with celite 
and was subsequently purified by column chromatography (CH2Cl2/MeOH/NH3 in 
MeOH 85:14:1) yielding 2.21 (1.64 g, 68%) as a yellow oil. Only small traces of the 
disubstituted ethanolamine were formed (0.02%). 
1H NMR (300 MHz, DMSO-d6): 
 = 1.20 (t, J = 7.2 Hz, 6H, OCH2CH3), 1.51 – 1.62 
(m, 2H, CH2CH2P), 1.66 – 1.77 (m, 2H, CH2CH2P), 2.48 – 2.56 (m, 4H, 
CH2NCH2CH2OH), 3.38 – 3.43 (m, 2H, NCH2CH2OH), 3.89 – 4.00 (m, 4H, 
OCH2CH3), 4.41 (br. s, 1H, OH) ppm.  
Exact mass (ESI-MS): calculated for C9H21NO4P [M-H]-: 238.1207, found: 238.1236. 
Side product 2.22 
N P
O
OEt
OEtHO
P
O
OEt
OEt
 
1H NMR (300 MHz, DMSO-d6): 
 = 1.20 (t, J = 7.2 Hz, 12H, OCH2CH3), 1.45 – 1.61 
(m, 4H, CH2CH2P), 1.63 – 1.74 (m, 4H, CH2CH2P), 2.40 – 2.49 (m, 6H, 
(CH2)2NCH2CH2OH), 3.36 – 3.42 (m, 2H, NCH2CH2OH), 3.89 – 4.01 (m, 8H, 
OCH2CH3), 4.31 (br. s, 1H, OH) ppm. 
 
Diethyl [3-(N-(2-hydroxyethyl)acetamido)propyl]phosphonate (2.23a) 
N P OEt
OEt
Me
O
OH
O
 
Amine 2.21 (500 mg, 2.0 mmol) was dissolved in a mixture of THF (20 mL) and 50% 
NaOAc solution (20 mL). Acetyl chloride (128 L, 1.80 mmol) was added dropwise 
over 30 min and the reaction mixture was stirred for 3 h at room temperature. Ethyl 
acetate (40 mL) was added and the phases were separated. The aqueous layer was 
extracted three times with ethyl acetate (3 × 40 mL) and the combined organic phase 
was dried over MgSO4. After removal of the solvent under reduced pressure, the 
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mixture was purified by column chromatography (CH2Cl2/MeOH 95:5) yielding 26a 
(390 mg, 70%) as a yellow oil. 
1H NMR (300 MHz, DMSO-d6): mixture of amide rotamers 
 = 1.17 – 1.23 (m, 6H, 
OCH2CH3), 1.60 – 1.75 (m, 4H, CH2CH2P), 1.96 and 1.98 (2 × s, 3H, CH3C=O), 3.22 
– 3.35 (m, 4H, CH2NCH2CH2OH), 3.38 – 3.50 (m, 2H, NCH2CH2OH), 3.88 – 4.02 (m, 
4H, OCH2CH3), 4.64 and 4.81 (2 × t, J = 5.1 Hz, 1H, OH) ppm.  
Exact mass (ESI-MS): calculated for C11H23NO5P [M-H]-: 280.1312, found: 
280.1324. 
 
[3-(N-(2-Hydroxyethyl)acetamido)propyl]phosphonic acid (2.6) 
N P OH
OH
Me
O
OH
O
 
Trimethylsilyl bromide (1.12 g, 7.3 mmol) was added dropwise at 0 °C with stirring to 
a solution of phosphonic ester 2.23a (390 mg, 1.39 mmol) in dichloromethane (8 mL), 
and stirring was continued at room temperature for 2 h. Organic solvents were 
removed in vacuo. The crude yellow foam was dissolved in ethanol and decolourized 
over a active carbon patch to yield the pure phosphonic acid 2.6 in almost 
quantitative yield. 
1H NMR (300 MHz, D2O): 
 = 1.08 – 1.22 (m, 2H, CH2P), 1.48 – 1.65 (m, 2H, 
CH2CH2P), 1.96 and 1.97 (2 × s, 3H, CH3C=O), 3.14 – 3.26 (m, 2H, NCH2CH2CH2), 
3.30 – 3.38 (m, 2H, NCH2CH2OH), 3.51 – 3.60 (m, 2H, NCH2CH2OH) ppm.  
13C-NMR (75 MHz, D2O): mixture of amide rotamers 
 = 20.93 and 21.13 (CH3), 
22.43 and 23.46 (d, 2JC,P = 3.4 Hz, PCH2CH2), 26.50 and 26.71 (d, 1JC,P = 131 Hz, 
PCH2), 47.93 and 50.58 (NCH2CH2OH), 47.48 and 51.45 (d, 3JC,P = 19.9 Hz, 
NCH2CH2CH2), 59.19 and 59.24 (NCH2CH2OH), 174.59 and 174.72 (C=O) ppm.  
Exact mass (ESI-MS): calculated for C7H15NO5P [M-H]-: 224.0687, found: 224.0668. 
 
Diethyl [3-(N-(2-hydroxyethyl)benzamido)propyl]phosphonate (2.23b) 
N P OEt
OEt
O
OH
O
 
 - 142 -
Amine 2.21 (334 mg, 1.4 mmol) was dissolved in a mixture of THF (20 mL) and 50% 
NaOAc solution (20 mL). Benzoyl chloride (147 L, 1.27 mmol) was added dropwise 
over 30 min and the reaction mixture was stirred for 3 h at room temperature. Ethyl 
acetate (40 mL) was added and the phases were separated. The aqueous layer was 
extracted three times with ethyl acetate (3 × 40 mL) and the combined organic phase 
was dried over MgSO4. After removal of the solvent under reduced pressure, the 
mixture was purified by column chromatography (CH2Cl2/MeOH 95:5) yielding 2.23b 
(383 mg, 79%) as a yellow oil. 
1H NMR (300 MHz, DMSO-d6): 
 = 1.22 (m, 6H, OCH2CH3), 1.20 – 1.78 (m, 4H, 
CH2CH2P), 3.23 – 3.60 (m, 6H, CH2NCH2CH2OH), 3.98 (m, 4H, OCH2CH3), 4.75 (br. 
s, 1H, OH), 7.36 – 7.39 (m, 5H, arom. H) ppm.  
Exact mass (ESI-MS): calculated for C16H25NO5P [M-H]-: 342.1469, found: 
342.1486. 
 
[3-(N-(2-Hydroxyethyl)benzamido)propyl]phosphonic acid (2.7) 
N P OH
OH
O
OH
O
 
Trimethylsilyl bromide (897 mg, 5.85 mmol) was added dropwise at 0 °C with stirring 
to a solution of phosphonic ester 2.23b (383 mg, 1.12 mmol) in dichloromethane (4 
mL), and stirring was continued at room temperature for 2 h. Organic solvents were 
removed in vacuo. The crude yellow foam was dissolved in ethanol and decolourized 
over a active carbon patch to yield the pure phosphonic acid 2.7 in almost 
quantitative yield. 
1H NMR (300 MHz, DMSO-d6): 
 = 1.54 – 1.66 (m, 2H, CH2P), 1.80 – 1.89 (m, 2H, 
CH2CH2P), 3.04 – 3.09 (m, 2H, NCH2CH2CH2), 3.35 (m, 2H, NCH2CH2OH), 4.49 (m, 
2H, NCH2CH2OH), 7.33 – 8.09 (m, 5H, arom. H), 8.82 (br. s, 3H, OH) ppm.  
13C-NMR (75 MHz, DMSO-d6): 
 = 20.48 (d, 2JC,P = 4.0 Hz, PCH2CH2), 25.75 (d, 1JC,P 
= 137.3 Hz, PCH2), 46.61 (NCH2CH2OH), 48.73 (d, 3JC,P = 15.5 Hz, NCH2CH2CH2), 
61.43 (NCH2CH2OH), 130.08 (=CH), 130.72 (=CH), 131.09 (=CH), 135.04 (=C), 
167.21 (C=O) ppm.  
Exact mass (ESI-MS): calculated for C12H17NO5P [M-H]-: 286.0844, found: 
286.0852. 
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Diethyl [3-(N-(2-hydroxyethyl)-2-naphthamido)propyl]phosphonate (2.23c) 
N P OEt
OEt
O
OH
O
 
Amine 2.21 (358 mg, 1.5 mmol) was dissolved in a mixture of THF (20 mL) and 50% 
NaOAc solution (20 mL). 1-Naphthoyl chloride (204 L, 1.35 mmol) was added 
dropwise over 30 min and the reaction mixture was stirred for 3 h at room 
temperature. Ethyl acetate (40 mL) was added and the phases were separated. The 
aqueous layer was extracted three times with ethyl acetate (3 × 40 mL) and the 
combined organic phase was dried over MgSO4. After removal of the solvent under 
reduced pressure, the mixture was purified by column chromatography 
(CH2Cl2/MeOH 95:5) yielding 2.23c (487 mg, 82%) as a yellow oil. 
1H NMR (300 MHz, DMSO-d6): 
 = 1.05 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.25 (t, J = 7.0 
Hz, 3H, OCH2CH3), 1.32 – 1.60 (m, 2H, CH2CH2P), 1.77 – 1.96 (m, 2H, CH2CH2P), 
2.95 – 3.21 (m, 2H, NCH2), 3.42 – 3.55 (m, 2H, NCH2CH2OH), 3.69 – 3.78 (m, 2H, 
NCH2CH2OH), 3.97 – 4.09 (m, 4H, OCH2CH3), 4.63 and 4.86 (2 × br. s, 1H, OH), 
7.39 – 7.99 (m, 7H, arom. H) ppm.  
Exact mass (ESI-MS): calculated for C20H27NO5P [M-H]-: 392.1624, found: 
392.1632. 
 
 
[3-(N-(2-Hydroxyethyl)-2-naphthamido)propyl]phosphonic acid (2.8) 
N P OH
OH
O
OH
O
 
Trimethylsilyl bromide (995 mg, 6.5 mmol) was added dropwise under Nitrogen at 0 
°C with stirring to a solution of phosphonic ester 2.23c (487 mg, 1.24 mmol) in dry 
dichloromethane (4 mL), and stirring was continued at room temperature for 2 h. 
Organic solvents were removed in vacuo. The crude yellow foam was taken up in 
acetone (6 mL) with vigorous shaking to result in a thin suspension. Water (0.25 mL) 
was added to give a gummy precipitate which solidified instantly. The suspension 
was shaken vigorously for 10 minutes, filtered and washed with acetone to give a 
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yellow solid compound. The solid was taken up in boiling water and the hot solution 
was filtered through a fluted filter paper to remove a small amount of insoluble 
material. The aqueous solution was cooled and crystallization began at once to yield 
the pure phosphonic acid 2.8. 
1H NMR (300 MHz, DMSO-d6): 
 = 1.08 – 1.20 (m, 2H, CH2P), 1.56 – 1.67 (m, 2H, 
CH2CH2P), 3.02 – 3.09 (m, 2H, NCH2CH2CH2), 3.30 – 3.49 (m, 2H, NCH2CH2OH), 
3.72 (m, 2H, NCH2CH2OH), 4.58 (br. s, 1H, OH), 7.28 – 8.83 (m, 7H, arom. H) ppm.  
13C-NMR (75 MHz, DMSO-d6): mixture of amide rotamers 
 = 22.70 (d, 2JC,P = 6.7 
Hz, PCH2CH2), 24.91 (d, 1JC,P = 138 Hz, PCH2), 38.56 (NCH2CH2OH), 48.11 (d, 3JC,P 
= 19.3 Hz, NCH2CH2CH2), 61.55 (NCH2CH2OH), 125.34 (=CH), 125.86 (=CH), 
127.26 (=CH), 127.32 (=CH), 127.51 (=CH), 128.00 (=CH), 128.45 (=CH), 131.64 
(=C), 132.89 (=C), 133.60 (=C), 170.49 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C16H19NO5P [M-H]-: 336.0999, found: 
336.0990. 
 
Diethyl [3-(N-(2-hydroxyethyl)palmitamido)propyl]phosphonate (2.23d) 
N P OEt
OEtC15H31
O
OH
O
 
Amine 2.21 (240 mg, 1.0 mmol) was dissolved in a mixture of THF (20 mL) and 50% 
NaOAc solution (20 mL). Palmitoyl chloride (277 L, 1.0 mmol) was added dropwise 
over 30 min and the reaction mixture was stirred for 3 h at room temperature. Ethyl 
acetate (40 mL) was added and the phases were separated. The aqueous layer was 
extracted three times with ethyl acetate (3 × 40 mL) and the combined organic phase 
was dried over MgSO4. After removal of the solvent under reduced pressure, the 
mixture was purified by column chromatography (CH2Cl2/MeOH 95:5) yielding 2.23d 
(585 mg, 73%) as a yellow oil. 
1H NMR (300 MHz, DMSO-d6): mixture of amide rotamers 
 = 0.81 – 0.82 (m, 3H, 
CH3), 1.17 – 1.22 (m, 32H), 1.60 – 1.73 (m, 4H, CH2CH2P), 2.21 – 2.31 (m, 2H, 
CH2C=O), 3.24 – 3.33 (m, 4H, CH2NCH2CH2OH), 3.35 – 3.47 (m, 2H, NCH2CH2OH), 
3.90 – 4.02 (m, 4H, OCH2CH3), 4.59 and 4.76 (2 × t, J = 5.1 Hz, 1H, OH) ppm.  
Exact mass (ESI-MS): calculated for C25H51NO5P [M-H]-: 476.3503, found: 
476.3517. 
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[3-(N-(2-Hydroxyethyl)-2-palmitamido)propyl]phosphonic acid (2.9) 
N P OH
OH
O
OH
O
C15H31
 
Trimethylsilyl bromide (585 mg, 3.82 mmol) was added dropwise at 0 °C with stirring 
to a solution of phosphonic ester 2.23d (348 mg, 0.73 mmol) in dichloromethane (4 
mL), and stirring was continued at room temperature for 2 h. Organic solvents were 
removed in vacuo. The crude yellow foam was dissolved in ethanol and decolourized 
over a active carbon patch to yield the pure phosphonic acid 2.9 in almost 
quantitative yield. 
1H NMR (300 MHz, DMSO-d6): 
 = 0.96 (m, 3H, CH3), 1.29 (m, 30H), 2.25 (m, 2H), 
3.50 (m, 6H) ppm.  
Exact mass (ESI-MS): calculated for C21H43NO5P [M-H]-: 420.2878, found: 
420.2893. 
 
Diethyl [4-(benzyloxy)butan-2-yl]phosphonate (2.25) 
O P
O OEt
OEt
 
In a three-necked flask of 250 mL was brought a 1.6 M solution of nBuLi in hexane 
(5.8 mL). At a temperature of -20 °C was added THF (5.8 mL) and the solution was 
cooled to -78 °C. Dropwise diethyl ethylphosphonate (1.55 g, 9.3 mmol) was added 
in THF (2 mL) by -78 °C. After 20 min benzyl 3-bromoethyl ether (1.47 mL, 9.3 mmol) 
was added in THF (4 mL). The reaction mixture was brought to room temperature 
and H2O was slowly added and the mixture was extracted four times with CH2Cl2. 
The organic layer was dried over MgSO4 and concentrated under reduced pressure. 
The residue was purified by flash chromatography (CH2Cl2/MeOH 99:1) to give 2.25 
in 28% yield. 
1H NMR (300 MHz, DMSO-d6): 
 = 0.99 and 1.05 (2 × d, J = 7.5 Hz, 3H, CH3), 1.18 
(t, J = 7.0 Hz, 6 H, OCH2CH3), 1.36 − 1.52 (m, 1H, CH2CH2CH), 1.84 − 2.02 (m, 2H, 
CH2CH2CH), 3.40 − 3.54 (m, 2H, CH2CH2CH), 3.90 − 4.20 (m, 4 H, OCH2CH3), 4.40 
(1 H, d, AB system, J = 12.0 Hz, OCH2Ph), 4.46 (1 H, d, AB system, J = 12.0 Hz, 
OCH2Ph), 7.17 − 7.30 (m, 5 H, arom. H) ppm. 
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Exact mass (ESI-MS): calculated for C15H26O4P [M + H]+: 301.1569, found 
301.1573. 
 
Diethyl [4-hydroxybutan-2-yl]phosphonate (2.26) 
HO P
O OEt
OEt
 
Phosphonate 2.25 (0.77 g, 2.6 mmol) was dissolved in MeOH (62 mL) and 
hydrogenated at atmospheric pressure in the presence of Pd (10 wt.-% on activated 
carbon, 843 mg). After stirring for 5 h, the reaction mixture was filtered through a 
Celite pad. The solvent was removed under vacuum, and the crude mixture was 
purified by column chromatography on silica gel 2.26 in 83% yield (CH2Cl2/MeOH, 
99:1	98:2	97:3). 
1H NMR (300 MHz, DMSO-d6 + D2O): 
 = 0.99 and 1.06 (2 × d, J = 7.5 Hz, 3H, CH3), 
1.40 (t, J = 7.0 Hz, 6 H, OCH2CH3), 1.25 − 1.45 (m, 1H, CH2CH2CH), 1.72 − 1.85 (m, 
1H, CH2CH2CH), 1.85 − 2.02 (m, 1H, CH2CH2CH), 3.38 − 3.52 (m, 2H, CH2CH2CH), 
3.90 − 4.05 (m, 4 H, OCH2CH3), 4.51 (t, 1H, OH) ppm. 
Exact mass (ESI-MS): calculated for C8H20O4P [M + H]+: 211.1099, found 211.1103. 
 
Diethyl [4-azidobutan-2-yl]phosphonate (2.28) 
P
O
N3
OEt
OEt
 
Methanesulfonylchloride (638 mg, 5.6 mmol) was added to a solution of compound 
2.26 (300 mg, 1.4 mmol) in pyridine (8 mL) at 0 °C. The reaction mixture was stirred 
at 0 °C for 20 h, and then the solvent was evaporated to dryness under reduced 
pressure. The residue was dissolved in CH2Cl2 (150mL), washed with NaHCO3 
solution and H2O, and dried over anhydrous MgSO4. The solvent was removed under 
diminished pressure to give a syrup (2.27) which was used in the following reaction 
without further purification. A solution of compound 2.27 and sodium azide (1.4 g, 
21.4 mmol) in DMF (50 mL) was heated with stirring at 95 °C for 1.5 h. The reaction 
mixture was evaporated to dryness in vacuo and the 
residue was dissolved in CH2Cl2 (50 mL). The organic layer was washed with water 
(3 × 20 mL), dried over anhydrous MgSO4, and evaporated to give a syrup, which 
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was purified by silica gel column (CH2Cl2/MeOH, 95:5, v/v) to yield 0.19 g (56%) of 
product as a syrup. 
1H NMR (300 MHz, DMSO-d6): 
 = 0.99 and 1.52 (2 × d, J = 7.5 Hz, 3H, CH3), 1.40 
(t, J = 7.0 Hz, 6 H, OCH2CH3), 1.40 − 1.58 (m, 1H, CH2CH2CH), 1.77 − 2.02 (m, 2H, 
CH2CH2CH), 3.36 − 3.56 (m, 2H, CH2CH2CH), 3.88 − 4.05 (m, 4 H, OCH2CH3) ppm. 
Exact mass (ESI-MS): calculated for C8H22N3O3P [M + H]+: 239.1399, found 
239.1406. 
 
Diethyl [4-aminobutan-2-yl]phosphonate (2.29) 
P
O
H2N
OEt
OEt
 
Compound 2.28 (190 mg, 0.79 mmol) and triphenylphosphine (333 mg, 1.27 mmol) 
were dissolved in pyridine (8 mL) and stirred at room temperature. After 1 h, 
concentrated ammonium hydroxide (8 mL) was added and the solution was allowed 
to stir for an additional 2 h. Pyridine was removed at reduced pressure, water (20 mL) 
was added, and the unreacted triphenylphosphine and triphenylphosphine oxide was 
removed by filtration. The filtrate was extracted with toluene and then water and 
concentrated to dryness to give a syrup which was purified by flash chromatography 
(CH2Cl2/MeOH/NH3 in MeOH, 95:4:1, v/v/v) to yield 0.10 g (63%) of product 2.29 as a 
syrup. 
1H NMR (300 MHz, DMSO-d6): 
 = 0.99 and 1.05 (2 × d, J = 7.5 Hz, 3H, CH3), 1.21 
(t, J = 7.0 Hz, 6 H, OCH2CH3), 1.25 − 1.40 (m, 1H, CH2CH2CH), 1.60 − 1.74 (m, 1H, 
CH2CH2CH), 1.82 − 2.01 (m, 1H, CH2CH2CH), 2.54 − 2.71 (m, 2H, CH2CH2CH), 3.91 
− 4.05 (m, 4 H, OCH2CH3) ppm. 
Exact mass (ESI-MS): calculated for C8H21NO3P [M + H]+: 210.1259, found 
210.1244. 
 
Diethyl [4-acetamidobutan-2-yl]phosphonate (2.30) 
P
OH
NMe
O
OEt
OEt
 
A solution of phosphonate 2.29 (103 mg, 0.5 mmol) in CH2Cl2 (0.5 mL) containing 
pyridine (0.12 mL , 1.5 mmol) was cooled in an ice bath, followed by addition of 
acetylchloride (0.11 mL, 1.5 mmol). After 1.5 – 2 h the reaction was diluted with 
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CH2Cl2 (50 mL) and washed with water (50 mL). After drying of the organic layer with 
MgSO4, the solvent was removed in vacuo and the crude reaction mixture was 
chromatographed (CH2Cl2/MeOH 99:1	96:4). Compound 2.30 was obtained as 
yellow oil in a yield of 86%.  
1H NMR (300 MHz, DMSO-d6): 
 = 1.00 and 1.06 (2 × d, J = 7.5 Hz, 3H, CH3), 1.20 
(t, J = 7.0 Hz, 6 H, OCH2CH3), 1.22 − 1.33 (m, 1H, CH2CH2CH), 1.69 − 1.88 (m, 2H, 
CH2CH2CH), 1.76 (s, 3H, CH3C=O), 3.01 – 3.16 (m, 2H, CH2CH2CH), 3.91 − 4.01 (m, 
4 H, OCH2CH3), 7.82 (br. s, 1H, NH) ppm. 
Exact mass (ESI-MS): calculated for C10H23NO4P [M + H]+: 252.1365, found 
252.1379. 
 
Diethyl [4-(N-methylacetamido)butan-2-yl]phosphonate (2.31) 
P
O
NMe
O
Me OEt
OEt
 
To a solution of phosphonate 2.30 (0.48 g, 1.9 mmol) in THF (10 mL) was added 
sodium hydride (57 mg, 2.3 mmol) in small portions. This reaction mixture was stirred 
by room temperature for 30 minutes. Iodomethane (0.35 g, 2.5 mmol) was added 
dropwise to the reaction mixture and the solution was stirred overnight. H2O was 
slowly added and the mixture was extracted four times with ethyl acetate. The 
organic layer was dried over MgSO4 and concentrated under reduced pressure. The 
residue was purified by flash chromatography (CH2Cl2/MeOH 99:1	98:2	97:3) to 
give 2.31 in 25% yield. 
1H NMR (300 MHz, DMSO-d6): mixture of amide rotamers 
 = 1.00 – 1.12 (m, 3H, 
H(C)CH3), 1.78 – 1.23 (m, 6H, OCH2CH3), 1.24 – 1.52 (m, 1H, CH2CH2CH), 1.55 − 
1.87 (m, 2H, CH2CH2CH), 1.94 and1.95 (2 × s, 3H, CH3C=O), 2.73 and 2.88 (2 × 
assymetric d, 3H, NCH3), 3.13 – 3.50 (m, 2H, CH2CH2CH), 3.91 – 4.01 (m, 4 H, 
OCH2CH3) ppm. 
Exact mass (ESI-MS): calculated for C11H25NO4P [M + H]+: 266.1521, found 
266.1532. 
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4-(N-Methylacetamido)butan-2-ylphosphonic acid (2.5) 
P OHOH
O
NMe
O
Me
 
Trimethylsilyl iodide (343 mg, 1.7 mmol) was added dropwise at 0 °C with stirring to a 
solution of phosphonic ester 2.31 (111 mg, 0.42 mmol) in dichloromethane (10 mL) , 
and stirring was continued at room temperature for 2 h. Organic solvents were 
removed in vacuo. The crude yellow foam was dissolved in ethanol, decolourized 
over a active carbon patch and subsequently crystallized from ethanol/Et2O to yield 
the pure phosphonic acid 2.5 in almost quantitative yield. 
1H-NMR (300 MHz, D2O): mixture of amide rotamers 
 = 0.82 – 0.99 (m, 3H, 
H(C)CH3), 1.10 – 1.37 (m, 2H, CH2CHP), 1.72 – 1.99 (m, 1H, CH2CHP), 1.93 and 
1.98 (2 × s, 3H, CH3C=O, minor and major form), 2.74 – 2.89 (2 × s, 3H, NCH3, major 
and minor form), 3.16 – 3.39 (m, 2H, NCH2) ppm. 
13C-NMR (75 MHz, D2O): mixture of amide rotamers 
 = 14.15 and 14.32, 20.32 and 
21.06, 28.81 and 29.80, 31.57, 33.62 and 36.21, 46.89 and 50.45, 173.9 ppm. 
Exact mass (ESI-MS): calculated for C7H15NO4P [M + H]+: 208.0737, found 
208.0753. 
 
Methyl -bromobutyrate (2.33) 
OMe
Br
O
 
A solution of -butyrolactone (3 mL, 3.4 g, 39 mmol) in a 33% solution of hydrogen 
bromide in acetic acid (11.5 mL) was refluxed for 4 h at 75 °C, cooled to room 
temperature, treated with methanol (18 mL), and stirred overnight. Evaporation of the 
solvent gave a dark oil, which was dissolved in ethyl acetate (50 mL) and washed 
successively with saturated sodium bicarbonate (2 × 50 mL) and saturated sodium 
chloride (50 mL), dried over MgSO4, and evaporated to yield a clear oil (3.76 g, 53%).  
1H NMR (300 MHz, CDCl3): 
 = 2.17 (quintet, J = 7.0 Hz, 2H, CH2), 2.51 (t, J = 7.3 
Hz, 2H, CH2), 3.47 (t, J = 6.5 Hz, 2H, CH2), 3.69 (s, 3H, OCH3).  
13C NMR (75 MHz, CDCl3): 
 = 27.92, 32.41, 32.98, 51.99, 173.26. 
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Exact mass (ESI-MS): calculated for C5H10O2Br [M + H]+: 180.9865, found 
180.9892. 
 
Methyl -phthalimidooxybutyrate (2.34) 
OMe
OPht
O
 
A mixture of methyl -bromobutyrate (3.75 g, 20.8 mmol), N-hydroxyphthalimide (3.4 
g, 20.8 mmol), and triethylamine (5.86 mL, 4.22 g, 41.7 mol) in acetonitrile (30 mL) 
was refluxed for 3 h. The insoluble solid was removed by filtration, and the filtrate 
was evaporated. The residue was diluted with ethyl acetate (50 mL), and this solution 
was washed successively with water (3 × 50 mL) and saturated sodium chloride (50 
mL), dried over MgSO4, and evaporated. The solid was recrystallized from hot 
ethanol to give 3.85 g (71%). 
1H NMR (300 MHz, CDCl3): 
 = 2.09 (2H, quintet, J = 7.2 Hz, CH2), 2.67 (2H, t, J = 
7.3 Hz, CH2), 3.71 (3H, s, OCH3), 4.26 (t, J = 6.2 Hz, 2H, CH2), 7.74 – 7.85 (m, 4H, 
phthalimido ring).  
13C NMR (75 MHz, CDCl3): 
 = 23.75, 30.20, 51.98, 77.67, 123.81, 129.11, 134.76, 
163.87, 173.72. 
Exact mass (ESI-MS): calculated for C13H14NO5 [M + H]+: 264.0872, found 
264.0858 
 
Methyl -aminooxybutyrate (2.35) 
OMe
ONH2
O
 
A solution of methyl -phthalimidooxybutyrate (2.76 g, 10.49 mmol) in 
dichloromethane (50 mL) was cooled to –10 °C and treated dropwise, with stirring, 
with methylhydrazine (0.86 mL, 0.74 g, 15.7 mmol). Stirring was continued for 1.5 h 
at –10 to 0 °C, and the mixture was then filtered. The filtrate was concentrated, and 
the residue, in ethyl acetate (50 mL), was washed with 1:1 saturated sodium 
chloride:saturated sodium bicarbonate (20 mL). The aqueous layer was washed with 
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ethyl acetate (50 mL), and the combined organic extracts were dried over anhydrous 
magnesium sulfate and evaporated to give a yellow oil (1.44 g, 100%). 
1H NMR (300 MHz, CDCl3): 
 = 1.86 (quintet, J = 6.2 Hz, 2H, CH2), 2.32 (t, J = 7.3 
Hz, 2H, CH2), 3.62 (s, 3H, OCH3), 3.63 (t, J = 6.2 Hz, 2H, CH2). 
13C NMR (75 MHz, CDCl3): 
 = 23.37, 30.91, 52.06, 76.08, 174.24. 
Exact mass (ESI-MS): calculated for C5H12NO3 [M + H]+: 134.0817, found 134.0728. 
 
[1,2]Oxazinan-3-one (2.36) 
NH
O
O
 
A solution of methyl -aminooxybutyrate (1.37 g, 10.4 mmol) in toluene (100 mL) was 
treated with a 2.0 mol/L solution of trimethylaluminium in hexanes (10.5 mL, 21 
mmol). The resulting mixture was refluxed for 2 h, cooled to room temperature, and 
quenched with acetone (8 mL) with stirring for 30 min and then by slow addition of 
water (20 mL). Most of the solvent was removed under reduced pressure, and 1:4 
dichloromethane:tetrahydrofuran (150 mL) was added. Filtration through Celite to 
remove aluminium salts and evaporation of the filtrate gave an oil which was purified 
by column chromatography (n-hexane/ethyl acetate, 1:7) (0.2 g, 20%). 
1H NMR (300 MHz, CDCl3): 
 = 2.10 (quintet, J = 6.7 Hz, 2H, C=OCH2CH2), 2.52 (t, J 
= 7.3 Hz, 2H, C=OCH2), 4.02 (t, J = 6.2 Hz, 2H, CH2O). 
13C NMR (75 MHz, CDCl3): 
 = 21.81, 27.86, 69.49, 163.24. 
Exact mass (ESI-MS): calculated for C4H8NO2 [M + H]+: 102.0555, found 102.0553. 
 
Diethyl [3-(3-oxomorpholino)propyl]phosphonate (2.37) 
N
O
O
P
O OEt
OEt
 
To a solution of 2.36 (46.5 mg, 0.46 mmol) in acetone (2 mL) was added potassium 
carbonate (0.13 g, 0.92 mmol). The suspension was heated at reflux for 1 h, then 
cooled at room temperature. Diethyl(3-bromo-propyl)phosphonate (2.16) (0.088 mL, 
0.46 mmol) was hence added and, after refluxing for 12 h, the crude reaction mixture 
was diluted with acetone (10 mL) and poured into water (10 mL) and extracted with 
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dichloromethane (3 × 10 mL). After the work up, the dark brown residue was 
chromatographed on silica gel (CH2Cl2/MeOH, 95:5) to give 2.37 (57 mg, 43% yield). 
1H NMR (300 MHz, CDCl3): 
 = 1.32 (t, J = 7.0 Hz, 6H, OCH2CH3), 1.69 – 1.81 (m, 
2H, PCH2), 1.85 – 1.99 (m, 2H, PCH2CH2), 2.09 (quintet, J = 7.0 Hz, 2H, 
C=OCH2CH2), 2.49 (t, J = 7.3 Hz, 2H, C=OCH2), 3.67 (t, J = 6.7 Hz, 2H, NCH2), 4.03 
(t, J = 6.8 Hz, 2H, CH2O), 4.04 – 4.16 (m, 2H, OCH2CH3). 
13C NMR (75 MHz, CDCl3): 
 = 16.70 (d, J = 6.1 Hz, OCH2CH3), 20.64 (d, J = 4.6 Hz, 
PCH2CH2), 22.55 (C=OCH2CH2), 23.34 (d, J = 143.1 Hz, PCH2), 28.36 (CH2C=O), 
46.42 (d, J = 19.9 Hz, NCH2), 61.82 (d, J = 6.6 Hz, OCH2CH3), 69.21 (CH2O), 170.70 
(C=O). 
Exact mass (ESI-MS): calculated for C11H23NO5P [M + H]+: 280.1314, found 
280.1299. 
 
3-(3-Oxomorpholino)propylphosphonic acid (2.38) 
N
O
O
P
O OH
OH
 
Trimethylsilyl bromide (125 mg, 0.8 mmol) was added dropwise with stirring to a 
solution of phosphonic ester 2.37 (57 mg, 0.2 mmol) in dichloromethane (2 mL), and 
stirring was continued at room temperature for 2 h. Organic solvents were removed in 
vacuo. The crude product was dissolved in H2O and purified with preparative HPLC 
on a C18 column (5 m, Phenomenex, Luna, 250 × 21.2 mm) with a linear gradient 
of acetonitrile (0	100 %) in 5 mM NH4OAc solution at a flow rate of 17.5 mL/min 
over 20 min. The compound was detected by a UV-detector and ELSD-dectector. 
The purity of the target compound was assessed by analytical HPLC [5 m, 
Phenomenex, C18(2), 250 × 4.6 mm] using the same gradient at a flow rate of 1 
mL/min. The phosphonic acid 2.38 was obtained as a yellow hygroscopic powder 
after lyophilisation (16 mg, 36% yield). 
1H NMR (300 MHz, D2O): 
 = 1.33 – 1.44 (m, 2H, PCH2), 1.60 – 1.71 (m, 2H, 
PCH2CH2), 1.92 (quintet, J = 6.7 Hz, 2H, C=OCH2CH2), 2.32 (t, J = 7.0 Hz, 2H, 
C=OCH2), 3.50 (t, J = 6.7 Hz, 2H, NCH2), 3.94 (t, J = 7.0 Hz, 2H, CH2O). 
13C NMR (75 MHz, D2O): 
 = 20.98 (d, J = 3.7 Hz, PCH2CH2), 21.60 (C=OCH2CH2), 
25.24 (d, J = 134.5 Hz, PCH2), 27.23 (CH2C=O), 47.42 (d, J = 19.9 Hz, NCH2), 69.93 
(CH2O), 171.83 (C=O). 
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Exact mass (ESI-MS): calculated for C7H15NO5P [M + H]+: 224.0688, found 
224.0674. 
 
Diethyl (1-phenylbut-3-enyl)phosphonate (3.6a)  
P
O
EtO OEt
 
To a stirred solution of 3.5a (12 mL, 57.4 mmol) in dry THF (100 mL) cooled to -50 to-
70 °C, was added a 1.6 M solution of nBuLi (39 mL, 63.2 mmol) in hexane under N2. 
After stirring at the same temperature for 15 min, allyl bromide (5 mL, 57.4 mmol) 
was added, 1 h after this addition, the reaction mixture was refluxed for 2 h. After 
cooling to room temperature, the reaction mixture was concentrated in vacuo, and 
the resulting oil was diluted with toluene (200 mL), washed with 10 % NH4Cl (200 
mL) and water (200 mL), dried with MgSO4 and concentrated in vacuo. Purification of 
the residue by flash chromatography (n-hexane/ethyl acetate, 8:2	7:3	6:4) yielded 
compound 3.6a as a transparent oil (14.96 g, 97 %).  
1H NMR (300 MHz, CDCl3): 
 = 1.06 (t, J = 7.0 Hz, 3 H, OCH2CH3), 1.25 (t, J = 7.0 
Hz, 3 H, OCH2CH3), 2.61 − 2.74 (m, 1 H, allyl CH2), 2.76 − 2.88 (m, 1 H, allyl CH2), 
3.05 (ddd, JH,P = 22.0 Hz, J = 4.4, 11.1 Hz, 1 H, CHP), 3.62 − 3.75 (m, 1 H, 
OCH2CH3), 3.80 − 3.93 (m, 1 H, OCH2CH3), 3.95 − 4.09 (m, 2 H, OCH2CH3), 4.85 − 
4.89 (m, 1 H, CH=CH2,cis), 4.93 − 5.00 (m, 1 H, CH=CH2,trans), 5.51 − 5.65 (m, 1 H, 
CH=CH2), 7.17 − 7.30 (m, 5 H, arom. H) ppm. 
13C NMR (75 MHz, CDCl3): 
 = 16.46 (d, 3JC,P = 5.7 Hz, OCH2CH3), 16.63 (d, 3JC,P = 
6.0 Hz, OCH2CH3), 34.26 (d, 2JC,P = 2.9, CH2CHP), 44.81 (d, 1JC,P = 137.1 Hz, CHP), 
62.00 (d, 2JC,P = 7.2 Hz, OCH2CH3), 62.77 (d, 2JC,P = 7.2 Hz, OCH2CH3), 117.03, 
127.34, 128.62, 129.55, 135.56, 135.82 ppm.  
Exact mass (ESI-MS): calculated for C14H22O3P [M + H]+: 269.1306, found 
269.1292. 
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Diethyl 1-p-tolylbut-3-enylphosphonate (3.6b) 
P
O
EtO OEt
Me
 
The procedure as described for 3.5a was used to produce the title compound in a 
yield of 33 %. 
1H-NMR (300 MHz, acetone-d6): 
 = 1.06 (t, J = 7.3 Hz, 3H, OCH2CH3), 1.25 (t, J = 
7.0 Hz, 3H, OCH2CH3), 2.29 (s, 3H, p-CH3), 2.56 – 2.68 (m, 1H, allyl CH2), 2.70 – 
2.83 (m, 1H, allyl CH2), 3.10 (ddd, JH,P = 22.0 Hz, J = 4.1 Hz en J = 11.1 Hz, 1H, CHP), 
3.65 – 3.78 (m, 1H, OCH2CH3), 3.79 – 3.92 (m, 1H, OCH2CH3), 3.96 – 4.09 (m, 2H, 
OCH2CH3), 4.83 – 4.88 (m, 1 H, CH=CH2, cis), 4.93 – 5.00 (m, 1 H, CH=CH2, trans), 
5.56 – 5.69 (m, 1 H, CH=CH2), 7.11 – 7.14 (m, 2 H, arom. H), 7.22 – 7.25 (m, 2 H, 
arom. H) ppm. 
13C-NMR (75 MHz, acetone-d6): 
 = 15.94 (d, 3JC,P = 5.5 Hz, OCH2CH3), 16.12 (d, 
3JC,P = 5.7 Hz, OCH2CH3), 20.38 (p-CH3), 34.35 (d, 2JC,P = 2.6, CH2CHP), 43.80 (d, 
1JC,P = 137.4 Hz, CHP), 61.38 (d, 2JC,P = 7.2 Hz, OCH2CH3), 61.99 (d, 2JC,P = 6.9 Hz, 
OCH2CH3), 116.11, 128.99, 129.58, 133.40, 136.15, 136.43 ppm.  
Mass (ESI-MS): calculated for C15H24O3P [M+H]+: 283.1462, found: 283.1. 
 
(E)-3-(4-chlorophenyl)acrylaldehyde (3.7d) 
O
H
Cl
 
To a stirred solution of 1-chloro-4-iodobenzene (2 g, 8.39 mmol) in DMF (30 mL) 
were added acrolein diethyl acetal (3.84 mL, 8.39 mmol), nBu4NOAc (5.06 g, 16.8 
mmol), K2CO3 (1.74 g, 12.6 mmol), KCl (0.63 g, 8.39 mmol) and Pd(OAc)2 (0.056 g, 
0.25 mmol). The mixture was stirred for 1.5 h at 90 °C. After cooling, 2 N HCl was 
slowly added and the reaction mixture was stirred at room temperature for 10 min. 
Subsequently, it was diluted with ether (200 mL) and washed with water (200 mL). 
The organic layer was dried over MgSO4 and concentrated under reduced pressure. 
The residue was purified by flash chromatography (n-hexane/ethylacetate 8:2) to give 
3.7d in 74% yield. 
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1H-NMR (300 MHz, CDCl3): 
 = 6.67 (dd, J = 7.6 and 16.1 Hz, 1H, CHC(O)H), 7.42 
(d, J
 
= 16.1 Hz, 1H, CH=CHC(O)H), 7.44 (m, 4H, arom. H), 9.69 (d, J = 7.6 Hz, 1 H, 
C(O)H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 129.19 (=CH), 129.65 (=CH), 129.83 (=CH), 132.73 
(=C), 137.48 (=C), 151.20 (=CH), 193.53 (C=O) ppm. 
Mass (ESI-MS): calculated for C9H8ClO [M+H]+: 167.0264, found: 167.1. 
 
(E)-3-(3,4-dichlorophenyl)acrylaldehyde (3.7e) 
O
H
Cl
Cl
 
A synthetic procedure as described for 3.7d using 1,2-dichloro-4-iodobenzene gave 
58% of the title compound. 
1H-NMR (300 MHz, CDCl3): 
 = 6.68 (dd, , J = 7.3 and 16.1 Hz, 1H, CHC(O)H), 7.37 
(d, J
 
= 16.1 Hz, 1H, CH=CHC(O)H), 7.45 (m, 3H, arom. H), 9.71 (d, J = 7.3 Hz, 1 H, 
C(O)H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 127.42 (=CH), 130.12 (=CH), 130.26 (=CH), 131.36 
(=CH), 133.80 (=C), 134.22 (=C), 135.48 (=C), 149.56 (=CH), 193.14 (C=O) ppm. 
Mass (ESI-MS): calculated for C9H7Cl2O [M+H]+: 200.9874, found: 200.1. 
 
General Method for the Synthesis of 3.8c-e: A mixture of the appropriate acrylic 
aldehyde (6.17 mmol), triethyl phosphite (1.34 mL, 7.71 mmol) and phenol (1.54 g, 
16 mmol) was heated to 100 °C. After 24 h, TLC analysis (hexane/ethyl acetate, 6:4) 
indicated that the reaction was finished, and the reaction mixture was subsequently 
concentrated. The crude product was purified by flash chromatography, eluting with 
hexane/ethyl acetate, 6:4. After concentration of the pure fractions, the desired 
acetals 3.8c-e were obtained as slightly yellow oils. 
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Diethyl [1-(4-methoxyphenyl)-3,3-diphenoxypropyl]phosphonate (3.8c). Yield: 
81%. 
O
O
MeO
P OEtOEtO
 
1H-NMR (300 MHz, CDCl3): 
 = 1.08 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.25 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.45 – 2.59 (m, 1H, PCHCH2), 2.68 – 2.79 (m, 1H, PCHCH2), 
3.36 (ddd, JH,P = 22.4 Hz, J = 4.6 Hz and J = 10.9 Hz, 1H, CHP), 3.64 – 3.75 (m, 1H, 
OCH2CH3), 3.80 (s, 3H, OCH3), 3.83 – 3.96 (m, 1H, OCH2CH3), 3.97 – 4.10 (m, 2H, 
OCH2CH3), 5.61 (dd, J = 7.3 Hz and J = 3.8 Hz, 1H, CH(OPh)2), 6.81 – 6.92 (m, 6H, 
arom. H), 6.95 – 7.02 (m, 1H, arom. H), 7.18 – 7.30 (m, 7H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.45 (d, 3JC,P = 7.2 Hz, OCH2CH3), 16.53 (d, 3JC,P = 
6.1 Hz, OCH2CH3), 34.89 (PCHCH2), 39.51 (d, 1JC,P = 140.2 Hz, CHP), 55.31 
(OCH3), 62.07 (d, 2JC,P = 7.2 Hz, OCH2CH3), 62.93 (d, 2JC,P = 7.2 Hz, OCH2CH3), 
99.60 (d, 3JC,P = 16.7 Hz, CH(OPh)2), 114.36 (d, =CH), 117.58 (=CH), 117.73 (=CH), 
122.68 (=CH), 122.81 (=CH), 127.15 (d, =C), 129.71 (=CH), 129.72 ( =CH), 130.44 
(d, =CH), 156.18 (=C), 156.31 (=C), 159.22 (d, =C) ppm. 
31P-NMR (120 MHz, CDCl3): 
 = 29.09 ppm. 
Mass (ESI-MS): calculated for C26H32O6P [M+H]+: 471.1937, found: 471.2. 
 
Diethyl [1-(4-chlorophenyl)-3,3-diphenoxypropyl]phosphonate (3.8d). Yield: 
85%. 
O
O
Cl
P OEtOEtO
 
1H-NMR (300 MHz, CDCl3): 
 = 1.09 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.25 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.46 – 2.60 (m, 1H, PCHCH2), 2.71 – 2.83 (m, 1H, PCHCH2), 
3.41 (ddd, JH,P = 22.6 Hz, J = 4.7 Hz and J = 10.6 Hz, 1H, CHP), 3.67 – 3.80 (m, 1H, 
OCH2CH3), 3.85 – 3.96 (m, 1H, OCH2CH3), 3.98 – 4.11 (m, 2H, OCH2CH3), 5.63 
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(ddd, J
 
= 7.3 Hz
 
and
 
J
 
= 4.4 Hz, JH,P = 0.88 Hz, 1H, CH(OPh)2), 6.81 – 6.92 (m, 4H, 
arom. H), 6.96 – 7.02 (m, 2H, arom. H), 7.18 – 7.26 (m, 8H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.46 (d, 3JC,P = 5.8 Hz, OCH2CH3), 16.56 (d, 3JC,P = 
6.1 Hz, OCH2CH3), 34.70 (PCHCH2), 39.88 (d, 1JC,P = 139.9 Hz, CHP), 62.39 (d, 
2JC,P = 7.5 Hz, OCH2CH3), 63.13 (d, 2JC,P = 7.2 Hz, OCH2CH3), 99.47 (d, 3JC,P = 16.7 
Hz, CH(OPh)2), 117.67 (=CH), 117.73 (=CH), 122.91 (d, =CH), 129.13 (=CH), 
129.16 (=CH), 129.79 (=CH), 129.81 (=CH), 130.77 (d, =CH), 133.67 (=C), 134.24 
(=C), 156.09 (=C), 156.11 (=C) ppm. 
Exact mass (ESI-MS): calculated for C25H28ClO5PNa [M+Na]+: 497.1260, found: 
497.1261. 
 
Diethyl [1-(3,4-Dichlorophenyl)-3,3-diphenoxypropyl]phosphonate (3.8e). Yield: 
2.29 g (70%).  
O
O
Cl
P OEtOEtO
Cl
 
1H NMR (300 MHz, CDCl3): δ = 1.13 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.25 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.43 − 2.57 (m, 1H, PCHCH2), 2.70 − 2.82 (m, 1H, PCHCH2), 
3.38 (ddd, JH,P = 22.7 Hz, J = 4.7, 10.3 Hz, 1H, CHP), 3.74 − 3.87 (m, 1H, 
OCH2CH3), 3.89 − 3.99 (m, 1H, OCH2CH3), 3.99 − 4.12 (m, 2H, OCH2CH3), 5.66 [dd, 
J = 6.8, 4.4 Hz, 1H, CH(OPh)2], 6.84 − 6.92 (m, 3H, arom. H), 6.97 − 7.03 (m, 2H, 
arom. H), 7.18 − 7.27 (m, 6H, arom. H), 7.37 − 7.45 (m, 2H, arom. H) ppm.  
13C NMR (75 MHz, CDCl3): δ = 16.51 (app. t, 3JC,P = 5.8 Hz, OCH2CH3), 34.61 (d, 
2JC,P too small for detection, PCHCH2), 39.70 (d, 1JC,P = 139.9 Hz, CHP), 62.57 (d, 
2JC,P = 7.2 Hz, OCH2CH3), 63.16 (d, 2JC,P = 6.6 Hz, OCH2CH3), 99.34 [d, 3JC,P = 15.8 
Hz, CH(OPh)2], 117.66 (arom. C), 117.68 (arom. C), 122.99 (arom. C), 123.01 (arom. 
C), 128.75 (d, arom. C), 129.83 (arom. C), 129.85 (arom. C), 130.81 (d, arom. C), 
131.29 (d, arom. C), 131.87 (d, arom. C), 133.01 (d, arom. C), 136.27 (d, arom. C), 
155.95 (arom. C), 156.04 (arom. C) ppm.  
Exact mass (ESI-MS): calculated for C25H27Cl2O5PNa [M + Na]+ 531.0871, found 
531.0872. 
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Diethyl 3-oxocyclopentylphosphonate (3.19). Yield: 90%. 
O
P
O OEt
OEt
 
1H-NMR (300 MHz, CDCl3): 
 = 1.31 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.32 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.02 – 2.56 (m, 7H, C5H7P), 4.05 – 4.19 (m, 4H, OCH2CH3) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.73 (d, 3JC,P = 5.5 Hz, OCH2CH3), 23.74 (d, JC,P = 
3.7 Hz, CH2), 33.11 (d, 1JC,P = 153.5 Hz, CHP), 37.89 (d, JC,P = 7.9 Hz, CH2), 38.97 
(d, JC,P = 2.9 Hz, CH2), 62.25 (app t, 2JC,P = 6.9 Hz, OCH2CH3), 216.66 (d, 3JC,P = 
15.5 Hz, C=O) ppm. 
31P-NMR (120 MHz, CDCl3): 
 = 31.66 ppm. 
Exact mass (ESI-MS): calculated for C9H18O4P [M+H]+: 221.0943, found: 221.0936. 
 
General Method for the Synthesis of 3.9a,b: To a mixture of alkene 3.6a or 3.6b 
(6.56 mmol) and 4-methylmorpholine N-oxide (0.92 g, 7.87 mmol) in dioxane (40 mL) 
was added an aqueous 1% solution of OsO4 (99.1 mg, 0.39 mmol). After stirring with 
protection from light at room temperature overnight, the starting material was 
completely converted according to TLC. Sodium periodate (2.24 g, 10.5 mmol) was 
then added in small portions. After completion of the reaction (2 h), the mixture was 
diluted with ethyl acetate (100 mL), filtered through Celite, and solids were washed 
with ethyl acetate. The combined filtrates were washed with saturated aqueous NaCl 
(100 mL), dried with MgSO4, and the solvents were evaporated under vacuum to 
yield crude 3.9a or 3.9b, which were used in the next step without further purification. 
 
General Method for Synthesis of 3.9c-e: Acetals 3.8c-e (5.0 mmol) were 
hydrolyzed by treatment with a mixture of water (7 mL), acetone (35 mL) and 2 N HCl 
(8 mL). After heating to 60-70 °C for 3-4 h, TLC analysis (ethyl acetate) confirmed 
that the reaction was finished. The solvents were evaporated under vacuum, and the 
residue was dissolved in ethyl acetate (200 mL) and transferred to a separating 
funnel, where it was washed twice with water (200 mL). The organic layer was dried 
with MgSO4 and the solvents were evaporated. The residue was purified by flash 
chromatography using ethyl acetate as eluent to yield 3.9c-e as transparent oils. 
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NMR revealed, by disappearance of the CH=O signals, that 3.9a-e are prone to 
oxidation upon storage when dissolved in CDCl3. 
 
Diethyl [2-formyl-1-(4-methoxyphenyl)ethyl]phosphonate (3.9c). Yield: 77%. 
O
H
MeO
P OEtOEtO
 
1H-NMR (300 MHz, CDCl3): 
 = 1.12 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.27 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.99 – 3.20 (m, 2H, PCHCH2), 3.66 (ddd, JH,P = 22.6 Hz, J = 5.3 
Hz
 
and
 
J
 
= 9.1
 
Hz, 1H, CHP), 3.71 – 3.80 (m, 1H, OCH2CH3), 3.78 (s, 3H, OCH3), 
3.82 – 3.95 (m, 1H, OCH2CH3), 3.97– 4.09 (m, 2H, OCH2CH3), 6.83 – 6.86 (m, 2H, 
arom. H), 7.25 – 7.29 (m, 2H, arom. H), 9.66 (app q, 1H, HC=O) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.57 (app t, 3JC,P = 6.9 Hz, OCH2CH3), 37.32 (d, 
1JC,P = 142.2 Hz, CHP), 44.34 (PCHCH2), 55.46 (OCH3), 62.36 (d, 2JC,P = 7.2 Hz, 
OCH2CH3), 63.16 (d, 2JC,P = 6.9 Hz, OCH2CH3), 114.33 (d, 4JC,P = 2.3 Hz, =CmH), 
127.14 (d, 2JC,P = 7.2 Hz, =Ci), 130.35 (d, 3JC,P = 6.6 Hz, =CoH), 159.18 (d, 5JC,P = 3.2 
Hz, =Cp), 199.41 (d, 3JC,P = 15.8 Hz, HC=O) ppm. 
31P-NMR (120 MHz, CDCl3): 
 = 28.49 ppm. 
Exact mass (ESI-MS): calculated for C14H22O5P [M+H]+: 301.1205, found: 301.1206. 
 
Diethyl [1-(4-chlorophenyl)-2-formylethyl]phosphonate (3.9d). Yield: 83%. 
O
H
Cl
P OEtOEtO
 
1H-NMR (300 MHz, CDCl3): 
 = 1.13 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.27 (t, J = 7.0 
Hz, 3H, OCH2CH3), 3.00 – 3.23 (m, 2H, PCHCH2), 3.69 (ddd, JH,P = 22.7 Hz, J = 4.7 
Hz
 
and
 
J
 
= 9.4
 
Hz, 1H, CHP), 3.72 – 3.82 (m, 1H, OCH2CH3), 3.83– 3.96 (m, 1H, 
OCH2CH3), 3.97– 4.09 (m, 2H, OCH2CH3), 7.28 (s, 4H, arom. H), 9.65 – 9.66 (m, 1H, 
HC=O) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.43 (app t, 3JC,P = 6.1 Hz, OCH2CH3), 37.30 (d, 
1JC,P = 142.2 Hz, CHP), 44.01 (PCHCH2), 62.84 (d, 2JC,P = 7.5 Hz, OCH2CH3), 63.44 
(d, 2JC,P = 7.2 Hz, OCH2CH3), 129.06 (d, 4JC,P = 2.6 Hz, =CmH), 130.63 (d, 3JC,P = 6.3 
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Hz, =CoH), 133.75 (d, 5JC,P = 5.5 Hz, =Cp), 133.92 (d, 2JC,P = 7.2 Hz, =Ci), 198.55 (d, 
3JC,P = 15.8 Hz, HC=O) ppm. 
Exact mass (ESI-MS): calculated for C13H18ClO4P [M+H]+: 305.0710, found: 
305.0702. 
 
Diethyl [1-(3,4-dichlorophenyl)-2-formylethyl]phosphonate (3.9e). Yield: 1.28 g 
(76%). 
O
H
Cl
P OEtOEtO
Cl
 
1H NMR (300 MHz, CDCl3): 
 = 1.11 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.23 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.95 − 3.20 (m, 2H, PCHCH2), 3.62 (ddd, JH,P = 22.7 Hz, J = 4.7, 
9.7 Hz, 1H, CHP), 3.74 − 3.83 (m, 1H, OCH2CH3), 3.84 − 3.95 (m, 1H, OCH2CH3), 
3.96 − 4.07 (m, 2H, OCH2CH3), 7.12 − 7.40 (m, 3H, arom. H), 9.61 − 9.62 (m, 1H, 
HC=O) ppm.  
13C NMR (75 MHz, CDCl3): 
 = 16.54 (app. t, 3JC,P = 6.2 Hz, OCH2CH3), 37.20 (d, 
1JC,P = 141.9 Hz, CHP), 44.09 (d, 2JC,P = 2.3 Hz, PCHCH2), 62.75 (d, 2JC,P = 7.2 Hz, 
OCH2CH3), 63.34 (d, 2JC,P = 6.9 Hz, OCH2CH3), 128.70 (d, 3JC,P = 6.3 Hz, arom. Co), 
130.75 (d, 4JC,P = 2.6 Hz, arom. Cm), 131.15 (d, 3JC,P = 6.9 Hz, arom. Co), 131.95 (d, 
5JC,P = 3.7 Hz, arom. Cp), 132.92 (d, 4JC,P = 2.9 Hz, arom. Cm), 136.03 (d, 2JC,P = 7.2 
Hz, arom. Ci), 198.13 (d, 3JC,P = 15.0 Hz, HC=O) ppm.  
Exact mass (ESI-MS): calculated for C13H18Cl2O4P [M + H]+ 339.03204, found 
339.0325. 
 
General Method for the Synthesis of 3.10a-e and 3.20: A mixture of aldehydes 
3.9a-e (3.86 mmol) and O-benzylhydroxylamine hydrochloride (0.61 g, 3.86 mmol) in 
pyridine/ethanol, 1:1 (14 mL) was stirred at room temperature under nitrogen for 1.5-
6 h. After the solvent was removed by evaporation, the residue was co-evaporated 
three times with toluene and subsequently purified by chromatography on a silica gel 
column (n-hexane/ethyl acetate, 6:4 or 6:4	1:1) to give a mixture of benzyloxyimines 
3.10a-e as transparent oils. 
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Diethyl [(E)- and (Z)-3-(benzyloxy)imino-1-phenylpropylphosphonate (3.10a). 
Yield: 82% from 3.6a. 
N
H
P OEtOEtO
OBn
 
1H-NMR (300 MHz, CDCl3): 
 = 1.09 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.27 (dt, J = 7.0 
Hz, JH,P = 4.4 Hz, 3H, OCH2CH3), 2.79 – 3.15 (m, 2H, CHPCH2), 3.16 – 3.33 (m, 1H, 
PCH), 3.64 – 3.78 (m, 1H, OCH2CH3), 3.82 – 3.94 (m, 1H, OCH2CH3), 3.95 – 4.10 
(m, 2H, OCH2CH3), 4.98 (s, 1H, OCH2Ph), 5.08 (s, 1H, OCH2Ph), 6.56 (t, J = 5.0 Hz, 
1H, HC=N), 7.24 – 7.33 (m, 10H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.46 (d, 3JC,P = 5.8 Hz, OCH2CH3), 16.63 (d, 3JC,P = 
7.2 Hz, OCH2CH3), 26.68 (br d, CH2CHP), 30.33 (d, 2JC,P = 2.3 Hz, CH2CHP), 41.73 
(d, 1JC,P = 139.8 Hz, CHP), 42.55 (d, 1JC,P = 139.1 Hz, CHP), 62.26 (d, 2JC,P = 4.9 Hz, 
OCH2CH3), 62.36 (d, 2JC,P = 4.9 Hz, OCH2CH3), 63.00 (d, 2JC,P = 2.9 Hz, OCH2CH3), 
63.09 (d, 2JC,P = 2.9 Hz, OCH2CH3), 75.87 (OCH2Ph), 76.14 (OCH2Ph), 127.75 
(arom. C), 128.03 (arom. C), 128.28 (arom. C), 128.60 (arom. C), 128.85 (arom. C), 
129.43 (arom. C), 135.11 (arom. C), 137.89 (arom. C), 148.83 (d, 3JC,P = 16.7 Hz, 
HC=N), 149.37 (d, 3JC,P = 15.8 Hz, HC=N) ppm. (most aromatic peaks are double 
due to coupling with P or because of the presence of two isomers) 
Exact mass (ESI-MS): calculated for C20H27NO4P [M+H]+: 376.1678, found: 
376.1670. 
 
Diethyl [(E)- and (Z)-3-(benzyloxy)imino-1-p-tolylpropylphosphonate (3.10b). 
Yield: 82% from 3.6b. 
N
H
Me
P OEtOEtO
OBn
 
1H-NMR (300 MHz, CDCl3): 
 = 1.05 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.20 (dt, J = 7.0 
Hz, JH,P = 4.4 Hz, 3H, OCH2CH3), 2.25 (s, 3H, p-CH3), 2.69 – 3.05 (m, 2H, CHPCH2), 
3.06 – 3.22 (m, 1H, PCH), 3.59 – 3.74 (m, 1H, OCH2CH3), 3.77– 3.88 (m, 1H, 
OCH2CH3), 3.90 – 4.03 (m, 2H, OCH2CH3), 4.92 (s, 1H, OCH2Ph), 5.02 (s, 1H, 
OCH2Ph), 6.49 (t, J = 5.0 Hz, 1H, HC=N), 7.02 – 7.29 (m, 9H, arom. H) ppm. 
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13C-NMR (75 MHz, CDCl3): 
 = 15.24 (d, 3JC,P = 5.8 Hz, OCH2CH3), 15.39 (d, 3JC,P = 
6.1 Hz, OCH2CH3), 20.08 (p-CH3), 25.46 (d, CH2CHP), 29.08 (d, CH2CHP), 40.04 (d, 
1JC,P = 139.6 Hz, CHP), 40.88 (d, 1JC,P = 139.3 Hz, CHP), 60.99 (d, 2JC,P = 7.2 Hz, 
OCH2CH3), 61.06 (d, 2JC,P = 7.2 Hz, OCH2CH3), 61.70 (d, 2JC,P = 6.9 Hz, OCH2CH3), 
61.73 (d, 2JC,P = 6.9 Hz, OCH2CH3), 74.57 (OCH2Ph), 74.85 (OCH2Ph), 126.74 
(arom. C), 127.01 (arom. C), 127.32 (arom. C), 127.99 (arom. C), 128.32 (arom. C), 
130.63 (arom. C), 136.10 (arom. C), 136.68 (arom. C), 147.76 (d, 3JC,P = 17.0 Hz, 
HC=N), 148.25 (d, 3JC,P = 15.8 Hz, HC=N) ppm. (most aromatic peaks are double 
due to coupling with P or because of the presence of two isomers) 
Mass (ESI-MS): calculated for C21H29NO4P [M+H]+: 390.1834, found: 390.2. 
 
Diethyl [(E)- and (Z)-3-(benzyloxy)imino-1-(4-methoxyphenyl)propylfosfonaat 
(3.10c). Yield: 67%. 
N
H
MeO
P OEtOEtO
OBn
 
1H-NMR (300 MHz, CDCl3): 
 = 1.11 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.26 (dt, J = 7.0 
Hz, JH,P = 4.4 Hz, 3H, OCH2CH3), 2.73 – 3.11 (m, 2H, CHPCH2), 3.12 – 3.27 (m, 1H, 
PCH), 3.66 – 3.80 (m, 1H, OCH2CH3), 3.77 and 3.83 (2 x s, 3H, OCH3, (E) and (Z)-
isomers), 3.82– 3.94 (m, 1H, OCH2CH3), 3.96– 4.08 (m, 2H, OCH2CH3), 4.98 (s, 1H, 
OCH2Ph), 5.08 (s, 1H, OCH2Ph), 6.55 (t, J = 5.0 Hz, 1H, HC=N), 6.80 – 6.85 (m, 2H, 
arom. H), 7.19 – 7.34 (m, 7H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.52 (d, 3JC,P = 5.8 Hz, OCH2CH3), 16.64 (d, 3JC,P = 
5.6 Hz, OCH2CH3), 26.75 (d, CH2CHP), 30.42 (d, CH2CHP), 40.83 (d, 1JC,P = 140.2 
Hz, CHP), 41.64 (d, 1JC,P = 139.9 Hz, CHP), 55.43 (OCH3), 62.20 (d, 2JC,P = 7.2 Hz, 
OCH2CH3), 62.27 (d, 2JC,P = 7.2 Hz, OCH2CH3), 62.94 (d, 2JC,P = 6.9 Hz, OCH2CH3), 
62.98 (d, 2JC,P = 6.9 Hz, OCH2CH3), 75.81 (OCH2Ph), 76.11 (OCH2Ph), 114.27 
(=CH), 126.72 – 127.11 (=C), 127.96 and 128.00 (=CH), 128.21 and 128.29 (=CH), 
128.55 and 128.58 (=CH), 130.32 – 130.55 (=CH), 137.84 and 138.102 (=C), 148.94 
(d, 3JC,P = 17.3 Hz, HC=N), 149.46 (d, 3JC,P = 16.1 Hz, HC=N), 159.10 – 159.21 (=C) 
ppm. (most aromatic peaks are double due to coupling with P or because of the 
presence of two isomers) 
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Exact mass (ESI-MS): calculated for C21H29NO5P [M+H]+: 406.1783, found: 
406.1793. 
 
Diethyl [(E)- and (Z)-3-(benzyloxy)imino-1-(4-chlorophenyl)propylphosphonate 
(3.10d). Yield: 85%. 
N
H
Cl
P OEtOEtO
OBn
 
1H-NMR (300 MHz, CDCl3): 
 = 1.13 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.27 (dt, J = 7.0 
Hz, JH,P = 3.8 Hz, 3H, OCH2CH3), 2.74 – 3.08 (m, 2H, CHPCH2), 3.18 – 3.32 (m, 1H, 
PCH), 3.74 – 3.85 (m, 1H, OCH2CH3), 3.86 – 3.96 (m, 1H, OCH2CH3), 3.97 – 4.09 
(m, 2H, OCH2CH3), 4.97 (s, 1H, OCH2Ph), 5.08 (s, 1H, OCH2Ph), 6.54 (t, J = 5.0 Hz, 
1H, HC=N), 7.19 – 7.35 (m, 9H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.51 (d, 3JC,P = 5.8 Hz, OCH2CH3), 16.62 (d, 3JC,P = 
6.9 Hz, OCH2CH3), 26.60 (d, 2JC,P = 2.0 Hz, CH2CHP), 30.26 (d, 2JC,P = 2.0 Hz, 
CH2CHP), 41.19 (d, 1JC,P = 139.9 Hz, CHP), 41.80 (d, 1JC,P = 139.6 Hz, CHP), 62.44 
(d, 2JC,P = 7.2 Hz, OCH2CH3), 62.50 (d, 2JC,P = 7.2 Hz, OCH2CH3), 63.09 (d, 2JC,P = 
7.2 Hz, OCH2CH3), 75.89 (OCH2Ph), 76.24 (OCH2Ph), 128.02 – 128.11 (=CH), 
128.28 (=CH), 128.57 – 128.61 (=CH), 128.94 – 129.05 (=CH), 130.60 – 130.87 
(=CH), 133.50 – 133.64 (=C), 133.70 – 134.02 (=C), 137.77 – 137.95 (=C), 148.21 
(d, 3JC,P = 17.0 Hz, HC=N), 148.81 (d, 3JC,P = 15.6 Hz, HC=N) ppm. (most aromatic 
peaks are double due to coupling with phosphor or because of the presence of two 
isomers) 
Exact mass (ESI-MS): calculated for C20H26ClNO4P [M+H]+: 410.1288, found: 
410.1284. 
 
Diethyl [(E)- and (Z)-3-(benzyloxy)imino-1-(3,4-dichlorophenyl)propyl]- 
phosphonate (3.10e). Yield: 1.57 g (92%). 
N
H
Cl
P OEtOEtO
OBn
Cl
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1H NMR (300 MHz, CDCl3): 
 = 1.17 (dt, JH,P = 1.47 Hz, J = 7.0 Hz, 3H, OCH2CH3), 
1.28 (dt, JH,P = 3.2 Hz, J = 7.0 Hz, 3H, OCH2CH3), 2.72 − 3.05 (m, 2H, CHPCH2), 
3.17 − 3.32 (m, 1H, PCH), 3.81 − 3.90 (m, 1H, OCH2CH3), 3.93 − 3.98 (m, 1H, 
OCH2CH3), 3.99 − 4.10 (m, 2H, OCH2CH3), 4.97 (s, 1H, OCH2Ph), 5.08 (s, 1H, 
OCH2Ph), 6.55 (t, J = 5.3 Hz, 1H, HC=N), 7.11 − 7.39 (m, 8H, arom. H) ppm. 
Exact mass (ESI-MS): calculated for C20H25Cl2NO4P [M + H]+ 444.090, found 
444.091. 
 
Diethyl {3-[(benzyloxy)imino]cyclopentyl}phosphonate (3.20). Yield: 3.07 g 
(90%). 
N
P
O OEt
OEt
BnO
 
1H NMR (300 MHz, CDCl3): 
 = 1.30 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.31 (t, J = 7.0 
Hz, 3H, OCH2CH3), 1.80 − 2.89 (m, 7H, C5H7P), 4.04 − 4.15 (m, 4H, OCH2CH3), 5.06 
(s, 2H, CH2Ph), 7.26 − 7.34 (m, 5H, arom. H) ppm.  
13C NMR (75 MHz, CDCl3): 
 = 16.74 (d, 3JC,P = 5.8 Hz, OCH2CH3), 25.68 (d, JC,P = 
2.6 Hz, CH2), 26.03 (d, JC,P = 3.2 Hz, CH2), 27.92 (d, JC,P = 12.1 Hz, CH2), 29.19 (d, 
JC,P = 1.7 Hz, CH2), 30.91 (d, JC,P = 11.5 Hz, CH2), 32.07 (d, JC,P = 1.4 Hz, CH2), 
34.77 (d, JC,P = 151.4 Hz, CHP), 34.99 (d, JC,P = 151.7 Hz, CHP), 62.06 (m, 
OCH2CH3), 75.92 (OCH2Ph), 75.95 (OCH2Ph), 127.93 (arom. C), 127.95 (arom. C), 
128.16 (arom. C), 128.18 (arom. C), 128.56 (arom. C), 128.55 (arom. C), 138.26 
(arom. C), 138.33 (arom. C), 164.12 (d, 3JC,P = 13.8 Hz, C=N), 164.33 (d, 3JC,P = 15.0 
Hz, C=N) ppm.  
31P NMR (120 MHz, CDCl3): 
 = 32.12, 32.36 ppm.  
Exact mass (ESI-MS): calculated for C16H25NO4P [M + H]+ 326.1521, found 
326.1523. 
 
General Procedure for the Reduction of the O-Benzyloximes 3.10a-e to 3.11a-e 
and 3.20 to 3.21: Sodium cyanoborohydride (12.95 mmol, 0.81 g) was added to a 
solution of O-benzyloximes 3.10a-e (2.59 mmol) in methanol (15 mL). Two drops of 
methyl orange indicator were added followed by dropwise addition of concentrated 
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hydrochloric acid, until the solution remained pink and milky for at least 0.5 h. The 
reaction mixture was stirred at room temperature for 3 − 16 h, and the solvent was 
removed under vacuum. The residue was taken up in CH2Cl2 (100 mL) and washed 
until alkaline with 1 M potassium hydroxide solution, and the aqueous portion 
extracted with CH2Cl2 (3 × 100 mL). The combined organic extracts were dried with 
MgSO4, filtered and the solvent was removed. The residue was purified on a silica 
gel column and eluted with CH2Cl2/MeOH, 95:5 or n-hexane/ethyl acetate, 4:6. After 
concentration of the appropriate fractions, O-benzyloxyamines 3.11a-e and 3.21 were 
obtained as clear oils. 
Diethyl [3-(benzyloxyamino)-1-phenylpropyl]phosphonate (3.11a). Yield: 96%. 
N
H
P OEtOEtO OBn
 
1H-NMR (300 MHz, CDCl3): 
 = 1.09 (dt, J = 7.0 Hz and JH,P = 0.6 Hz, 3H, 
OCH2CH3), 1.27 (t, J = 7,0 Hz, 3H, OCH2CH3), 2.14 – 2.30 (m, 1H, CH2CHP), 2.38 – 
2.53 (m, 1H, CH2CHP), 2.81 – 2.90 (m, 1H, CH2N), 2.93 – 3.05 (m, 1H, CH2N), 3.25 
(ddd, JH,P = 22.0 Hz, J = 4.7 Hz and J = 10.8 Hz, 1H, CHP), 3.64 – 3.79 (m, 1H, 
OCH2CH3), 3.85 – 3.97 (m, 1H, OCH2CH3), 3.99 – 4.14 (m, 2H, OCH2CH3), 4.81 (app 
s, 2H, PhCH2O), 7.22 – 7.37 (m, 10H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.48 (d, 3JC,P = 5.7 Hz, OCH2CH3), 16.64 (d, 3JC,P = 
6.0 Hz, OCH2CH3), 26.99 (CH2CHP), 42.18 (d, 1JC,P = 138.5 Hz, CHP), 49.42 (d, 3JC,P 
= 15.3 Hz, NCH2), 61.28 (d, 2JC,P = 7.2 Hz, OCH2CH3), 63.02 (d, 2JC,P = 6.9 Hz, 
OCH2CH3), 76.64 (OCH2Ph), 127.61 (JC,P = 3.2 Hz, =CH), 128.49 (=CH), 128.71 
(=CH), 128.87 (JC,P = 2.6 Hz, =CH), 128.93 (=CH), 129.48 (JC,P = 6.6 Hz, =CH), 
135.65 (JC,P = 6.9 Hz, =C), 136.72 (=C) ppm. 
Exact mass (ESI-MS): calculated for C20H27NO4P [M-H]-: 376.1676, found: 
376.1677. 
 
Diethyl [3-(benzyloxyamino)-1-p-tolylpropyl]phosphonate (3.11b). Yield: 95%. 
N
H
Me
P OEtOEtO OBn
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1H-NMR (300 MHz, CDCl3): 
 = 1.06 (m, 3H, OCH2CH3), 1.25 (m, 3H, OCH2CH3), 
2.11 – 2.24 (m, 1H, CH2CHP), 2.25 (s, 3H, p-CH3), 2.38 – 2.87 (m, 1H, CH2CHP), 
2.89 (m, 1H, CH2N), 2.96 (m, 1H, CH2N), 3.15 (ddd, JH,P = 22.4 Hz, J = 4.4 Hz and J = 
11.4
 
Hz, 1H, CHP), 3.60 – 3.76 (m, 1H, OCH2CH3), 3.78 – 3.89 (m, 1H, OCH2CH3), 
3.90 – 4.05 (m, 2H, OCH2CH3), 4.69 (app s, 2H, PhCH2O), 7.03 – 7.13 (m, 2H, arom. 
H), 7.26 – 7.31 (m, 7H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.52 (d, 3JC,P = 5.7 Hz, OCH2CH3), 16.67 (d, 3JC,P = 
6.1 Hz, OCH2CH3), 21.34 (p-CH3), 27.60 (br d, CH2CHP), 41.71 (d, 1JC,P = 139.0 Hz, 
CHP), 49.75 (d, 3JC,P = 15.8 Hz, NCH2), 61.05 (d, 2JC,P = 7.2 Hz, OCH2CH3), 62.80 
(d, 2JC,P = 6.9 Hz, OCH2CH3), 76.60 (OCH2Ph), 128.13 (=CH), 128.64 (d, =CH), 
129.31 (=CH), 129.40 (=CH), 129.52 (=CH), 132.65 (d, JC,P = 6.9 Hz, =C), 137.07 (d, 
JC,P = 3.5 Hz, =C), 137.76 (=C) ppm. 
Mass (ESI-MS): calculated for C21H31NO4P [M+H]+: 392.1991, found: 392.3. 
 
Diethyl [3-(benzyloxyamino)-1-(4-methoxyphenyl)propyl]phosphonate (3.11c). 
Yield: 95%. 
N
H
MeO
P OEtOEtO OBn
 
1H-NMR (300 MHz, CDCl3): 
 = 1.10 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.27 (t, J = 7,0 
Hz, 3H, OCH2CH3), 2.03 – 2.19 (m, 1H, CH2CHP), 2.29 – 2.43 (m, 1H, CH2CHP), 
2.71 – 2.80 (m, 1H, CH2N), 2.87 – 2.96 (m, 1H, CH2N), 3.18 (ddd, JH,P = 22.6 Hz, J = 
3.8
 
Hz
 
and
 
J
 
= 11.1
 
Hz, 1H, CHP), 3.65 – 3.80 (m, 1H, OCH2CH3), 3.78 (OCH3), 3.83 
– 3.93 (m, 1H, OCH2CH3), 3.96 – 4.12 (m, 2H, OCH2CH3), 4.69 (app s, 2H, 
PhCH2O), 6.82 – 6.86 (m, 2H, arom. H), 7.21 – 7.34 (m, 7H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.54 (d, 3JC,P = 5.8 Hz, OCH2CH3), 16.67 (d, 3JC,P = 
6.3 Hz, OCH2CH3), 27.77 (d, 2JC,P = too small for detection, CH2CHP), 41.23 (d, 1JC,P 
= 139.6 Hz, CHP), 49.77 (d, 3JC,P = 15.8 Hz, NCH2), 55.54 (OCH3), 61.98 (d, 2JC,P = 
7.5 Hz, OCH2CH3), 62.77 (d, 2JC,P = 7.2 Hz, OCH2CH3), 76.60 (OCH2Ph), 114.20 (d, 
JC,P = 0.03 Hz, =CH), 127.74 (d, JC,P = 7.2 Hz, =C), 128.07 (=CH), 128.60 (=CH), 
129.26 (d, JC,P = 4.9 Hz, =CH), 131.50 (d, JC,P = 6.9 Hz, =CH), 137.93 (=C), 158.97 
(d, JC,P = 3.2 Hz, =C) ppm. 
31P-NMR (120 MHz, CDCl3): 
 = 30.20 ppm. 
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Exact mass (ESI-MS): calculated for C21H31NO5P [M+H]+: 408.1940, found: 
408.1932. 
 
Diethyl [3-(benzyloxyamino)-1-(4-chlorophenyl)propyl]phosphonate (3.11d). 
Yield: 93%. 
N
H
Cl
P OEtOEtO OBn
 
1H-NMR (300 MHz, CDCl3): 
 = 1.14 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.26 (dt, J = 7.0 
Hz, JH,P = 1.76 Hz, 3H, OCH2CH3), 2.14 – 2.30 (m, 1H, CH2CHP), 2.42 – 2.59 (m, 
1H, CH2CHP), 2.95 – 3.00 (m, 1H, CH2N), 3.01 – 3.12 (m, 1H, CH2N), 3.32 (ddd, JH,P 
= 22.7 Hz, JHH = 4.7 Hz and J = 10.3 Hz, 1H, CHP), 3.73 – 3.87 (m, 1H, OCH2CH3), 
3.89 – 3.96 (m, 1H, OCH2CH3), 3.97 – 4.12 (m, 2H, OCH2CH3), 4.94 (s, 2H, 
PhCH2O), 7.18 – 7.38 (m, 9H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.54 (app t, 3JC,P = 6.3 Hz, OCH2CH3), 25.75 (m, 
CH2CHP), 41.45 (d, 1JC,P = 138.8 Hz, CHP), 48.67 (d, 3JC,P = 13.5 Hz, NCH2), 62.83 
(d, 2JC,P = 7.2 Hz, OCH2CH3), 63.24 (d, 2JC,P = 7.2 Hz, OCH2CH3), 77.44 (OCH2Ph), 
128.28 (=C), 128.70 (=CH), 128.88 (=CH), 129.16 (=CH), 129.41 (=CH), 130.72 (d, 
JC,P = 6.6 Hz, =CH), 133.77 (d, JC,P = 3.2 Hz, =C), 133.94 (d, JC,P = 7.5 Hz, =C) ppm. 
Exact mass (ESI-MS): calculated for C20H28ClNO4P [M+H]+: 412.1445, found: 
412.1312. 
 
Diethyl [3-(benzyloxyamino)-1-(3,4-dichlorophenyl)propyl]phosphonate (3.11e). 
Yield: 1.05 g (91%).  
N
H
Cl
P OEtOEtO OBn
Cl
 
1H NMR (300 MHz, CDCl3): 
 = 1.16 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.28 (t, J = 7.0 
Hz, 3H, OCH2CH3), 1.97 − 2.13 (m, 1H, CH2CHP), 2.28 − 2.42 (m, 1H, CH2CHP), 
2.64 − 2.74 (m, 1H, CH2N), 2.85 − 2.93 (m, 1H, CH2N), 3.20 (ddd, JH,P = 22.6 Hz, J = 
4.1, 11.1 Hz, 1H, CHP), 3.77 − 3.89 (m, 1H, OCH2CH3), 3.91 − 3.99 (m, 1H, 
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OCH2CH3), 3.99 − 4.13 (m, 2H, OCH2CH3), 4.61 − 4.70 (m, 2H, PhCH2O), 7.13 − 
7.17 (m, 1H, arom. H), 7.26 − 7.40 (m, 7H, arom. H) ppm. 
13C NMR (75 MHz, CDCl3): 
 = 16.56 (d, 3JC,P = 7.8 Hz, OCH2CH3), 16.64 (d, 3JC,P = 
8.1 Hz, OCH2CH3), 27.73 (d, 2JC,P = 2.9 Hz, CH2CHP), 41.35 (d, 1JC,P = 139.6 Hz, 
CHP), 49.48 (d, 3JC,P = 15.3 Hz, NCH2), 62.36 (d, 2JC,P = 6.9 Hz, OCH2CH3), 62.88 
(d, 2JC,P = 6.9 Hz, OCH2CH3), 77.88 (OCH2Ph), 128.13 (arom. C), 128.61 (arom. C), 
128.63 (arom. C), 128.87 (d, JC,P = 6.6 Hz, arom. C), 130.65 (d, JC,P = 2.6 Hz, arom. 
C), 131.42 (d, JC,P = 6.9 Hz, arom. C), 131.53 (arom. C), 132.74 (d, JC,P = 2.9 Hz, 
arom. C), 136.73 (d, JC,P = 6.9 Hz, arom. C), 137.88 (arom. C) ppm.  
Exact mass (ESI-MS): calculated for C20H27Cl2NO4P [M + H]+ 446.1055, found 
446.1060. 
 
Diethyl [3-(benzyloxyamino)cyclopentyl]phosphonate (3.21): Yield: 1.83 g, 
mixture of cis and trans (80%). 
NH
P
O OEt
OEt
BnO
 
1H NMR (300 MHz, CDCl3): 
 = 1.30 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.30 (t, J = 7.0 
Hz, 3H, OCH2CH3), 1.42 − 2.40 (m, 8H, C5H8P), 3.58 − 3.69 (m, 1H, NH), 4.03 − 4.15 
(m, 4H, OCH2CH3), 4.69 (s, 1H, CH2Ph), 4.75 (s, 1H, CH2Ph), 7.26 − 7.56 (m, 5H, 
arom. H) ppm.  
13C NMR (75 MHz, CDCl3): 
 = 16.76 (d, 3JC,P = 5.8 Hz, OCH2CH3), 25.27 (d, JC,P = 
2.9 Hz, CH2), 25.72 (d, JC,P = 2.6 Hz, CH2), 30.18 (CH2), 30.34 (CH2), 31.54 (d, JC,P = 
2.3 Hz, CH2), 31.67 (d, JC,P = 2.1 Hz, CH2), 33.73 (d, JC,P = 147.9 Hz, CHP), 34.55 (d, 
JC,P = 147.4 Hz, CHP), 61.65 − 62.13 (m, OCH2CH3 and NCH), 77.59 (OCH2Ph), 
76.95 (OCH2Ph), 128.11 (arom. C), 128.61 (arom. C), 128.67 (arom. C), 129.57 
(arom. C), 130.42, 137.86 (arom. C) ppm.  
Exact mass (ESI-MS): calculated for C16H27NO4P [M + H]+ 328.1678, found 
328.1660. 
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Formylation of Compounds 3.11 and 3.21 
Method A: Formic acid (1 equiv.) and 2-mercaptothiazoline (1 equiv.) were dissolved 
in CH2Cl2 (0.5 M), cooled to 0 °C and DCC (1 equiv.) was added in one portion. After 
the reaction mixture was filtered and concentrated, the residue was purified by 
chromatography (CH2Cl2) to afford 2-thioxothiazolidine-3-carbaldehyde as a yellow 
solid. 
Diethyl {3-[N-(benzyloxy)formamido]-1-phenylpropyl}phosphonate (3.12a).  
2-Thioxothiazolidine-3-carbaldehyde (1 equiv.) was dissolved in CH2Cl2 and added to 
a solution of 11a (1 equiv.) in CH2Cl2 (0.1 M). The reaction mixture was stirred for 3 
d. The reaction mixture was extracted with water, dried with MgSO4 and concentrated 
in vacuo. The residue was purified by flash chromatography (CH2Cl2/MeOH, 95:5) to 
yield 3.12a in 89 % yield.  
N
P OEtOEtO
OBn
O
H
 
1H NMR (300 MHz, CDCl3): 
 = 1.07 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.26 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.17 (m, 1H, CH2CHP), 2.45 − 2.48 (m, 1H, CH2CHP), 3.06 (ddd, 
JH,P = 23.0 Hz, J = 4.1, 11.1 Hz, 1H, CHP), 3.39 (m, 1H, CH2N), 3.50 (m, 1H, CH2N), 
3.62 − 3.75 (m, 1H, OCH2CH3), 3.81 − 3.91 (m, 1H, OCH2CH3), 3.97 − 4.10 (m, 2H, 
OCH2CH3), 4.74 and 4.94 (2 × br. s, 2H, PhCH2O), 7.26 − 7.35 (m, 10H, arom. H), 
8.16 (br. s, 1H, HC=O) ppm.  
13C NMR (75 MHz, CDCl3): 
 = 16.40 (d, 3JC,P = 5.7 Hz, OCH2CH3), 16.58 (d, 3JC,P = 
6.0 Hz, OCH2CH3), 27.42 (m, CH2CHP), 40 (d, 1JC,P = 140 Hz, CHP), 43.11 (m, 
NCH2), 62.19 (d, 2JC,P = 7.2 Hz, OCH2CH3), 63.96 (d, 2JC,P = 7.2 Hz, OCH2CH3), 
77.42 (OCH2Ph), 127.77 (arom. C), 128.91 (arom. C), 129.26 (arom. C), 129.47 
(arom. C), 129.56 (arom. C), 129.63 (arom. C), 131.10 (arom. C), 135.09 (arom. C), 
163.32 (m, HC=O) ppm.  
Mass (ESI-MS): calculated for C21H29NO5P [M + H]+ 406.1783, found 406.1. 
Method B: To a three-neck flask containing a solution of formic acid (0.61 mmol, 30 
L) in CH2Cl2 (0.6 mL) was added 1,1’-carbonyldiimidazole (0.64 mmol, 0.10 g). After 
20 min, benzyloxyamines 3.11c,e (0.61 mmol) were dissolved in CH2Cl2 (1 mL) and 
then transferred to the three-neck flask. After 5 h, the mixture was partitioned 
between water (70 mL) and CH2Cl2 (70 mL). The water layer was extracted twice 
with CH2Cl2 (70 mL). The combined organic layers were dried with MgSO4 and 
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concentrated in vacuo, and the residue was purified by flash chromatography (n-
pentane/acetone, 6:4) to give 3.12c,e as transparent oils. 
Diethyl {3-[N-(benzyloxy)formamido]-1-(4-methoxyphenyl)propyl}phosphonate 
(3.12c). Yield: 79%. 
N
MeO
P OEtOEtO
OBn
O
H
 
1H-NMR (300 MHz, CDCl3): 
 = 1.09 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.26 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.17 (m, 1H, CH2CHP), 2.41 – 2.49 (m, 1H, CH2CHP), 3.00 (ddd, 
JH,P = 22.9 Hz, J = 3.8 Hz and J = 11.4 Hz, 1H, CHP), 3.40 (m, 1H, CH2N), 3.55 (m, 
1H, CH2N), 3.62 – 3.80 (m, 1H, OCH2CH3), 3.82 – 3.96 (m, 1H, OCH2CH3), 3.94 
(OCH3), 3.97 – 4.11 (m, 2H, OCH2CH3), 4.74 and 4.94 (2 x br. s, 2H, PhCH2O), 6.84 
– 7.36 (m, 9H, arom. H), 8.16 (br. s, 1H, HC=O) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.50 (d, 3JC,P = 5.0 Hz, OCH2CH3), 16.63 (d, 3JC,P = 
5.8 Hz, OCH2CH3), 27.39 (m, CH2CHP), 40 (d, 1JC,P = 140 Hz, CHP), 42.60 (m, 
NCH2), 55.47 (OCH3), 62.14 (d, 2JC,P = 7.2 Hz, OCH2CH3), 63.94 (d, 2JC,P = 7.2 Hz, 
OCH2CH3), 77.45 (OCH2Ph), 114.36 (arom. C), 126.80 (arom. C), 128.93 (arom. C), 
129.32 (arom. C), 129.66 (arom. C), 130.50 (arom. C), 158.50 (arom. C), 159.21 
(arom. C), 163.27 (m, HC=O) ppm. 
Exact mass (ESI-MS): calculated for C22H31NO6P [M+H]+: 436.1889, found: 
436.1888. 
 
Diethyl {3-[N-(benzyloxy)formamido]-1-(4-chlorophenyl)propyl}phosphonate 
(3.12d). Yield: 89%. 
N
Cl
P OEtOEtO
OBn
O
H
 
1H-NMR (300 MHz, CDCl3): 
 = 1.10 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.27 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.05 – 2.26 (m, 1H, CH2CHP), 2.38 – 2.53 (m, 1H, CH2CHP), 
3.03 (ddd, JH,P = 23.2 Hz, J = 3.8 Hz and J = 11.1 Hz, 1H, CHP), 3.39 (m, 1H, CH2N), 
3.47 (m, 1H, CH2N), 3.68 – 3.81 (m, 1H, OCH2CH3), 3.83 – 3.94 (m, 1H, OCH2CH3), 
3.98 – 4.11 (m, 2H, OCH2CH3), 4.75 and 4.93 (2 x br. s, 2H, PhCH2O), 7.22 – 7.36 
(m, 9H, arom. H), 8.16 (br. s, 1H, HC=O) ppm. 
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13C-NMR (75 MHz, CDCl3): 
 = 16.48 (d, 3JC,P = 5.8 Hz, OCH2CH3), 16.61 (d, 3JC,P = 
5.8 Hz, OCH2CH3), 27.37 (m, CH2CHP), 41.62 (d, 1JCP = 139.6 Hz, CHP), 42.55 (m, 
NCH2), 62.37 (d, 2JC,P = 7.2 Hz, OCH2CH3), 63.04 (d, 2JC,P = 6.9 Hz, OCH2CH3), 
77.45 (OCH2Ph), 128.97 (arom. C), 139.09 (arom. C), 129.38 (arom. C), 129.66 
(arom. C), 130.77 (arom. C), 130.86 (arom. C), 133.68 (arom. C), 134.38 (arom. C), 
163.27 (m, HC=O) ppm. 
Exact mass (ESI-MS): calculated for C21H28ClNO5P [M+H]+: 440.1395, found: 
440.1406.  
 
Diethyl {3-[N-(benzyloxy)formamido]-1-(3,4-dichlorophenyl)propyl}phosphonate 
(3.12e). Yield: 245 mg (85%).  
N
Cl
P OEtOEtO
OBn
O
H
Cl
 
1H NMR (300 MHz, CDCl3): 
 = 1.14 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.27 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.07 − 2.21 (m, 1H, CH2CHP), 2.37 − 2.51 (m, 1H, CH2CHP), 
3.00 (ddd, JH,P = 23.0 Hz, J = 4.1, 11.4 Hz, 1H, CHP), 3.23 − 3.38 (m, 1H, CH2N), 
3.44 − 3.46 (m, 1H, CH2N), 3.78 − 3.88 (m, 1H, OCH2CH3), 3.89 − 3.99 (m, 1H, 
OCH2CH3), 3.99 − 4.11 (m, 2H, OCH2CH3), 4.75 and 4.91 (2 × br. s, 2H, PhCH2O), 
7.12 − 7.40 (m, 8H, arom. H), 8.16 (br. s, 1H, HC=O) ppm.  
13C NMR (75 MHz, CDCl3): 
 = 16.50 (d, 3JC,P = 6.1 Hz, OCH2CH3), 16.61 (d, 3JC,P = 
6.1 Hz, OCH2CH3), 27.34 (m, CH2CHP), 41.46 (d, 1JC,P = 138.48 Hz, CHP), 42.50 (m, 
NCH2), 62.59 (d, 2JC,P = 7.2 Hz, OCH2CH3), 63.09 (d, 2JC,P = 6.9 Hz, OCH2CH3), 
78.29 (OCH2Ph), 128.86 (arom. C), 128.95 (arom. C), 129.94 (arom. C), 129.69 
(arom. C), 130.81 (arom. C), 131.24 (arom. C), 131.92 (arom. C), 132.93 (arom. C), 
134.27 (arom. C), 135.87 (arom. C), 163.32 (m, HC=O) ppm.  
Exact mass (ESI-MS): calculated for C21H27Cl2NO5P [M + H]+ 474.1004, found 
474.1000. 
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Diethyl {3-[N-(benzyloxy)formamido]cyclopentyl}phosphonate (3.22). Yield: 1.3 
g, mixture of cis and trans (97%).  
N
P
O OEt
OEt
BnO
H
O
 
1H NMR (300 MHz, CDCl3): 
 = 1.23 (m, 6H, OCH2CH3), 1.64 − 2.39 (m, 7H, C5H7P), 
3.98 − 4.09 (m, 4H, OCH2CH3), 4.4 (m, 1H, CHN), 4.90 (br. s, 2H, OCH2Ph), 7.30 − 
7.32 (m, 5H, arom. H), 8.10 and 8.13 (2 × s, 1H, HC=O) ppm.  
13C NMR (75 MHz, CDCl3): 
 = 16.76 (d, 3JC,P = 5.8 Hz, 2 C, OCH2CH3), 24.40 (d, 
JC,P = 2.0 Hz, CH2), 25.60 (CH2), 29.98 (d, JC,P = 7.8 Hz, CH2), 33.31 (d, 1JC,P = 150.6 
Hz, CHP), 33.66 (d, 1JC,P = 149.7 Hz, CHP), 57.73 (m, CHN), 59.03 (m, CHN), 62.01 
(m, OCH2CH3), 79.50 (m, OCH2Ph), 128.95 − 129.63 (3 arom. C), 134.72 (arom. C), 
165.10 (m, HC=O) ppm.  
Exact mass (ESI-MS): calculated for C17H27NO5P [M + H]+ 356.1627, found 
356.1629. 
 
General method for synthesis of 3.13a-e and 3.23 
A solution of benzyloxyamines 3.11a-e (2.43 mmol) in CH2Cl2 (12 mL) containing 
(Et)3N (1.03 mL , 7.23 mmol) was cooled in an ice bath, followed by addition of 
acetylchloride (0.21 mL, 2.91 mmol). After 1.5 – 2 h the reaction was diluted with 
CH2Cl2 (100 mL) and washed with water (100 mL). After drying of the organic layer 
with MgSO4, the solvent was removed in vacuo and the crude reaction mixture was 
chromatographed (CH2Cl2/MeOH 95:5 or n-hexane/ethyl acetate 6:4	1:1). 
Compounds 3.13a-e were obtained as transparent oils.  
 
Diethyl {3-[N-(benzyloxy)acetamido]-1-phenylpropyl}phosphonate (3.13a). Yield: 
85%. 
N
P OEtOEtO
OBn
O
Me
 
1H-NMR (300 MHz, CDCl3): 
 = 1.05 (t, J = 7.6 Hz, 3H, OCH2CH3), 1.25 (t, J = 7.0 
Hz, 3H, OCH2CH3), ), 2.00 (s, 3H, CH3C=O), 2.18 – 2.34 (m, 1H, CH2CHP), 2.37 – 
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2.51 (m, 1H, CH2CHP), 3.06 (ddd, JH,P = 23.0 Hz, J = 4.1 Hz and J = 11.4 Hz, 1H, 
CHP), 3.39 – 3.49 (m, 1H, CH2N), 3.54 – 3.61 (m, 1H, CH2N), 3.63 – 3.74 (m, 1H, 
OCH2CH3), 3.79 – 3.95 (m, 1H, OCH2CH3), 3.95 – 4.07 (m, 2H, OCH2CH3), 4.67 (m, 
2H, PhCH2O), 7.22 – 7.36 (m, 10H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.43 (d, 3JC,P = 5.8 Hz, OCH2CH3), 16.60 (d, 3JC,P = 
6.0 Hz, OCH2CH3), 20.67 (CH3C=O), 27.07 (CH2CHP), 42.34 (d, 1JC,P = 137.9 Hz, 
CHP), 44.01 (br m, NCH2), 62.24 (d, 2JC,P = 7.2 Hz, OCH2CH3), 62.98 (d, 2JC,P = 7.2 
Hz, OCH2CH3), 76.54 (OCH2Ph), 127.62 (d, JC,P = 3.2 Hz, =CH), 128.82 (d, JC,P = 2.9 
Hz, =CH), 128.89 (=CH), 129.16 (=CH), 129.41 (=CH), 129.52 (d, JC,P = 6.6 Hz, 
=CH), 134.49 (=C), 135.27 (d, JC,P = 7.2 Hz, =C), 172.56 (CH3C=O) ppm. 
Exact mass (ESI-MS): calculated for C22H31NO5P [M+H]+: 420.1940, found: 
420.1931. 
 
Diethyl {3-[N-(benzyloxy)acetamido]-1-p-tolylpropyl}phosphonate (3.13b). Yield: 
60%. 
N
P OEtOEtO
OBn
O
Me
 
1H-NMR (300 MHz, CDCl3): 
 = 1.09 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.25 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.02 (s, 3H, CH3C=O), 2.21 – 2.30 (m, 1H, CH2CHP), 2.32 (p-
CH3), 2.39 – 2.46 (m, 1H, CH2CHP), 3.02 (ddd, JH,P = 22.9 Hz, J = 4.1 Hz and J = 11.7 
Hz, 1H, CHP), 3.39 – 3.49 (m, 1H, CH2N), 3.60 (m, 1H, CH2N), 3.65 – 3.77 (m, 1H, 
OCH2CH3), 3.81 – 3.92 (m, 1H, OCH2CH3), 3.94 – 4.07 (m, 2H, OCH2CH3), 4.69 (m, 
2H, PhCH2O), 7.11 – 7.38 (m, 9H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.47 (d, 3JC,P = 5.7 Hz, OCH2CH3), 16.62 (d, 3JC,P = 
6.0 Hz, OCH2CH3), 20.71 (CH3C=O), 21.32 (p-CH3), 27.05 (CH2CHP), 41.86 (d, 1JC,P 
= 138.5 Hz, CHP), 43.80 (br m, NCH2), 62.13 (d, 2JC,P = 7.2 Hz, OCH2CH3), 62.82 (d, 
2JC,P = 6.9 Hz, OCH2CH3), 76.49 (OCH2Ph), 128.86 (=CH), 129.13 (=CH), 129.28 
(=CH), 129.39 (d, JC,P = 3.8 Hz, =CH), 129.52 (d, JC,P = 2.6 Hz, =CH), 132.081 (d, 
JC,P = 7.2 Hz, =C), 134.52 (=C), 137.17 (d, JC,P = 3.4 Hz, =C), 172.50 (CH3C=O) 
ppm. 
Mass (ESI-MS): calculated for C23H33NO5P [M+H]+: 434.2096, found: 434.3. 

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Diethyl {3-[N-(benzyloxy)acetamido]-1-(4-methoxyphenyl)propyl}phosphonate 
(3.13c). Yield: 93%. 
N
P OEtOEtO
OBn
O
Me
MeO
 
1H-NMR (300 MHz, CDCl3): 
 = 1.09 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.26 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.02 (s, 3H, CH3C=O), 2.14 – 2.30 (m, 1H, CH2CHP), 2.36 – 
2.50 (m, 1H, CH2CHP), 3.01 (ddd, JH,P = 22.9 Hz, J = 3.5 Hz and J = 11.4 Hz, 1H, 
CHP), 3.40 – 3.49 (m, 1H, CH2N), 3.56 – 3.63 (m, 1H, CH2N), 3.65 – 3.76 (m, 1H, 
OCH2CH3), 3.80 (OCH3), 3.83 – 3.92 (m, 1H, OCH2CH3), 3.94 – 4.08 (m, 2H, 
OCH2CH3), 4.7 (m, 2H, PhCH2O), 6.84 – 7.38 (m, 9H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.52 (d, 3JC,P = 5.5 Hz, OCH2CH3), 16.64 (d, 3JC,P = 
5.8 Hz, OCH2CH3), 20.65 (CH3C=O), 27.19 (CH2CHP), 41.44 (d, 1JC,P = 138.8 Hz, 
CHP), 44.00 (br m, NCH2), 55.46 (OCH3), 62.11 (d, 2JC,P = 7.2 Hz, OCH2CH3), 62.85 
(d, 2JC,P = 6.9 Hz, OCH2CH3), 76.54 (OCH2Ph), 114.24 (d, JC,P = 2.6 Hz, =CH), 
127.13 (d, JC,P = 7.2 Hz, =C), 129.89 (=CH), 129.16 (=CH), 129.40 (=CH), 130.51 (d, 
JC,P = 6.6 Hz, =CH), 134.90 (=C), 159.07 (d, JC,P = 3.2 Hz, =C), 172.00 (CH3C=O) 
ppm. 
31P-NMR (120 MHz, CDCl3): 
 = 29.48 ppm. 
Exact mass (ESI-MS): calculated for C23H33NO6P [M+H]+: 450.2046, found: 
450.2043. 
 
Diethyl {3-[N-(benzyloxy)acetamido]-1-(4-chlorophenyl)propyl}phosphonate 
(3.13d). Yield: 95%. 
N
P OEtOEtO
OBn
O
Me
Cl
 
1H-NMR (300 MHz, CDCl3): 
 = 1.08 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.23 (t, J = 7.0 
Hz, 3H, OCH2CH3), ), 1.99 (s, 3H, CH3C=O), 2.09 – 2.27 (m, 1H, CH2CHP), 2.35 – 
2.49 (m, 1H, CH2CHP), 3.01 (ddd, JH,P = 22.9 Hz, J = 3.8 Hz and J = 11.4 Hz, 1H, 
CHP), 3.37 – 3.46 (m, 1H, CH2N), 3.49 – 3.58 (m, 1H, CH2N), 3.66 – 3.79 (m, 1H, 
OCH2CH3), 3.81 – 3.91 (m, 1H, OCH2CH3), 3.93 – 4.06 (m, 2H, OCH2CH3), 4.67 (m, 
2H, PhCH2O), 7.19 – 7.36 (m, 9H, arom. H) ppm. 
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13C-NMR (75 MHz, CDCl3): 
 = 16.48 (d, 3JC,P = 5.8 Hz, OCH2CH3), 16.61 (d, 3JC,P = 
5.8 Hz, OCH2CH3), 20.65 (CH3C=O), 27.02 (d, 2JC,P = 2.3 Hz, CH2CHP), 41.74 (d, 
1JC,P = 139.1 Hz, CHP), 43.80 (br d, NCH2), 62.35 (d, 2JC,P = 7.5 Hz, OCH2CH3), 
62.96 (d, 2JC,P = 7.2 Hz, OCH2CH3), 76.66 (OCH2Ph), 128.92 (=CH), 128.97 (=CH), 
129.23 (=CH), 129.39 (=CH), 130.83 (d, JC,P = 6.9 Hz, =CH), 133.44 (d, JC,P = 4.0 Hz, 
=C), 134.03 (d, JC,P = 7.5 Hz, =C), 134.43 (=C), 172.53 (CH3C=O) ppm. 
Exact mass (ESI-MS): calculated for C22H30ClNO5P [M+H]+: 454.1550, found: 
454.1552. 
 
Diethyl {3-[N-(benzyloxy)acetamido]-1-(3,4-dichlorophenyl)propyl}phosphonate 
(3.13e). Yield: 85%. 
N
P OEtOEtO
OBn
O
Me
Cl
Cl
 
1H-NMR (300 MHz, CDCl3): 
 = 1.14 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.26 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.02 (s, 3H, CH3C=O), 2.08 – 2.26 (m, 1H, CH2CHP), 2.35 – 
2.49 (m, 1H, CH2CHP), 3.00 (ddd, JH,P = 23.0 Hz, J = 3.8 Hz and J = 11.1 Hz, 1H, 
CHP), 3.27 – 3.59 (m, 2H, CH2N), 3.75 – 3.86 (m, 1H, OCH2CH3), 3.86 – 3.97 (m, 
1H, OCH2CH3), 3.97 – 4.11 (m, 2H, OCH2CH3), 4.71 (m, 2H, PhCH2O), 7.12 – 7.43 
(m, 8H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.48 (app t, 3JC,P = 6.6 Hz, OCH2CH3), 20.62 
(CH3C=O), 27.01 (CH2CHP), 41.66 (d, 1JC,P = 139.1 Hz, CHP), 44.07 (br m, NCH2), 
62.52 (d, 2JC,P = 7.2 Hz, OCH2CH3), 62.98 (d, 2JC,P = 6.9 Hz, OCH2CH3), 76.80 
(OCH2Ph), 128.91 (=CH), 129.33 (=CH), 129.60 (=CH), 130.40 (=CH), 130.67 (d, JC,P 
= 2.9 Hz, =CH), 131.30 (d, JC,P = 6.6 Hz, =CH), 131.69 (d, JC,P = 4.0 Hz, =C), 132.78 
(d, JC,P = 3.2 Hz, =C), 134.39 (=C), 136.10 (d, JC,P = 7.2 Hz, =C), 172.54 (CH3C=O) 
ppm. 
Exact mass (ESI-MS): calculated for C22H29Cl2NO5P [M+H]+: 488.1161, found: 
488.1160. 
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Diethyl {3-[N-(benzyloxy)acetamido]cyclopentyl}phosphonate (3.23). Yield: 95% 
(mixture of cis and trans). 
N
P
O OEt
OEt
BnO
Me
O
 
1H-NMR (300 MHz, CDCl3): 
 = 1.25 (m, 6H, OCH2CH3), 1.62 – 2.46 (m, 7H, C5H7P), 
2.12 and 2.14 (2 x s, 3H, CH3C=O), 3.98 – 4.10 (m, 4H, OCH2CH3), 4.65 – 4.67 (m, 
1H, CHN), 4.81 – 4.89 (m, 2H, OCH2Ph), 7.32 – 7.35 (m, 5H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.67 (d, 3JC,P = 5.8 Hz, OCH2CH3), 21.37 (CH3C=O), 
21.65 (CH3C=O), 24.15 (d, JC,P = 3.2 Hz, CH2), 25.83 (d, JC,P = 3.5 Hz, CH2), 27.87 
(s, CH2), 27.98 (s, CH2), 29.60 (m, CH2), 32.98 (d, JC,P = 149.4 Hz, CHP), 33.86 (d, 
JC,P = 148.3 Hz, CHP), 58.88 (d, JC,P = 18.13 Hz, CHN), 59.49 (d, JC,P = 8.64 Hz, 
CHN), 61.86 (m, OCH2CH3), 78.98 (OCH2Ph), 79.45 (OCH2Ph), 129.01 (two times 
three =CH signals), 134.60 (two =C signals), 174.23 (m, CH3C=O) ppm. 
Exact mass (ESI-MS): calculated for C18H29NO5P [M+H]+: 370.1783, found: 
370.1780. 
 
General Method for the Benzyl Deprotection of 3.12, 3.13, 3.22 and 3.23: A 
solution of compounds 3.12 and 3.13 or 3.22 and 3.23 (0.9 mmol) in MeOH (8 mL) 
was hydrogenated at atmospheric pressure in the presence of Pd (10 wt.-% on 
activated carbon, 40 mg). After stirring for 5 h, the reaction mixture was filtered 
through a Celite pad. The solvent was removed under vacuum, and the crude mixture 
was purified by column chromatography on silica gel (CH2Cl2/MeOH, 95:5). 
Diethyl [3-(N-hydroxyformamido)-1-(4-methoxyphenyl)propyl]phosphonate 
(3.14c). Yield: 25%. 
N
MeO
P OEtOEtO
OH
O
H
 
1H-NMR (300 MHz, CDCl3): 
 = 1.05 – 1.10 (m, 3H, OCH2CH3), 1.17 – 1.23 (m, 3H, 
OCH2CH3), 2.16 (m, 1H, CH2CHP), 2.53 (m, 1H, CH2CHP), 2.99 – 3.08 (m, 1H, 
CHP), 3.24 – 3.30 (m, 1H, CH2N), 3.40 – 3.62 (m, 1H, CH2N), 3.66 – 3.71 (m, 1H, 
OCH2CH3), 3.73 (OCH3), 3.81 – 3.86 (m, 1H, OCH2CH3), 3.91 – 3.99 (m, 2H, 
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OCH2CH3), 6.81 – 6.85 (m, 2H, Hm), 7.17 – 7.19 (m, 2H, Ho), 7.52 (br. s, 1H, HC=O), 
8.31 (s, 1H, NOH) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.05 (d, 3JC,P = 5.9 Hz, OCH2CH3), 16.15 (d, 3JC,P = 
5.9 Hz, OCH2CH3), 26.40 (CH2CHP, major), 27.02 (CH2CHP, minor), 39.56 (d, 1JC,P = 
139.2 Hz, CHP, major), 40.66 (d, 1JC,P = 137.2 Hz, CHP, minor), 44.56 (d, 3JC,P = 16.6 
Hz, NCH2, minor), 47.05 (d, 3JC,P = 16.1 Hz, NCH2, major), 55.03 (OCH3), 62.07 (d, 
2JC,P = 6.9 Hz, OCH2CH3, major), 62.25 (d, 2JC,P = 6.8 Hz, OCH2CH3, minor), 62.69 
(d, 2JC,P = 6.3 Hz, OCH2CH3, major), 62.83 (d, 2JC,P = 5.9 Hz, OCH2CH3, minor), 
113.89 (=CmH, minor), 114.11 (=CmH, major), 125.94 (d, 2JC,P = 7.3 Hz, =Ci, major), 
126.75 (d, 2JC,P = 6.4 Hz, =Ci, minor), 130.05 (=CoH), 158.77 (=Cp, minor), 158.90 
(=Cp, major), 156.84 (C=O, major), 162.56 (C=O, minor) ppm. 
Exact mass (ESI-MS): calculated for C15H25NO6P [M+H]+: 346.1420, found: 
346.1427. 
 
Diethyl [1-(3,4-dichlorophenyl)-3-(N-hydroxyformamido)propyl]phosphonate 
(3.14e). Yield: 157 mg (57%).  
N
Cl
P OEtOEtO
OH
O
H
Cl
 
1H NMR (300 MHz, CDCl3): 
 = 1.09 − 1.24 (m, 6H, OCH2CH3), 2.11 (m, 1H, 
CH2CHP), 2.46 (m, 1H, CH2CHP), 3.01 − 3.17 (m, 1H, CHP), 3.22 − 3.35 (m, 1H, 
CH2N), 3.45 − 3.56 (m, 1H, CH2N), 3.77 − 4.04 (m, 4H, OCH2CH3), 7.08 − 7.11 (m, 
1H, arom. H), 7.32 − 7.37 (m, 2H, arom. H), 7.55 (br. s, 1H, HC=O), 8.24 (s, 1H, 
NOH) ppm.  
13C NMR (75 MHz, CDCl3): 
 = 16.48 (app. t, 3JC,P = 5.8 Hz, OCH2CH3), 26.90 
(CH2CHP, major), 27.08 (CH2CHP, minor), 40.09 (d, 1JC,P = 139.3 Hz, CHP, major), 
40.96 (d, 1JC,P = 139.3 Hz, CHP, minor), 44.60 (d, 3JC,P = 15.8 Hz, NCH2, minor), 
47.45 (d, 3JC,P = 15.0 Hz, NCH2, major), 62.84 (d, 2JC,P = 6.9 Hz, OCH2CH3, major), 
63.01 (d, 2JC,P = 7.2 Hz, OCH2CH3, minor), 63.24 (d, 2JC,P = 6.9 Hz, OCH2CH3, 
major), 63.32 (d, 2JC,P = 6.1 Hz, OCH2CH3, minor), 128.81 (d, JC,P = 6.3 Hz, arom. C, 
major), 128.95 (d, JC,P = 6.9 Hz, arom. C, minor), 130.69 (arom. C, minor), 130.91 
(arom. C, major), 131.14 (d, JC,P = 6.9 Hz, arom. C, major), 131.24 (d, JC,P = 9.2 Hz, 
arom. C, minor), 131.74 (d, JC,P = 3.8 Hz, arom. C, minor), 131.98 (d, JC,P = 3.8 Hz, 
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arom. C, major), 132.70 (d, JC,P = 2.6 Hz, arom. C, minor), 133.01 (d, JC,P = 2.6 Hz, 
arom. C, major), 135.60 (d, JC,P = 7.2 Hz, arom. C, major), 136.00 (d, JC,P = 7.5 Hz, 
arom. C, minor), 157.37 (C=O, major), 163.03 (C=O, minor) ppm.  
Exact mass (ESI-MS): calculated for C14H21Cl2NO5P [M + H]+ 384.0535, found 
384.0530. 
 
Diethyl [3-(N-hydroxyacetamido)-1-phenylpropyl]phosphonate (3.15a). Yield: 
62%. 
N
P OEtOEtO
OH
O
Me
 
1H-NMR (300 MHz, CDCl3): 
 = 1.01 (m, 3H, OCH2CH3), 1.19 (m, 3H, OCH2CH3), 
1.98 (s, 3H, CH3C=O), 2.20 (m, 1H, CH2CHP), 2.36 (m, 1H, CH2CHP), 3.04 (m, 1H, 
CHP), 3.38 (m, 1H, CH2N), 3.62 (m, 1H, CH2N), 3.64 (m, 1H, OCH2CH3), 3.78 (m, 
1H, OCH2CH3), 3.92 (m, 2H, OCH2CH3), 7.23 (m, 5H, arom. H), 9.70 (br. s, 1H, 
NOH) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.46 (OCH2CH3), 20.65 (CH3C=O), 27.34 
(CH2CHP), 42.11 (d, 1JC,P = 137.7 Hz, CHP), 46.34 (d, 3JC,P = 17.0 Hz, NCH2), 62.57 
(OCH2CH3), 63.21 (OCH2CH3), 127.66 (=CH), 128.80 (=CH), 129.38 (=CH), 135.43 
(=C), 172.90 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C15H25NO5P [M+H]+: 330.1470, found: 
330.1475. 
 
Diethyl [3-(N-hydroxyacetamido)-1-p-tolylpropyl]phosphonate (3.15b). Yield: 
20%. 
N
P OEtOEtO
OH
O
Me
 
1H-NMR (300 MHz, CDCl3): 
 = 1.03 – 1.25 (m, 6H, OCH2CH3), 2.10 (s, 3H, 
CH3C=O), 2.25 (s, 3H, p-CH3), 2.20 (m, 1H, CH2CHP), 2.49 (m, 1H, CH2CHP), 2.95 – 
3.07 (m, 1H, CHP), 3.30 (m, 1H, CH2N), 3.47 (m, 1H, CH2N), 3.70 – 4.02 (m, 4H, 
OCH2CH3), 7.04 – 7.12 (m, 4H, arom. H) ppm. 
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13C-NMR (75 MHz, CDCl3): 
 = 16.50 (OCH2CH3), 20.66 (CH3C=O), 21.31 (p-CH3), 
28.45 (CH2CHP), 41.68 (d, 1JC,P = 135.9 Hz, CHP), 46.74 (d, 3JC,P = 11.2 Hz, NCH2), 
63.02 (d, 2JC,P = 6.6 Hz, OCH2CH3), 63.31 (d, 2JC,P = 7.8 Hz, OCH2CH3), 129.14 
(=CH), 129.68 (=CH), 133.69 (=C), 137.34 (=C), 172.90 (C=O) ppm. 
Mass (ESI-MS): calculated for C16H27NO5P [M+H]+: 344.1627, found: 344.2. 
 
Diethyl [3-(N-hydroxyacetamido)-1-(4-methoxyphenyl)propyl]phosphonate 
(3.15c). Yield: 82%. 
N
P OEtOEtO
OH
O
Me
MeO
 
1H-NMR (300 MHz, CDCl3): 
 = 1.13 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.23 (t, J = 6.7 
Hz, 3H, OCH2CH3), 2.09 (s, 3H, CH3C=O), 2.17 (m, 1H, CH2CHP), 2.44 (m, 1H, 
CH2CHP), 3.04 (m, 1H, CHP), 3.36 (m, 1H, CH2N), 3.53 (m, 1H, CH2N), 3.77 (s, 3H, 
OCH3), 3.70 – 4.01 (m, 4H, OCH2CH3), 6.82 (2H, arom. H), 7.19 (2H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.52 (OCH2CH3), 20.70 (CH3C=O), 27.93 
(CH2CHP), 41.22 (d, 1JC,P = 138.2 Hz, CHP), 46.49 (d, 3JC,P = 14.1 Hz, NCH2), 62.64 
(OCH2CH3), 63.23 (OCH2CH3), 114.27 (=CH), 127.66 (=C), 130.34 (d, JC,P = 6.1 Hz, 
=CH), 159.08 (=C), 172.45 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C16H27NO6P [M+H]+: 360.1576, found: 
360.1573. 
 
Diethyl [1-(4-chlorophenyl)-3-(N-hydroxyacetamido)propyl]phosphonate 
(3.15d). Yield: 70%. 
N
P OEtOEtO
OH
O
Me
Cl
 
1H-NMR (300 MHz, CDCl3): 
 = 0.94 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.07 (t, J = 7.0 
Hz, 3H, OCH2CH3), 1.83 (s, 3H, CH3C=O), 2.00 (m, 1H, CH2CHP), 2.22 (m, 1H, 
CH2CHP), 2.88 – 2.98 (m, 1H, CHP), 3.23 (m, 1H, CH2N), 3.38 (m, 1H, CH2N), 3.55 
– 3.64 (m, 1H, OCH2CH3), 3.67 – 3.75 (m, 1H, OCH2CH3), 3.77 – 3.84 (m, 2H, 
OCH2CH3), 7.09 (m, 4H, arom. H), 9.57 (br. s, 1H, NOH) ppm. 
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13C-NMR (75 MHz, CDCl3): 
 = 16.29 (d, 3JC,P = 5.8 Hz, OCH2CH3), 16.40 (d, 3JC,P = 
6.0 Hz, OCH2CH3), 20.35 (CH3C=O), 26.98 (CH2CHP), 41.27 (d, 1JC,P = 138.8 Hz, 
CHP), 45.99 (d, 3JC,P = 17.3 Hz, NCH2), 62.55 (d, 2JC,P = 7.5 Hz, OCH2CH3), 63.04 
(d, 2JC,P = 7.2 Hz, OCH2CH3), 128.75 (=CH), 130.68 (d, JC,P = 6.6 Hz, =CH), 133.26 
(d, JC,P = 3.8 Hz, =C), 133.88 (d, JC,P = 7.5 Hz, =C), 172.01 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C15H24ClNO5P [M+H]+: 364.1081, found: 
364.1080. 
 
Diethyl [1-(3,4-dichlorophenyl)-3-(N-hydroxyacetamido)propyl]phosphonate 
(3.15e). Yield: 62%. 
N
P OEtOEtO
OH
O
Me
Cl
Cl
 
1H-NMR (300 MHz, CDCl3): 
 = 1.23 (m, 6H, OCH2CH3), 1.87 (m, 1H, CH2CHP), 
2.11 (s, 3H, CH3C=O), 2.49 (m, 1H, CH2CHP), 3.07 (m, 1H, CHP), 3.40 (m, 1H, 
CH2N), 3.59 (m, 1H, CH2N), 3.98 (m, 4H, OCH2CH3), 7.14 (m, 1H, arom. H), 7.38 (m, 
2H, arom. H), 9.45 (br. s, 1H, NOH) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.53 (OCH2CH3), 20.80 (CH3C=O), 26.91 
(CH2CHP), 41.37 (d, 1JC,P = 139.4 Hz, CHP), 46.34 (NCH2), 63.17 (OCH2CH3), 63.47 
(OCH2CH3), 128.78 (=CH), 130.71 (=CH), 131.26 (=CH), 131.81 (=C), 132.816 (=C), 
136.87 (=C), 172.73 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C15H22Cl2NO5P [M+H]+: 398.0691, found: 
398.0695. 
 
Diethyl [3-(formamido)-1-(phenyl)propyl]phosphonate (3.16a). Yield: 76%. 
N
H
P OEtOEtO
O
H
 
1H-NMR (300 MHz, CDCl3): 
 = 1.11 (t, J = 6.7 Hz, 3H, OCH2CH3), 1.27 (t, J = 7.0 
Hz, 3H, OCH2CH3), 2.06 – 2.23 (m, 1H, CH2CHP), 2.24 – 2.40 (m, 1H, CH2CHP), 
3.08 (ddd, JH,P = 22.9 Hz, J = 5.2 Hz and J = 9.9 Hz, 1H, CH2CHP), 3.16 – 3.37 (m, 
2H, NCH2), 3.66 – 3.82 (m, 1H, OCH2CH3), 3.84 – 3.97 (m, 1H, OCH2CH3), 3.98 – 
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4.12 (m, 2H, OCH2CH3), 5.90 (NH), 7.26 – 7.35 (m, 5H, arom. H), 8.11 (br. s, 1H, 
HC=O) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.42 (d, 3JC,P = 5.8 Hz, OCH2CH3), 16.58 (d, 3JC,P = 
6.0 Hz, OCH2CH3), 30.26 (CH2CHP), 36.75 (d, 3JC,P = 14.7 Hz, NCH2), 42.72 (d, 1JC,P 
= 138.8 Hz, CH), 62.30 (d, 2JC,P = 7.2 Hz, OCH2CH3), 63.03 (d, 2JC,P = 7.2 Hz, 
OCH2CH3), 127.75 (d, JC,P = 2.8 Hz, arom. =CmH), 128.95 (d, JC,P = 2.2 Hz, arom. 
=Ci), 129.33 (d, JC,P = 6.6 Hz, arom. =CoH), 135.75 (d, JC,P = 7.4 Hz, arom. =Cp), 
161.35 (C=O) ppm. 
Mass (ESI-MS): calculated for C14H23NO4P [M+H]+: 300.1324, found: 300.2. 
 
Diethyl [3-(formamido)-1-(4-methoxyphenyl)propyl]phosphonate (3.16c).Yield: 
27%. 
N
H
MeO
P OEtOEtO
O
H
 
1H-NMR (300 MHz, CDCl3): 
 = 0.998 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.15 (t, J = 6.9 
Hz, 3H, OCH2CH3), 1.94 – 2.04 (m, 1H, CH2CHP), 2.10 – 2.20 (m, 1H, CH2CHP), 
2.95 (ddd, JH,P = 22.7 Hz, J = 4.1 Hz and J = 11.0 Hz, 1H, CH2CHP), 3.00 – 3.10 (m, 
2H, NCH2), 3.58 – 3.65 (m, 1H, OCH2CH3), 3.67 (OCH3), 3.73 – 3.81 (m, 1H, 
OCH2CH3), 3.84 – 3.96 (m, 2H, OCH2CH3), 6.72 – 6.77 (d, JH,P = 8.5 Hz, 2H, arom. 
Hm), 7.04 (NH), 7.11 – 7.13 (d, JH,P = 8.5 Hz, 2H, arom. Ho), 7.93 (br. s, 1H, HC=O) 
ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 15.89 (d, 3JC,P = 4.8 Hz, OCH2CH3), 16.03 (d, 3JC,P = 
5.0 Hz, OCH2CH3), 29.45 (CH2CHP), 35.80 (d, 3JC,P = 16.5 Hz, NCH2), 40.89 (d, 1JC,P 
= 116.2 Hz, CHP), 54.85 (OCH3), 61.68 (d, 2JC,P = 7.8 Hz, OCH2CH3), 62.35 (d, 2JC,P 
= 6.7 Hz, OCH2CH3), 113.93 (d, JC,P = 2.0 Hz, =CmH), 126.61 (d, JC,P = 7.4 Hz, =Ci), 
129.78 (d, JC,P = 6.6 Hz, =CoH), 158.58 (d, JC,P = 2.8 Hz, =Cp), 161.25 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C15H25NO5P [M+H]+: 330.1430, found: 
330.1454. 
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Diethyl [3-(N-hydroxyformamido)cyclopentyl]phosphonate (cis-3.24). Yield: 90 
mg (19%). 
N
P
O OEt
OEt
HO
H
O
N
P
O OEt
OEt
HO
H
O
 
1H NMR (300 MHz, CDCl3): 
 = 1.26 (m, 6H, OCH2CH3), 1.75 − 2.42 (m, 7H, C5H7P), 
4.03 − 4.22 (m, 4H, OCH2CH3), 4.83 (s, 1H, CHNOH), 7.88 (s, 1H, HC=O), 8.25 (s, 
1H, HC=O), 9.70 (s, 1H, NOH) ppm.  
13C NMR (75 MHz, CDCl3): 
 = 16.65 (d, 3JC,P = 5.8 Hz, OCH2CH3), 26.15 (CH2, 
major), 26.66 (CH2, minor), 29.21 (d, JC,P = 12.7 Hz, CH2, minor), 29.81 (d, JC,P = 
11.5 Hz, CH2, major), 29.81 (CH2, minor), 30.44 (CH2, major), 33,54 (d, 1JC,P = 148.3 
Hz, CHP, major), 35,51 (d, 1JC,P = 148.9 Hz, CHP, minor), 55.08 (d, 3JC,P = 12.7 Hz, 
CHN, major), 60.19 (d, 3JC,P = 11.5 Hz, CHN, minor), 62.05 (OCH2CH3), 62.15 
(OCH2CH3), 156.49 (C=O, major), 162.37 (C=O, minor) ppm.  
Exact mass (ESI-MS): calculated for C10H21NO5P [M + H]+ 266.1158, found 
266.1131. 
 
Diethyl [3-(N-hydroxyformamido)cyclopentyl]phosphonate (trans-3.24). Yield: 
170 mg (35%).  
N
P
O OEt
OEt
HO
H
O
N
P
O OEt
OEt
HO
H
O
 
1H NMR (300 MHz, CDCl3): 
 = 1.18 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.18 (t, J = 6.8 
Hz, 3H, OCH2CH3), 1.75 − 2.08 (m, 7H, C5H7P), 3.95 (m, 4H, OCH2CH3), 4.68 (s, 1H, 
CHNOH), 7.80 (s, 1H, HC=O, minor), 8.17 (s, 1H, HC=O, major), 9.78 (br. s, 1H, 
NOH) ppm.  
13C NMR (75 MHz, CDCl3): 
 = 16.60 (d, 3JC,P = 5.5 Hz, OCH2CH3), 25.25 (CH2), 
28.08 (d, JC,P = 10.4 Hz, CH2, major), 28.83 (d, JC,P = 11.2 Hz, CH2, minor), 29.4 (s, 
CH2, major), 30.07 (CH2, minor), 33.41 (d, 1JC,P = 148.3 Hz, CHP, major), 34.22 (d, 
1JC,P = 150.0 Hz, CHP, minor), 55.44 (d, 3JC,P = 15.8 Hz, CHN, major), 60.50 (d, 3JC,P 
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= 18.1 Hz, CHN, minor), 62.10 − 62.47 (m, 2C, OCH2CH3), 156.43 (C=O, minor), 
162.48 (C=O, major) ppm.  
Exact mass (ESI-MS): calculated for C10H21NO5P [M + H]+ 266.1158, found 
266.1143. 
 
Diethyl [3-(N-hydroxyacetamido)cyclopentyl]phosphonate (cis-3.25). Yield: 21%. 
N
P
O OEt
OEt
HO
Me
O
N
P
O OEt
OEt
HO
Me
O
 
1H-NMR (300 MHz, CDCl3): 
 = 1.23 (m, 6H, OCH2CH3), 1.61 – 2.33 (m, 7H, C5H7P), 
2.03 (m, 3H, CH3C=O), 3.99 (m, 4H, OCH2CH3), 4.96 (m, 1H, CHNOH), 9.60 (s, 1H, 
NOH) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.67 (OCH2CH3), 21.02 (CH3C=O), 26.74 (CH2), 
29.39 (CH2), 29.82 (CH2), 34.36 (d, 1JC,P = 145.4 Hz, CHP), 55.52 (CHN), 62.12 
(OCH2CH3), 171.95 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C11H23NO5P [M+H]+: 280.1314, found: 
280.1311. 
 
Diethyl [3-(N-hydroxyacetamido)cyclopentyl]phosphonate (trans-3.25). Yield: 
46%. 
N
P
O OEt
OEt
HO
Me
O
N
P
O OEt
OEt
HO
Me
O
 
1H-NMR (300 MHz, CDCl3): 
 = 1.18 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.20 (t, J = 7.0 
Hz, 3H, OCH2CH3), 1.65 – 2.14 (m, 7H, C5H7P), 2.01 (m, 3H, CH3C=O), 3.96 (m, 4H, 
OCH2CH3), 4.85 (m, 1H, CHNOH), 9.53 (s, 1H, NOH) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.58 (d, 3JC,P = 4.3 Hz, OCH2CH3), 20.95 (CH3C=O), 
24.88 (CH2), 27.71 (d, JC,P = 9.2 Hz, CH2), 29.45 (CH2), 33.15 (d, 1JC,P = 148.3 Hz, 
CHP), 56.11 (d, 3JC,P = 15.8 Hz, CHN), 62.24 (m, OCH2CH3), 171.91 (C=O) ppm. 
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Exact mass (ESI-MS): calculated for C11H23NO5P [M+H]+: 280.1314, found: 
280.1310. 
 
General Method for the Phosphonate Deprotection: Esters 3.14, 3.15, 3.16, 3.24 
or 3.25 (0.84 mmol) were dissolved in CH2Cl2 (10 mL) and treated dropwise with 
TMSBr (3.36 mmol, 0.50 g) under N2. The reaction mixture was stirred at room 
temperature for 2 h. After completion of the reaction, the volatile compounds were 
removed in vacuo to give the corresponding phosphonic acids in almost quantitative 
yield. All final compounds were purified using a preparative HPLC system on a C18 
column (5 m, Phenomenex, Luna, 250 × 21.2 mm) with a linear gradient of 
acetonitrile (0	100 %) in 5 mM NH4OAc solution at a flow rate of 17.5 mL/min over 
20 min. The compounds were detected by a UV-detector and ELSD-dectector. The 
purity of all target compounds was assessed by analytical HPLC [5 m, 
Phenomenex, C18(2), 250 × 4.6 mm] using the same gradient at a flow rate of 1 
mL/min. All final compounds were obtained as hygroscopic powders after 
lyophilisation. All powders were white, except the five-membered cyclic analogues 
which were obtained as orange powders. 
[3-(N-Hydroxyformamido)-1-(4-methoxyphenyl)propyl]phosphonic acid (3.1c). 
N
MeO
P OHOHO
OH
O
H
 
1H NMR (300 MHz, D2O): 
 = 1.97 – 2.12 (m, 1H, -CH), 2.24 – 2.38 (m, 1H, -CH), 
2.74 (ddd, JH,P = 21.9 Hz, J = 3.2 Hz and J = 15.8 Hz, 1H, -CH), 3.13 – 3.47 (m, 2H, 
-CH2), 3.71 (s, 3H, OCH3), 6.83 – 6.87 (m, 2H, arom. H), 7.12 – 7.15 (m, 2H, arom. 
H), 7.38 and 8.08 (2 × s, 1H, major and minor HC=O) ppm. 
13C NMR (75 MHz, D2O): 
 = 26.59 (s, -CH2), 42.37 (d, -CH, 1JC,P = 131.3 Hz), 
48.87 (d, -CH2, 3JC,P = 17.3 Hz), 55.55 (s, OCH3), 114.28 (d, JC,P = 2.3 Hz, =CH), 
130.33 (d, JC,P = 6.1 Hz, =CH), 130.53 (d, JC,P = 7.2 Hz, =C), 157.74 (d, JC,P = 2.9 Hz, 
=C), 159.74 and 163.70 (2 x s, major and minor C=O) ppm. 
31P NMR (121 MHz, D2O): 
 = 23.18 and 23.47 ppm. (major and minor isomer) 
Exact mass (ESI-MS): calculated for C11H15NO6P [M-H]-: 288.0636, found: 
288.0630. 
 
 - 185 -
[1-(3,4-Dichlorophenyl)-3-(N-hydroxyformamido)propyl]phosphonic acid (3.1e).  
N
Cl
P OHOHO
OH
O
H
Cl
 
1H NMR (300 MHz, D2O): 
 = 1.93 − 2.15 (m, 1H, -CH), 2.24 − 2.38 (m, 1H, -CH), 
2.73 − 2.87 (m, 1H, -CH), 3.17 − 3.47 (m, 2H, -CH2), 7.07 − 7.12 (m, 1H, arom. H), 
7.33 − 7.39 (m, 2H, arom. H), 7.44 and 8.07 (2 × s, 1 H, HC=O) ppm.  
13C NMR (75 MHz, D2O): 
 = 26.49 (s, -CH2), 42.82 (d, 1JC,P = 129.6 Hz, -CH), 
48.86 (d, 3JC,P = 17.0 Hz, -CH2), 128.92 (d, JC,P = 5.8 Hz, arom. C), 130.04 (d, JC,P = 
3.8 Hz, arom. C), 130.55 (d, JC,P = 2.6 Hz, arom. C), 130.73 (d, JC,P = 6.0 Hz, arom. 
C), 131.88 (d, JC,P = 3.2 Hz, arom. C), 138.80 (d, JC,P = 7.2 Hz, arom. C), 159.70 
(C=O, major) and 163.76 (C=O, minor) ppm.  
31P NMR (121 MHz, D2O): 
 = 21.46, 21.78 (major and minor isomers) ppm.  
Exact mass (ESI-MS): calculated for C10H11Cl2NO5P [M-H]- 325.9751, found 
325.9745. 
 
[3-(N-Hydroxyacetamido)-1-phenylpropyl]phosphonic acid (3.2a). 
N
P OHOHO
OH
O
Me
 
1H NMR (300 MHz, D2O): 
 = 1.57 and 1.90 (2 × s, 3H, minor and major CH3), 2.04 – 
2.14 (m, 1H, -CH), 2.19 – 2.27 (m, 1H, -CH), 2.70 – 2.87 (m, 1H, -CH), 3.21 – 
3.30 (m, 1H, -CH), 3.38 – 3.53 (m, 1H, -CH), 7.16 – 7.27 (m, 5H, arom. H) ppm. 
13C NMR (75 MHz, D2O): 
 = 19.35 (s, CH3), 26.99 (s, -CH2), 44.06 (d, 1JC,P = 129.3 
Hz, -CH), 46.36 (d, 3JC,P = 17.3 Hz, -CH2), 126.59 (d, =CH), 128.51 (d, JC,P = 2.3 
Hz, =CH) , 129.29 (d, JC,P = 5.8 Hz, =CH), 138.93 (m, JC,P = 7.2 Hz, =C), 173.72 (s, 
C=O) ppm. 
Exact mass (ESI-MS): calculated for C11H15NO5P [M-H]-: 272.0687, found: 
272.0684. 
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[3-(N-Hydroxyacetamido)-1-p-tolylpropyl]phosphonic acid (3.2b). 
N
Me
P OHOHO
OH
O
Me
 
1H NMR (300 MHz, D2O): 
 = 1.48 and 1.80 (2 × s, 3H, minor and major CH3), 1.84 – 
2.04 (m, 1H, -CH), 2.10 (s, 3H, p-CH3), 2.15 – 2.32 (m, 1H, -CH), 2.58 – 2.70 (m, 
1H, -CH), 3.12 – 3.20 (m, 1H, -CH), 3.24 – 3.42 (m, 1H, -CH), 6.99 – 7.02 (m, 4H, 
arom. H) ppm. 
13C NMR (75 MHz, D2O): 
 = 19.25 (s, CH3), 20.15 (s, p-CH3), 26.87 (s, -CH2), 
43.50 (d, 1JC,P = 129.8 Hz, -CH), 46.30 (d, 3JC,P = 17.6 Hz, -CH2), 128.98 (d, JC,P = 
2.3 Hz, =CH), 129.12 (d, JC,P = 6.0 Hz, =CH) , 135.50 (d, JC,P = 6.9 Hz, =C), 136.54 
(d, JC,P = 3.2 Hz, =C), 173.60 (s, C=O) ppm. 
Exact mass (ESI-MS): calculated for C12H17NO5P [M-H]-: 286.0843, found: 
286.0839. 
 
[3-(N-Hydroxyacetamido)-1-(4-methoxyphenyl)propyl]phosphonic acid (3.2c). 
N
MeO
P OHOHO
OH
O
Me
 
1H NMR (300 MHz, D2O): 
 = 1.55 and 1.88 (2 × s, 3H, minor and major CH3), 1.98 – 
2.11 (m, 1H, -CH), 2.15 – 2.35 (m, 1H, -CH), 2.67 – 2.84 (m, 1H, -CH), 3.23 – 
3.34 (m, 1H, -CH), 3.35 – 3.50 (m, 1H, -CH), 3.70 (s, 1H, OCH3), 6.82 – 6.88 (m, 
2H, arom. H), 7.11 – 7.17 (m, 2H, arom. H) ppm. 
13C NMR (75 MHz, D2O): 
 = 19.33 (s, CH3), 26.89 (s, -CH2), 43.04 (d, 1JC,P = 131.3 
Hz, -CH), 46.35 (d, 3JC,P = 17.3 Hz, -CH2), 55.55 (s, OCH3), 114.16 (d, =CH), 
130.32 (d, JC,P = 6.1 Hz, =CH) , 131.10 (d, JC,P = 7.2 Hz, =C), 157.61 (m, =C), 173.70 
(s, C=O) ppm. 
31P NMR (121 MHz, D2O): 
 = 23.32 and 23.67 ppm. (minor and major isomer) 
Exact mass (ESI-MS): calculated for C12H17NO6P [M-H]-: 302.0792, found: 
302.0794. 
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[1-(4-Chlorophenyl)-3-(N-hydroxyacetamido)propyl]phosphonic acid (3.2d). 
N
Cl
P OHOHO
OH
O
Me
 
1H NMR (300 MHz, D2O): 
 = 1.58 and 1.87 (2 × s, 3H, minor and major CH3), 1.95 – 
2.14 (m, 1H, -CH), 2.17 – 2.36 (m, 1H, -CH), 2.72 – 2.84 (m, 1H, -CH), 3.22 – 
3.32 (m, 1H, -CH), 3.35 – 3.50 (m, 1H, -CH), 7.13 – 7.20 (m, 2H, arom. H), 7.20 – 
7.28 (m, 2H, arom. H) ppm. 
13C NMR (75 MHz, D2O): 
 = 19.28 (s, CH3), 26.77 (s, -CH2), 43.46 (d, 1JC,P = 129.6 
Hz, -CH), 46.23 (d, 3JC,P = 17.6 Hz, -CH2), 128.40 (d, =CH), 130.65 (d, JC,P = 5.8 
Hz, =CH) , 131.77 (d, =C), 137.24 (d, JC,P = 7.2 Hz, =C), 173.70 (s, C=O) ppm. 
Exact mass (ESI-MS): calculated for C11H14ClNO5P [M-H]-: 306.0297, found: 
306.0293. 
 
[1-(3,4-Dichlorophenyl)-3-(N-hydroxyacetamido)propyl]phosphonic acid (3.2e). 
N
Cl
P OHOHO
OH
O
Me
Cl
 
1H NMR (300 MHz, D2O): 
 = 1.61 and 1.86 (2 × s, 3H, minor and major CH3), 1.97 – 
2.12 (m, 1H, -CH), 2.17 – 2.34 (m, 1H, -CH), 2.78 (ddd, JH,P = 21.8 Hz, J = 2.9 Hz 
and
 
J
 
= 12.3
 
Hz, 1H, -CH), 3.25 – 3.34 (m, 1H, -CH), 3.36 – 3.49 (m, 1H, -CH), 
7.06 – 7.13 (m, 1H, arom. H), 7.32 – 7.40 (m, 2H, arom. H) ppm. 
13C NMR (75 MHz, D2O): 
 = 19.23 (s, CH3), 26.68 (s, -CH2), 43.36 (d, 1JC,P = 129.3 
Hz, -CH), 48.86 (d, 3JC,P = 17.0 Hz, -CH2), 128.93 (d, JC,P = 5.8 Hz, =CH), 129.78 
(d, =C) , 130.26 (d, =CH), 130.93 (d, JC,P = 6.3 Hz, =CH), 131.51 (d, =C), 139.24 (d, 
JC,P = 7.2 Hz, =C), 173.70 (s, C=O) ppm. 
31P NMR (121 MHz, D2O): 
 = 21.51 and 21.90 ppm. (minor and major isomer) 
Exact mass (ESI-MS): calculated for C11H13Cl2NO5P [M-H]-: 339.9907, found: 
339.9901. 
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[3-(Formamido)-1-(phenyl)propyl]phosphonic acid (3.17a). 
N
H
P OHOHO
O
H
 
1H NMR (300 MHz, D2O): 
 = 2.05 – 2.29 (m, 2H, -CH), 2.88 – 3.00 (m, 1H, -CH), 
3.02 – 3.20 (m, 2H, -CH2), 7.26 – 7.39 (m, 5H, arom. H), 7.90 (s, 1H, HC=O) ppm. 
13C NMR (75 MHz, D2O): 
 = 29.29 (s, -CH2), 36.53 (d, 3JC,P = 17.0 Hz, -CH2), 
43.99 (d, 1JC,P = 129.8 Hz, -CH), 126.63 (d, JC,P = 2.9 Hz, =CH), 128.53 (d, JC,P = 
2.3 Hz, =CH), 129.22 (d, JC,P = 6.1 Hz, =CH), 138.70 (d, JC,P = 6.6 Hz, =C), 164.11 
(s, C=O) ppm. 
Exact mass (ESI-MS): calculated for C10H13NO4P [M-H]-: 242.0581, found: 
242.0590. 
 
[3-(Formamido)-1-(4-methoxyphenyl)propyl]phosphonic acid (3.17c). 
N
H
MeO
P OHOHO
O
H
 
1H NMR (300 MHz, D2O): 
 = 1.85 – 1.99 (m, 1H, -CH), 1.99 – 2.12 (m, 1H, -CH), 
2.69 – 2.81 (m, 1H, -CH), 2.82 – 3.04 (m, 2H, -CH2), 3.65 (s, 3H, OCH3), 6.78 – 
6.83 (m, 2H, arom. H), 7.08 – 7.12 (m, 2H, arom. H), 7.74 (s, 1H, HC=O) ppm. 
13C NMR (75 MHz, D2O): 
 = 29.38 (s, -CH2), 36.55 (d, -CH2, 3JC,P = 17.0 Hz), 
43.00 (d, -CH, 1JC,P = 131.3 Hz), 55.52 (s, OCH3), 114.06 (d, JC,P = 2.3 Hz, =CH), 
130.30 (d, JC,P = 6.0 Hz, =CH), 131.11 (d, JC,P = 7.2 Hz, =C), 157.61 (d, JC,P = 2.9 Hz, 
=C), 164.13 (s, C=O) ppm. 
31P NMR (121 MHz, D2O): 
 = 23.69 ppm. 
Exact mass (ESI-MS): calculated for C11H15NO5P [M-H]-: 272.0687, found: 
272.0693. 
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[(1R,3R)-3-(N-Hydroxyformamido)cyclopentyl]phosphonic acid and [(1S,3S)-3-
(N-hydroxyformamido)cyclopentyl]phosphonic acid (trans-3.3).  
N
P
O OH
OH
HO
H
O
N
P
O OH
OH
HO
H
O
 
1H NMR (300 MHz, D2O): 
 = 1.73 − 2.04 (m, 7H, -CH and CH2), 4.13 (br. s, 1H, 
NCH), 7.84, 8.07 (2 × s, 1H, major and minor HC=O) ppm.  
13C NMR (75 MHz, D2O): 
 = 25.55 (d, JC,P = 1.2 Hz, CH2), 28.56 (d, JC,P = 10.4 Hz, 
CH2), 31.10 (s, CH2), 35.94 (d, 1JC,P = 141.7 Hz, -CH), 61.46 (d, JC,P = 17.3 Hz, 
NCH), 159.23 (C=O) ppm. 
31P NMR (121 MHz, D2O): 
 = 27.71, 27.91 (major and minor isomers) ppm.  
Exact mass (ESI-MS): calculated for C6H11NO5P [M-H]- 208.0374, found 208.0366. 
 
[(1R,3S)-3-(N-Hydroxyformamido)cyclopentyl]phosphonic acid and [(1S,3R)-3-
(N-hydroxyformamido)cyclopentyl]phosphonic acid (cis-3.3).  
N
P
O OH
OH
HO
H
O
N
P
O OH
OH
HO
H
O
 
1H NMR (300 MHz, D2O): 
 = 1.49 − 2.17 (m, 7H, -CH and CH2), 4.21 (br. m, 1H, 
NCH), 7.88, 8.09 (2 × s, 1H, major and minor HC=O) ppm.  
13C NMR (75 MHz, D2O): 
 = 26.73 (d, JC,P = 1.1 Hz, CH2), 29.89 (d, JC,P = 11.2 Hz, 
CH2), 30.76 (CH2), 36.47 (d, 1JC,P = 141.5 Hz, -CH), 61.36 (d, JC,P = 10.9 Hz, NCH), 
159.11 (C=O) ppm.  
31P NMR (121 MHz, D2O): 
 = 27.74 ppm.  
Exact mass (ESI-MS): calculated for C6H11NO5P [M-H]- 208.0374, found 208.0378. 
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[(1R,3R)-3-(N-Hydroxyacetamido)cyclopentyl]phosphonic acid and [(1S,3S)-3-
(N-hydroxyacetamido)cyclopentyl]phosphonic acid (trans-3.4). 
N
P
O OH
OH
HO
Me
O
N
P
O OH
OH
HO
Me
O
 
1H NMR (300 MHz, D2O): 
 = 1.67 – 2.04 (m, 7H, -CH and CH2), 1.95 (s, 3H, CH3), 
4.36 – 4.65 (br. m, 1H, NCH) ppm. 
13C NMR (75 MHz, D2O): 
 = 19.84 (s, CH3), 25.60 (d, CH2), 27.80 (d, JC,P = 11.2 Hz, 
CH2), 30.47 (s, CH2), 35.94 (d, 1JC,P = 141.1 Hz, -CH), 56.98 (d, JC,P = 15.3 Hz, 
NCH) , 173.60 (s, C=O) ppm. 
31P NMR (121 MHz, D2O): 
 = 27.64 and 27.91 ppm. (minor and major isomer) 
Exact mass (ESI-MS): calculated for C7H13NO5P [M-H]-: 222.0530, found: 222.0503. 
 
[(1R,3S)-3-(N-Hydroxyacetamido)cyclopentyl]phosphonic acid and [(1S,3R)-3-
(N-hydroxyacetamido)cyclopentyl]phosphonic acid (cis-3.4). 
N
P
O OH
OH
HO
Me
O
N
P
O OH
OH
HO
Me
O
 
1H NMR (300 MHz, D2O): 
 = 1.47 – 2.15 (m, 7H, -CH and CH2), 1.99 (s, 3H, CH3), 
4.45 – 4.74 (br. m, 1H, NCH) ppm. 
13C NMR (75 MHz, D2O): 
 = 19.84 (s, CH3), 26.89 (d, CH2), 29.34 (d, JC,P = 11.5 Hz, 
CH2), 30.21 (s, CH2), 36.66 (d, 1JC,P = 140.8 Hz, -CH), 56.73 (d, JC,P = 11.8 Hz, 
NCH) , 173.56 (s, C=O) ppm. 
31P NMR (121 MHz, D2O): 
 = 27.90 and 28.11 ppm. (minor and major isomer) 
Exact mass (ESI-MS): calculated for C7H13NO5P [M-H]-: 222.0530, found: 222.0508. 
 
Dibenzyl hydroxymethylphosphonate (4.21)  
OBnPHO
O
OBn
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Dibenzyl phosphite (20 mL, 76.27 mmol), triethylamine (10.60 mL, 76.27 mmol), and 
paraformaldehyde (2.45 g, 130 mmol) were mixed in a reaction vessel. The vessel 
was tightly sealed and the mixture was mechanically stirred for 12 h at 90 °C. All 
volatile components were subsequently removed under reduced pressure, and the 
remaining semisolid was dissolved in 25 mL of CH2Cl2. The solution was 
successively washed with saturated aqueous solutions of NH4Cl, K2CO3 and again 
NH4Cl, dried with MgSO4 and the solvent removed under reduced pressure. The 
residue, a pale-yellow oil, was purified by column chromatography (CH2Cl2/ethyl 
acetate, 2:1 to CH2Cl2/acetone 1:1, after al benzyl alcohol had eluted from the 
column) to yield compound 4.21 (12.48 g, 42.7 mmol, 56%).  
1H-NMR (300 MHz, CDCl3): 
 = 3.92 (d, J = 5.6 Hz, 2 H, CH2P), 5.06 (m, 4 H, 
CH2Ph), 7.34 (s, 10 H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 57.66 (d, J = 160.7 Hz, HOCH2), 68.27 (d, J = 6.6 Hz 
OCH2Ar), 128.26 (=CH), 128.78 (=CH), 128.86 (=CH), 136.29 (=C) ppm.  
Exact mass (ESI-MS): calculated for C15H16O4P [M-H]-: 291.0785, found: 291.0772. 
 
N-(benzyloxy)formamide (4.14) 
NH
OBn
H
O
 
Formic acid (1.18 mL, 31.3 mmol) was dissolved in dry CH2Cl2 (60 mL). To this 
solution CDI (5.08 g, 31.3 mmol) was added. After stirring for 30 min a suspension of 
benzylhydroxylamine hydrochloride (5 g, 31.3 mmol) in 31 mL of CH2Cl2 containing 
Et3N (4.35 ml, 31.3 mmol) was added. When TLC revealed disappearance of all the 
starting material, the reaction mixture was diluted with 150 mL CH2Cl2 and washed 
six times with 1N HCl (100 mL). The organic layer was dried over MgSO4, 
concentrated under reduced pressure and the residue purified by chromatography 
(CH2Cl2/MeOH 95:5) to yield 4.13 g of N-(benzyloxy)formamide 4.14 (yield 87%) as a 
pale yellow oil. 
1H-NMR (300 MHz, CDCl3): mixture of amide rotamers 
 = 4.74 and 4.80 (2 × s, 2 H, 
CH2Ph, minor and major), 7.30 (m, 5 H, arom. H), 7.67 and 8.01 (2 × s, 1 H, C(O)H, 
major and minor), 9.60 and 10.32 (2 × s, 1 H, NH, minor and major) ppm. 
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13C-NMR (75 MHz, CDCl3): mixture of amide rotamers 
 = 78.56 and 81.05 (2 × s, 
OCH2Ar, major and minor), 128.79 (=CH), 129.07 (=CH), 129.41 (=CH), 135.09 (=C), 
158.35 and 165.08 (2 × s, C(O)H, major and minor) ppm.  
Exact mass (ESI-MS): calculated for C8H10NO2 [M+H]+: 152.0712, found: 152.0426. 
 
N-(benzyloxy)acetamide (4.15) 
NH
OBn
Me
O
 
O-benzylhydroxylamine hydrochloride (1g, 6.2 mmol) was dissolved in CH2Cl2 (20 
mL) and triethylamine (1 mL, 6.8 mmol) and stirred for 1 h. This suspension was 
treated with acetyl chloride (0.5 mL, 6.8 mmol) dropwise and stirred for 1.5 h at room 
temperature. The reaction mixture was diluted with 60 mL of CH2Cl2 and washed with 
100 mL of water. The organic solvent was removed under reduced pressure and the 
residue was purified (CH2Cl2/MeOH 95:5) to yield 0.43 g of N-(benzyloxy)acetamide 
4.15 (yield 86%) as white cristals.  
1H-NMR (300 MHz, CDCl3): mixture of amide rotamers 
 = 1.80 and 1.96 (2 × s, 3 H, 
C(O)CH3, major and minor), 4.77 and 4.84 (2 × s, 2 H, CH2Ph, minor and major), 
7.30 (m, 5 H, arom. H), 8.57 and 9.59 (2 × s, 1 H, NH, minor and major) ppm. 
13C-NMR (75 MHz, CDCl3): mixture of amide rotamers 
 = 19.95 and 19.96 (2 × s, 
CH3, minor and major), 78.24 and 79.53 (2 × s, OCH2Ar, major and minor), 128.74 
(=CH), 128.82 (=CH), 129.32 (=CH), 135.67 (=C), 168.45 and 175.23 (2 × s, 
C(O)CH3, major and minor) ppm.  
Exact mass (ESI-MS): calculated for C9H12NO2 [M+H]+: 166.0868, found: 166.0875. 
 
General method for hydroxymethylation of 4.14 and 4.15. 
 
A mixture of the N-benzyloxyamide (5.71 mmol), paraformaldehyde (0.26 g, 8.56 
mmol) and tBuOK (0.064 g, 0.57 mmol) was heated, in the absence of solvent, at 60 
°C during 4 h. The reaction mixture was cooled and diluted with water (80 mL). After 
extraction with CH2Cl2 (3 x 80 mL) the organic layer was dried over anhydrous 
Na2SO4 and evaporated in vacuo. The residue was purified by chromatography 
(hexane/ethyl acetate, 1:1 for 4.17 or pentane/acetone/Et3N, 6:4:0.1 for 4.16 ) to give 
4.16 and 4.17 in 79% and 48% yield as white solids. 
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N-(benzyloxy)-N-(hydroxymethyl)formamide (4.16) 
OHN
OBn
H
O
 
1H-NMR (300 MHz, CDCl3): 
 = 3.91 (br. s, 1 H, OH), 4.76 (s, 2 H, CH2Ph), 4.98 (br. 
s, 2 H, HOCH2), 7.37 (m, 5 H, arom. H), 8.08 (s, 1H, C(O)H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 69.55 (s, HOCH2, major), 73.10 (s, HOCH2, minor), 
77.71 (s, CH2Ph, minor), 79.81 (s, CH2Ph, major), 128.96 (=CH), 129.37 (=CH), 
129.87 (=CH), 134.54 (=C), 159.48 (s, C(O)H, minor), 164.27 (s, C(O)H, major) ppm.  
Exact mass (ESI-MS): calculated for C9H12NO3 [M+H]+: 182.0817, found: 182.0832.  
 
N-(benzyloxy)-N-(hydroxymethyl)acetamide (4.17) 
OHN
OBn
Me
O
 
1H-NMR (300 MHz, CDCl3): 
 = 2.06 (s, 3 H, C(O)CH3), 3.96 (br. s, 1 H, OH), 4.93 (s, 
2 H, CH2Ph), 5.03 (br. s, 2 H, HOCH2), 7.38 (m, 5 H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 20.86 (s, CH3), 71.17 (s, HOCH2), 78.45 (s, OCH2Ar), 
128.94 (=CH), 128.94 (=CH), 128.94 (=CH), 134.65 (=C), 174.26 (s, C(O)CH3) ppm.  
Exact mass (ESI-MS): calculated for C10H14NO3 [M+H]+: 196.0974, found:196.0981.  
 
General method for synthesis of N-(benzyloxy)-N-(chloromethyl)formamide (4.18) 
and N-(benzyloxy)-N-(chloromethyl)acetamide (4.19) 
 
To a cooled solution (10 °C) of 4.16 or 4.17 (2.7 mmol) in 5.5 mL of CH2Cl2 was 
added thionyl chloride (0.55 mL, 7.5 mmol). After stirring for 30 min, the mixture was 
evaporated under vacuum to yield an oily residue that could be solidified by adding a 
drop of hexane and connecting the flask to high vacuum. In our hands it was not 
possible to recrystallize 4.19 from ethyl acetate due to hydrolysis to the alcohol 4.17. 
Therefore, 4.19 was directly used in the next step without further purification. The 
same holds for 4.18. 
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Dibenzyl(N-(N-benzyloxyformamido)methoxy)methylphosphonic acid (4.22) 
OBnPO
O
OBn
N
OBn
H
O
 
To a solution of crude 4.18 (± 0.37 mmol) in 5 mL of CH2Cl2 was added a solution 
4.21 (0.16 g, 0.54 mmol) in 5 mL of CH2Cl2. After stirring for 16 h at room 
temperature the mixture was evaporated to dryness and purified by column 
chromatography (CH2Cl2/ethyl acetate, 2:1), affording 4.22 (35 mg, 21%) as a clear 
oil. 
1H-NMR (300 MHz, CDCl3): 
 = 3.75 – 3.87 (m, 2H, CH2P), 4.74 – 5.15 (m, 8H, 
NCH2O and PhCH2O), 7.28 – 7.35 (m, 15H, arom. H), 8.07 and 8.15 (br. s and br. s, 
1H, C(O)H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 63.60 (d, 1JC,P = 171.0 Hz, CH2P), 68.24 and 68.32 (2 
× s, PhCH2), 80.04 (NCH2O), 128.33 (=CH), 128.86 (=CH), 129.37 (=CH), 129.80 
(=CH), 134.44 (=C), 136.18 (=C), 164.25 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C24H27NO6P [M+H]+: 456.1576, found: 
456.1580. 
 
Dibenzyl(N-(N-benzyloxyacetamido)methoxy)methylphosphonic acid (4.23) 
OBnPO
O
OBn
N
OBn
Me
O
 
To a solution of crude 4.19 (± 2.5 mmol) in 2 mL of CH2Cl2 was added a solution 4.21 
(1.46 g, 5 mmol) in 3 mL of CH2Cl2. After stirring for 16 h at room temperature the 
mixture was evaporated to dryness and purified by column chromatography 
(CH2Cl2/ethyl acetate, 2:1) to give 4.23 (0.44 g, 38%) as a clear oil. 
1H-NMR (300 MHz, DMSO-d6): 
 = 2.06 (s, 3H, C(O)CH3), 3.97 (d, J = 8.8 Hz, 2H, 
CH2P), 4.92 (s, 2H, NCH2O), 5.02 (s, 2H, PhCH2), 5.05 (d, J = 1.5 Hz, 2H, PhCH2), 
5.08 (d, J = 2.0 Hz, 2H, PhCH2), 7.30 – 7.40 (m, 15H, arom. H) ppm. 
13C-NMR (75 MHz, DMSO-d6): 
 = 21.16 (CH3), 62.76 (d, 1JC,P = 219.3 Hz, CH2P), 
67.70 and 67.78 (2 × s, PhCH2), 77.41 (NCH2O), 128.48 (=CH), 128.93 (=CH), 
129.13 (=CH), 129.15 (=CH), 129.40 (=CH), 130.10 (=CH), 135.35 (=C), 137.03 (d, 
JC,P = 6.1 Hz, =C), 173.18 (C=O) ppm. 
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Exact mass (ESI-MS): calculated for C25H29NO6P [M+H]+: 470.1733, found: 
470.1728. 
 
General procedure for the benzyl deprotection of 4.22 and 4.23 
A solution of compounds 4.22 or 4.23 (140 mg) in MeOH (3 mL) was hydrogenated at 
atmospheric pressure in the presence of Pd 10 wt. % on activated carbon (70 mg). 
After 3 h stirring the reaction mixture was filtered over a celite pad. The solvent was 
removed under vacuum and the crude mixture was purified by column 
chromatography on silica gel (CH2Cl2/MeOH 90:10). Phosphonic acids 4.1 and 4.2 
were purified according to the purification of compounds 4.3-4.6. 
(N-(N-hydroxyformamido)methoxy)methylphosphonic acid (4.1): Yield: 34% 
according to HPLC analysis. 
OHPO
O
OH
N
OH
H
O
 
1H-NMR (300 MHz, D2O): 
 = 3.68 (d, JH,P = 9.4 Hz, 2H, CH2P), 5.01 (s, 2H, OCH2), 
7.94 (s, 1H, C(O)H, minor), 8.21 (s, 1H, C(O)H, major) ppm. 
13C-NMR (75 MHz, D2O): 
 = 58.11(d, 1JC,P = 153.88 Hz, CH2P, major), 63.98 (d, 
1JC,P = 153.88 Hz, CH2P, minor), 81.26 (s, OCH2, major), 81.40 (s, OCH2, minor), 
160.19 (s, C=O, minor), 161.032 (s, C=O, major) ppm. 
31P-NMR (121 MHz, D2O): 
 = 15.05 ppm. 
Exact mass (ESI-MS): calculated for C3H7NO6P [M-H]-: 184.0010, found: 184.0025. 
 
(N-(N-hydroxyacetamido)methoxy)methylphosphonic acid (4.2): Yield: 43% 
according to HPLC analysis. 
OHPO
O
OH
N
OH
Me
O
 
1H-NMR (300 MHz, D2O): 
 = 2.07 (s, 3H, CH3, major), 2.08 (s, 3H, CH3, minor), 3.43 
(d, JH,P = 8.9 Hz, 2H, CH2P, major), 3.49 (d, JH,P = 8.9 Hz, 2H, CH2P, minor), 4.87 (s, 
2H, OCH2, major), 4.95 (s, 2H, OCH2, minor) ppm. 
13C-NMR (75 MHz, D2O): 
 = 19.79 (CH3), 66.38 (d, 1JC,P = 137.0 Hz, CH2P, major), 
70.87 (d, 1JC,P = 137.0 Hz, CH2P, minor), 77.78 (s, OCH2, major), 77.93 (s, OCH2, 
minor), 175.74 (C=O) ppm. 
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31P-NMR (121 MHz, D2O): 
 = 15.16 ppm. 
Exact mass (ESI-MS): calculated for C4H11NO6P [M+H]+: 200.0324, found: 
200.0632. 
 
Diethyl ((ethoxycarbonyl)methoxy)methylphosphonate (4.30) 
O P OEt
O
OEtEtO
O
 
Sodium hydride (400 mg, 11.9 mmol) was added to a solution of 
diethylhydroxymethyl phosphonate (1 g, 5.9 mmol) in THF (26 mL) and stirred for 1 h. 
Subsequently, ethyl bromoacetate (1.29 g, 7.7 mmol) was added and, after 3 h, the 
reaction was quenched with sat. NH4Cl (aq.). EtOAc was added, the two phases 
separated and the aqueous layer further extracted with three portions of EtOAc (100 
mL). The combined organic layers were dried over MgSO4 and the solvent was 
removed under reduced pressure. The residue was purified by flash chromatography 
(CH2Cl2/MeOH, 95:5) to give 4.30 (1.21 g, 80%) as an oil. 
1H-NMR (300 MHz, CDCl3): 
 = 1.25 (t, J = 7.0 Hz, 6H, C(O)OCH2CH3), 1.32 (t, J = 
7.0 Hz, 6H, POCH2CH3), 3.91 (d, JH,P = 8.5 Hz, 2H, CH2P), 4.12 – 4.22 (m, 8H, 
C(O)CH2O and POCH2CH3) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 14.37 (C(O)OCH2CH3), 16.64 (d, 3JC,P = 5.8 Hz, 
POCH2CH3), 61.19 (C(O)OCH2CH3), 62.79 (d, 2JC,P = 6.3 Hz, POCH2CH3), 65.30 (d, 
1JC,P = 165.5 Hz, CH2P), 69.66 (d, 3JC,P = 11.2 Hz, C(O)CH2O), 169.79 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C9H20O6P [M+H]+: 255.0998, found: 255.0987. 
 
2-((Ethoxyphosphono)methoxy)acetic acid (4.32) 
O P OEt
O
OEtHO
O
 
A solution of 4.30 (1.21 g, 4.8 mmol) in 4.8 mL 1N aq. NaOH was stirred for 2 h at 30 
°C. When the hydrolysis was finished, as indicated by TLC, the reaction mixture was 
neutralized with 1N HCl until PH  9. The desired carboxylic acid was extracted with 
CH2Cl2 (5 × 50 mL) and EtOAc (3 × 50 mL). The combined organic layers were dried 
over MgSO4 and concentrated in vacuo. Purification by flash chromatography 
(CH2Cl2/MeOH/ HCOOH, 95:5:0.1) afforded 4.31 (1.0 g, 94%). The carboxylic acid 
was visualized on TLC with bromocresol green. 
 - 197 -
1H-NMR (300 MHz, CDCl3): 
 = 1.36 (t, J = 7.0 Hz, 6H, OCH2CH3), 3.98 (d, JH,P = 8.2 
Hz, 2H, CH2P), 4.16 – 4.26 (m, 6H, C(O)CH2O and OCH2CH3), 6.79 (br. s, 1H, OH) 
ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.61 (d, 3JC,P = 5.8 Hz, OCH2CH3), 63.34 (d, 2JC,P = 
6.3 Hz, OCH2CH3), 65.40 (d, 1JC,P = 165.8 Hz, CH2P), 69.74 (d, 3JC,P = 10.1 Hz, 
C(O)CH2O), 171.91 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C7H16O6P [M+H]+: 227.0685, found: 227.0683. 
 
Diethyl ((benzyloxycarbamoyl)methoxy)methylphosphonate (4.32) 
O P OEt
O
OEtNH
O
BnO
 
Compound 4.31 (0.80 g, 3.5 mmol) was dissolved in CH2Cl2 (4 mL). To this solution 
1.1 eq. CDI (0.60 g, 3.7 mmol) was added. After stirring for 0.5 h, a suspension of 
benzylhydroxylamine hydrochloride (0.59 g, 3.7 mmol) in 4 mL of CH2Cl2 containing 
Et3N (0.38 g, 3.7 mmol) was added. After disappearance of all starting material as 
indicated by TLC, the reaction mixture was diluted with 50 mL CH2Cl2 and washed 
with 1N HCl (60 mL). The organic layer was dried over MgSO4 and concentrated in 
vacuo. Purification by flash chromatography (CH2Cl2/MeOH, 95:5) afforded 4.32 as 
an oil in 83% yield (970 mg). 
1H-NMR (300 MHz, CDCl3): 
 = 1.31 (t, J = 7.0 Hz, 6H, OCH2CH3), 3.76 (d, JH,P = 8.8 
Hz, 2H, CH2P), 4.07 – 4.17 (m, 6H, C(O)CH2O and OCH2CH3), 4.96 (s, 2H, 
PhCH2O), 7.34 – 7.44 (m, 5H, arom. H), 9.46 (br. s, 1H, NH) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.65 (d, 3JC,P = 5.8 Hz, OCH2CH3), 63.01 (d, 2JC,P = 
6.6 Hz, OCH2CH3), 66.19 (d, 1JC,P = 168.4 Hz, CH2P), 72.33 (d, 3JC,P = 10.1 Hz, CH2), 
78.59 (PhCH2O), 128.78 (=CH), 128.95 (=CH), 129.39 (=CH), 135.0 (=C), 168.91 
(C=O) ppm. 
Exact mass (ESI-MS): calculated for C14H23NO6P [M+H]+: 332.1263, found: 
332.1272. 
 
Diethyl ((hydroxycarbamoyl)methoxy)methylphosphonate (4.33) 
O P OEt
O
OEtNH
O
HO
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Benzyl deprotection of 4.32 was essentially performed as described for 4.1 and 4.2, 
yielding the title compound in 80% yield (92 mg). 
1H-NMR (300 MHz, CDCl3): 
 = 1.30 (m, 6H, OCH2CH3), 3.85 (m, 2H, CH2P), 4.14 
(m, 6H, C(O)CH2O and OCH2CH3), 10.02 (br. s, 1H, NH) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.59 (d, 3JC,P = 5.5 Hz, OCH2CH3), 63.23 (d, 2JC,P = 
6.3 Hz, OCH2CH3), 65.91 (d, 1JC,P = 166.7 Hz, CH2P), 71.57 (d, 3JC,P = 10.0 Hz, 
C(O)CH2O), 166.24 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C8H17NO6P [M+H]+: 254.0794, found: 
254.0806. 
 
Diethyl ((N-(benzyloxy)-N-methylcarbamoyl)methoxy)methylphosphonate (4.34) 
O P OEt
O
OEtN
O
BnO
Me
 
To solution of 4.32 (0.51 g, 1.5 mmol) in 16 mL of THF was added sodium hydride 
(67 mg, 1.7 mmol) and methyl iodide (0.24 g, 1.7 mmol). The mixture was stirred 
overnight at room temperature, quenched with a saturated solution of NH4Cl (40 mL) 
and extracted with ether (3 × 40 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo. Purification by flash chromatography (CH2Cl2/MeOH, 95:5) 
afforded 4.34 (300 mg, 56%). 
1H-NMR (300 MHz, CDCl3): 
 = 1.30 (t, J = 7.0 Hz, 6H, OCH2CH3), 3.17 (s, 3H, 
NCH3), 3.83 (d, JH,P = 8.2 Hz, 2H, CH2P), 4.09 – 4.19 (m, 4H, OCH2CH3), 4.25 (s, 2H, 
C(O)CH2O), 4.77 (s, 2H, PhCH2O), 7.26 – 7.37 (m, 5H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.63 (d, 3JC,P = 5.8 Hz, OCH2CH3), 33.73 (NCH3), 
62.71 (d, 2JC,P = 6.6 Hz, OCH2CH3), 65.11 (d, 1JC,P = 164.7 Hz, CH2P), 69.91 (d, 3JC,P 
= 11.5 Hz, C(O)CH2O), 76.53 (PhCH2O), 129.00 (=CH), 129.42 (=CH), 129.65 
(=CH), 134.28 (=C), 171.13 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C15H25NO6P [M+H]+: 346.1420, found: 
346.1408. 
 
Diethyl ((N-hydroxy-N-methylcarbamoyl)methoxy)methylphosphonate (4.35) 
O P OEt
O
OEtN
O
HO
Me
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Benzyl deprotection of 4.34 was essentially performed as described for 4.1 and 4.2, 
yielding the title compound in 89% yield (140 mg). 
1H-NMR (300 MHz, CDCl3): 
 = 1.31 (t, J = 7.0 Hz, 6H, OCH2CH3), 3.19 (s, 3H, 
NCH3), 3.91 (d, JH,P = 8.2 Hz, 2H, CH2P), 4.09 – 4.19 (m, 4H, OCH2CH3), 4.41 (s, 2H, 
C(O)CH2O), 9.38 (br. s, 1H, OH) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.57 (d, 3JC,P = 5.8 Hz, OCH2CH3), 36.03 (NCH3), 
63.22 (d, 2JC,P = 6.6 Hz, OCH2CH3), 65.02 (d, 1JC,P = 166.1 Hz, CH2P), 70.01 (d, 3JC,P 
= 11.8 Hz, C(O)CH2O), 169.83 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C8H19NO6P [M+H]+: 256.0950, found: 
256.1052. 
 
Dimethyl 2(N-benzyloxycarbonyloxy)ethylphosphonate (4.37) 
O P OMe
O
OMeNH
BnO
O
 
The title compound was prepared in 73% yield from dimethyl 2-
hydroxyethylphosphonate (4.36) using a similar procedure as described for 4.32. 
1H-NMR (300 MHz, CDCl3): 
 = 2.13 (dt, JH,H = 7.3 Hz and JH,P = 18.8 Hz, 2H, CH2P), 
3.68 (d, J = 11.1 Hz, 6H, OCH3), 4.30 (dt, JH,H = 7.6 Hz and JH,P = 12.9 Hz , 2H, 
CH2CH2P), 4.81 (s, 2H, PhCH2O), 7.29 – 7.34 (m, 5H, arom. H), 8.15 (br. s, 1H, NH) 
ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 25.42 (d, 1JC,P = 140.5 Hz, CH2P), 52.73 (d, 2JC,P = 
6.6 Hz, OCH3), 59.79 (CH2CH2P), 78.78 (PhCH2O), 128.69 (=CH), 128.78 (=CH), 
129.32 (=CH), 135.68 (=C), 157.16 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C12H19NO6P [M+H]+: 304.0950, found: 
304.0947. 
 
Dimethyl 2(N-hydroxycarbonyloxy)ethylphosphonate (4.38) 
O P OMe
O
OMeNH
HO
O
 
Benzyl deprotection of 4.37 was essentially performed as described for 4.1 and 4.2, 
yielding the title compound in 98% yield (350 mg). 
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1H-NMR (300 MHz, CDCl3): 
 = 2.21 (dt, JH,H = 7.0 Hz and JH,P = 18.8 Hz, 2H, CH2P), 
3.77 (d, J = 11.1 Hz, 6H, OCH3), 4.40 (dt, JH,H = 7.0 Hz and JH,P = 15.3 Hz , 2H, 
CH2CH2P), 7.40 (br. s, 1H, NH) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 25.45 (d, 1JC,P = 141.4 Hz, CH2P), 52.96 (d, 2JC,P = 
6.6 Hz, OCH3), 59.82 (CH2CH2P), 158.38 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C5H13NO6P [M+H]+: 214.0481, found: 
214.0479. 
 
Dimethyl 2(N-benzyloxy-N-methylcarbonyloxy)ethylphosphonate (4.39) 
O P OMe
O
OMeN
BnO
O
Me
 
The title compound was prepared in 68% yield from 4.37 using a similar procedure as 
described for 4.34. 
1H-NMR (300 MHz, CDCl3): 
 = 2.03 (dt, JH,H = 7.0 Hz and JH,P = 18.8 Hz, 2H, CH2P), 
2.91 (s, 3H, NCH3), 3.56 (d, J = 10.8 Hz, 6H, OCH3), 4.20 (dt, JH,H = 7.3 Hz and JH,P 
= 13.2 Hz , 2H, CH2CH2P), 4.69 (s, 2H, PhCH2O), 7.15 – 7.25 (m, 5H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 25.33 (d, 1JC,P = 140.5 Hz, CH2P), 36.89 (NCH3), 
52.52 (d, 2JC,P = 6.3 Hz, OCH3), 60.08 (CH2CH2P), 76.65 (PhCH2O), 128.52 (=CH), 
128.70 (=CH), 129.48 (=CH), 135.47 (=C), 157.06 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C13H21NO6P [M+H]+: 318.1107, found: 
318.1111. 
 
Dimethyl-2(N-hydroxy-N-methylcarbonyloxy)ethylphosphonate (4.40) 
O P OMe
O
OMeN
HO
O
Me
 
Benzyl deprotection of 4.39 was essentially performed as described for 4.1 and 4.2, 
yielding the title compound in 97% yield (300 mg). 
1H-NMR (300 MHz, CDCl3): 
 = 2.09 (dt, JH,H = 6.2 Hz and JH,P = 18.8 Hz, 2H, CH2P), 
3.08 (s, 3H, NCH3), 3.64 (d, J = 10.8 Hz, 6H, OCH3), 4.40 (dt, JH,H = 6.5 Hz and JH,P 
= 13.8 Hz , 2H, CH2CH2P) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 25.27 (d, 1JC,P = 140.5 Hz, CH2P), 38.34 (NCH3), 
52.82 (d, 2JC,P = 6.3 Hz, OCH3), 59.76 (CH2CH2P), 157.22 (C=O) ppm. 
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Exact mass (ESI-MS): calculated for C6H15NO6P [M+H]+: 228.0637, found: 
228.0624. 
 
General method for the phosphonate deprotection towards compounds 4.3, 4.4, 4.5 
and 4.6. 
Esters 4.33, 4.35, 4.38 or 4.40 (0.39 mmol) were dissolved in CH2Cl2 (1.1 mL) and 
treated dropwise with 2 eq. of TMSBr (0.77 mmol, 83 mg) under N2. The reaction 
mixture was stirred for 2 h at room temperature. After completion of the reaction the 
volatile compounds were removed in vacuo to give the corresponding phosphonic 
acids. All final compounds were purified using a preparative HPLC system on a C18 
column (5m, Phenomenex, Luna, 250 x 21.2 mm) with a linear gradient of 
acetonitrile in 5 mM NH4OAc solution over 20 min at a flow rate of 17.5 mL/min. The 
purity of all target compounds was assessed by analytical HPLC (5m, Phenomenex, 
C18(2), 250 x 4.6 mm) using the same gradient at a flow rate of 1 mL/min. All final 
compounds were obtained as hygroscopic foams or slight yellow oils after 
lyophilisation. For compounds 4.3 and 4.4, this procedure was not very efficient since 
the target compounds showed poor retention (elution time: 3.6 min). Nevertheless it 
permitted to produce a pure fraction. 
 
((Hydroxycarbamoyl)methoxy)methylphosphonic acid (4.3): Yield: 52% 
according to HPLC analysis. 
O P OH
O
OHNH
O
HO
 
1H-NMR (300 MHz, D2O): 
 = 3.49 (d, JH,P = 9.1 Hz, 2H, CH2P), 3.92 (s, 2H, 
C(O)CH2O, minor), 4.07 (s, 2H, C(O)CH2O, major) ppm. 
13C-NMR (75 MHz, D2O): 
 = 69.47 (d, 1JC,P = 152.3 Hz, CH2P), 70.76 (d, 3JC,P = 13.3 
Hz, C(O)CH2OO), 169.31 (C=O) ppm. 
31P-NMR (121 MHz, D2O): 
 = 15.58 ppm. 
Exact mass (ESI-MS): calculated for C3H7NO6P [M-H]-: 184.0010, found: 184.0456. 
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((N-hydroxy-N-methylcarbamoyl)methoxy)methylphosphonic acid (4.4): Yield: 
45% according to HPLC analysis. 
O P OH
O
OHN
O
HO
Me
 
1H-NMR (300 MHz, D2O): 
 = 3.16 (s, 3H, NCH3, major), 3.22 (s, 3H, NCH3, minor), 
3.51 (d, JH,P = 8.5 Hz, 2H, CH2P), 4.25 (s, 2H, C(O)CH2O, minor), 4.38 (s, 2H, 
C(O)CH2O, major) ppm. 
13C-NMR (75 MHz, D2O): 
 = 36.09 (NCH3), 68.40 (d, 1JC,P = 157.5 Hz, CH2P), 69.37 
(d, 3JC,P = 11.5 Hz, C(O)CH2O), 171.73 (C=O) ppm. 
31P-NMR (121 MHz, D2O): 
 = 15.42 ppm. 
Exact mass (ESI-MS): calculated for C4H9NO6P [M-H]-: 198.0166, found: 198.0160. 
 
2(N-hydroxycarbonyloxy)ethylphosphonic acid (4.5): Yield: 71 mg (quantitative). 
O P OH
O
OHNH
HO
O
 
1H-NMR (300 MHz, MeOD): 
 = 2.14 (dt, JH,H = 7.0 Hz and JH,P = 19.1 Hz, 2H, 
CH2P), 4.31 (dt, JH,H = 7.6 Hz and JH,P = 10.6 Hz , 2H, CH2CH2P) ppm. 
13C-NMR (75 MHz, MeOD): 
 = 27.51 (d, 1JC,P = 137.0 Hz, CH2P), 59.97 (CH2CH2P), 
159.15 (C=O) ppm. 
31P-NMR (121 MHz, MeOD): 
 = 25.63 ppm. 
Exact mass (ESI-MS): calculated for C3H8NO6P [M-H]-: 184.0010, found: 184.0007. 
 
2(N-hydroxy-N-methylcarbonyloxy)ethylphosphonic acid (4.6): Yield: 153 mg 
(quantitative). 
O P OH
O
OHN
HO
O
Me
 
1H-NMR (300 MHz, MeOD): 
 = 2.16 (m, 2H, CH2P), 3.16 (s, 3H, NCH3), 4.32 (m, 
2H, CH2CH2P) ppm. 
13C-NMR (75 MHz, MeOD): 
 = 27.43 (d, 1JC,P = 138.2 Hz, CH2P), 37.68 (NCH3), 
60.68 (CH2CH2P), 157.74 (C=O) ppm. 
31P-NMR (121 MHz, MeOD): 
 = 25.92 ppm. 
Exact mass (ESI-MS): calculated for C4H9NO6P [M-H]-: 198.0166, found: 198.0173. 
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(E)-Ethyl 5-(benzyloxy)-2-methylpent-2-enoate (5.18) 
O
OBnEtO
 
To a cold solution (0 °C) of 3-(benzyloxy)propan-1-ol (1.59 mL, 10 mmol) in CH2Cl2 
(20 mL) was added Dess-Martin periodinane 15 wt% (50 mL, 25 mmol). One drop of 
H2O was added and the reaction mixture was stirred at room temperature for 1 h. 
After this time the reaction mixture was diluted with saturated aqueous Na2S2O3 
(100mL). The mixture was extracted three times with CH2Cl2 (100mL) . The combined 
organic layers were dried over MgSO4 and concentrated in vacuo to give crude 3-
(benzyloxy)propanal 5.17 (Rf = 0.33 in EtOAc/hexane 1:4), which was used without 
further purification. 
The residue thus obtained was dissolved in 50 mL of toluene. 
Ethylidenetriphenylphosphorane (5 g, 11 mmol) was added and the reaction mixture 
was heated under reflux for 30 min, after which time the solvent was removed by 
evaporation. The residue was triturated with pentane and the resulting solid was 
removed by filtration. The filtrate was concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (EtOAc/hexane, 1:99 to 2:98) to 
provide 1.69 g of 5.18 (Rf = 0.54 in EtOAc/hexane 2:8) as an oil which predominantly 
consisted of the E-isomer based on 1H NMR analysis. The yield of both steps was 
68.3%. 
1H-NMR (300 MHz, CDCl3): 
 = 1.29 (dt, J = 0.6 Hz and 7.0 Hz, 3H, OCH2CH3), 1.85 
(d, J = 0.6 Hz, 3H, CH3C=C), 2.50 (virtual q, AB system, J = 6.9 Hz, 2H, CH2CH2CH), 
3.57 (t, J = 6.7 Hz, 2H, OCH2CH2), 4.19 (dq, J = 0.6 Hz and 7.0 Hz, 2H, OCH2CH3), 
4.53 (s, 2H, OCH2Ph), 6.78 (dt, J = 0.6 Hz and 7.3 Hz, 1H, CH2CH=C), 7.25 − 7.76 
(m, 5H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 17.28, 19.02, 34.16, 65.20, 73.36, 77.74, 132.37, 
133.14, 134.16, 135.06, 137.79, 142.96, 168.00 ppm. 
Exact mass (ESI-MS): calculated for C15H20NaO3 [M+Na]+: 271.1309, found: 
271.1290. 
 
(2S,3R)-Ethyl 5-(benzyloxy)-2,3-dihydroxy-2-methylpentanoate (5.19) 
O
OBnEtO
OHH
OHMe
 
 - 204 -
MeSO2NH2 was added to a solution of AD-mix- (3.61 g) in t-butyl alcohol (13 mL) 
and H2O (13mL). Stirring was continued at room temperature until both phases were 
clear. Then the reaction mixture was cooled to 0 °C, whereupon the inorganic salts 
partially precipitated. The olefin (E)-ethyl 5-(benzyloxy)-2-methylpent-2-enoate 5.18 
(0.64 g, 2.58 mmol) was added at once and the reaction mixture was stirred 
vigorously at 0 °C until TLC revealed the absence of the starting olefin (24 h). The 
reaction was quenched at 0 °C by addition of sodium sulfite and then warmed to 
room temperature and stirred for 45 min. The reaction mixture was extracted five 
times with ethyl acetate (5 × 100 mL). The combined organic layers were washed 
with 2 N KOH (100 mL) to remove most of the sulphonamide. Organic solvents were 
dried over MgSO4 and removed in vacuo. The residue was purified by flash 
chromatography (silica gel, EtOAc/hexane 2:98, 2:8, 4:6) (Rf = 0.35 in EtOAc/hexane 
4:6) to give the product 5.19 (0.48 g, 1.71 mmol) as a clear oil in 66% yield and with 
an enatiomeric excess of 92%. 
[]D25 = + 6.4 (in EtOH) 
1H-NMR (300 MHz, DMSO-d6): 
 = 1.17 (2 × 3 H, m, OCH2CH3 and CH3C), 1.48 (1 
H, m, OCH2CH2), 1.75 (1 H, m, OCH2CH2), 3.52 (2 H, m, OCH2CH2), 3.65 (1 H, 
virtual septet, J = 2.1 Hz, 8.2 Hz and 9.2 Hz, HCOH), 4.06 (2 H, m, OCH2CH3), 4.43 
(2 H, s, OCH2Ph), 4.57 (1 H, d, J = 8.2 Hz, HCOH), 4.81 (1 H, s, MeCOH), 7.23 − 
7.36 (5 H, m, arom. H) ppm. 
13C-NMR (75 MHz, DMSO-d6): 
 = 14.15, 21.91, 30.46, 60.25, 66.97, 71.87, 72.09, 
77.36, 127.35, 127.44, 128.26, 138.77, 175.13 ppm. 
Exact mass (ESI-MS): calculated for C15H22NaO5 [M+Na]+: 305.1365, found: 
305.1351. 
 
(4S,5R)-Ethyl 5-(2-(benzyloxy)ethyl)-2,2,4-trimethyl-1,3-dioxolane-4-carboxylate 
(5.20) 
O
OBn
O
Me
O OEt
 
A solution of (2S,3R)-ethyl 5-(benzyloxy)-2,3-dihydroxy-2-methylpentanoate 5.19 
(0.48 g, 1.7 mmol) in anhydrous acetone (20 mL) was treated with 2,2-
dimethoxypropane (0.88 g, 8.5 mmol, 1.08 mL) and TsOH (0.05 eq), and the 
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resulting mixture was stirred at room temperature for 4 h. Then the reaction mixture 
was poured into 80 mL of a 7% NaHCO3 solution and extracted thrice with 80 mL of 
CH2Cl2. Evaporation of the organic solution afforded a crude product consisting of 
practically pure 5.20 which was used in the next step after flash chromatography 
(silica gel, EtOAc/hexane 3:97, Rf = 0.10). The yield was 94%. 
[]D25 = + 36.0 (in CHCl3) 
1H-NMR (300 MHz, CDCl3): 
 = 1.27 (t, J = 7.3 Hz, 3H, OCH2CH3), 1.34 (s, 3H, 
CH3C), 1.39 (s, 3H, CH3C), 1.46 (s, 3H, CH3C) 1.93 (m, 2H, OCH2CH2), 3.63 (m, 2H, 
OCH2CH2), 4.19 (m, 2H, OCH2CH3), 
 4.36 (dd, J = 3.5 Hz and 9.7 Hz, 1H, CH), 4.50 
(d, AB system, J = 11.7 Hz, 1H, OCH2Ph), 4.77 (d, AB system, J = 12.0 Hz, 1H, 
OCH2Ph), 7.27 − 7.34 (m, 5H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 14.34, 20.13, 25.74, 28.47, 30.33, 61.62, 67.59, 
73.16, 82.62, 109.22, 127.79, 128.59, 138.61, 163.24, 173.29 ppm. 
Exact mass (ESI-MS): calculated for C18H26NaO5 [M+Na]+: 345.1677, found: 
345.1666. 
 
1-((4S,5R)-5-(2-(benzyloxy)ethyl)-2,2,4-trimethyl-1,3-dioxolan-4-yl)ethanone 
(5.22) 
O
OBn
O
Me
O Me
 
A solution of ester (4S,5R)-ethyl 5-(2-(benzyloxy)ethyl)-2,2,4-trimethyl-1,3-dioxolane-
4-carboxylate 5.20 (0.51 g, 1.60 mmol) and KOH (0.13g, 2.23 mmol) in MeOH (0.5 
mL) and H2O (0.2 mL) was stirred at reflux for 1 h. The reaction mixture was cooled 
and extracted with Et2O (80 mL). The aqueous layer was acidified with concentrated 
HCl and extracted thrice with Et2O (3 × 80 mL). The combined extracts were washed 
with brine, dried over MgSO4 and concentrated under reduced pressure to yield 0.44 
g of crude acid. The yield was 93%. 
MeLi (2.04 mL of a 1.6 M solution in ether, 3.25 mmol) was added drop wise to a 
solution of the above acid (0.44 g, 1.49 mmol) in dry THF (12 mL) at 0 °C. The 
reaction mixture was allowed to warm up to 25 °C over the period of 1 h and 
quenched by transferring it into an ice-1 N HCl mixture by cannula. The reaction 
mixture was extracted thrice with Et2O (3 × 80 mL). The combined extracts were 
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washed with brine, dried over MgSO4 and concentrated under reduced pressure to 
yield a mixture of the methyl keton and the corresponding tertiary alcohol. Flash 
chromatography gave 0.29 g (yield 69%) of 5.22 (Rf = 0.13 in EtOAc/hexane 3:97). 
1H-NMR (300 MHz, CDCl3): 
 = 1.22 (s, 3H, CH3), 1.39 (s, 3H, CH3 of 
isopropylidene), 1.47 (s, 3H, CH3 of isopropylidene), 1.86 (m, 2H, OCH2CH2), 2.27 (s, 
3H, CH3C=O), 3.59 (m, 2H, OCH2CH2), 4.36 (dd, J = 3.5 Hz and 9.4 Hz, 1H, CH), 
4.48 (d, AB system, J = 12.0 Hz, 1H, OCH2Ph), 4.52 (d, AB system, J = 12.0 Hz, 1H, 
OCH2Ph), 7.34 (m, 5H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 14.34, 20.13, 25.74, 28.47, 30.32, 61.64, 67.60, 
73.17, 82.62, 109.24, 127.80, 128.60, 138.59, 163.23, 173.31 ppm. 
Exact mass (ESI-MS): calculated for C17H24NaO4 [M+Na]+: 315.1572, found: 
315.1578. 
 
1-((4S,5R)-5-(2-Hydroxyethyl)-2,2,4-trimethyl-1,3-dioxolan-4-yl)ethanone (5.23) 
O
OH
O
Me
O Me
 
Compound 5.22 (0.29 g, 0.99 mmol) was dissolved in methanol (15 mL) under 
nitrogen atmosphere and Pd on carbon (10%) (40 mg) was added to the solution. 
The suspension was drawn in vacuo by the pump. A balloon with H2 gas was placed 
on the recipient and the suspension was stirred for 24 h. After spotting (Rf = 0.31 in 
EtOAc/hexane 4:6) of the reaction a balloon with fresh H2 gas was placed on the 
recipient. When the reaction was finished the reaction mixture was filtered and 
concentrated under reduced pressure. Flash chromatography (silica gel, 
EtOAc/hexane 8:2 > 4:6, Rf = 0.29 in EtOAc/hexane 4:6) gave 0.15 g of product 5.23 
(yield 71%). 
1H-NMR (300 MHz, CDCl3): 
 = 1.25 (s, 3H, CH3), 1.38 (s, 3H, CH3 of 
isopropylidene), 1.48 (s, 3H, CH3 of isopropylidene), 1.85 (m, 2H, CH2CH2OH), 2.29 
(s, 3H, CH3C=O), 3.79 (m, 2H, CH2CH2OH), 4.14 (dd, J = 4.5 Hz and 8.6 Hz, 1H, 
CH) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 19.56, 25.88, 26.18, 28.58, 32.40, 61.17, 77.75, 
87.60, 109.13, 212.32 ppm. 
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Exact mass (ESI-MS): calculated for C10H18NaO4 [M+Na]+: 225.1102, found: 
225.1106. 
 
Diethyl 2-((4S,5R)-5-acetyl-2,2,5-trimethyl-1,3-dioxolan-4-yl)ethylphosphonate 
(5.25) 
O
P
O
Me
O Me O
OEt
OEt
 
To a solution of compound 5.23 (0.15 g, 0.71 mmol) and imidazole (0.11 g, 1.43 
mmol) in 7 mL of dry toluene was added with stirring under nitrogen freshly distilled 
chlorodiphenylphosphane (0.21 g, 0.93 mmol). The resulting cloudy mixture was 
treated with iodine in small portions at room temperature, and stirring was continued 
until complete conversion. An equal volume of 2 N NaOH was added, the mixture 
was shaken thoroughly for 5 min, and more iodine was added until the brown colour 
persisted in the organic phase. The layers were separated, and the organic phase 
was washed with saturated sodium thiosulfate and water, and then dried with MgSO4. 
The colourless material obtained after concentration of the solution in vacuo proved 
of sufficient purity and, because of its presumed lability, the product was used in the 
next step without further purification.  
A solution of crude iodide 5.24 in 0.6 mL triethyl phosphite was heated at 130 °C 
under nitrogen for 12 h. The excess triethylphosphite and other volatile compounds 
were removed under reduced pressure. The residue was purified by flash 
chromatography (silica gel, EtOAc/hexane 4:6, Rf = 0.32 in CH2Cl2/MeOH 9:1) to 
yield 5.25 as colourless oil (yield 81%). 
1H-NMR (300 MHz, CDCl3): 
 = 1.22 (s, 3H, CH3), 1.32 (t, J = 7.0 Hz, 6H, 
P(O)OCH2CH3), 1.36 (s, 3H, CH3 of isopropylidene), 1.46 (s, 3H, CH3 of 
isopropylidene), 1.90 (m, 4H, CH2CH2P), 2.28 (s, 3H, CH3C=O), 3.99 (m, 1H, CH), 
4.09 (m, 4H, OCH2CH3) ppm. 
13C-NMR (75 MHz, CDCl3): 
 = 16.69, 19.28, 23.14, 23.38, 25.70, 26.18, 28.59, 
29.93, 61.83, 78.59, 87.45, 211.84 ppm. 
Exact mass (ESI-MS): calculated for C14H27 NaO6P1 [M+Na]+: 345.1411, found: 
345.1444. 
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(3S,4R)-3,4-Dihydroxy-4-methyl-5-oxohexylphosphonic acid (5.1) 
P
O
OH
OH
(R)(S)Me
O
HO Me
OH
 
The ester 5.22 (0.19 g, 0.58 mmol) was dissolved in 2 mL CH2Cl2 and treated drop 
wise with TMSBr (0.35 g, 2.31 mmol). The reaction mixture was stirred under 
nitrogen for 2 h by room temperature. After removal of the volatile compounds in 
vacuo the residue was dissolved in water. The residue was purified on RP-HPLC in a 
same way as described for the other analogues, to yield 5.1 as a slight yellow powder 
in almost quantitative yield. 
1H-NMR (300 MHz, D2O): 
 = 1.15 (s, 3H, CH3), 1.42 (m, 2H, PCH2), 1.67 (m, 2H, 
PCH2CH2), 2.13 (s, 3H, CH3C=O), 3.76 (m, 1H, CH) ppm. 
13C-NMR (75 MHz, D2O): 20.64 (s, CH3), 24,16 (d, 2JC,P = 3.5 Hz, PCH2CH2), 24.76 
(d, 1JC,P = 134.2 Hz, PCH2), 24.79 (s, CH3C=O), 75.56 (d, 3JC,P = 16.7 Hz, CH), 82.57 
(Cq), 215.88 (CH3C=O) ppm. 
Exact mass (ESI-MS): calculated for C7H15NaO6P1 [M+Na]+: 249.0504, found: 
249.0505. 
 
4.2. BIOLOGICAL EVALUATION OF THE ANTIMALARIAL 
ACTIVITY 
4.2.1. DXR INHIBITION ASSAY 
 
The assay was performed in a reaction mixture containing 100 mM Tris HCl 
(pH 7.5), 0.2 % BSA, 1 mM MnCl2, 1 mM NADPH, 0.3 mM DOXP, and 1 µg/ml 
recombinant DOXP reductoisomerase from E. coli. The mixture was incubated with a 
dilution series of the test compounds on a 96 well plate, and the reaction started by 
addition of DOXP. The decrease of absorption was monitored at 340 nm using a 
SpectraMax 340PC microplate reader (Molecular Devices, Ismaning). 
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4.2.2. P. FALCIPARUM GROWTH INHIBITION ASSAY 262 
 
In vitro culture of P. falciparum  
The P. Falciparum culture takes place in RPMI 1640-Medium, which is 
completed with 10% human serum and HEPES buffer.263 Human Erythrocytes serve 
as hostcells. For the preservation culture Petri plates with 10 cm diameters are used. 
The culture volume per bowl amounts to 10 ml with a hematocrit of 5%. The cultures 
are preserved under an atmosphere of 5% O2, 3% CO2 and 92% N2 and by 37 °C. 
The medium is daily changed, and the cultures are diluted when reaching a 
parasitemia of maximally 5%. The parasitemia is determined microscopically with a 
Giemsa colored blood swab.  
 
Determination in vitro antimalaria activity 
Attempts for the determination of the in vitro antimalaria activity are 
accomplished on a 96 well plate.264,265 Each well is filled with infected erythrocytes 
(200 l per well, with 2% hematocrit and 0.4% parasitemia). Subsequently, serial 
dilution of the test substances are add to the wells. The substances are first solved in 
DMSO and dilute with complete culture medium. The plates are incubated first for 48 
hours. After the addition of 0.8-Ci [3H]-hypoxanthine in 30 l of medium per well, the 
plates were further incubated for 24 hours. The parasites are filtered on glass-fiber 
filters (Micromate 196, Packard). Incorporated radioactivity was counted with a β-
Counter (matrix 9600, Packard). The only difference of this protocol to the Desjardins 
protocol is that we were incubating the parasites for 2 days instead of 1 day before 
adding labelled hypoxanthine. This made the assay more sensitive. 
 
Determination in vivo antimalaria activity 
The determination of the in vivo antimalaria activity takes place in a P. vinckei 
infected Balb/c mice model according to a modified protocol of Peters.266 On day 0 
the mice are infected through i.p. injection of approx. 5 × 107 erythrocytes from the 
                                            
262
 Gorlitzer, K., Gabriel, B., Jomaa, H., Wiesner, J., Pharmazie 2006, 61, 278-84. German. 
263
 Trager, W., Jensen, J. B. Science 1976, 193, 673-675. 
264
 Ancelin, M. L., Calas, M., Bompart, J., Cordina, G., Martin, D., Ben Bari, M., Jei, T., Druilhe, P., 
Vial, H. J. et al. Blood 1998, 91, 1426-1437. 
265
 Desjardins, R. E., Canfield, C. J., Haynes, J. D., Chulay, J. D. Antimicrob. Agents Chemother. 
1979, 16, 710-718.  
266
 Peters, W. Malaria, Kreier, J. P. Ed. (Academic Press, New York, 1980), vol. 1, pp. 160-161. 
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blood of an infected donor mouse. The treatment takes place on days 1, 2 and 3 
through i.p. or p.o. application of the test substance in a volume of each time 0.2 ml. 
The substance is dissolved in a concentration of 150 mg/ml in DMSO and before the 
application diluted with H2O. For each group of doses 3 mice are used. On day 4 the 
parasitemia is counted out with a Giemsa colored blood swab. 
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5. CONCLUSIONS AND PERSPECTIVES 
 
This Ph.D. study constitutes part of an extensive project dealing with the design 
and development of new agents with antimalarial activity. The enzyme 1-deoxy-D-
xylulose-5-phosphate reductoisomerase (DXR), which is involved in the DOXP 
pathway for isoprenoid synthesis, was chosen as drug target. This non-mevalonate 
pathway is not operating in humans and inhibitors of DXR can therefore be 
considered as selective for parasites. Fosmidomycin and its methyl homologue 
FR900098, well-known inhibitors of this enzyme that show antimalarial activity in 
vivo, were used as lead compounds for inhibitor design.  
 
H N P OH
O
OH O
OH
Fosmidomycin (1.83)
N P OH
O
OH O
OH
FR900098 (1.84)
 
 
The structure of fosmidomycin is characterized by a retrohydroxamic acid 
group, which acts as a ligand for the metal ion in DXR, and a phosphonate group, 
which mimics the phosphate group in the substrate structure. It was our objective to 
further expand the structure-activity relationship (SAR) of fosmidomycin as DXR 
inhibitor and to discover analogues showing superior activity against the enzyme 
and/or better antimalarial activity.  
Modifications were applied to the retrohydroxamic acid group and the propyl 
chain of the parent structures. Synthetic pathways to these modified fosmidomycines 
were elaborated. As initial screening method all new compounds were tested for their 
ability to inhibit DXR of Escherichia coli. The most promising inhibitors were further 
tested in an in vitro assay on two different Plasmodium falciparum strains. 
 
Our investigations are discussed in 4 chapters. 
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1. To explore the impact of structural modifications of the hydroxyl group of the 
retrohydroxamic moiety, analogues were synthesized with methyl, ethyl or hydroxyl 
ethyl substituents on the nitrogen (2.1-2.9). 
 
N
O
O
P
O OH
OH
2.38
N P
O OH
OHMe R
2.1 R = CH3
2.2 R = C2H5
O
N P
O
OH
OH
H
R
2.3 R = CH3
2.4 R = C2H5
O
N P
O
OH
OH
R
OH
 2.6 R = CH3
 2.7 R = Ph
 2.8 R = 1-naphtyl
 2.9 R = C15H31
O
P OHOH
O
NMe
O
Me
2.5
 
 
These modifications did not produce any acceptable inhibitors, which demonstrates 
the importance of the hydroxyl group in ligating the divalent metal.  
 
2. A synthetic procedure for the preparation of -aryl-substituted fosmidomycin 
analogues was developed starting from the corresponding benzylphosphonates or 
the appropriate cinnamaldehydes. 
 
a: R1 = H; R2 = H
b: R1 = Me; R2 = H
c: R1 = OMe; R2 = H
d: R1 = Cl; R2 = H
e: R1 = Cl; R2 = Cl
N
R1
P OHOHO
OH
O
R
R2
3.1c,e (R = H)
3.2a-e (R  = CH3)
N
H
R1
P OHOHO
O
R
R2
3.17a,c (R = H)
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Seven analogues were synthesized, allowing to perform an initial SAR study of this 
-aryl series (3.1c,e and 3.2a-e). Although the -aryl analogues were generally 
weaker DXR inhibitors than fosmidomycin, these analogues unambiguously 
surpassed the activity of fosmidomycin in inhibiting P. falciparum growth. 
Remarkably, the formyl analogues 3.1c and 3.1e consistently outperformed the 
acetyl derivatives 3.2c and 3.2e, both in the enzyme and the parasite growth 
inhibition assays. Compound 3.1e emerged as the most promising analogue with an 
IC50 value of 0.059 M. Due to their straightforward synthesis these compounds are 
suitable for upscaling in further drug development programmes. The deoxygenated 
sideproducts 3.17a,c demonstrated the contribution of the hydroxyl group to the 
overall affinity. 
 
The Michael addition procedure, used to prepare the -substituted analogues from 
phenyl-substituted cinnamaldehydes, proved also valuable to prepare the 
fosmidomycin cyclopentyl analogues 3.3 and 3.4. 
 
N
P
O OH
OH
HO
R
O
trans-3.3 (R = H)
cis-3.3 (R = H)
trans-3.4 (R = CH3)
cis-3.4 (R = CH3)
 
 
These compounds, featuring a restricted mobility, showed that a trans orientation of 
the retrohydroxamic acid moiety and the phosphonate group is optimal for binding 
the enzyme.  
 
3. An efficient and reliable synthesis was established for - and -oxa fosmidomycin 
analogues.  
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H N O P OH
O
OH O
OH
N O P OH
O
OH O
OH
N
H
O P OH
O O
OH
O P OH
O
OHN
O
HO HO
N
H
O P OH
O O
OH
O P OH
O
OHN
O
HO HO
4.1 4.2
4.3 4.4
4.5 4.6
 
 
Analogue 4.4, which combines a -oxa modification with a hydroxamate moiety was 
almost as potent in inhibiting DXR as FR900098. In an in vitro assay it proved almost 
twice as active as FR900098 in inhibiting the growth of a P.falciparum 3D7 strain. 
 
4. Several synthetic pathways towards the transition state analogue 5.1 were 
explored. A 10-step sequence, involving an asymmetric dihydroxylation, afforded 
compound 5.1 in a reasonable yield.  
 
5.1
P
O
OH
OH
(R)(S)Me
O
HO Me
OH
 
 
Unfortunately, this compound did not show any worth mentioning inhibitory activity. 
 
In conclusion, this Ph.D. thesis highlights some important structural requirements for 
DXR inhibitors. This study also provides valuable information for modifications on 
fosmidomycin toward new and more efficient inhibitors: introducing aryl modifications 
on the -position of the phosphonate moiety significantly improves the antiplasmodial 
activity in vitro and one oxa analogue with a hydroxamic acid proved to be a more 
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potent inhibitor and to show superior antiplasmodial activity than the parent 
compound, fosmidomycin. 
 
Further investigation on analogues 3.1e and 4.4 is desirable since these compounds 
are significantly more potent than fosmidomycin on P. falciparum strains. Especially 
the latter one is very interesting, since it can be easily synthesized. Before further 
development the toxicological properties of these analogues need to be investigated 
and their pharmacokinetic profile needs to be established. In vivo studies, employing 
murine and monkeys models, are required. Further drug design may involve other 
sterically hindered analogues as well as prodrugs of the most promising analogues. 
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6. BESLUITEN EN PERSPECTIEVEN 
 
Dit doctoraatsonderzoek maakt deel uit van een omvangrijk project omtrent het 
design en de ontwikkeling van nieuwe agentia met antimalaria activiteit. Het enzyme 
1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), dat betrokken is in de 
DOXP pathway voor isoprenoïde biosynthese, werd gekozen als target. Deze 
mevalonaat onafhankelijke “pathway” is niet actief in mensen en inhibitoren van DXR 
kunnen daardoor beschouwd worden als selectief tegen parasieten. Fosmidomycine 
en zijn methyl analoog FR900098, bekende inhibitoren voor dit enzyme die 
antimalaria activiteit vertonen in vivo, werden gebruikt als “lead” componenten voor  
het design van nieuwe inhibitoren. 
 
 
H N P OH
O
OH O
OH
Fosmidomycin (1.83)
N P OH
O
OH O
OH
FR900098 (1.84)
 
 
 De structuur van fosmidomycine wordt gekenmerkt door een 
retrohydroxamzuur, welke dienst doet als ligand voor het metaal ion in DXR, en een 
fosfonaat groep, welke de fosfaat groep in de substraat structuur nabootst. Het was 
onze doelstelling om de structuur-activiteitsrelatie (SAR) van fosmidomycine als DXR 
inhibitor verder uit te breiden en om nieuwe analogen te ontdekken die een hogere 
activiteit tegen het enzyme en/of een betere antimalaria activiteit vertonen. 
 Modificaties werden aangebracht aan de retrohydroxamzure groep en de 
propylketen van de twee lead componenten. Verschillende synthese wegen werden 
uitgewerkt voor deze gemodifieerde fosmidomycine analogen. Als initiële 
screeningsmethode werden alle nieuwe componenten getest op hun vermogen om 
DXR van Escherichia coli te inhiberen. De meest beloftevolle inhibitoren werden 
vervolgens getest in een in vitro test op twee verschillende Plasmodium falciparum 
stammen. 
 
Ons onderzoek wordt in vier hoofdstukken besproken. 
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1. Om de impact van structurele veranderingen van de hydroxyl groep van de 
retrohydroxamzure groep na te gaan, werden analogen gemaakt met een methyl-, 
ethyl- of hydroyxethyl substituent op de stikstof (2.1-2.9). 
 
N
O
O
P
O OH
OH
2.38
N P
O OH
OHMe R
2.1 R = CH3
2.2 R = C2H5
O
N P
O
OH
OH
H
R
2.3 R = CH3
2.4 R = C2H5
O
N P
O
OH
OH
R
OH
 2.6 R = CH3
 2.7 R = Ph
 2.8 R = 1-naphtyl
 2.9 R = C15H31
O
P OHOH
O
NMe
O
Me
2.5
 
 
Deze modificaties resulteerden niet in aanvaardbare inhibitoren, hetgeen het belang 
van de hydroxyl functie aantoont in de binding van het divalent metaalion. 
 
2. Een synthetische procedure voor de aanmaak van -aryl gesubstitueerde 
fosmidomycine analogen werd ontwikkeld.  Deze procedure startte van de 
betreffende benzylfosfonaten of de geschikte cinnamaldehydes.  
 
a: R1 = H; R2 = H
b: R1 = Me; R2 = H
c: R1 = OMe; R2 = H
d: R1 = Cl; R2 = H
e: R1 = Cl; R2 = Cl
N
R1
P OHOHO
OH
O
R
R2
3.1c,e (R = H)
3.2a-e (R  = CH3)
N
H
R1
P OHOHO
O
R
R2
3.17a,c (R = H)
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Zeven analogen werden gemaakt, hetgeen ons toeliet een initiële SAR studie van 
deze -aryl analogen (3.1c,e en 3.2a-e) uit te voeren. Alhoewel deze analogen 
allemaal zwakkere DXR inhibitoren dan fosmidomycine waren, vertoonden ze toch 
een ontegensprekelijke betere activiteit in de inhibitie van P. falciparum groei dan 
fosmidomycine. Opmerkelijk is dat de formyl analogen 3.1c en 3.1e duidelijk de 
acetyl derivaten 3.2c en 3.2e overtroffen, zowel in de enzyme als de parasietgroei 
inhibitietest. Component 3.1e kwam naar voor als het meest beloftevolle analoog met 
een IC50 waarde van 0.059 M. De ontwikkelde synthesemethode is geschikt voor 
opschaling naar verdere geneesmiddelontwikkeling toe. De minder actieve 
gedesoxygeneerde nevenproducten 3.17a,c tonen de bijdrage van de hydroxyl groep 
voor de totale activiteit aan.  
 
The Michael additie die gebruikt werd om de -gesubstitueerde analogen te maken 
vanuit de phenyl gesubstitueerde cinnamaldehydes, bleek ook een beproefde 
methode om cyclopentyl fosmidomycine analogen 3.3 en 3.4 te maken. 
 
N
P
O OH
OH
HO
R
O
trans-3.3 (R = H)
cis-3.3 (R = H)
trans-3.4 (R = CH3)
cis-3.4 (R = CH3)
 
 
Deze componenten met een gereduceerde flexibiliteit van de propylketen, maakten 
duidelijk dat een trans orientatie van het retrohydroxamzuur en de fosfonaat groep 
optimaal is voor de binding aan het enzyme. 
 
3. Een efficiënte en betrouwbare synthese werd ontwikkeld voor - en -oxa 
fosmidomycine analogen. 
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Analoog 4.4, welke een -oxa modificatie combineerd met een hydroxamaat groep, 
bleek bijna even potent in het inhiberen van DXR als FR900098. In een in vitro test 
bleek het bijna twee maal zo actief als FR900098 te zijn in het inhiberen van de groei 
van een P. falciparum 3D7 stam. 
 
4. Verschillende pogingen tot de synthese van een transitietoestand analoog 5.1 
werden ondernomen. Een 10-staps sequentie, met een asymmetrische 
dihydroxylatie, leverde component 5.1 in een aanvaardbaar rendement. 
 
5.1
P
O
OH
OH
(R)(S)Me
O
HO Me
OH
 
 
Helaas vertoonde dit analoog een niet noemenswaardige inhibitie.  
 
Als besluit kunnen we stellen dat dit doctoraatswerk enkele belangrijke structurele 
eigenschappen voor DXR inhibitoren aantoont. Deze studie levert ook waardevolle 
informatie voor modificaties aan fosmidomycine met het oog op nieuwe en meer 
efficiënte inhibitoren. Zo verbetert de introductie van aryl modificaties op de -positie 
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van de fosfonaat groep opmerkelijk de antiplasmodiale activiteit in vitro. Ook bleek 
een oxa analoog met een hydroxamzuur een meer potente inhibitor en toonde een 
sterkere antiplasmodiale activiteit dan de moeder molecule, fosmidomycine. 
 
Verder onderzoek op analogen 3.1e and 4.4 is wenselijk, aangezien deze 
componenten significant meer potent zijn dan fosmidomycine op P. falciparum 
stammen. Vooral de laatste is zeer interessant omdat het gemakkelijk 
gesynthetiseerd kan worden. Alvorens verdere ontwikkelingen te plannen moeten de 
toxicologische eigenschappen van deze analogen onderzocht worden en moet hun 
farmacokinetisch profiel bekeken worden. In vivo studies die gebruik maken van 
knaagdier- en aapmodellen zijn noodzakelijk. Verder geneesmiddelen design kan 
o.a. zowel sterisch gehinderde analogen als “prodrugs” van de meest beloftevolle 
analogen inhouden. 
 - 228 -
 
 - 229 -
OVERVIEW OF SYNTHESIZED AND EVALUATED COMPOUNDS 
a: R1 = H; R2 = H
b: R1 = Me; R2 = H
c: R1 = OMe; R2 = H
d: R1 = Cl; R2 = H
e: R1 = Cl; R2 = Cl
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